GENE	MUTATION_REMARK	GENOMIC_MUTATION_ID	FUSION_ID	MUTATION_AA_SYNTAX	DISEASE	ACTIONABILITY_RANK	DEVELOPMENT_STATUS	DRUG_COMBINATION	TESTING_REQUIRED	TRIAL_STATUS	TRIAL_ID	TRIAL_NAME	COMPLETION_STATUS	TRIAL_PRIMARY_COMPLETION_DATE	PATIENT_PRESCREENING	RESULTS_AVAILABILITY	PROGRESSION_REMARK	SOURCE_TYPE	SOURCE	TREATMENT_HISTORY	PATIENT_AGE	PRIMARY_OUTCOME_MEASURE	NUMBER_OF_PATIENTS	TREATED_NUMBER	CONTROL_NUMBER	CONTROL_TREATMENT	ORR_TREAT	ORR_CON	ORR_CI	ORR_PVAL	DOR_TREAT	DOR_CON	DOR_CI	DOR_PVAL	PFS_TREAT	PFS_CON	PFS_HR	PFS_CI	PFS_PVAL	TTP_TREAT	TTP_CON	TTP_HR	TTP_CI	TTP_PVAL	DCR_TREAT	DCR_CON	DCR_PVAL	OS_TREAT	OS_CON	OS_HR	OS_CI	OS_PVAL	OBJ_RR_TREAT	CR_COUNT	PR_COUNT	SD_COUNT	RFS_TREAT	RFS_CON	RFS_HR	RFS_CI	RFS_PVAL	BLOOD_RESPONSE	RESPONSE_VALUE	TIMEPOINT	CLASSIFICATION_ID	LAST_UPDATED	COSMIC_PHENOTYPE_ID	SITE_PRIMARY_COSMIC	SITE_SUBTYPE1_COSMIC	SITE_SUBTYPE2_COSMIC	SITE_SUBTYPE3_COSMIC	HISTOLOGY_COSMIC	HIST_SUBTYPE1_COSMIC	HIST_SUBTYPE2_COSMIC	HIST_SUBTYPE3_COSMIC	disease_type
CDKN2A	(CDKN2A_unspecified and TP53_unspecified) or MYC_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Adavosertib		Terminated	NCT02688907		PCD	2017Dec27	Yes	Yes	Change regimen	4	NCT02688907			Overall Response Rate	7	7																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CDKN2A	(CDKN2A_unspecified and TP53_unspecified) or MYC_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Adavosertib		Completed	NCT02593019	SUKES-C	PCD	2018Oct01	Expression confirmed	Yes		2	10.1200/JCO.2019.37.15_suppl.8514			Overall Response Rate	7	7			0																											0	0	3									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
AKT1	AKT1_unspecified or PIK3CA_unspecified or PTEN_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	MK2206		"Active, not recruiting"	NCT01306045	Arm 8	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	2	2																																									COSO29915333	2022Dec15	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
ATM	ATM_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Completed	NCT03009682	SUKSES-B	PCD	2021Jan01	Expression confirmed	Yes	Primary outcome not met	2	10.1200/JCO.2021.39.15_suppl.8562			Overall Response Rate	15	15			6.7								1.25			-1.18							26.7			8.56			-6.62														COSO29915333	2021Aug17	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
ATM	ATM_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BCL2	BCL2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 1	Cisplatin + Etoposide + Navitoclax		Completed	NCT00878449		PCD	2011Jul01	No	No		4	NCT00878449			Maximum tolerated dose/toxicity	12	12																																									COSO29915333	2023Jan16	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BCL2	BCL2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Interferon alpha-2B + Isotretinoin + Paclitaxel		Completed	NCT00062010		PCD	2011May01	No	Yes	Expression not correlated with efficacy	1	24858462	Previously-treated		Response rate	34	34											2													6.2							3	5									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BCL2	BCL2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Oblimersen sodium + Paclitaxel		Completed	NCT00005032		PCD	2001Jan01	No	No		4	NCT00005032			Maximum tolerated dose/toxicity	12	12																																									COSO29915333	2022Oct28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BLM	BLM_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified or HRAS_unspecified or KRAS_unspecified or NRAS_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT01306045	Arm 5	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	1	1																																									COSO29915333	2022Dec15	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Completed	NCT03009682	SUKSES-B	PCD	2021Jan01	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2021.39.15_suppl.8562			Overall Response Rate	15	15			6.7								1.25			-1.18							26.7			8.56			-6.62														COSO29915333	2021Aug17	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Approved FDA	Atezolizumab + Carboplatin + Etoposide	Not required	"Active, not recruiting"	NCT02763579	IMpower133	PCD	2018Apr24	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf			"PFS, ORR"	403	201	202		60	64			4.2	3.9			5.2	4.3	0.77	0.62-0.96	0.017									12.3	10.3	0.7	0.54-0.91	0.0069													COSO29915333	2023Jan23	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 1	Atezolizumab + Lurbinectedin		Recruiting	NCT04253145		ECD	2022Feb01	No	No		4	NCT04253145	Previously-treated		Maximum tolerated dose/toxicity	25	25																																									COSO29915333	2022Jun01	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Atezolizumab		Completed	NCT03059667		PCD	2018Sep10	No	Yes		2	10.1016/j.jtho.2019.01.008			Response rate	63	43	20	Chemotherapy	2.3	10							1.4	4.3									20.9	65		9.5	8.7	0.84	0.45-1.58	0.6													COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Chemotherapy + Olaparib + Pembrolizumab		Not yet recruiting	NCT05623319		ECD	2026Aug01	No	No		4	NCT05623319	Previously-treated		Progression free survival	60	60																																									COSO29915333	2023Jan13	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Carboplatin + Etoposide + Lenvatinib + Pembrolizumab		Recruiting	NCT05384015	PEERS	ECD	2026Jul30	Expression confirmed	No		4	NCT05384015	Untreated		Progression free survival	85	85																																									COSO29915333	2023Jan16	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	BMS-986012 + Carboplatin + Etoposide + Nivolumab		Recruiting	NCT04702880		ECD	2024Feb19	No	No		4	NCT04702880	Untreated		Progression free survival	120			Carboplatin + Etoposide + Nivolumab																																							COSO29915333	2023Jan16	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT03703297	ADRIATIC	ECD	2024May10	No	No		4	NCT03703297	Previously-treated		"OS, PFS"	730			Placebo																																							COSO29915333	2022Jun10	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 3	Adebrelimab + Cisplatin + Etoposide		Not yet recruiting	NCT05496166		ECD	2027Aug01	No	No		4	NCT05496166			Progression free survival	348			Adebrelimab + Cisplatin + Etoposide + Radiotherapy																																							COSO29915333	2023Jan16	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 3	Carboplatin + Etoposide + Serplulimab		"Active, not recruiting"	NCT04063163		PCD	2021Oct22	No	Yes		2	10.1200/JCO.2022.40.16_suppl.8505			Overall survival	585	389	196	Carboplatin + Etoposide + Placebo	80.2	70.4			5.6	3.2			5.8	4.3	0.47	0.38-0.59	<0.001									15.4	10.9	0.63	0.49-0.82	<0.0001													COSO29915333	2023Jan16	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 3	Chemotherapy + Olaparib + Pembrolizumab + Radiotherapy		Recruiting	NCT04624204	KEYLYNK-013	ECD	2027Oct28	No	No		4	NCT04624204			"OS, PFS"	672			Chemotherapy + Placebo + Radiotherapy																																							COSO29915333	2022Jul29	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 3	Chemotherapy + Pembrolizumab + Radiotherapy		Recruiting	NCT04624204	KEYLYNK-013	ECD	2027Oct28	No	No		4	NCT04624204			"OS, PFS"	672			Chemotherapy + Placebo + Radiotherapy																																							COSO29915333	2022Jul29	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 3	Durvalumab + Placebo		"Active, not recruiting"	NCT03703297	ADRIATIC	ECD	2024May10	No	No		4	NCT03703297	Previously-treated		"OS, PFS"	730			Placebo																																							COSO29915333	2022Jun10	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Erlotinib		"Active, not recruiting"	NCT01306045	Arm 2	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	0	0																																									COSO29915333	2022Dec15	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Lapatinib		"Active, not recruiting"	NCT01306045	Arm 11	PCD	2014Feb12	Expression confirmed	Yes		1	25667274			Response rate	1	1																																									COSO29915333	2022Dec15	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
KIT	KIT_unspecified or PDGFRA_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Sunitinib		"Active, not recruiting"	NCT01306045	Arm 14	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	0	0																																									COSO29915333	2022Dec15	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
MRE11	MRE11_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Completed	NCT03009682	SUKSES-B	PCD	2021Jan01	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2021.39.15_suppl.8562			Overall Response Rate	15	15			6.7								1.25			-1.18							26.7			8.56			-6.62														COSO29915333	2021Aug17	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
MRE11	MRE11_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
NBN	NBN_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
POU2F3	POU2F3_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Expression confirmed	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD50	RAD50_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD51B	RAD51B_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD51C	RAD51C_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD51D	RAD51D_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD51	RAD51_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD52	RAD52_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RAD54L	RAD54L_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RECQL4	RECQL4_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RECQL5	RECQL5_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RECQL	RECQL_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RICTOR	RICTOR_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Vistusertib		Completed	NCT02593019	SUKES-D	PCD	2018Oct01	Expression confirmed	Yes		2	10.1200/JCO.2019.37.15_suppl.8514			Overall Response Rate	4	4			0																											0	0	0									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
RPA1	RPA1_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
SLFN11	SLFN11_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Expression confirmed	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	ALRN-6924		Terminated	NCT04022876		PCD	2022Jul30	Yes	No		4	NCT04022876			Clinical activity	35	35																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Ad5CMV-p53 gene		Completed	NCT00617409		PCD	2015Sep21	No	Yes		4	NCT00617409			"Disease control rate, Clinical benefit rate"	38	20	18																				30	44.4		6.3	12.2																COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Ad5CMV-p53 gene + Tretinoin		Completed	NCT00617409		PCD	2015Sep21	No	Yes		4	NCT00617409			"Disease control rate, Clinical benefit rate"	49	31	18																				38.7	44.4		6.2	12.2																COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
WRN	WRN_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Bevacizumab + Olaparib		Recruiting	NCT04939662	SUKSES-B2	ECD	2023Jun01	Yes	No		4	NCT04939662	Previously-treated		Overall Response Rate	28	28																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
WT1	WT1_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		"Active, not recruiting"	NCT03761914		ECD	2022Nov30	Expression confirmed	No		4	NCT03761914			"Complete response, Pathological complete response"	90	90																																									COSO29915333	2022Nov28	COSO29915333	lung	NS	NS	NS	carcinoma	small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R or EGFR_T790M) and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Osimertinib + Savolitinib		Recruiting	NCT05261399	SAFFRON	ECD	2025Jul18	Yes	No		4	NCT05261399	Previously-treated		Progression free survival	324			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R) and CD274_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alflutinib		Recruiting	NCT05255406		ECD	2023Dec31	Yes	No		4	NCT05255406			Progression free survival	62	62																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R) and CD274_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Cisplatin + Pemetrexed + Tislelizumab		Not yet recruiting	NCT05394233		ECD	2023Dec01	Expression confirmed	No		4	NCT05394233			Progression free survival	20	20																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R) and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Erlotinib + Telisotuzumab vedotin		Recruiting	NCT02099058	Arm A	ECD	2023Dec08	Expression confirmed	Yes	PFS 6m 0.51	2	10.1200/JCO.2019.37.15_suppl.3011			Maximum tolerated dose/toxicity	29	29			34.5		17.9-54.3				-2.8					-2.8																1											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R) and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capmatinib + Erlotinib		Terminated	NCT02468661		PCD	2017Nov15	Yes	Yes	Slow accrual	4	NCT02468661	Previously-treated		Maximum tolerated dose/toxicity	23	23		Cisplatin + Pemetrexed																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R) and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capmatinib + Nazartinib		Terminated	NCT02335944	Group 1 + Ph1b	PCD	2020Nov10	Comparison with wt	Yes		2	10.1016/j.annonc.2020.08.1598	Previously-treated		Overall Response Rate	66	23	43		43.5	27.9			6.3	9.3			7.7	5.4												18.8	17.2																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	(EGFR_Exon19del or EGFR_L858R) and TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Osimertinib + Pemetrexed		Not yet recruiting	NCT04695925	TOP	ECD	2022Sep30	Yes	No		4	NCT04695925			Progression free survival	291			Osimertinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	(FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified) and CD274_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pemigatinib + Sintilimab		Not yet recruiting	NCT05004974		ECD	2023Sep01	Expression confirmed	No		4	NCT05004974			Overall Response Rate	20	20																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AKT1	AKT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	SY-3505		Recruiting	NCT05257512		ECD	2022Nov30	Expression confirmed	No		4	NCT05257512			Maximum tolerated dose/toxicity	70	70																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AKT1	AKT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capivasertib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	9	9	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AKT1	AKT1_unspecified or PIK3CA_unspecified or PTEN_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	MK2206		"Active, not recruiting"	NCT01306045	Arm 7	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	4	4																																									COSO29915674	2022Dec15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AKT1	AKT1_unspecified or PTEN_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capivasertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort F3	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	11	11											2			1.0-4.8																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_C1156Y	66562303		p.C1156Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_C1156Y	66562303		p.C1156Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_C1156Y	66562303		p.C1156Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_F1174			p.F1174X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_F1174			p.F1174X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_F1174			p.F1174X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_G1202				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_G1202				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_I1171				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_I1171				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_I1171				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_L1196				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_L1196				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_L1196				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_L1196				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_L1196				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_L1198F	66556391		p.L1198F	lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_V1180				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_V1180				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_V1180				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 1	XZP-3621		Recruiting	NCT05055232		ECD	2023Mar12	Yes	No		4	NCT05055232			Maximum tolerated dose/toxicity	120	120																																									COSO29915674	2021Nov17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 1	Autologous personalized DC vaccine		Recruiting	NCT05195619		ECD	2024Sep01	Yes	No		4	NCT05195619			Maximum tolerated dose/toxicity	16	16																																									COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 1	TAS-116		Completed	NCT02965885		PCD	2019May03	Yes	No		4	NCT02965885			Overall Response Rate	31	31																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Not yet recruiting	NCT05361564		ECD	2024Jun01	Yes	No		4	NCT05361564			Biomarker discovery	12	12																																									COSO29915674	2022Aug03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	IBI-322 + Lenvatinib + Platinum-based chemotherapy		Not yet recruiting	NCT05296278		ECD	2023Apr01	Yes	No		4	NCT05296278	Previously-treated		Progression free survival	80	80																																									COSO29915674	2022Apr27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Chemotherapy + Pembrolizumab		Not yet recruiting	NCT05266846		ECD	2023Feb16	Yes	No		4	NCT05266846			Progression free survival	30	30																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensatinib		Not yet recruiting	NCT05186506		ECD	2025Dec15	Yes	No		4	NCT05186506			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	152	152		Platinum-based chemotherapy																																							COSO29915674	2022Feb01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	XZP-3621		Not yet recruiting	NCT05482087		ECD	2025May07	Yes	No		4	NCT05482087			Overall Response Rate	190	190																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib + Carboplatin + Docetaxel + Pemetrexed		"Active, not recruiting"	NCT05081674	BLISS	ECD	2023Jun30	Yes	No		4	NCT05081674			Cost of therapy	154	154																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib + Nivolumab		"Active, not recruiting"	NCT02393625	CheckMate 370 Group E	ECD	2023Apr11	Yes	Yes	Severe hepatic toxicity	1	29518553	Untreated		Overall Response Rate	13	13																															5										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		Not yet recruiting	NCT05241028		ECD	2027Feb01	Yes	No		4	NCT05241028			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	80	80																																									COSO29915674	2022Apr27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 3	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed		"Active, not recruiting"	NCT04194203	IMpower151	ECD	2023Feb03	No	No		4	NCT04194203			Progression free survival	304			Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 4	Lorlatinib		Recruiting	NCT04362072		ECD	2024Jan30	Yes	No		4	NCT04362072			Overall Response Rate	85	85																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions and TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Ensartinib		Not yet recruiting	NCT05491811		ECD	2023Nov01	Yes	No		4	NCT05491811			Progression free survival	77	77																																									COSO29915674	2022Sep23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions or ROS1_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Entrectinib		"Active, not recruiting"	NCT02568267	STARTRK-2	ECD	2024Dec31	Yes	No		4	NCT02568267	Previously-treated		Overall Response Rate	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_fusions or ROS1_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 4	Crizotinib		Unknown					Yes	Yes		1	34686712			Not defined	32	10	22	Chemotherapy																						34	6	0.266	0.104-0.678	0.0056													COSO29915674	2021Nov25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Crizotinib	Required	Completed	NCT00932893	PROFILE 1007	PCD	2012Mar01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	Previously-treated		Progression free survival	347	173	174	Chemotherapy									7.7	3	0.49	0.37-0.64	<0.001																										COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Brigatinib	Not required	Completed	NCT02094573	ALTA 90-180 mg	PCD	2016Feb29	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf	Previously-treated		Overall Response Rate	110	110			53		43-62		13.8		-9.3																																COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Brigatinib		Completed	NCT02737501	ALTA-1L	PCD	2020Jul28	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf			Progression free survival	275	137	138	Crizotinib	74	62		0.0342	33.1	13.8			24	11	0.49		<0.0001																										COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Brigatinib	Not required	Completed	NCT02094573	ALTA 90 mg	PCD	2016Feb29	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf	Previously-treated		Overall Response Rate	112	112			48		39-58		13.8		-7.4																																COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Alectinib	Required	Completed	NCT01801111	NP28673	PCD	2014Oct24	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	Previously-treated		Overall Response Rate	138	138			44				11.2																								61										COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Alectinib	Required	Completed	NCT01588028	NP28761	PCD	2014Oct01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	Previously-treated		Maximum tolerated dose/toxicity	87	87			38		28-49		7.5																								33										COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Alectinib	Required	"Active, not recruiting"	NCT02075840	ALEX	PCD	2017Feb09	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	Untreated		Progression free survival	303	152	151	Crizotinib	79	72		0.1652					25.7	10.4	0.53	0.38-0.73	<0.0001																										COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Lorlatinib	Required	"Active, not recruiting"	NCT03052608	CROWN (B7461006)	PCD	2020Mar20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf	Untreated		Progression free survival	296	149	147	Crizotinib	76	58				11				9.3	0.28	0.19-0.41	<0.0001																										COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Lorlatinib	Required	"Active, not recruiting"	NCT01970865	B7461001	PCD	2017Mar15	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf	Untreated		Overall Response Rate	215	215			48		42-55		12.5		8.4-27.3																																COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Ceritinib	Required	Completed	NCT01283516 	ASCEND-1	PCD	2016May01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	Previously-treated		Maximum tolerated dose/toxicity	163	163			55		47-62		7.4		5.4-10.1																					2	86										COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Ceritinib	Required	"Active, not recruiting"	NCT01828099	ASCEND-4	PCD	2016Jun24	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	Untreated		Progression free survival	375	189	187	Chemotherapy									16.6	8.1	0.55	5.8-11.1	<0.00001																										COSO29915674	2023Jan18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Crizotinib	Required	Completed	NCT01154140	PROFILE 1014	PCD	2013Nov30	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	Untreated		Progression free survival	343	172	171	Chemotherapy	74	45		<0.001					10.9	7	0.45	0.35-0.60	<0.001																										COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Ensartinib		Recruiting	NCT05498064		ECD	2025Dec31	Expression confirmed	No		4	NCT05498064			Progression free survival	490	490																																									COSO29915674	2022Sep23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Pemetrexed		Unknown					Yes	Yes		1	21642865			Unknown	15	15			46.7													9.2															7	6									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ipilimumab + Nivolumab		Recruiting	NCT04013542		ECD	2023Jun29	Yes	No		4	NCT04013542			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Erlotinib + Ipilimumab		Completed	NCT01998126		PCD	2017May09	Yes	Yes	Serious adverse events	2	10.1016/j.jtho.2017.09.010			Maximum tolerated dose/toxicity	3	3											24.1																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Bevacizumab + Carboplatin + Ensartinib + Pemetrexed		Recruiting	NCT04837716		ECD	2022Sep23	Yes	No		4	NCT04837716			Maximum tolerated dose/toxicity	12	12																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Lorlatinib + PF-07284892		Recruiting	NCT04800822	Cohort 3	ECD	2026Feb04	Expression confirmed	No		4	NCT04800822	Untreated		Overall Response Rate	211	211																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Lorlatinib + PF-07284892		Recruiting	NCT04800822	Cohort 1/2	ECD	2026Feb04	Expression confirmed	No		4	NCT04800822	Previously-treated		Overall Response Rate	211	211																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Binimetinib + Cetuximab + Encorafenib + Lorlatinib + PF-07284892		Recruiting	NCT04800822		ECD	2026Feb04	Expression confirmed	No		4	NCT04800822			Overall Response Rate	211	211																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Lorlatinib + Temozolomide		"Active, not recruiting"	NCT04541407		PCD	2022Apr25	Yes	No		4	NCT04541407			Maximum tolerated dose/toxicity	1	1																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Pembrolizumab + Stereotactic Body Radiation Therapy		Terminated	NCT03436056	PRIMING	PCD	2019Jul08	No	No		4	NCT03436056			Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	DV281		Completed	NCT03326752		PCD	2019Sep19	Yes	No		4	NCT03326752			"ORR, DOR"	26	26																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Brigatinib + Midazolam		Completed	NCT03420742		PCD	2020Mar25	Yes	No		4	NCT03420742			Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Everolimus		"Active, not recruiting"	NCT02321501		ECD	2023Jun30	Yes	No		4	NCT02321501			Maximum tolerated dose/toxicity	37	37																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alkotinib		Recruiting	NCT03607188		ECD	2022Feb28	No	No		4	NCT03607188			Maximum tolerated dose/toxicity	18	18																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Pembrolizumab		Terminated	NCT02511184		PCD	2017Dec01	Yes	Yes	Slow accrual	4	NCT02511184			Maximum tolerated dose/toxicity	9	9																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Luminespib		Completed	NCT01752400		PCD	2017Jun01	Yes	Yes		4	NCT01752400			Overall Response Rate	6	6			0								1.43			1.3-2.8																											COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	PLB1003		Unknown	NCT03130881		ECD	2020Dec30	Yes	Yes		2	10.1016/j.jtho.2019.08.1375			Maximum tolerated dose/toxicity	14	14			71																		86										10	2									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Binimetinib + Brigatinib		Terminated	NCT04005144		PCD	2022Oct01	Yes	No		4	NCT04005144			Maximum tolerated dose/toxicity	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Conteltinib		Unknown	NCT02695550		ECD	2018Mar01	Yes	Yes		1	32181989			Maximum tolerated dose/toxicity	13	13			77								13			9.98-16.00							85									1	10										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Ganetespib		Completed	NCT01579994		PCD	2020Dec28	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.8064			Maximum tolerated dose/toxicity	12	12																															8	2									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Ribociclib		Completed	NCT02292550		PCD	2018Sep26	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Dose-determination-results-from-a-Phase-Ib-II-study-of-ceritinib-CER-ribociclib-RIB-in-ALK-positive-ALK-non-small-cell-lung-cancer-NSCLC			Maximum tolerated dose/toxicity	27	27			48.1																											1	12										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Luminespib		Completed	NCT01772797		PCD	2016Jan01	Yes	No		4	NCT01772797			Maximum tolerated dose/toxicity	22	22																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Nivolumab		"Active, not recruiting"	NCT02393625		ECD	2023Apr11	Yes	No		4	NCT02393625			Maximum tolerated dose/toxicity	57	57																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alectinib + Atezolizumab		Completed	NCT02013219		PCD	2020Feb05	Yes	No		4	NCT02013219			Maximum tolerated dose/toxicity	52	52																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Atezolizumab + Erlotinib		Completed	NCT02013219		PCD	2020Feb05	Yes	Yes		2	10.1016/j.jtho.2016.11.1841			Maximum tolerated dose/toxicity	28	28			75		51-91		9.7		4.2-11.7		11.3			8.4-NE							90																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Ipilimumab		Completed	NCT01998126		PCD	2017May09	Yes	No		4	NCT01998126			Maximum tolerated dose/toxicity	14	14																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ensartinib		Recruiting	NCT02959619		PCD	2019Oct31	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.e21122			Maximum tolerated dose/toxicity	14	14																															9	3									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Brigatinib		"Active, not recruiting"	NCT03707938	BRIGHTSTAR	ECD	2023Jan28	Yes	No		4	NCT03707938	Untreated		Maximum tolerated dose/toxicity	35	35																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alectinib		Terminated	NCT03131206		PCD	2018Nov08	Yes	Yes	"Slow accrual, no benefit of treatment"	4	NCT03131206			Overall Response Rate	5	5			20		0.52-71.63																																				COSO29915674	2021Oct29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib		Completed	NCT00585195	PROFILE 1001	PCD	2020Jul30	Yes	Yes		4	NCT00585195			Maximum tolerated dose/toxicity	116	116			61.2		51.7-70.1						10			8.2-14.7																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib		Withdrawn	NCT02277457		ECD	2021Jun01	Yes	No		4	NCT02277457			Unknown	0	0																																									COSO29915674	2022May04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	2014Feb01	No	Yes		1	26899759			Maximum tolerated dose/toxicity	70	70																															1	32									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ipilimumab + Nivolumab		Completed	NCT03256136		PCD	2019Aug19	Yes	Yes		4	NCT03256136			Overall Response Rate	1	1			0								0.7										0																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib + Chemotherapy		Recruiting	NCT05200481	MASTERPROTOCOL ALK	ECD	2025Apr01	Expression confirmed	No		4	NCT05200481			Progression free survival	110			Brigatinib																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Chemotherapy + Resection		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Foritinib		Recruiting	NCT04237805		ECD	2022Dec31	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.9076			Overall Response Rate	104	104			92.3		85.4-96.6																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed		Recruiting	NCT04989322		ECD	2024Aug01	Yes	No		4	NCT04989322			Overall Response Rate	46	46																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib + TNO155		Recruiting	NCT04292119		ECD	2022Dec01	Yes	No		4	NCT04292119			Overall Response Rate	96	96																																									COSO29915674	2021Jun21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Binimetinib + Lorlatinib		Recruiting	NCT04292119		ECD	2022Dec01	Yes	No		4	NCT04292119			Overall Response Rate	96	96																																									COSO29915674	2021Jun21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	TPX-0131		"Active, not recruiting"	NCT04849273		ECD	2025Apr01	Expression confirmed	No		4	NCT04849273			Overall Response Rate	11	11																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Cetuximab + Gemcitabine + SIM1803-1A + SNK01		Recruiting	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	No		4	NCT04872634	Previously-treated		Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Gemcitabine + SNK01		Recruiting	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	No		4	NCT04872634	Previously-treated		Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Nivolumab + Pemetrexed		Completed	NCT03256136		PCD	2019Aug19	Yes	Yes		4	NCT03256136			Overall Response Rate	1	1			100								2.8										100																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pembrolizumab + Recombinant EphB4-HSA fusion protein		"Active, not recruiting"	NCT03049618		ECD	2024Mar10	Yes	No		4	NCT03049618			Overall Response Rate	42	42																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Nivolumab + Plinabulin		Terminated	NCT02846792		PCD	2018Jul12	Yes	Yes	Changed business priorities	4	NCT02846792			Overall Response Rate	5	5																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Pemetrexed		Unknown	NCT03778138	ALTER-L025	ECD	2019Dec31	Yes	No		4	NCT03778138			Progression free survival	51	51																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Avelumab + Axitinib + Palbociclib		"Active, not recruiting"	NCT03386929	SPRING	ECD	2023Oct01	Yes	No		4	NCT03386929			Progression free survival	130	130																																									COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Docetaxel + Sintilimab		Completed	NCT03798743	Success	PCD	2021Dec30	Yes	No		4	NCT03798743	Previously-treated		Overall Response Rate	30	30																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Radiotherapy		Unknown	NCT04193007	BRATR	ECD	2021Dec30	Yes	No		4	NCT04193007			Progression free survival	100	100																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Iruplinalkib		Unknown	NCT04641754		ECD	2020Dec01	Expression confirmed	Yes	OS 18m 81.9%	2	10.1200/JCO.2022.40.16_suppl.9073			Overall Response Rate	146	146			67.8		59.6-75.3		13.1		-8.3		14.4			-9.7							96.6																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Iruplinalkib		Unknown	NCT03389815		ECD	2020Jun01	Yes	Yes		2	10.1093/annonc/mdz260.007			Maximum tolerated dose/toxicity	44	44			65.9																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Lorlatinib		Recruiting	NCT04292119		ECD	2022Dec01	Yes	No		4	NCT04292119			Overall Response Rate	96	96																																									COSO29915674	2021Jun21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	EphB4-HSA Fusion Protein + Pembrolizumab		"Active, not recruiting"	NCT03049618		ECD	2024Mar10	Yes	No		4	NCT03049618			Overall Response Rate	42	42																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Avelumab + Lorlatinib		Completed	NCT02584634	Javelin Lung 101	PCD	2021Feb02	Yes	Yes		4	NCT02584634			Overall Response Rate	43	43			46.4		27.5-66.1																									1	12										COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Stereotactic Body Radiation Therapy		"Active, not recruiting"	NCT02314364		PCD	2021Nov01	Yes	No		4	NCT02314364			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ganetespib		Completed	NCT01562015		PCD	2014Aug01	Yes	Yes		4	NCT01562015			Overall Response Rate	12	12			37.5		8.5-75.5						0													0																	COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT04042558		ECD	2022Jun01	Yes	No		4	NCT04042558			Overall Response Rate	149	149																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Chemotherapy + Pembrolizumab		"Active, not recruiting"	NCT03242915		ECD	2022Nov01	Yes	No		4	NCT03242915	Previously-treated		Overall Response Rate	33	33																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Durvalumab + Ensartinib		Completed	NCT02898116		PCD	2017Aug04	Yes	Yes	Slow accrual	4	NCT02898116			Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Cobimetinib		Recruiting	NCT03202940		ECD	2022Nov30	Yes	No		4	NCT03202940			Maximum tolerated dose/toxicity	31	31																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Retaspimycin		Terminated	NCT01228435		PCD	2012Feb01	Yes	Yes	Slow accrual	4	NCT01228435			Response rate	3	3																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	TQ-B3139		Unknown	NCT04056572		ECD	2021Oct30	Yes	No		4	NCT04056572	Previously-treated		Overall Response Rate	135	135																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib + Trametinib		Terminated	NCT03087448		PCD	2022Apr30	Yes	No	Slow accrual	4	NCT03087448			Overall Response Rate	9	9																																									COSO29915674	2022Dec12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Bevacizumab		Recruiting	NCT03779191		ECD	2022Jul01	Yes	Yes	EFS 12m 97.1	2	10.1200/JCO.2022.40.16_suppl.9074			Progression free survival	36	36			97.2		91-99									-8.9																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Bevacizumab		Unknown	NCT02521051		ECD	2020Nov01	Yes	Yes		1	34896762			Maximum tolerated dose/toxicity	11	11				81.8							19.1			-4.3							100																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Erlotinib		Completed	NCT00965731		PCD	2011Dec01	No	Yes	Changed business priorities	4	NCT00965731			Progression free survival	27	27		Erlotinib																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Pemetrexed		Terminated	NCT02134912		PCD	2016Sep01	Yes	Yes	Development discontinued	4	NCT02134912	Previously-treated		Unknown	1	1																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Onalespib lactate		Completed	NCT01712217		PCD	2016Dec01	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2016.34.15_suppl.9059			Overall Response Rate	136	68	68		55.4	45.3							8.84	8.74																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT05380024		ECD	2023Dec30	Yes	No		4	NCT05380024			Major pathologic response	10	10																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT05341583		ECD	2025Jun01	Expression confirmed	No		4	NCT05341583			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	202			Placebo																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT05178511	ERSGATR	ECD	2023Jul01	Yes	No		4	NCT05178511	Previously-treated		Overall Response Rate	40	40																																									COSO29915674	2022Feb01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Unknown	NCT04415320		ECD	2020Dec01	Yes	No		4	NCT04415320			Overall Response Rate	37	37																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Unknown	NCT03215693		ECD	2018Sep01	Yes	Yes		1	31628085	Previously-treated		Overall Response Rate	156	156			52																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Completed	NCT01625234		PCD	2020Sep17	Yes	Yes		2	10.1158/1078-0432.CCR-17-2398			Maximum tolerated dose/toxicity	60	60			66		47.4-71.4		12.8		5.6-24.4		9.2			5.6-11.7																	36	13									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Unknown	NCT03753685		ECD	2020Jul01	Yes	No		4	NCT03753685			Overall Response Rate	37	37																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Completed	NCT01449461		PCD	2015Nov01	Yes	Yes		1	27836716	Untreated		Overall Response Rate	8	8			100																											3	5										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Completed	NCT01449461		PCD	2015Nov01	Yes	Yes		1	27836716	Previously-treated		Overall Response Rate	71	71			62								13.2			9.1-18.7																4	40	11									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Completed	NCT03410108	J-ALTA	PCD	2020Sep29	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.9537			Overall Response Rate	72	72			30.6				6.1				7.3										78.7																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		"Active, not recruiting"	NCT03535740	ALTA-2	PCD	2020Sep30	Yes	Yes		4	NCT03535740	Previously-treated		Overall Response Rate	103	103			26.2		18.0-35.8	0.076																																			COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Recruiting	NCT02706626	ALTA-1L	ECD	2022Jan01	Yes	Yes		1	33039599	Previously-treated		Overall Response Rate	20	20			40		19-62		5.3		-3.6		7			4.6-10.1																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Recruiting	NCT05015010	ALNEO	ECD	2023May28	Yes	No		4	NCT05015010			Major pathologic response	33	33																																									COSO29915674	2021Aug25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Completed	NCT03155009	ATALK	PCD	2019Sep26	Yes	Yes		3	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection			Overall Response Rate	39	39			51.3																											4	16										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Recruiting	NCT02314481	DARWIN II	ECD	2024Nov01	Yes	No		4	NCT02314481			Progression free survival	119	119																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Completed	NCT01871805		PCD	2014Oct24	Yes	Yes		1	29748847			Maximum tolerated dose/toxicity	134	134																								29.1			21.3-39.0														COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03909971	Cohort 2	PCD	2020Aug10	Yes	Yes	SAE 33.33%	4	NCT03909971	Previously-treated		Overall Response Rate	42	42			47.6		32.0-63.6		11.2		-2.9		5.6			2.9-9.7																											COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT04127110	ALKALINE	ECD	2023Dec01	Yes	No		4	NCT04127110			Progression free survival	100	100																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT02927340		ECD	2022Jan01	Yes	Yes		1	35584349			"Disease control rate, Clinical benefit rate"	23	23			59								24.6			-20.2																6	7										COSO29915674	2022Sep14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		"Active, not recruiting"	NCT03909971	Cohort 1	PCD	2020Aug10	Yes	Yes	SAE 13.43%	4	NCT03909971	Previously-treated		Overall Response Rate	67	67			70.1		57.7-80.7	<0.0001																																			COSO29915674	2022Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 5	PCD	2019Feb06	Yes	Yes		4	NCT02336451			Overall Response Rate	18	18			16.7		3.6-41.4																66.7																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 4	PCD	2019Feb06	Yes	Yes		4	NCT02336451	Untreated		Overall Response Rate	44	44			59.1		43.2-73.7																70.5																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 3	PCD	2019Feb06	Yes	Yes		4	NCT02336451	"Previously-treated, platinum-resistant"		Overall Response Rate	12	12			50		21.1-78.9																66.7																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 2	PCD	2019Feb06	Yes	Yes		4	NCT02336451	"Previously-treated, platinum-resistant"		Overall Response Rate	40	40			30		16.6-46.5																82.5																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT01685060	ASCEND-2	PCD	2016Mar29	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.8059	Previously-treated		Overall Response Rate	140	140			38.6		30.5-47.2																																				COSO29915674	2022Aug17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT01685138	ASCEND-3	PCD	2018Jan22	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.8060	Untreated		Overall Response Rate	124	124			63.7				9.3				11.1																														COSO29915674	2022Aug17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02040870	ASCEND-6	PCD	2017Jul27	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib	Previously-treated		Maximum tolerated dose/toxicity	103	103			42		31.2-50.9						5.7			5.4-7.5							80																				COSO29915674	2022Aug17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Terminated	NCT02513667		PCD	2020May29	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2020.38.15_suppl.e21571			Progression free survival	14	14																																									COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02450903		PCD	2017Jul31	Yes	Yes		4	NCT02450903	Previously-treated		Unknown	20	20			25		8.7-49.1		6.3		3.5-9.2		3.7			1.9-5.3							70																				COSO29915674	2022Aug17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 1	PCD	2019Feb06	Yes	Yes		4	NCT02336451	"Previously-treated, platinum-resistant"		Overall Response Rate	42	42			35.7		21.6-52.0																66.7																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Withdrawn	NCT01500824		ECD	2016May01	Yes	No		4	NCT01500824			Overall Response Rate	0	0																																									COSO29915674	2022May04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Completed	NCT00932451		PCD	2015Mar01	Yes	Yes		4	NCT00932451			Overall Response Rate	1069	1069			54.1		50.8-57.4		11.8		10.4-12.8		8.4			7.1-9.7							70.8			21.8			19.4-24.0						6.1			2.7-16.4					COSO29915674	2022May04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Durvalumab		Recruiting	NCT05170204		ECD	2029Jun17	Expression confirmed	No		4	NCT05170204	Previously-treated		Progression free survival	320	320																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		Recruiting	NCT03991403		ECD	2022Dec31	Yes	No		4	NCT03991403			Progression free survival	228			Chemotherapy																																							COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	TQ-B3139		Unknown	NCT04009317		ECD	2021Oct30	Yes	No		4	NCT04009317			Progression free survival	260	260																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Ensartinib		"Active, not recruiting"	NCT02767804	eXalt3	PCD	2020Jun30	Yes	Yes		2	10.1016/j.jtho.2020.08.003			Progression free survival	247	121	126	Crizotinib	75	67							25.8	12.7	0.51	0.35-0.72	0.0001																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Brigatinib		Recruiting	NCT03596866		ECD	2023Apr03	Yes	No		4	NCT03596866	Previously-treated		Progression free survival	246	246																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Recruiting	NCT05170204		ECD	2029Jun17	Expression confirmed	No		4	NCT05170204	Previously-treated		Progression free survival	320	320																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Unknown	NCT02838420	ALESIA	PCD	2018May31	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC	Untreated		Progression free survival	187	125	62	Crizotinib										11.1	0.37	0.13-0.38																											COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Recruiting	NCT03178552	B-FAST Cohort A	ECD	2024Apr27	Yes	Yes	PFS 12m 78.4%	2	10.1093/annonc/mdz394.079			Overall Response Rate	87	87			92		84.1-96.7																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Completed	NCT02604342	ALUR	PCD	2017Jan26	Yes	Yes		4	NCT02604342	Previously-treated		Progression free survival	119	79	40	Chemotherapy									10.9	1.4	0.2	0.12-0.33	<0.001																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		"Active, not recruiting"	NCT03456076		ECD	2023Jun30	Yes	No		4	NCT03456076			Progression free survival	257			Chemotherapy																																							COSO29915674	2022May11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Ceritinib		"Active, not recruiting"	NCT01828112	ASCEND-5	PCD	2016Jan26	Yes	Yes		4	NCT01828112	Previously-treated		Progression free survival	231	115	116	Chemotherapy									5.4	1.6	0.49	0.36-0.67	<0.001																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Crizotinib		Completed	NCT01639001		PCD	2015Jun30	Yes	Yes		4	NCT01639001	Untreated		Progression free survival	207	104	103	Chemotherapy	87.5	45.6		<0.0001					11.1	6.8	0.4		<0.001									28.5	27.7	0.9	0.56-1.45	0.33													COSO29915674	2022May04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Crizotinib		Recruiting	NCT02201992	ALCHEMIST	ECD	2036May01	Yes	No		4	NCT02201992			Overall survival	168			Best supportive care																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Crizotinib		Recruiting	NCT02194738	ALCHEMIST	ECD	2026Sep28	No	No		4	NCT02194738			Unknown	8300			Placebo																																							COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 4	Lorlatinib		Completed	NCT04541706		PCD	2022Jul20	Yes	No		4	NCT04541706			Maximum tolerated dose/toxicity	100	100																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 4	Lorlatinib		Recruiting	NCT05144997		ECD	2026Dec28	Yes	No		4	NCT05144997	Previously-treated		Maximum tolerated dose/toxicity	200	200																																									COSO29915674	2022Feb01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Autologous dendritic cell-adenovirus CCL21 vaccine + Pembrolizumab		Recruiting	NCT03546361		ECD	2023Jun30	No	No		4	NCT03546361			Overall Response Rate	24	24																																									COSO29915674	2022Aug03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	ITIL-168		"Active, not recruiting"	NCT05393635	 DELTA-2 Cohort 3	ECD	2024Feb01	No	No		4	NCT05393635			Maximum tolerated dose/toxicity	27	27																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Radiotherapy + Tyrosine Kinase Inhibitor		Recruiting	NCT05236946		ECD	2024Jul01	Yes	No		4	NCT05236946			Progression free survival	190			Tyrosine Kinase Inhibitor																																							COSO29915674	2022Apr27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or MET_unspecified or ROS1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib		Completed	NCT03088930		PCD	2021Jan13	Yes	Yes		4	NCT03088930	Untreated		Overall Response Rate	3	3			100																																						COSO29915674	2022May04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or ROS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	TGRX-326		Recruiting	NCT05441956		ECD	2022Dec31	Yes	No		4	NCT05441956			Maximum tolerated dose/toxicity	100	100																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or ROS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Completed	NCT02276027		PCD	2019Oct15	Yes	Yes		4	NCT02276027			Overall Response Rate	26	26			73.1																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified or ROS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Iruplinalkib + Platinum-based chemotherapy + Radiotherapy		Recruiting	NCT05351320		ECD	2026Apr30	Yes	No		4	NCT05351320			Maximum tolerated dose/toxicity	40	40																																									COSO29915674	2022May26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ATM	ATM_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	BAY1895344 + Pembrolizumab		"Active, not recruiting"	NCT04095273	cohort 4	ECD	2023Mar16	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	56	56																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AXL	AXL_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	XZP-3621		Not yet recruiting	NCT05204628		ECD	2025May07	Expression confirmed	No		4	NCT05204628			Progression free survival	238			Crizotinib																																							COSO29915674	2022Feb01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AXL	AXL_unspecified or CBL_unspecified or KDR_unspecified or KIT_unspecified or MET_unspecified or NTRK1_unspecified or NTRK2_unspecified or NTRK3_unspecified or PDGFRA_unspecified or RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		"Active, not recruiting"	NCT02219711		PCD	2022Apr27	Expression confirmed	Yes		1	35767205			Maximum tolerated dose/toxicity	53	53			13.2				3		1.8-10.2		4.3			2.9-5.7										11.6			6.6-18.2				7	30									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
AXL	AXL_unspecified or MET_unspecified or NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cabozantinib		Recruiting	NCT01639508	Group B	ECD	2023Jul01	Expression confirmed	No		4	NCT01639508			Overall Response Rate	86	86																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BAX	BAX_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Docetaxel + Radiotherapy		Terminated	NCT00378404		PCD	2009Jun01	No	Yes	Slow accrual	4	NCT00378404			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BCL2L11	BCL2L11_unspecified and EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Gefitinib + Vorinostat		Unknown	NCT02151721	VICTORY-J 	ECD	2018Feb20	Yes	Yes		1	31782583	Previously-treated		Maximum tolerated dose/toxicity	12	12											5.2										83.3			22.4								10									COSO29915674	2022Dec13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BCL2L11	BCL2L11_unspecified and EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Retrospective/Meta-analysis	Bevacizumab + EGFR-TKI		Unknown					Yes	Yes		2	10.1200/PO.20.00404	Untreated		Unknown	33	18	15	EGFR-TKI	94.4	40		>0.001					11.12	7.87			>0.001									30.9	25.4			0.06													COSO29915674	2021May21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BCL2L1	BCL2L1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Docetaxel + Radiotherapy		Terminated	NCT00378404		PCD	2009Jun01	No	Yes	Slow accrual	4	NCT00378404			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BCL2	BCL2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Docetaxel + Radiotherapy		Terminated	NCT00378404		PCD	2009Jun01	No	Yes	Slow accrual	4	NCT00378404			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_G466			p.G466?	lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		"Active, not recruiting"	NCT02304809	AcSe	PCD	2019May07	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	4	4																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_G469			p.G469X	lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		"Active, not recruiting"	NCT02304809	AcSe	PCD	2019May07	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	4	4																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_G596V	99951808		p.G596V	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		"Active, not recruiting"	NCT02304809	AcSe	PCD	2019May07	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	1	1																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_G596V	99951808		p.G596V	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Unknown		EURAF			Yes	Yes		1	26200454			Unknown	1	1																															1										COSO29915674	2022May11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_K601				lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		"Active, not recruiting"	NCT02304809	AcSe	PCD	2019May07	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	5	5																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_N581				lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		"Active, not recruiting"	NCT02304809	AcSe	PCD	2019May07	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Pexidartinib + Vemurafenib		Terminated	NCT01826448		PCD	2014Sep22	Yes	Yes	"No benefit of treatment, Protocol violation"	4	NCT01826448			Maximum tolerated dose/toxicity	13	13																																									COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	ASN003		Terminated	NCT02961283		PCD	2019Feb01	Yes	No		4	NCT02961283			"Disease control rate, Clinical benefit rate"	24	24																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Atezolizumab + Cobimetinib + Vemurafenib		Completed	NCT01656642		PCD	2020Mar25	Yes	Yes		1	31171876			Maximum tolerated dose/toxicity	39	39			71.8																											8	20	4									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Atezolizumab + Vemurafenib		Completed	NCT01656642		PCD	2020Mar25	Yes	Yes		1	31171876			Maximum tolerated dose/toxicity	17	17			76.5																											3	10	2									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Interferon alfa-2B + Interleukin-2 + Vemurafenib		Completed	NCT01603212		PCD	2017Jul05	Yes	No		4	NCT01603212			Maximum tolerated dose/toxicity	6	6																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Recruiting	NCT02314481	DARWIN II	ECD	2024Nov01	Yes	No		4	NCT02314481			Progression free survival	119	119																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	CFT1946 + Trametinib		Recruiting	NCT05668585	Arm B2		2027Mar11	Yes	No		4	NCT05668585	Untreated		Overall Response Rate	122	122																																									COSO29915674	2023Jan06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Cobimetinib + Resection + Vemurafenib		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	HLX208		Recruiting	NCT05065398		ECD	2023Jun30	Yes	No		4	NCT05065398			Overall Response Rate	20	20																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Encorafenib		Withdrawn	NCT02109653		ECD	2017Nov01	Yes	No		4	NCT02109653			Overall Response Rate	0	0																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 3	Atezolizumab + Cobimetinib + Vemurafenib		Recruiting	NCT03178552	B-FAST Cohort E	ECD	2024Apr27	Yes	No		4	NCT03178552			Unknown	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Dabrafenib + Trametinib	Required	Completed	NCT01336634	BRF113928	PCD	2015Oct01	Yes	Yes		1	29438093	Previously-treated		Overall Response Rate	57	57		Dabrafenib	63				12.6																							2	36										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Dabrafenib + Trametinib	Required	Completed	NCT01336634	BRF113928	PCD	2015Oct01	Yes	Yes		1	29438093	Untreated		Overall Response Rate	36	36			61																											1	21										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Dabrafenib + Trametinib		Unknown	NCT03543306		ECD	2020Jun30	Yes	No		4	NCT03543306			Overall Response Rate	27	27																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Vemurafenib		Completed		EURAF			Yes	Yes		1	26200454			Unknown	25	25			54																		96									2	11	10									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Vemurafenib		Completed	NCT01524978	VE-BASKET	PCD	2016Oct28	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.9074 	Untreated		Best overall response	8	8			37.5																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Vemurafenib		Completed	NCT01524978	VE-BASKET	PCD	2016Oct28	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.9074 	Previously-treated		Best overall response	54	54			37								12.9																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Binimetinib + Encorafenib		Recruiting	NCT05195632	OCEANII	ECD	2025Mar01	Yes	No		4	NCT05195632			Overall Response Rate	55	55																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Dabrafenib + Trametinib		Recruiting	NCT04452877		ECD	2023Oct02	Yes	Yes	55% SAE	2	10.1016/j.jtho.2022.07.734			Overall Response Rate	18	18			75		50.9-91.3																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Dabrafenib + Trametinib		Completed	NCT04775095	BLaDE	PCD	2021Dec31	Yes	No		4	NCT04775095	Previously-treated		Overall survival	163	163																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600E and CD274_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	HLX208 + Serplulimab		Not yet recruiting	NCT05641493		ECD	2025Mar04	Expression confirmed	No		4	NCT05641493			Overall Response Rate	49	49																																									COSO29915674	2023Jan06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_V600G	56080151		p.V600G	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Completed	NCT01524978	VE-BASKET	PCD	2016Oct28	Yes	Yes		1	26287849			Best overall response	5	5																																1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Naporafenib + Ribociclib		"Active, not recruiting"	NCT02974725		ECD	2023Apr25	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	241	241																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	RO4987655		Unknown					Yes	No		1	24947927			Unknown	17	17																															4										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LTT462 + Naporafenib		"Active, not recruiting"	NCT02974725		ECD	2023Apr25	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	241	241																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Naporafenib + Trametinib		"Active, not recruiting"	NCT02974725		ECD	2023Apr25	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	241	241																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sorafenib		Completed	NCT00098540		PCD	2007May01	Yes	No		4	NCT00098540			Response rate	46	46																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	BGB-3245 + Mirdametinib		Recruiting	NCT05580770	Dose expansion C	ECD	2026Oct31	Yes	No		4	NCT05580770			Overall Response Rate	136	136																																									COSO29915674	2023Jan05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified and EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Gemcitabine + Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2023Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified or DDR2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dasatinib		Terminated	NCT01514864		PCD	2014Jul01	Yes	Yes	"Slow accrual, Lack of efficacy"	4	NCT01514864			Overall Response Rate	19	19																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified or HRAS_unspecified or KRAS_unspecified or NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT01306045	Arm 4	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	9	9																																									COSO29915674	2022Dec15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRAF	BRAF_unspecified or NRAS_unspecified or KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Completed	NCT02276027		PCD	2019Oct15	Yes	Yes		4	NCT02276027			Overall Response Rate	22	22			9.1																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Gemcitabine + Veliparib		Terminated	NCT01282333		PCD	2013Feb01	No	No		4	NCT01282333			Maximum tolerated dose/toxicity	44	44																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Rucaparib		"Active, not recruiting"	NCT03845296		PCD	2022Jan01	Yes	Yes	Lack of efficacy	2	10.1200/JCO.2021.39.15_suppl.9024	Previously-treated		Overall Response Rate	23	23			13																																						COSO29915674	2022Dec02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified or ATM_unspecified or BARD1_unspecified or BRIP1_unspecified or CDK12_unspecified or CHEK2_unspecified or FANCA_unspecified or NBN_unspecified or PALB2_unspecified or RAD51C_unspecified or RAD51D_unspecified or RAD51_unspecified or RAD54L_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib		Recruiting	NCT04276376	ARIANES cohort 1a	ECD	2024Apr01	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																									COSO29915674	2022Dec02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified or CD274_unspecified or ERCC1_unspecified or KEAP1_unspecified or SLFN11_unspecified or STK11_unspecified or TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Durvalumab		Recruiting	NCT05568212	Arm A	ECD	2024May01	No	No		4	NCT05568212	Previously-treated		Overall survival	176			Chemotherapy																																							COSO29915674	2023Jan05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified or CD274_unspecified or ERCC1_unspecified or KEAP1_unspecified or SLFN11_unspecified or STK11_unspecified or TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Durvalumab + Platinum-doublet chemotherapy		Recruiting	NCT05568212	Arm D	ECD	2024May01	No	No		4	NCT05568212	Previously-treated		Overall survival	176			Chemotherapy																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
BRCA1	BRCA1_unspecified or BRCA2_unspecified or CD274_unspecified or ERCC1_unspecified or KEAP1_unspecified or SLFN11_unspecified or STK11_unspecified or TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Durvalumab + Olaparib + Platinum-doublet chemotherapy		Recruiting	NCT05568212	Arm C	ECD	2024May01	No	No		4	NCT05568212	Previously-treated		Overall survival	176			Chemotherapy																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CBL	CBL_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		"Active, not recruiting"	NCT02219711		PCD	2022Apr27	Yes	Yes		4	NCT02219711			Maximum tolerated dose/toxicity	2	2																															1										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	CCDC6-RET_fusion COSF1271				lung / carcinoma / non small cell carcinoma	4	Case study	Docetaxel + Nintedanib		Completed	NCT00876460		PCD	2012Sep01	Yes	Yes		4	NCT00876460			Maximum tolerated dose/toxicity	1	1																																1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CCND1	CCND1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort C4	ECD	2023Mar01	Overexpression	Yes		1	32669708			"ORR, PFS, DOR"	18	18											3.7			2.3-6.5																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CCND1	CCND1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		Completed	NCT02785939		PCD	2017Jun01	Overexpression	Yes	Primary outcome not met	1	31302234	Previously-treated			26	26																															2										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CCND2	CCND2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		Completed	NCT02785939		PCD	2017Jun01	Overexpression	Yes	Primary outcome not met	1	31302234	Previously-treated			3	3																															0										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CCND3	CCND3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		Completed	NCT02785939		PCD	2017Jun01	Overexpression	Yes	Primary outcome not met	1	31302234	Previously-treated			2	2																															0										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Ipilimumab + Nivolumab	Required	"Active, not recruiting"	NCT02477826	CheckMate 227 Part 1a PD-L1 tumor expression >1%	ECD	2024Aug29	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf	Untreated		"OS, PFS"	793	396	397	Carboplatin + Paclitaxel or Pemetrexed	36	30			23.2	6.2			5.1	5.6	0.82	0.69-0.97										17.1	14.9	0.79	0.67-0.94	0.0066													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Carboplatin + Paclitaxel or Nab-paclitaxel + Pembrolizumab	Not required	"Active, not recruiting"	NCT02775435	KEYNOTE-407	PCD	2018Apr03	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Untreated		"OS, PFS"	559	278	281	Chemotherapy	58	35		0.0008	7.2	4.9			6.4	4.8	0.56	0.45-0.70	<0.0001									15.9	11.3	0.64	0.49-0.85	0.0017													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab + Platinum-doublet chemotherapy	Not required	"Active, not recruiting"	NCT02998528	CHECKMATE-816	PCD	2021Sep08	No	Yes	"EFS m 31.6 v 20.8 HR 0.63 95%CI 0.45-0.87 p=0.0052, pCR 24.0 v 2.2% p<0.0001"	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf			"CR, EFS"	358	179	179	Platinum-doublet chemotherapy																								0.57	0.38-0.87														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Chemotherapy + Ipilimumab + Nivolumab	Required	"Active, not recruiting"	NCT03215706	CheckMate 9LA	PCD	2019Aug16	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s114lbl.pdf	Untreated		Overall survival	719	361	358	Chemotherapy	38	25		0.0003	10	5.1			6.8	5	0.7	0.57-0.86	0.0001									14.1	10.7	0.69	0.55-0.87	0.0006													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Atezolizumab + Carboplatin + Paclitaxel	Not required	Completed	NCT02366143	IMpower150 Arm A	PCD	2019Sep13	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf			"OS, PFS"	686	349	337	Bevacizumab + Carboplatin + Paclitaxel	43	42			9.5	6.5			6.7	7	0.94	0.79-1.13	0.5219									19.4	14.7	0.84	0.72-1.08	0.204													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Cemiplimab	Required	"Active, not recruiting"	NCT03088540	Study 1624	ECD	2024Apr30	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf			"OS, PFS"	712	356	354	Platinum-based chemotherapy	37	21			21	6			6.2	5.6	0.59	0.49-0.72	<0.0001									22.1	14.3	0.68	0.53-0.87	0.0022													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Atezolizumab + Chemotherapy	Required	"Active, not recruiting"	NCT02486718	IMpower010 PD-L1 TC ?1% group	ECD	2023Dec01	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	470	248	228	Chemotherapy																																35.3	0.66	0.5-0.88	0.004				COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab + Pemetrexed + Platinum-based chemotherapy	Not required	"Active, not recruiting"	NCT02578680	KEYNOTE-189 	PCD	2017Nov08	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Untreated		"OS, PFS"	616	410	206	Pemetrexed + Placebo + Platinum-based chemotherapy	48	19		<0.0001	11.2	7.8			8.8	4.9	0.52	0.43-0.64	<0.0001										11.3	0.49	0.38-0.64	<0.0001													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Atezolizumab	Not required	Completed	NCT02008227	OAK	PCD	2016Jul07	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	Previously-treated		Overall survival	850	425	425	Docetaxel	58	57			16.3	6.2			2.8	4	0.95	0.82-1.10										13.8	9.6	0.74	0.63-0.87	0.0004													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Atezolizumab	Not required	Completed	NCT02409342	IMpower110 High PD-L1 	PCD	2020Feb04	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	Untreated		Overall survival	205	107	98	Atezolizumab + Cisplatin or carboplatin + Pemetrexed or Gemcitabine	38	29							8.1	5	0.63	0.449-0.884										20.2	13.1	0.59	0.4-0.89	0.0106													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01673867	CHECKMATE-057 PD-L1 < 10%	PCD	2015Feb05	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf			Overall survival	455	165	290	Docetaxel																						19.4	8	0.4															COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01673867	CHECKMATE-057 PD-L1 < 5%	PCD	2015Feb05	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf			Overall survival	455	181	274	Docetaxel																						18.2	8.1	0.43															COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01673867	CHECKMATE-057 PD-L1 < 1%	PCD	2015Feb05	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf			Overall survival	455	246	209	Docetaxel																						17.1	9	0.59															COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01673867	CHECKMATE-057	PCD	2015Feb05	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf			Overall survival	582	292	290	Docetaxel	19	12		0.02	17	6			2.3	4.2	0.92	0.77-1.11	0.39									12.2	9.4	0.73	0.60-0.89	0.0015													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01642004	CHECKMATE-017 PD-L1 -	PCD	2014Nov17	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf	Previously-treated		Overall survival				Docetaxel																								0.69	0.45-1.05														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01642004	CHECKMATE-017 PD-L1 +	PCD	2014Nov17	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf	Previously-treated		Overall survival				Docetaxel																								0.58	0.37-0.92														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Nivolumab	Not required	Completed	NCT01642004	CHECKMATE-017	PCD	2014Nov17	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf	Previously-treated		Overall survival	272	135	137	Docetaxel	20	9		0.0083		8.4			3.5	2.8	0.62	0.47-0.81	0.0004									9.2	6	0.59	0.44-0.79	0.0002													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Atezolizumab + Carboplatin + Nab-paclitaxel	Not required	Completed	NCT02367781	IMpower130	PCD	2018Mar15	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf			"OS, PFS"	681	453	228	Carboplatin + Nab-paclitaxel	46	32			10.8	7.8			7.2	6.5	0.75	0.63-0.91	0.0024									18.6	13.9	0.8	0.64-0.99	0.0384													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	Not required	Completed	NCT02366143	IMpower150 Arm B	PCD	2019Sep13	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf			"OS, PFS"	696	359	337	Bevacizumab + Carboplatin + Paclitaxel	55	42			10.8	6.5			8.5	7	0.71	0.59-0.85	0.0002									19.2	14.7	0.78	0.64-0.96	0.016													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT01905657	KEYNOTE-010 PD-L1 TPS >1%	PCD	2015Sep30	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Previously-treated		"OS, PFS"	349	156	193	Docetaxel	19	9		<0.001					4	4	0.79	0.66-0.94	0.005									12.7	8.5	0.61	0.49-0.75	<0.001													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT01905657	KEYNOTE-010 PD-L1 TPS >1%	PCD	2015Sep30	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Previously-treated		"OS, PFS"	365	172	193	Docetaxel	18	9		<0.001					3.9	4	0.88	0.73-1.04	0.068									10.4	8.5	0.71	0.58-0.88	<0.001													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT01905657	KEYNOTE-010 PD-L1 TPS >50%	PCD	2015Sep30	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Previously-treated		"OS, PFS"	303	151	152	Docetaxel	29	8		<0.001		8.1			5.2	4.1	0.59	0.45-0.78	<0.001									17.3	8.2	0.5	0.36-0.70	<0.001													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT01905657	KEYNOTE-010 PD-L1 TPS >50%	PCD	2015Sep30	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Previously-treated		"OS, PFS"	291	139	152	Docetaxel	30	8		<0.001		8.1			5.2	4.1	0.58	0.43-0.77	<0.001									14.9	8.2	0.54	0.38-0.77	<0.001													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT02142738	KEYNOTE-024	PCD	2016May09	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Untreated		Progression free survival	305	154	151	Chemotherapy	45	28		0.001		6.3			10.3	6	0.5	0.37-0.68	<0.001									30	14.2	0.6	0.41-0.89	0.005													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT02220894	KEYNOTE-042 PD-L1 TPS >50%	PCD	2018Feb26	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Untreated		Overall survival	599	299	300	Carboplatin + Paclitaxel or Pemetrexed	39	32							6.9	6.4	0.82	0.68-0.99										20	12.2	0.69	0.56-0.85	0.0006													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Pembrolizumab	Required	Completed	NCT02220894	KEYNOTE-042 PD-L1 TPS >1%	PCD	2018Feb26	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf	Untreated		Overall survival	1274	637	637	Carboplatin + Paclitaxel or Pemetrexed	27	27							5.4	6.5	1.07	0.94-1.21										16.7	12.1	0.81	0.71-0.93	0.0036													COSO29915674	2022Nov30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Observational	Pembrolizumab		Completed	NCT05321212	PEMBREIZH	PCD	2019Jan02	Expression confirmed	No		4	NCT05321212			Progression free survival	108	108																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT02007070	KEYNOTE-025	PCD	2015Jul09	Expression confirmed	Yes		4	NCT02007070			Overall Response Rate	11	11			27.3		6.0-61.0						4.1			1.6-19.1										17.9			-5.9														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Atezolizumab + GDC-1971 + Omeprazole		Recruiting	NCT05487235		ECD	2025May31	Expression confirmed	No		4	NCT05487235			Maximum tolerated dose/toxicity	232	232																																									COSO29915674	2022Sep23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Carboplatin + Durvalumab + Paclitaxel + Papaverine + Radiotherapy		Recruiting	NCT05136846		ECD	2023Dec31	No	No		4	NCT05136846			Maximum tolerated dose/toxicity	28	28																																									COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Interleukin-2 + Pembrolizumab		Not yet recruiting	NCT05493566		ECD	2024Jan07	Expression confirmed	No		4	NCT05493566			Immune response	15	15																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Autologous PD-L1/CD80/CD86-targeted CAR-T cells		Unknown	NCT03060343		ECD	2018Nov28	No	No		4	NCT03060343			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022Jul26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	AZD7789		Recruiting	NCT04931654		ECD	2025Jan23	No	No		4	NCT04931654			Maximum tolerated dose/toxicity	81	81																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab + Venetoclax		Terminated	NCT04274907		PCD	2021Feb02	Overexpression	Yes	Changed business priorities	4	NCT04274907			Tumour volume	2	2																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	IMU-201		Recruiting	NCT04432207	IMPRINTER	ECD	2022Dec01	No	No		4	NCT04432207			Maximum tolerated dose/toxicity	22	22																																									COSO29915674	2022Sep21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Durvalumab + Sirolimus		"Active, not recruiting"	NCT04348292		ECD	2023Dec25	No	No		4	NCT04348292			"Complete response, Pathological complete response"	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Ipilimumab + Nivolumab + Stereotactic radiotherapy		Recruiting	NCT03223155	COSINR	ECD	2022Dec01	No	No		4	NCT03223155			Maximum tolerated dose/toxicity	80	80																																									COSO29915674	2022Jul22	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Anlotinib + CBT-502		Unknown	NCT03910127		ECD	2020Dec31	No	Yes	SAE 67.7 v 21.2	3	https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress/the-efficacy-and-safety-of-tq-b2450-alone-with-anlotinib-in-previously-treated-advanced-non-small-cell-lung-cancer-nsclc-a-multicenter-randomiz	Previously-treated		Progression free survival	101	68	33	CBT-502 + Placebo	30.9	3		0.0043					6.9	2.7	0.43	0.25-0.73	0.0014																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	ASP1951 + Pembrolizumab		"Active, not recruiting"	NCT03799003		ECD	2023Aug31	No	No		4	NCT03799003			Maximum tolerated dose/toxicity	120	120																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Ipilimumab + Nivolumab + Radiotherapy		Recruiting	NCT04013542		ECD	2023Jun29	No	No		4	NCT04013542			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	RO7121661		"Active, not recruiting"	NCT03708328	Part B3	ECD	2023Feb11	Expression confirmed	No		4	NCT03708328	Untreated		"ORR, PFS, DOR"	134	134																																									COSO29915674	2022Jun27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	RO7121661		"Active, not recruiting"	NCT03708328	Part B2	ECD	2023Feb11	Expression confirmed	No		4	NCT03708328	Previously-treated		"ORR, PFS, DOR"	134	134																																									COSO29915674	2022Jun27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	IBI323		Recruiting	NCT04916119	Cohort C	ECD	2023Jun23	No	No		2	NCT04916119			Maximum tolerated dose/toxicity	322	322																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Cyclophosphamide + Fludarabine + PD-L1 CAR-T cells		Terminated	NCT03330834		PCD	2020Apr14	Expression confirmed	Yes	Serious adverse events	4	NCT03330834			Maximum tolerated dose/toxicity	1	1																																									COSO29915674	2022Oct24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Anetumab Ravtansine + Atezolizumab		Terminated	NCT03455556		PCD	2019Sep11	No	Yes	Slow accrual	4	NCT03455556			Overall Response Rate	1	1																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	ES101		Terminated	NCT04009460		PCD	2022Apr22	No	Yes	Changed business priorities	4	NCT04009460			Maximum tolerated dose/toxicity	22	22																																									COSO29915674	2022Jun01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	GAd-PEV + MVA-PEV		Recruiting	NCT04990479	Cohort 2b	ECD	2024Oct31	Expression confirmed	No		4	NCT04990479			Clinical activity	34	34																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Atezolizumab + Chemotherapy		Completed	NCT01633970		PCD	2020Feb26	Expressed/not	Yes	No difference in OS or PFS	1	30053670			Maximum tolerated dose/toxicity	48	31	17		45.2	41.2			7.4	9.5			5.6	6												15	12.9																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Ociperlimab + Tislelizumab		Recruiting	NCT04047862	Cohort 10	ECD	2024May01	Expression confirmed	No		4	NCT04047862			Overall Response Rate	542	542																																									COSO29915674	2022Jun07	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Ociperlimab + Tislelizumab		Recruiting	NCT04047862	Cohort 3	ECD	2024May01	Expression confirmed	No		4	NCT04047862			Overall Response Rate	542	542																																									COSO29915674	2022Jun07	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab + Stereotactic Body Radiation Therapy		Terminated	NCT03436056	PRIMING	PCD	2019Jul08	No	No		4	NCT03436056			Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Durvalumab		Completed	NCT01693562		PCD	2020Feb28	No	Yes		4	NCT01693562	Previously-treated		Overall Response Rate	68	68			10.3		4.2-20.1		17.74		5.6-38.0																																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01295827	KEYNOTE-001 PS <1% Validation Set	PCD	2018Nov05	Expression confirmed	Yes		1	25891174			Overall Response Rate	28	28			10.7		2.3-28.2						4			2.1-6.2										10.4			-5.8														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01295827	KEYNOTE-001 PS <1% Training Set	PCD	2018Nov05	Expression confirmed	Yes		1	25891174			Overall Response Rate	40	40			10		2.8-23.7						2.1			1.8-2.5										6.7			3.9-10.0														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01295827	KEYNOTE-001 PS 1-49% Validation Set	PCD	2018Nov05	Expression confirmed	Yes		1	25891174			Overall Response Rate	103	103			16.5		9.9-25.1						4.1			2.3-4.4										10.6			-7.3														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01295827	KEYNOTE-001 PS 1-49% Training Set	PCD	2018Nov05	Expression confirmed	Yes		1	25891174			Overall Response Rate	43	43			9.3		2.6-22.1		7.2		4.6-8.3		2.1			2.0-2.9										5.9			4.2-8.2														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01295827	KEYNOTE-001 PS ?50% Validation Set	PCD	2018Nov05	Expression confirmed	Yes		1	25891174			Overall Response Rate	73	73			45.2		33.5-57.3						6.4			-4.2																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01295827	KEYNOTE-001 PS ?50% Training Set	PCD	2018Nov05	Expression confirmed	Yes		1	25891174			Overall Response Rate	38	38			34.2		19.6-51.4		23.3		2.1-23.3		4.5			1.9-12.5										13.7			-6.9														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ipilimumab + Nivolumab		Completed	NCT02659059	CheckMate 568 Part 1 PD-L1 >=1/<1%	PCD	2018Jun22	Expressed/not	Yes		4	NCT02659059	Untreated		Overall Response Rate	252	138	114		41.3	14.9							6.77	2.79													12.85																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Fecal Microbiota Transplant + Pembrolizumab		Not yet recruiting	NCT05669846		ECD	2025Jan01	Expression confirmed	No		4	NCT05669846	Previously-treated		Overall Response Rate	26	26																																									COSO29915674	2023Jan13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	LBL-007 + Tislelizumab		Not yet recruiting	NCT05635708	Arm 1B	ECD	2025Nov01	No	No		4	NCT05635708	Untreated		Overall Response Rate	300			Tislelizumab																																							COSO29915674	2023Jan13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	BGB-A445 + Tislelizumab		Not yet recruiting	NCT05635708	Arm 1A	ECD	2025Nov01	No	No		4	NCT05635708	Untreated		Overall Response Rate	300			Tislelizumab																																							COSO29915674	2023Jan13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dostarlimab + EOS884448		Recruiting	NCT05565378		ECD	2024Oct17	Expression confirmed	No		4	NCT05565378	Untreated		Overall Response Rate	300			Pembrolizumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	BNT116 + Cemiplimab		Not yet recruiting	NCT05557591	Arm B	ECD	2027Apr16	Expression confirmed	No		4	NCT05557591	Untreated		Overall Response Rate	107	107																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Tislelizumab + Tucidinostat		Not yet recruiting	NCT05519865		ECD	2023Oct01	Expression confirmed	No		4	NCT05519865	Untreated		Progression free survival	114	114																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Envafolimab + Pemetrexed		Not yet recruiting	NCT05465733		ECD	2025Jun30	Expression confirmed	No		4	NCT05465733			Progression free survival	25	25																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Axitinib + Erfonrilimab		Recruiting	NCT05420220		ECD	2023Mar29	Expression confirmed	No		4	NCT05420220	Untreated		Overall Response Rate	54	54																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab or Atezolizumab or Cemiplimab + Sargramostim + UV1 telomerase peptide vaccine		Recruiting	NCT05344209	LUNGVAC	ECD	2025Jul01	Expression confirmed	No		4	NCT05344209			Progression free survival	138	138																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	GRN-1201 + Pembrolizumab		"Active, not recruiting"	NCT03417882		ECD	2023Mar01	Expression confirmed	No		4	NCT03417882			Response rate	20	20																																									COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Sasanlimab		"Active, not recruiting"	NCT04181788		PCD	2022Mar03	No	No		4	NCT04181788			Overall Response Rate	155	155																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Avelumab + Platinum-doublet chemotherapy		Unknown	NCT03480230		ECD	2022Nov01	No	Yes	Primary outcome not met	1	32991781			Overall Response Rate	15	15																														1	3										COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin or carboplatin + Nivolumab + Pemetrexed + TG4010		Completed	NCT03353675		PCD	2019Nov20	No	Yes		4	NCT03353675			Overall Response Rate	40	40			32.5		20.4-46.6		17.29		4.48-21.37		5.7			1.5-11.1							75			14.9			-8														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pegilodecakin + Pembrolizumab		Terminated	NCT03382899		PCD	2019Dec06	No	Yes	SAE 62 v 19%	2	10.1200/JCO.2020.38.15_suppl.9563	Untreated		Overall Response Rate	101	51	50	Pembrolizumab	53	46		0.78					6.4	7.2	1.1	0.62-1.96	0.74									16.3		1.36	0.66-2.77	0.4													COSO29915674	2022Sep16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin or carboplatin + Durvalumab + Oral Restorative Microbiota Therapy + Pemetrexed		Not yet recruiting	NCT04105270		ECD	2028Jan01	Expression confirmed	No		4	NCT04105270	Untreated		Progression free survival	82																																										COSO29915674	2022Jul28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Zalifrelimab		Terminated	NCT03411473		PCD	2018May01	Expression confirmed	Yes	Changed treatment landscape	4	NCT03411473			Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Capmatinib + Pembrolizumab		"Active, not recruiting"	NCT04139317		PCD	2022Jan14	Expression confirmed	Yes	"SAE 37.3 v 16%, Primary outcome not met"	2	10.1200/JCO.2022.40.16_suppl.9118			Progression free survival	76	51	25	Pembrolizumab	15.7	28							6.3	4.3									56.9	56																			COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Nivolumab + Pembrolizumab		"Active, not recruiting"	NCT03228667	QUILT-3.055 Cohort 2	ECD	2023May01	Expression confirmed	No		4	NCT03228667			Overall Response Rate	145	145																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Linrodostat + Nivolumab		Terminated	NCT02750514	FRACTION-Lung Track 1	PCD	2020Jan29	Expression confirmed	Yes	Standard of care changed	4	NCT02750514			Overall Response Rate	0			Nivolumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Endostatin + Envafolimab		Not yet recruiting	NCT05203276		ECD	2023Jan23	Expression confirmed	No		4	NCT05203276			Overall Response Rate	40	40																																									COSO29915674	2022Jul26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Autologous activated NK cells + Sintilimab		Unknown	NCT03958097		ECD	2020May16	No	No		4	NCT03958097			Progression free survival	20	20																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin or carboplatin + Durvalumab + Pemetrexed or Vinorelbine + Radiotherapy		Recruiting	NCT04765709	BRIDGE	ECD	2026Jun01	No	No		4	NCT04765709			Progression free survival	65	65																																									COSO29915674	2022Jul21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	IO102 + Pembrolizumab		Completed	NCT03562871	KEYNOTE-764 Cohort A	PCD	2021Feb06	No	Yes in vitro		4	NCT03562871	Untreated		Overall Response Rate	109			Pembrolizumab																																							COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + IO102 + Pembrolizumab + Pemetrexed		Completed	NCT03562871	KEYNOTE-764 Cohort B	PCD	2021Feb06	No	Yes in vitro		4	NCT03562871	Untreated		Overall Response Rate	109			Carboplatin + Pembrolizumab + Pemetrexed																																							COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Mocetinostat		Terminated	NCT02805660		PCD	2019Dec14	Expressed/not	Yes	Changed business priorities	4	NCT02805660			Overall Response Rate	18	3	15		0	6.7							4	3									0	26.7																			COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bintrafusp alfa + Docetaxel		"Active, not recruiting"	NCT04396535		ECD	2023Dec01	No	No		4	NCT04396535			Progression free survival	80	80		Bintrafusp alfa																																							COSO29915674	2022Jul19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Pemetrexed		Recruiting	NCT04396457	CJLSG1901	ECD	2023May01	Expression confirmed	No		4	NCT04396457		Geriatric	Overall Response Rate	50	50																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ipilimumab + Nivolumab + Platinum-doublet chemotherapy		Completed	NCT02659059	CheckMate 568 Part 2	PCD	2018Jun22	No	Yes		4	NCT02659059	Untreated		Overall Response Rate	36	36			44.4		27.9-61.9						8.74			5.26-13.83																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Eribulin + Pembrolizumab		Completed	NCT03222856	KELLY	PCD	2018Oct31	No	Yes	SAE 31.8%	1	33794440			"Disease control rate, Clinical benefit rate"	44	44			40.9		26.3-56.8						6			3.7-8.4							56.8																				COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Tumor treating fields		Recruiting	NCT04892472	Keynote B36	ECD	2024Jul01	Expression confirmed	No		4	NCT04892472			Overall Response Rate	66	66																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Chemotherapy + Durvalumab + Radiotherapy		Recruiting	NCT04392505	DART	ECD	2023May01	Expressed/not	No		4	NCT04392505			Maximum tolerated dose/toxicity	100	100																																									COSO29915674	2022Jun28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Nivolumab + Stereotactic Body Radiation Therapy		Unknown	NCT03383302		ECD	2021Jun01	No	No		4	NCT03383302	Untreated		Maximum tolerated dose/toxicity	31	31																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Standard of care		"Active, not recruiting"	NCT04093167		ECD	2022Dec31	Expression confirmed	No		4	NCT04093167	Untreated		Complete molecular response	50	50																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Vactosertib		Recruiting	NCT04515979		ECD	2022Aug01	Expression confirmed	No		4	NCT04515979	Untreated		Overall Response Rate	55	55																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + PULSAR		Not yet recruiting	NCT04889066		ECD	2025Jan01	No	No		4	NCT04889066			"Disease control rate, Clinical benefit rate"	46	46		Durvalumab + Stereotactic radiotherapy																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Hypofractionated radiotherapy		Recruiting	NCT04351256	TRADE-hypo	ECD	2023Mar01	No	No		4	NCT04351256		Geriatric	Overall Response Rate	88			Durvalumab + Radiotherapy																																							COSO29915674	2022Jun24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Platinum-based chemotherapy + Tislelizumab		Recruiting	NCT05244837		ECD	2022Jul01	No	Yes	pCR 48.1%	2	10.1016/j.jtho.2022.07.493			Maximum tolerated dose/toxicity	27	27																																									COSO29915674	2022Dec02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	MK-0482 + Pembrolizumab		Recruiting	NCT04165083	KEYMAKER-U01B	ECD	2032Feb13	Expression confirmed	No		4	NCT04165083			Overall Response Rate	120	120																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	MK-4830 + Pembrolizumab		Recruiting	NCT04165083	KEYMAKER-U01B	ECD	2032Feb13	Expression confirmed	No		4	NCT04165083			Overall Response Rate	120	120																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Glumetinib + Toripalimab		Recruiting	NCT04797702	CT32	ECD	2023Jul31	No	No		4	NCT04797702	Previously-treated		Overall Response Rate	67	67																																									COSO29915674	2022Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + GB1211		Recruiting	NCT05240131		ECD	2023Jul30	No	No		4	NCT05240131			Tumour volume	102			Atezolizumab + Placebo																																							COSO29915674	2022Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	IO102 + IO103 + Pembrolizumab		Recruiting	NCT05077709	Arm A	ECD	2023Apr30	No	No		4	NCT05077709			"PFS, ORR"	90	90																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Axitinib + SEA-TGT + Sasanlimab		Recruiting	NCT04585815	Landscape 1011	ECD	2025Jan04	No	No		4	NCT04585815			Overall Response Rate	375	375																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Binimetinib + Encorafenib + Sasanlimab		Recruiting	NCT04585815	Landscape 1011	ECD	2025Jan04	No	No		4	NCT04585815			Overall Response Rate	375	375																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Sitravatinib		Recruiting	NCT04925986		ECD	2025Feb01	Expression confirmed	No		4	NCT04925986			Overall Response Rate	70	70																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Radiotherapy		"Active, not recruiting"	NCT03523702	SPRINT 	ECD	2022Nov18	Expression confirmed	Yes	PFS 1y 74%	2	10.1200/JCO.2022.40.16_suppl.8510			Progression free survival	25	25			48																											1	11										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Accelerated Hypofractionated Radiation Therapy + Durvalumab		"Active, not recruiting"	NCT03801902	ARCHON-1	PCD	2021Oct26	Expression confirmed	Yes	Primary outcome met	2	10.1200/JCO.2022.40.16_suppl.8513			Maximum tolerated dose/toxicity	26			Durvalumab + Radiotherapy																																							COSO29915674	2023Jan26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Niraparib + Pembrolizumab		Completed	NCT03308942	Cohort 2	PCD	2020May04	Expression confirmed	Yes		4	NCT03308942			Overall Response Rate	20	20			20		5.7-43.7		9.4		5.2-13.8		4.2			2.0-6.2							70																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Niraparib + Pembrolizumab		Completed	NCT03308942	Cohort 1	PCD	2020May04	Expression confirmed	Yes		4	NCT03308942			Overall Response Rate	16	16			56.3		29.9-80.2		19.7		10.1-22.8		8.4			3.9-24.6							87.5																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Denosumab + Nivolumab		"Active, not recruiting"	NCT03669523	DENIVOS	ECD	2023Dec31	No	No		4	NCT03669523	Previously-treated		Overall Response Rate	82	82																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bevacizumab + Camrelizumab		Terminated	NCT03666728		PCD	2020Mar11	Expression confirmed	Yes	Changed business priorities	4	NCT03666728			"PFS, ORR"	5	5																																									COSO29915674	2022Jun13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	GEN1046 + Pembrolizumab		Recruiting	NCT05117242		ECD	2024Mar01	No	No		4	NCT05117242	Previously-treated		Overall Response Rate	160	160																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	GEN1046		Recruiting	NCT05117242		ECD	2024Mar01	No	No		4	NCT05117242	Previously-treated		Overall Response Rate	160	160																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Azacitidine oral + Pembrolizumab		"Active, not recruiting"	NCT02546986		PCD	2017Apr13	No	No		1	30654297			Progression free survival	100	51	49	Pembrolizumab + Placebo	20	14							2.9	4	1.374											11.9		1.375															COSO29915674	2022Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Anlotinib + Pembrolizumab		Unknown	NCT04164745		ECD	2021Nov16	Expression confirmed	No		4	NCT04164745	Untreated		Progression free survival	49	49																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Nab-paclitaxel + Nivolumab		Recruiting	NCT04015778		ECD	2020Aug01	No	No		4	NCT04015778			Major pathologic response	48			Nivolumab																																							COSO29915674	2022Jun09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Chemotherapy + Pembrolizumab + Radiotherapy		Not yet recruiting	NCT05501665		ECD	2025Oct01	No	No		4	NCT05501665			Best overall response	25			Chemotherapy + Pembrolizumab																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Docetaxel + Pembrolizumab + Ramucirumab		Recruiting	NCT04340882	TaxRamPem	ECD	2023Jun30	No	No		4	NCT04340882			Progression free survival	41	41																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Domvanalimab + Etrumadenant + Zimberelimab		Recruiting	NCT04791839		ECD	2024Nov30	Expressed/not	No		4	NCT04791839			Overall Response Rate	30	30																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Domvanalimab + Etrumadenant + Zimberelimab		"Active, not recruiting"	NCT04262856	ARC-7 Arm 3	ECD	2024Feb01	Expression confirmed	No		4	NCT04262856			"PFS, ORR"	150	150																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Domvanalimab + Zimberelimab		"Active, not recruiting"	NCT04262856	ARC-7 Arm 2	ECD	2024Feb01	Expression confirmed	No		4	NCT04262856			"PFS, ORR"	150	150																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Cibisatamab		Recruiting	NCT03337698	Morpheus Lung	ECD	2024Apr12	Expression confirmed	No		4	NCT03337698			Overall Response Rate	435			Atezolizumab																																							COSO29915674	2022Jun08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AZD2936		Recruiting	NCT04995523	ARTEMIDE-01	ECD	2023Dec07	Expression confirmed	No		4	NCT04995523	Untreated			147	147		Cisplatin + Gemcitabine + Radiotherapy																																							COSO29915674	2022Jun08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AZD2936		Recruiting	NCT04995523	ARTEMIDE-01	ECD	2023Dec07	Expression confirmed	No		4	NCT04995523	Previously-treated		Overall Response Rate	147	147																																									COSO29915674	2022Jun08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Radiotherapy		Recruiting	NCT04716946		ECD	2023Feb01	No	No		4	NCT04716946			Progression free survival	40	40																																									COSO29915674	2022Jul19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Axitinib + Toripalimab		Not yet recruiting	NCT04459663		ECD	2023Sep30	No	No		4	NCT04459663			Overall Response Rate	50	50																																									COSO29915674	2022Jun07	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Itacitinib + Pembrolizumab		Terminated	NCT03425006		PCD	2021Jun17	Expression confirmed	Yes	Administrative reasons	4	NCT03425006			Response rate	31	31																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	NC318 + Pembrolizumab		Recruiting	NCT04699123	Arm 2	ECD	2025Jun01	No	No		4	NCT04699123	Untreated		Overall Response Rate	141	141																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	NC318 + Pembrolizumab		Recruiting	NCT04699123	Arm 1b	ECD	2025Jun01	No	No		4	NCT04699123	Previously-treated		Overall Response Rate	141	141																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	NC318		Recruiting	NCT04699123	Arm 1a	ECD	2025Jun01	No	No		4	NCT04699123	Previously-treated 		Overall Response Rate	141	141																																									COSO29915674	2022Jun07	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin or carboplatin + Nab-paclitaxel + Pemetrexed		Not yet recruiting	NCT04153734	Evolution	ECD	2021Nov30	Expression confirmed	No		4	NCT04153734			Progression free survival	21	21																																									COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Chemotherapy + Tiragolumab		Recruiting	NCT04832854		ECD	2027Feb28	No	No		4	NCT04832854	Untreated		Major pathologic response	82	82																																									COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Camrelizumab + Nab-paclitaxel		Unknown	NCT04167774	Compass-001	ECD	2022Jun30	No	No		4	NCT04167774			Overall Response Rate	62	62																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Nab-paclitaxel + Pembrolizumab		Terminated	NCT02382406		PCD	2022Apr14	No	No		4	NCT02382406			"PFS, ORR"	46	46																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ipilimumab + Pembrolizumab		Completed	NCT03302234	KEYNOTE-598	PCD	2020Sep01	Expression confirmed	Yes		4	NCT03302234			"OS, PFS"	568	284	284	Pembrolizumab + Placebo	45.4	45.4		0.51	16.1	17.3			8.2	8.4	1.06	0.86-1.30	0.717									21.4	21.9	1.08	0.85-1.37	0.742													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Radiotherapy + Tremelimumab		"Active, not recruiting"	NCT02888743		ECD	2022Dec31	No	Yes	Lack of efficacy	1	35033226			Overall Response Rate	52	26	26	Durvalumab + Tremelimumab	7.7	11.5																																					COSO29915674	2022Nov29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Chemotherapy + Durvalumab		Recruiting	NCT04499053		ECD	2023Sep01	No	No		4	NCT04499053			Radiographic response rate	18	18																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Envafolimab		Not yet recruiting	NCT05465733		ECD	2025Jun30	Expression confirmed	No		4	NCT05465733			Progression free survival	25	25																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Envafolimab		"Active, not recruiting"	NCT05055167		ECD	2024Dec30	Expression confirmed	No		4	NCT05055167		Geriatric	Overall Response Rate	20	20																																									COSO29915674	2022Jul27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Carboplatin + Paclitaxel		Unknown	NCT03102242	AFT-16	ECD	2020Mar01	Expressed/not	Yes		2	10.1200/JCO.2020.38.15_suppl.9045	Untreated		"Disease control rate, Clinical benefit rate"	49																						90.9	82.4																			COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Camrelizumab		Unknown	NCT03085069		ECD	2018Sep01	Expression confirmed	Yes	Response correlated with expression status	1	34668977			Overall Response Rate	146	146			17.8		12.0-25.0						3.2			2.0-3.4										14.8			10.2-18.7														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	CIMAvax + Pembrolizumab		Recruiting	NCT02955290	Study C	ECD	2022Dec09	Expression confirmed	No		4	NCT02955290			Overall survival	193	193																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Tiragolumab		Recruiting	NCT04832854		ECD	2027Feb28	No	No		4	NCT04832854	Untreated		Major pathologic response	82	82																																									COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Tiragolumab		"Active, not recruiting"	NCT03563716	CITYSCAPE	PCD	2019Jun30	Expression confirmed	Yes		1	35576957			"PFS, ORR"	135	67	68	Atezolizumab + Placebo	38.8	20.6		0.013					5.6	3.9	0.62	0.42-0.91	0.013																										COSO29915674	2022Jul20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Evolocumab + Ipilimumab + Nivolumab		Recruiting	NCT05144529	TOP2101	ECD	2023Dec01	Expression confirmed	No		4	NCT05144529			Immune cell infiltration	38			Ipilimumab + Nivolumab																																							COSO29915674	2022May31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	LN-145		Recruiting	NCT04614103		ECD	2024Jun01	No	No		4	NCT04614103			Overall Response Rate	95	95																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cemiplimab + Ipilimumab		Terminated	NCT03430063	Arm A	PCD	2021Oct27	No	Yes		2	10.1016/j.annonc.2020.08.1583	Previously-treated		Overall Response Rate	8	8			0		0.0-36.9																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cemiplimab + Ipilimumab		Terminated	NCT03430063	Arm C PD-L1 1-49%	PCD	2021Oct27	Expression confirmed	Yes		2	10.1016/j.annonc.2020.08.1583	Previously-treated		Overall Response Rate	8	8			0																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cemiplimab + Ipilimumab		Terminated	NCT03430063	Arm B PD-L1 1-49%	PCD	2021Oct27	Expression confirmed	Yes		2	10.1016/j.annonc.2020.08.1583	Previously-treated		Overall Response Rate	11	11			9.1																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cemiplimab		Not yet recruiting	NCT05557591	Arm A	ECD	2027Apr16	Expression confirmed	No		4	NCT05557591	Untreated		Overall Response Rate	107	107																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Zimberelimab		"Active, not recruiting"	NCT04262856	ARC-7 Arm 1	ECD	2024Feb01	Expression confirmed	No		4	NCT04262856			"PFS, ORR"	150	150																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Efineptakin alfa		Recruiting	NCT04984811		ECD	2023Sep01	Expression confirmed	No		4	NCT04984811	Untreated		Overall Response Rate	83	83																																									COSO29915674	2022May31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	HLX301		Recruiting	NCT05102214	Cohort A	ECD	2023Mar01	Expression confirmed	No		4	NCT05102214	Previously-treated		"DCR, ORR, DOR"	150	150																																									COSO29915674	2022May27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Lenalidomide + Pembrolizumab		Terminated	NCT02963610		PCD	2017Oct03	No	Yes	Lack of funding	4	NCT02963610			Progression free survival	3	3																																									COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Docetaxel + Nivolumab + Pemetrexed		"Active, not recruiting"	NCT05081674	BLISS	ECD	2023Jun30	Expression confirmed	No		4	NCT05081674			Cost of therapy	154	154																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Docetaxel + Pembrolizumab + Pemetrexed		"Active, not recruiting"	NCT05081674	BLISS	ECD	2023Jun30	Overexpression	No		4	NCT05081674			Cost of therapy	154	154																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dostarlimab		Recruiting	NCT05565378		ECD	2024Oct17	Expression confirmed	No		4	NCT05565378	Untreated		Overall Response Rate	300			Pembrolizumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Recruiting	NCT04563338	INTEGRATE Arm C	ECD	2024Dec05	No	No		4	NCT04563338			Progression free survival	36	36																																									COSO29915674	2022Jul27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT03014648		PCD	2021Dec31	No	No		4	NCT03014648	Previously-treated		Best overall response	28	28																																									COSO29915674	2022Jun08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		"Active, not recruiting"	NCT02927301	LCMC3	PCD	2020May07	Expressed/not	Yes	MPR 29.8 v 13.5% p=0.0395	4	NCT02927301			Major pathologic response	138	57	52		13.3	1.9		0.0358																																			COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT02031458	BIRCH TC2/3 or IC2/3	PCD	2015May28	Expression confirmed	Yes		4	NCT02031458	Previously-treated		Overall Response Rate	520	520			17.3		14.2-20.8				-5.8		5.5			2.7-8.3													-10.4														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT02031458	BIRCH TC2/3 or IC2/3	PCD	2015May28	Expression confirmed	Yes		4	NCT02031458	Untreated		Overall Response Rate	139	139			19.4		13.2-27.0		7.2		-5.7		4.1			2.8-5.4													-12.1														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT02031458	BIRCH TC3 or IC2/3	PCD	2015May28	Expression confirmed	Yes		4	NCT02031458	Previously-treated		Overall Response Rate	483	483			17.8		14.5-21.5		8.5		-5.6		5.6			3.3-8.3											14		-14														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT02031458	BIRCH TC3 or IC2/3	PCD	2015May28	Expression confirmed	Yes		4	NCT02031458	Untreated		Overall Response Rate	123	123			21.1		14.3-29.4		8.4		-6.9		2.8			2.7-3.0													-12.1														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT02031458	BIRCH TC3 or IC3	PCD	2015May28	Expression confirmed	Yes		4	NCT02031458	Previously-treated		Overall Response Rate	237	237			25.35		19.9-31.4		8.5		-5.6		5.5			3.0-6.9											14		-14														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT02031458	BIRCH TC3 or IC3	PCD	2015May28	Expression confirmed	Yes		4	NCT02031458	Untreated		Overall Response Rate	65	65			26.2		16.0-38.5		8.4		-6.9		2.8			2.7-2.9													-11.2														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT01846416	FIR Brain metastases	PCD	2015Jan07	Expression confirmed	Yes		4	NCT01846416			Overall Response Rate	13	13			23		May-54				2.8-9.9		2.5			1.0-11.3										6.8			3.2-19.5														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT01846416	FIR Second line	PCD	2015Jan07	Expression confirmed	Yes		4	NCT01846416	Previously-treated		Overall Response Rate	93	93			21		13-30		17		2.8-44.2		2.7			0.0-45.5										9.3			5.8-17.6														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab		Completed	NCT01846416	FIR First line	PCD	2015Jan07	Expression confirmed	Yes		4	NCT01846416	Untreated		Overall Response Rate	31	31			32		17-51		9.2		2.3-30.4		4.5			0.9-37.9										14.4			12.8-22.1														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Nivolumab + Relatimab		Terminated	NCT02750514	FRACTION-Lung Track 1	PCD	2020Jan29	Expression confirmed	Yes	Standard of care changed	4	NCT02750514			Overall Response Rate	0			Nivolumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AK112		Recruiting	NCT04900363		ECD	2023May01	Expression confirmed	No		4	NCT04900363			"PFS, ORR"	108	108																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Epacadostat + Pembrolizumab		Completed	NCT03322540	KEYNOTE-654-05	PCD	2019Jan10	Expression confirmed	Yes		4	NCT03322540			Overall Response Rate	154	77	77	Pembrolizumab + Placebo	32.5	39		0.8	6.2				6.7	6.2																													COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Sintilimab		Unknown	NCT04252365	CTONG1901 PD-L1 TPS <50%	ECD	2021Mar01	No	Yes		2	10.1200/JCO.2022.40.16_suppl.9032			Overall Response Rate	41	20	21	Pembrolizumab	55	28.6																																					COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Sintilimab		Unknown	NCT04252365	CTONG1901 PD-L1 TPS >=50%	ECD	2021Mar01	No	Yes		2	10.1200/JCO.2022.40.16_suppl.9032			Overall Response Rate	27	13	14	Pembrolizumab	30.8	28.6																																					COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Sintilimab		Recruiting	NCT03574402	TRUMP Arm 14	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dostarlimab + Niraparib		Completed	NCT03308942	Cohort 2A	PCD	2020May04	Expression confirmed	Yes		4	NCT03308942			Overall Response Rate	0	0																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dostarlimab + Niraparib		Completed	NCT03308942	Cohort 1A	PCD	2020May04	Expression confirmed	Yes		4	NCT03308942			Overall Response Rate	11	11			9.1		0.2-41.3						4.4			-2.2							54.5																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dostarlimab + Niraparib		Recruiting	NCT04940637	UNITO-001	ECD	2023Dec30	Expression confirmed	No		4	NCT04940637			Progression free survival	70	70																																									COSO29915674	2022Jul28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Pemetrexed + Tislelizumab		Not yet recruiting	NCT04507217		ECD	2022Sep01	No	No		4	NCT04507217			Progression free survival	78	78																																									COSO29915674	2022Jun09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Pemetrexed + Tislelizumab		Not yet recruiting	NCT04507217		ECD	2022Sep01	No	No		4	NCT04507217			Progression free survival	78	78																																									COSO29915674	2022Jun09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Bevacizumab		Recruiting	NCT04563338	INTEGRATE Arm B	ECD	2024Dec05	No	No		4	NCT04563338			Progression free survival	36	36																																									COSO29915674	2022Jul27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Bevacizumab		Not yet recruiting	NCT03896074	BEAT	ECD	2022May01	Expression confirmed	No		4	NCT03896074			Overall survival	206			Atezolizumab																																							COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Tremelimumab		Completed	NCT03373760	Acquired resistance	PCD	2020May18	No	Yes	Expression not correlated with efficacy	4	NCT03373760			Overall Response Rate	28	28			0								2.1			1.6-3.2										7.6			5.3-10.2														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Tremelimumab		Completed	NCT03373760	Primary resistance 	PCD	2020May18	No	Yes	Expression not correlated with efficacy	4	NCT03373760			Overall Response Rate	28	28			7								2			1.6-3.0										7.7			4.0-12.0														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Ramucirumab		Recruiting	NCT04040361	EAST ENERGY	ECD	2022Apr30	Expression confirmed	No		4	NCT04040361			Major pathologic response	24	24																																									COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Apatinib + Camrelizumab		Unknown	NCT03083041		ECD	2018Dec27	Comparison with wt	Yes		1	35498381	Untreated		Overall Response Rate	10	6	4		40	40																																					COSO29915674	2022Dec12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Apatinib + Camrelizumab		Unknown	NCT03083041		ECD	2018Dec27	Comparison with wt	Yes		2	10.1016/j.annonc.2020.08.1581	Previously-treated		Overall Response Rate	22	12	10		41.7	20		0.29					7.3	5.5			0.41																										COSO29915674	2022Dec12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Cabozantinib		"Active, not recruiting"	NCT03170960	Expansion Cohort 8	ECD	2022Dec01	No	No		4	NCT03170960			Overall Response Rate	1732	1732																																									COSO29915674	2022Oct12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dasatinib + Nivolumab		Terminated	NCT02750514	FRACTION-Lung Track 1	PCD	2020Jan29	Expression confirmed	Yes	Standard of care changed	4	NCT02750514			Overall Response Rate	4			Nivolumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Docetaxel + Sintilimab		Completed	NCT03798743	Success CTC PD-L1 >/< 32.5%	PCD	2021Dec30	Expressed/not	Yes		1	36064386			Overall Response Rate	30	15	15		60	13.3		0.021					6	3.5	0.44	0.20-0.96	0.011									15.8	9	0.43	0.19-0.97	0.038													COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Nivolumab		Terminated	NCT02750514	FRACTION-Lung Track 1	PCD	2020Jan29	Expression confirmed	Yes	Standard of care changed	4	NCT02750514			Overall Response Rate	40			Nivolumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Nivolumab		Unknown	NCT03304093	CHIVA2	ECD	2021Mar01	No	Yes	DCR 8w 62.5%	2	10.1016/j.annonc.2020.08.1703			"Disease control rate, Clinical benefit rate"	16	16											3.4			1.77-5.49										14			-2.17														COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		Recruiting	NCT04108026	SAVIMMUNE	ECD	2023May01	No	No		4	NCT04108026	Untreated		Maximum tolerated dose/toxicity	67	67																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		Terminated	NCT03030131	IONESCO	PCD	2019Aug28	No	Yes	Discontinued due to high postoperative death rate	3	https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-durvalumab-in-resectable-non-small-cell-lung-cancer-nsclc-preliminary-results-from-a-multicenter-study-ifct-1601-ionesco			Resection rate	46	46																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		"Active, not recruiting"	NCT02087423	ATLANTIC Cohort 2	PCD	2016Jun03	Expressed/not	Yes		4	NCT02087423			Overall Response Rate	239	146	93		16.4	7.5			12.3																	10.9	9.3																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		"Active, not recruiting"	NCT02087423	ATLANTIC Cohort 3	PCD	2016Jun03	Expression confirmed	Yes		4	NCT02087423			Overall Response Rate	68	68			30.9																					13.2																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		Completed	NCT02879617		PCD	2022Jun04	No	No		4	NCT02879617	Untreated		Overall survival	50	50																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		"Active, not recruiting"	NCT03620669		ECD	2022Dec31	Expression confirmed	No		4	NCT03620669			Overall survival	48	48																																									COSO29915674	2022Jun17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab		Completed	NCT02766335	Lung-MAP	PCD	2018Sep01	Expression confirmed	Yes		4	NCT02766335	Previously-treated		Overall Response Rate	14	14			14		0-33						2.3			1.4-4.2										10.7			9.2-14.3														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Niraparib		Completed	NCT03308942	Cohort 3	PCD	2020May04	Expression confirmed	Yes		4	NCT03308942			Overall Response Rate	2	2			0		0.0-84.2						4			1.3-6.6							50																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Cobimetinib		Recruiting	NCT03337698	Morpheus Lung	ECD	2024Apr12	Expression confirmed	No		4	NCT03337698			Overall Response Rate	435			Atezolizumab																																							COSO29915674	2022Jun08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab		Terminated	NCT02564380	PRIMUS	PCD	2020May23	No	Yes	Slow accrual	4	NCT02564380	Previously-treated		Progression free survival	41	41																																									COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab		Unknown	NCT03571360		ECD	2021Jan14	No	No		4	NCT03571360			"PFS, ORR"	42	42																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab		Recruiting	NCT03293680		ECD	2023May31	Expression confirmed	No		4	NCT03293680		Geriatric	Overall survival	82	82																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ipilimumab + Nivolumab		Terminated	NCT02750514	FRACTION-Lung Track 1	PCD	2020Jan29	Expression confirmed	Yes	Standard of care changed	4	NCT02750514			Overall Response Rate	3			Nivolumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ipilimumab + Nivolumab		"Active, not recruiting"	NCT03469960	DICIPLE	ECD	2023May01	Expression confirmed	No		4	NCT03469960	Untreated		Progression free survival	265			Observation																																							COSO29915674	2022Jun28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Cisplatin + Datopotamab Deruxtecan + Pembrolizumab		Not yet recruiting	NCT05555732	TROPION-Lung07	ECD	2027Aug01	Expression confirmed	No		4	NCT05555732	Untreated		"OS, PFS"	975			Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Platinum-based chemotherapy + QL1706		Not yet recruiting	NCT05487391		ECD	2028Oct01	Expression confirmed	No		4	NCT05487391			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	632			Placebo + Platinum-based chemotherapy																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab-Vibostolimab + Platinum-doublet chemotherapy + Radiotherapy		Recruiting	NCT05298423	KEYVIBE-006	ECD	2028Sep01	No	No		4	NCT05298423			"OS, PFS"	784			Durvalumab + Platinum-doublet chemotherapy + Radiotherapy																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Datopotamab Deruxtecan + Pembrolizumab		Not yet recruiting	NCT05555732	TROPION-Lung07	ECD	2027Aug01	Expression confirmed	No		4	NCT05555732	Untreated		"OS, PFS"	975			Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed																																							COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Datopotamab Deruxtecan + Pembrolizumab		Recruiting	NCT05215340	TROPION-Lung08	ECD	2026Jun01	Expression confirmed	No		4	NCT05215340	Untreated		"OS, PFS"	740			Pembrolizumab																																							COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Ociperlimab + Tislelizumab		Recruiting	NCT04866017		ECD	2025Jan30	No	No		4	NCT04866017	Previously-treated		"PFS, ORR"	900			Chemotherapy + Durvalumab																																							COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Paclitaxel + Pemetrexed + Sugemalimab		"Active, not recruiting"	NCT03789604	GEMSTONE-302	PCD	2020Jun08	No	Yes		2	10.1016/S1470-2045(21)00650-1			Progression free survival	479	320	159	Carboplatin + Paclitaxel + Pemetrexed									9	4.9	0.48	0.39-0.60	<0.0001																										COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Domvanalimab + Durvalumab		Recruiting	NCT05211895	PACIFIC-8	ECD	2027Jun02	No	No		4	NCT05211895	Previously-treated		Progression free survival	860			Durvalumab + Placebo																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Nab-paclitaxel + Serplulimab		"Active, not recruiting"	NCT04033354		PCD	2021Mar30	No	No		4	NCT04033354			Progression free survival	537			Carboplatin + Nab-paclitaxel + Placebo																																							COSO29915674	2022Jul28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab + Sacituzumab govitecan		Not yet recruiting	NCT05609968	KEYNOTE D46/EVOKE-03	ECD	2027Jan12	Expression confirmed	No		4	NCT05609968			"OS, PFS"	614			Pembrolizumab																																							COSO29915674	2023Jan13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Cemiplimab + Chemotherapy		"Active, not recruiting"	NCT03409614	EMPOWER-Lung 3	ECD	2023Jul28	No	Yes		1	36008722			Overall survival	466	312	154	Chemotherapy + Placebo																						21.9	13	0.71	0.53-0.93	0.0014													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Niraparib + Pembrolizumab		Recruiting	NCT04475939	ZEAL-1L	ECD	2024Dec20	No	No		4	NCT04475939	Previously-treated		"OS, PFS"	650			Pembrolizumab + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Camrelizumab + Famitinb		Recruiting	NCT05042375		ECD	2023Dec31	Expression confirmed	No		4	NCT05042375	Untreated		"OS, PFS"	450			Pembrolizumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed		"Active, not recruiting"	NCT04194203	IMpower151	ECD	2023Feb03	No	No		4	NCT04194203			Progression free survival	304			Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Cisplatin + Etoposide + Nivolumab + Radiotherapy		Terminated	NCT02768558		PCD	2019Jan23	No	Yes	Alternative treatment found efficacious	4	NCT02768558			"OS, PFS"	20			Cisplatin + Etoposide + Placebo + Radiotherapy																																							COSO29915674	2023Jan16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Platinum-based chemotherapy		"Active, not recruiting"	NCT03800134	AEGEAN	ECD	2024Apr30	No	No		4	NCT03800134			"CR, EFS"	825			Placebo + Platinum-based chemotherapy																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	CBT-502		Recruiting	NCT04325763		ECD	2022Dec01	No	No		4	NCT04325763			Progression free survival	315																																										COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	CBT-502 + Placebo		Recruiting	NCT04325763		ECD	2022Dec01	No	No		4	NCT04325763			Progression free survival	315																																										COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Cisplatin + Docetaxel + Paclitaxel + Pemetrexed + Toripalimab		Recruiting	NCT04158440		ECD	2022Dec31	Expressed/not	No		4	NCT04158440			Major pathologic response	500			Carboplatin + Cisplatin + Docetaxel + Paclitaxel + Pemetrexed + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Paclitaxel + Penpulimab		"Active, not recruiting"	NCT03866980		ECD	2023Jun30	Expression confirmed	No		4	NCT03866980	Untreated		Progression free survival	164			Carboplatin + Paclitaxel + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Paclitaxel + Penpulimab		Unknown	NCT03866993		ECD	2020Dec31	Expression confirmed	No		4	NCT03866993	Untreated		Progression free survival	338			Carboplatin + Paclitaxel + Placebo																																							COSO29915674	2022Jun07	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Bintrafusp alfa		"Active, not recruiting"	NCT03631706		PCD	2021Jun07	Expression confirmed	No		4	NCT03631706			"OS, PFS"	304			Pembrolizumab																																							COSO29915674	2022Jun22	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Durvalumab		Recruiting	NCT04550260	KUNLUN	ECD	2025Nov28	No	No		4	NCT04550260			"OS, PFS"	600		1375																																								COSO29915674	2022Jun24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Carboplatin + Paclitaxel		Completed	NCT02366143	IMpower150 Arm A PD-L1 TC1/2/3 or IC1/2/3 	PCD	2019Sep13	Expression confirmed	Yes		4	NCT02366143			"OS, PFS"	350	185	165	Bevacizumab + Carboplatin + Paclitaxel																						24.4	16	0.709	0.551-0.913	0.0073													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Carboplatin + Paclitaxel		Completed	NCT02366143	IMpower150 Arm A PD-L1 TC2/3 or IC2/3 	PCD	2019Sep13	Expression confirmed	Yes		4	NCT02366143			"OS, PFS"	240	124	116	Bevacizumab + Carboplatin + Paclitaxel																						26.1	17	0.662	0.484-0.907	0.0097													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Carboplatin + Paclitaxel		Completed	NCT02366143	IMpower150 Arm B PD-L1 TC1/2/3 or IC1/2/3 	PCD	2019Sep13	Expression confirmed	Yes		4	NCT02366143			"OS, PFS"	354	190	164	Bevacizumab + Carboplatin + Paclitaxel									11	6.8	0.486	0.386-0.639	<0.0001									22.5	16.4	0.771	0.575-1.035	0.0829													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Carboplatin + Paclitaxel		Completed	NCT02366143	IMpower150 Arm B PD-L1 TC2/3 or IC2/3 	PCD	2019Sep13	Expression confirmed	Yes		4	NCT02366143			"OS, PFS"	244	129	115	Bevacizumab + Carboplatin + Paclitaxel									11.1	6.8	0.471	0.352-0.647	<0.0001									22.2	16.7	0.824	0.580-1.169	0.2765													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Camrelizumab		Unknown	NCT04203485		ECD	2022Mar31	Expression confirmed	No		4	NCT04203485	Untreated		"OS, PFS"	762			Platinum-doublet chemotherapy																																							COSO29915674	2022Jun28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Tiragolumab		Recruiting	NCT04294810	SKYSCRAPER-01	ECD	2023Aug25	Expression confirmed	No		4	NCT04294810	Untreated		"OS, PFS"	635			Atezolizumab + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	MK-7684A		Recruiting	NCT04738487	KEYVIBE-003	ECD	2026Apr21	Expression confirmed	No		4	NCT04738487	Untreated		"OS, PFS"	1246			Pembrolizumab																																							COSO29915674	2022May31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Cemiplimab + Ipilimumab + Platinum-based chemotherapy		Terminated	NCT03515629		PCD	2021Jul29	Expression confirmed	No		4	NCT03515629			Progression free survival	5			Pembrolizumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Cemiplimab + Ipilimumab		Terminated	NCT03515629		PCD	2021Jul29	Expression confirmed	No		4	NCT03515629			Progression free survival	5			Pembrolizumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Monalizumab		Recruiting	NCT05221840	PACIFIC-9	ECD	2026May29	Expression confirmed	No		4	NCT05221840	Previously-treated		Progression free survival	999																																										COSO29915674	2022May30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Oleclumab		Recruiting	NCT05221840	PACIFIC-9	ECD	2026May29	Expression confirmed	No		4	NCT05221840	Previously-treated		Progression free survival	999																																										COSO29915674	2022May30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Domvanalimab		Recruiting	NCT04736173		ECD	2025Dec31	Expression confirmed	No		4	NCT04736173			"OS, PFS"	625	625																																									COSO29915674	2022May31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Zimberelimab		Recruiting	NCT04736173		ECD	2025Dec31	Expression confirmed	No		4	NCT04736173			"OS, PFS"	625	625																																									COSO29915674	2022Oct06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Paclitaxel + Pemetrexed		Recruiting	NCT04736173		ECD	2025Dec31	Expression confirmed	No		4	NCT04736173			"OS, PFS"	625	625																																									COSO29915674	2022May30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Tislelizumab		"Active, not recruiting"	NCT03358875	RATIONALE 303	ECD	2022Dec30	No	Yes		2	10.1158/1538-7445.AM2021-CT039	Previously-treated		Overall survival	805	535	270	Docetaxel																						17.2	11.9	0.64	0.527-0.778	<0.0001													COSO29915674	2022Sep16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Tislelizumab		"Active, not recruiting"	NCT03358875	RATIONALE 303 PD-L1 >=25%	ECD	2022Dec30	Expression confirmed	Yes		5	https://www.beigenemedical.com/CongressDocuments/Zhou_BGB-A317-303_AACR_presentation_2021.pdf	Previously-treated		Overall survival	393	277	116	Docetaxel																						19.1	11.9	0.52	0.384-0.713	<0.0001													COSO29915674	2022Sep21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Avelumab		"Active, not recruiting"	NCT02576574	JAVELIN Lung 100	PCD	2021Dec06	Expression confirmed	No		4	NCT02576574	Untreated		"OS, PFS"	1224			Platinum-based chemotherapy																																							COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Avelumab		Completed	NCT02395172	JAVELIN Lung 200 PD-L1 >=1	PCD	2017Nov22	Expression confirmed	Yes		4	NCT02395172	Previously-treated		Overall survival	529	264	265	Docetaxel	18.9	11.7							3.4	4.1	1.01	0.80-1.27										11.4	10.6	0.87	0.71-1.05	0.0721													COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ociperlimab + Tislelizumab		Recruiting	NCT04746924		ECD	2025Jan01	Expression confirmed	No		4	NCT04746924	Untreated		"OS, PFS"	660			Pembrolizumab + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ociperlimab + Tislelizumab		Recruiting	NCT04746924		ECD	2025Jan01	Expression confirmed	No		4	NCT04746924	Untreated		"OS, PFS"	660			Pembrolizumab + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Tislelizumab		Recruiting	NCT04866017		ECD	2025Jan30	No	No		4	NCT04866017	Previously-treated		"PFS, ORR"	900			Chemotherapy + Durvalumab																																							COSO29915674	2022Aug01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Camrelizumab + Carboplatin + Pemetrexed		Completed	NCT03134872	CameL	PCD	2019Jul27	Expression confirmed	No		4	NCT03134872	Untreated		Progression free survival	419			Carboplatin + Pemetrexed																																							COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		"Active, not recruiting"	NCT03191786	IPSOS	PCD	2022Apr30	Expression confirmed	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-congress/ipsos-results-from-a-phase-iii-study-of-first-line-1l-atezolizumab-atezo-vs-single-agent-chemotherapy-chemo-in-patients-pts-with-nsclc-not			Overall survival	453	302	151	Vinorelbine or Gemcitabine	16.9	7.9			14	7.8			4.2	4	0.87	0.70-1.07												0.78	0.63-0.97	0.028													COSO29915674	2022Sep16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		Terminated	NCT02409355	IMpower111	PCD	2017Dec07	Expression confirmed	Yes	Slow accrual	4	NCT02409355				8			Cisplatin or carboplatin + Gemcitabine																																							COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		Completed	NCT02008227	OAK TC1/2/3 or IC1/2/3 Subgroup	PCD	2016Jul07	Expression confirmed	Yes		4	NCT02008227	Previously-treated		Overall survival	463	241	222	Docetaxel	17.8	16.2			16	6.2		0.0006	2.8	4.1	0.91	0.74-1.12	0.3806									15.7	10.3	0.74	0.58-0.933	0.0102													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		Recruiting	NCT05047250		ECD	2024Dec31	Overexpression	No		4	NCT05047250			Progression free survival	114			Platinum-doublet chemotherapy																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		Completed	NCT02409342	IMpower110 TC2/3 or IC2/3-WT	PCD	2020Feb04	Expression confirmed	Yes		4	NCT02409342	Untreated		Overall survival	328	166	162	Atezolizumab + Cisplatin or carboplatin + Pemetrexed or Gemcitabine	33.7	32.1			38.9	5.8	0.135-0.409		7.3	5.5	0.641	0.501-0.820	0.0004									19.9	16.1	0.868	0.661-1.140	0.3091													COSO29915674	2023Jan20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		Completed	NCT02409342	IMpower110 TC1/2/3 or IC1/2/3-WT	PCD	2020Feb04	Expression confirmed	Yes		4	NCT02409342	Untreated		Overall survival	554	277	277	Atezolizumab + Cisplatin or carboplatin + Pemetrexed or Gemcitabine	31.4	32.1			26.3	5.7	0.190-0.424		5.8	5.6	0.716	0.595-0.863	0.0004									18.9	14.7	0.845	0.688-1.037	0.107													COSO29915674	2023Jan20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab		Completed	NCT02409342	IMpower110 TC3 or IC3-WT	PCD	2020Feb04	Expression confirmed	Yes		4	NCT02409342	Untreated		Overall survival	205	107	98	Atezolizumab + Cisplatin or carboplatin + Pemetrexed or Gemcitabine	38.3	28.6				6.7	0.166-0.800		8.1	5	0.63	0.449-0.884	0.007									20.2	13.1	0.595	0.398-0.890	0.0106													COSO29915674	2023Jan20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	AK112		Recruiting	NCT05499390		ECD	2024Jun17	Expression confirmed	No		4	NCT05496166			Progression free survival	388			Pembrolizumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Lenvatinib + Pembrolizumab		"Active, not recruiting"	NCT03829332	LEAP-007	PCD	2021May19	Expression confirmed	No	Primary outcome not met	2	10.1016/annonc/annonc787	Untreated		"OS, PFS"	623	309	314	Pembrolizumab + Placebo	40.5	27.7		0.00037					6.6	4.2	0.78	0.64-0.95	0.00624									14.1	16.4	1.1	0.87-1.39	0.797													COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Lenvatinib + Pembrolizumab		"Active, not recruiting"	NCT04676412	LEAP-007	PCD	2021May19	Expression confirmed	No		4	NCT04676412	Untreated		"OS, PFS"	27			Pembrolizumab																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT02453282	MYSTIC PD-L1 TC >=1%	PCD	2018Oct04	Expression confirmed	Yes		4	NCT02453282			"OS, PFS"	585	296	289	Standard of care									2.8	5.5	1.38	1.136-1.678	0.001									10.9	12.3	1.01	0.834-1.213	0.952													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT02453282	MYSTIC PD-L1 TC >=25%	PCD	2018Oct04	Expression confirmed	Yes		4	NCT02453282			"OS, PFS"	325	163	162	Standard of care									3.9	5.4	1.05	0.722-1.534	0.705									11.9	12.9	0.85	0.611-1.173	0.202													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT02542293	NEPTUNE PD-L1 TC ?50%	PCD	2020Sep21	No	Yes		4	NCT02542293			Overall survival	53	25	28	Chemotherapy																						36.6	15.8																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT02542293	NEPTUNE PD-L1 TC ?50%	PCD	2020Sep21	No	Yes		4	NCT02542293			Overall survival	231	115	116	Chemotherapy																						14.1	10.5																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT02542293	NEPTUNE PD-L1 TC ?25%	PCD	2020Sep21	No	Yes		4	NCT02542293			Overall survival	63	31	32	Chemotherapy																						36.6	15.8																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab + Tremelimumab		"Active, not recruiting"	NCT02542293	NEPTUNE PD-L1 TC ?25%	PCD	2020Sep21	No	Yes		4	NCT02542293			Overall survival	329	165	164	Chemotherapy																						12.2	10.4																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Apatinib + Camrelizumab		Unknown	NCT04203485		ECD	2022Mar31	Expression confirmed	No		4	NCT04203485	Untreated		"OS, PFS"	762			Platinum-doublet chemotherapy																																							COSO29915674	2022Jun28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Nivolumab		"Active, not recruiting"	NCT02613507	CheckMate 078 PD-L1 >= 1%	PCD	2017Sep15	Expression confirmed	Yes		4	NCT02613507			Overall survival	252	168	84	Docetaxel																						12.29	7.89	0.62	0.45-0.87														COSO29915674	2022Sep12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Nivolumab		Completed	NCT02041533	CheckMate 026 	PCD	2016Jul01	Expression confirmed	Yes		4	NCT02041533			Progression free survival	541	271	270	Chemotherapy	12.12	5.65							4.21	5.82	1.17	0.95-1.43										13.73	13.8	1.07	0.86-1.33														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Nivolumab		Completed	NCT02041533	CheckMate 026 PD-L1 Expression >= 5%	PCD	2016Jul01	Expression confirmed	Yes		4	NCT02041533	Previously-treated		Progression free survival	423	211	212	Chemotherapy	26.1	33.5							4.21	5.88	1.15	0.91-1.45	0.2511									14.36	13.21	1.02	0.8-1.30														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Nivolumab		"Active, not recruiting"	NCT02613507	CheckMate 078 PD-L1 < 1%	PCD	2017Sep15	Expression confirmed	Yes		4	NCT02613507			Overall survival	205	138	67	Docetaxel																						11.37	10.25	0.75	0.52-1.09														COSO29915674	2022Oct12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Toripalimab		Unknown	NCT03856411		ECD	2021Apr14	No	Yes		2	10.1200/JCO.2022.40.36_suppl.362936	Untreated		Progression free survival	465	309	156	Chemotherapy + Placebo									8.4	5.6	0.49	0.39-0.61	<0.0001										17.1	0.69	0.52-0.92	0.0099													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Pembrolizumab		Recruiting	NCT04267848	ACCIO	ECD	2024Dec15	No	No		4	NCT04267848			"DFS, OS"	1210			Chemotherapy																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Pembrolizumab		Recruiting	NCT04547504		ECD	2025Dec22	Expression confirmed	No		4	NCT04547504	Untreated		Progression free survival	292			Pembrolizumab																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT03706690	PACIFIC-5	ECD	2022Nov25	No	No		4	NCT03706690	Previously-treated		Progression free survival	407			Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02453282	MYSTIC PD-L1 TC >=1%	PCD	2018Oct04	Expression confirmed	Yes		4	NCT02453282			"OS, PFS"	568	279	289	Standard of care									3.6	5.5	1.09	0.894-1.339	0.383									14.6	12.3	0.88	0.725-1.067	0.194													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02453282	MYSTIC PD-L1 TC >=25%	PCD	2018Oct04	Expression confirmed	Yes		4	NCT02453282			"OS, PFS"	325	163	162	Standard of care									4.7	5.4	0.87	0.667-1.143	0.324									16.3	12.9	0.76	0.564-1.019	0.036													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT04642469	MERMAID-2	ECD	2023Oct31	No	No		4	NCT04642469			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	26			Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02273375		ECD	2023Jan31	No	No		4	NCT02273375			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1415			Placebo																																							COSO29915674	2022Jul27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02125461	PACIFIC PD-L1 TC < 1%	PCD	2017Feb13	No	Yes		1	32209338	Previously-treated		"OS, PFS"	148	90	58	Placebo									10.7	5.6	0.73	0.48-1.11										33.1	45.6	1.14	0.71-1.84														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02125461	PACIFIC PD-L1 TC >= 1%	PCD	2017Feb13	No	Yes		1	32209338	Previously-treated		"OS, PFS"	303	212	91	Placebo									17.8	5.6	0.45	0.33-0.64											29.6	0.59	0.41-0.83														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02125461	PACIFIC PD-L1 TC < 25%	PCD	2017Feb13	No	Yes		1	32209338	Previously-treated		"OS, PFS"	292	187	105	Placebo									16.9	6.9	0.59	0.43-0.82										39.7	37.4	0.89	0.63-1.25														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02125461	PACIFIC PD-L1 TC >= 25%	PCD	2017Feb13	No	Yes		1	32209338	Previously-treated		"OS, PFS"	159	115	44	Placebo									17.8	3.7	0.41	0.26-0.55											21.1	0.5	0.30-0.83														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02125461	PACIFIC	PCD	2017Feb13	No	Yes		4	NCT02125461	Previously-treated		"OS, PFS"	713	476	237	Placebo	30	17.8		<0.001		18.4			16.8	5.6	0.52	0.42-0.65	<0.0001										28.7	0.68	0.53-0.87	0.00251													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT03003962	PEARL	ECD	2022Oct27	Expression confirmed	Yes	Primary outcome not met	6	https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial.html	Untreated		Overall survival	671			Platinum-based chemotherapy																																							COSO29915674	2023Jan04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Durvalumab		"Active, not recruiting"	NCT02352948	ARCTIC Study A	PCD	2018Feb09	Expression confirmed	Yes	Clinically meaningful improvements in OS and PFS versus SoC	1	32201234	Previously-treated		"OS, PFS"	126	62	64	Chemotherapy	35.5	12.5			9.5	4.8			3.8	2.2	0.71	0.49-1.04										11.7	6.8	0.63	0.42-0.93														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		"Active, not recruiting"	NCT02504372	PEARLS/KEYNOTE-091 PD-L1 TPS ?50%	ECD	2021Aug19	Expression confirmed	Yes		2	10.1016/j.annonc.2022.02.224	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	333	168	165	Placebo																																	0.82	0.57-1.18	0.14				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		"Active, not recruiting"	NCT02504372	PEARLS/KEYNOTE-091	ECD	2021Aug19	No	Yes		2	10.1016/j.annonc.2022.02.224	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1177	590	570	Placebo																															53.6	42	0.76	0.63-0.91	0.0014				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		Completed	NCT03850444	KEYNOTE-042 PD-L1 TPS ?20%	PCD	2018Sep04	Expression confirmed	Yes		4	NCT03850444			Overall survival	262	128	134	Carboplatin + Paclitaxel or Pemetrexed	32.8	24.6							6.3	6.4	1	0.74-1.35										20	13.7	0.65	0.45-0.94														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		Completed	NCT03850444	KEYNOTE-042 PD-L1 TPS ?20%	PCD	2018Sep04	Expression confirmed	Yes		4	NCT03850444			Overall survival	204	101	103	Carboplatin + Paclitaxel or Pemetrexed	35.6	24.3							6.3	6.5	0.99	0.70-1.39										20	13.7	0.62	0.41-0.95														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		Completed	NCT03850444	KEYNOTE-042 PD-L1 TPS ?50%	PCD	2018Sep04	Expression confirmed	Yes		4	NCT03850444			Overall survival	146	72	74	Carboplatin + Paclitaxel or Pemetrexed	41.7	24.3							8.3	6.5	0.85	0.57-1.28										20	14	0.62	0.38-1.00														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		"Active, not recruiting"	NCT02864394	KEYNOTE-033 PD-L1 TPS ? 1%	ECD	2019Sep09	No	Yes		4	NCT02864394	Previously-treated		"OS, PFS"	423	213	212	Docetaxel	20.7	5.7		<0.0001					3.3	3	0.84	0.66-1.08	0.0847									12.9	10.6	0.75	0.6-0.95	0.0076													COSO29915674	2022Aug12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pembrolizumab		"Active, not recruiting"	NCT02864394	KEYNOTE-033 PD-L1 TPS ?50%	ECD	2019Sep09	No	Yes		4	NCT02864394	Previously-treated		"OS, PFS"	227	114	113	Docetaxel	28.1	7.1		<0.0001					4	2.5	0.76	0.54-1.07	0.0534									12.3	10.9	0.83	0.61-1.14	0.1276													COSO29915674	2022Aug12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ipilimumab + Nivolumab		"Active, not recruiting"	NCT03351361	eNERGY	PCD	2021Jul31	No	Yes		2	10.1200/JCO.2022.40.16_suppl.9011		Geriatric	Overall survival	204			Carboplatin + Paclitaxel or Pemetrexed									5.5	4.6			0.015									14.7	9.9	0.85	0.62-1.16														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ipilimumab + Nivolumab	Required	"Active, not recruiting"	NCT02477826	CheckMate 227 PD-L1 tumor expression >50%	ECD	2024Aug29	Expression confirmed	Yes	OS 2y 48.1 v 41.9%	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s106lbl.pdf	Untreated		"OS, PFS"	419	205	214						31.8	17.5																																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ipilimumab + Nivolumab		"Active, not recruiting"	NCT02477826	CheckMate 227 PD-L1 tumor expression >1%	ECD	2024Aug29	Expression confirmed	Yes	OS 2y 40 v 36.2%	1	31562796	Untreated		"OS, PFS"	792	396	396	Nivolumab					23.2	15.5																																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Ipilimumab + Nivolumab		"Active, not recruiting"	NCT02998528	CHECKMATE-816	PCD	2021Sep08	No	No		4	NCT02998528			"CR, EFS"	505			Platinum-doublet chemotherapy																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 4	Pembrolizumab		Recruiting	NCT03134456		PCD	2019Jul08	Expression confirmed	No		4	NCT03134456	Previously-treated		Response rate	50	50																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 4	Pembrolizumab		"Active, not recruiting"	NCT03715205	KEYNOTE-593 Cohort B	ECD	2024Jul22	Expression confirmed	No		4	NCT03715205			Maximum tolerated dose/toxicity	150	150																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Pembrolizumab		Recruiting	NCT04393883		ECD	2022Jul01	No	No		4	NCT04393883			Progression free survival	216	216																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and (ALK_unspecified or EGFR_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cetuximab + Durvalumab + Intensity modulated radiation therapy		"Active, not recruiting"	NCT02087423	ATLANTIC Cohort 1	PCD	2016Jun03	Expressed/not	Yes		4	NCT02087423			Overall Response Rate	102	74	28		12.2	3.6																				13.3	9.9																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Bevacizumab		"Active, not recruiting"	NCT04426825		PCD	2022Jan19	Expression confirmed	Yes	SAE 40%	3	https://oncologypro.esmo.org/meeting-resources/esmo-congress/ml41256-phase-ii-study-of-atezolizumab-atezo-in-combination-with-bevacizumab-beva-in-advanced-non-squamous-non-small-cell-lung-cancer-nsqnscl			Progression free survival	19	19			15.8								2.8										68.4										3	10									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib + Envafolimab		Not yet recruiting	NCT05534113		ECD	2025Jun01	Yes	No		4	NCT05534113			Progression free survival	38	38																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Cisplatin or carboplatin + Pemetrexed + Tislelizumab		Recruiting	NCT05527808		ECD	2025Jun30	Expression confirmed	No		4	NCT05527808			Major pathologic response	28	28																																									COSO29915674	2022Oct11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and KRAS_G12C 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Adagrasib + Pembrolizumab		Recruiting	NCT04613596	KRYSTAL-7	ECD	2023Oct30	Yes	No		4	NCT04613596			Overall Response Rate	250	250																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and KRAS_G12C 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Adagrasib + Pembrolizumab		Recruiting	NCT05609578		ECD	2025Jun29	Expression confirmed	No		4	NCT05609578			Overall Response Rate	90	90																																									COSO29915674	2023Jan05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified and KRAS_G12C and STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	JDQ443		Not yet recruiting	NCT05445843	Cohort B	ECD	2026Nov02	Expression confirmed	No		4	NCT05445843			Overall Response Rate	120	120																																									COSO29915674	2022Sep30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified or KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pembrolizumab + Trametinib		"Active, not recruiting"	NCT03225664		ECD	2023Sep30	No	No		4	NCT03225664			Overall Response Rate	37	37																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CDK4	CDK4_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort C3	ECD	2023Mar01	Overexpression	Yes		1	32669708			"ORR, PFS, DOR"	11	11											2.2			1.1-5.2																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CDK4	CDK4_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		Completed	NCT02785939		PCD	2017Jun01	Overexpression	Yes	Primary outcome not met	1	31302234	Previously-treated			1	1																															0										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CDKN1A	CDKN1A_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Docetaxel + Radiotherapy		Terminated	NCT00378404		PCD	2009Jun01	No	Yes	Slow accrual	4	NCT00378404			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CDKN2A	CDKN2A_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Yes	Yes		1	35050752	Previously-treated		"Disease control rate, Clinical benefit rate"	27	27											1.87			1.64-3.69							31			4.99			3.25-9.49			0	1	6									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CDKN2A	CDKN2A_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort C2	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	30	30											3.3			2.5-5.0																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CSF1R	CSF1R_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
CSF1R	CSF1R_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	58	29	29	Erlotinib + Placebo									4.4	2.52	0.55	0.16-1.92	0.17																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797	51766493 + 51766509 + 51818388 + 51832145		p.C797G + p.C797S + p.C797Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	BLU-701		Recruiting	NCT05153408	HARMONY	ECD	2024Jun10	Yes	No		4	NCT05153408			Overall Response Rate	160	160																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797	51766493 + 51766509 + 51818388 + 51832145		p.C797G + p.C797S + p.C797Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	WJ13404		Recruiting	NCT05662670		ECD	2025Sep01	Yes	No		4	NCT05662670			Overall Response Rate	162	162																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797 or EGFR_T790M	51765492 + 51766493 + 51766509 + 51818388 + 51832145		p.C797G + p.C797S + p.C797Y + p.T790M	lung / carcinoma / non small cell carcinoma	3	Phase 2	JIN-A02		Not yet recruiting	NCT05394831		ECD	2023Dec31	Yes	No		4	NCT05394831			Maximum tolerated dose/toxicity	95	95																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797S	51766493 + 51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib		"Active, not recruiting"	NCT03755102		ECD	2024Nov01	Yes	No		4	NCT03755102			Overall Response Rate	17	17																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797S	51766493 + 51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	Phase 1	QLH11811		Not yet recruiting	NCT05555212	Cohort 4	ECD	2024Dec03	Yes	No		4	NCT05555212	Previously-treated		Overall Response Rate	72	72																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797S	51766493 + 51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib + Osimertinib		"Active, not recruiting"	NCT03755102		ECD	2024Nov01	Yes	No		4	NCT03755102			Overall Response Rate	17	17																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797S	51766493 + 51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	Phase 2	HS-10375		Recruiting	NCT05435248		ECD	2025Mar31	No	No		4	NCT05435248			Overall Response Rate	354	354																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797S and EGFR_T790M 	51765492 + 51766493 + 51766509		p.C797S + p.T790M	lung / carcinoma / non small cell carcinoma	3	Phase 2	BLU-945		Recruiting	NCT04862780	Group 1	ECD	2025Jan31	Yes	No		4	NCT04862780	Previously-treated		Overall Response Rate	190	190																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_C797S and EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	BLU-945		Recruiting	NCT04862780	Group 3	ECD	2025Jan31	Yes	No		4	NCT04862780	Previously-treated		Overall Response Rate	190	190																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_E709K/A	51767260 + 51772956		p.E709A + p.E709K	lung / carcinoma / non small cell carcinoma	4	Case study	Afatinib		Unknown					Yes	Yes		1	26354527	Previously-treated		Unknown	4																	12.2																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_E709_T710delinsD	51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	4	Case study	Afatinib		Unknown					Yes	Yes		1	28625646			Unknown	1																																1										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_E709_T710delinsD	51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	7	Case study	Gefitinib		Unknown					Yes	Yes	No benefit of treatment	1	27785061			Unknown	5																																										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_E709_T710delinsD	51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	7	Case study	Erlotinib		Unknown					Yes	Yes	No benefit of treatment	1	27785061			Unknown	5																																										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon18				lung / carcinoma / non small cell carcinoma	3	Phase 2	Neratinib		"Active, not recruiting"	NCT01953926	SUMMIT	ECD	2022Oct31	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9068			Overall Response Rate	10	10			40		Dec-74		7.5		-4		9.1			-3.7										17.9			-5.7			0	4										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del				lung / carcinoma / non small cell carcinoma	3	Phase 1	TAS-116		Completed	NCT02965885		PCD	2019May03	Yes	Yes		1	30679388			Overall Response Rate	1	1																															1										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Pemetrexed		Completed	NCT01469000		PCD	2015Apr01	Yes	Yes		1	27507876	Untreated		Progression free survival	105	65	40	Gefitinib									17.1	11.1	0.67		0.078																54	3									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del and EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	3	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	2014Feb01	Yes	Yes		1	26899759			Maximum tolerated dose/toxicity	1	1																															1										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib		Completed	NCT02529995	AURAChinaPK	PCD	2016Jan28	Yes	Yes		1	29239002	Previously-treated		Maximum tolerated dose/toxicity	16	16			75																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 1	Fruquintinib + Genolimzumab		Recruiting	NCT03976856	Gxplore-015	ECD	2021Dec01	Yes	No		4	NCT03976856			Maximum tolerated dose/toxicity	42	42																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib + Rifampicin		Completed	NCT02197247		PCD	2015Jul09	Yes	Yes	Serious adverse events 17.65% 	4	NCT02197247	Previously-treated		Maximum tolerated dose/toxicity	41	41																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 1	Itraconazole + Osimertinib		"Active, not recruiting"	NCT02157883		PCD	2015Apr03	Yes	Yes	Serious adverse events 23%	1	29381826	Previously-treated		Absorption rate	39	39																																									COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib		Terminated	NCT02025218	NVALT 16	PCD	2017Jan01	Yes	No		4	NCT02025218	Previously-treated		"Disease control rate, Clinical benefit rate"	21	21																																									COSO29915674	2021Aug03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Vinorelbine		Unknown	NCT02319577	GENOA	ECD	2015Jun01	Yes	Yes	PFS 6m 48 vs 66% p=0.24	3	https://www.jto.org/article/S1556-0864(19)32471-2/pdf	No benefit of treatment		Progression free survival	23	21		Gefitinib	47	55		0.76					6.2	9.5			0.17									18.2				0.12													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Tepotinib 		Completed	NCT01982955	INSIGHT	PCD	2017Dec12	Yes	Yes		4	NCT01982955	Previously-treated		Progression free survival	55	31	24		45.2	33.3							10.15	4.37									83.9	70.8		17.25	18.69																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT04147351		ECD	2024Dec31	Yes	No		4	NCT04147351			Overall Response Rate	22	22																																									COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Luminespib		Completed	NCT01259089		PCD	2013Jun04	Yes	Yes	"Primary outcome not met, Response not correlated with T790M status"	1	25870087			"MTD, ORR, Toxicity"	25																																4										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Radiotherapy		Unknown	NCT03074864	TREND	ECD	2019Jun30	Yes	No		4	NCT03074864			Overall Response Rate	90	90																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib + Stereotactic Body Radiation Therapy		Terminated	NCT02893332	Sindas	PCD	2020Aug30	Yes	Yes	Termination recommended by IRB	4	NCT02893332	Untreated		Progression free survival	200	200																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Cetuximab		Completed	NCT01090011		PCD	2013Jan01	Yes	Yes		1	29110849	Previously-treated		Maximum tolerated dose/toxicity	36	36											2.9																				4										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 1	Necitumumab + Osimertinib		"Active, not recruiting"	NCT02496663		ECD	2023Jun30	Yes	No		4	NCT02496663	Previously-treated		Maximum tolerated dose/toxicity	100	100																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Pembrolizumab		Completed	NCT02364609		PCD	2018Apr26	Yes	No		4	NCT02364609	Previously-treated		Maximum tolerated dose/toxicity	11	11																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Patritumab deruxtecan		Recruiting	NCT03260491		PCD	2022Jan28	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9007	Previously-treated		Overall Response Rate	57	57			39		26.0-52.4		6.9		-3.1		8.2			4.4-8.3							72									1	21	19									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Gefitinib + Tremelimumab		Completed	NCT02040064		PCD	2016Mar01	Yes	Yes	Toxicity issues	1	34953624	Previously-treated		Maximum tolerated dose/toxicity	27	27											2.2			1.8-4.2																		19									COSO29915674	2022Dec14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Navitoclax + Osimertinib		"Active, not recruiting"	NCT02520778		ECD	2023Jul30	Yes	No		4	NCT02520778	Previously-treated		Maximum tolerated dose/toxicity	50	50																																									COSO29915674	2022Dec12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 2	Icotinib		Recruiting	NCT05536505		ECD	2025Oct01	Yes	No		4	NCT05536505			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	180	180																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Lazertinib + Pemetrexed		Not yet recruiting	NCT05477615		ECD	2023Jun01	Yes	No		4	NCT05477615			Overall Response Rate	28	28																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rociletinib		Terminated	NCT02630186		PCD	2017Sep05	Yes	Yes	Changed business priorities	4	NCT02630186			Overall Response Rate	3	3																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or EGFR_L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lazertinib		Recruiting	NCT05326425		ECD	2024Jun30	Yes	No		4	NCT05326425			Overall Response Rate	40	40																																									COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861G or EGFR_S768I or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Unknown	Osimertinib + Stereotactic radiotherapy		Recruiting	NCT05033691		ECD	2024Dec31	Yes	No		4	NCT05033691			Progression free survival	162	162																																									COSO29915674	2021Nov15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib		"Active, not recruiting"	NCT03382795		ECD	2023Mar31	Yes	No		4	NCT03382795			Overall Response Rate	63	63																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT04233021	ORBITAL	ECD	2023Apr01	Yes	No		4	NCT04233021			Overall Response Rate	69	69																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib		"Active, not recruiting"	NCT03382795		ECD	2023Mar31	Yes	No		4	NCT03382795			Overall Response Rate	63	63																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dasatinib + Osimertinib		"Active, not recruiting"	NCT02954523		ECD	2022Jun01	Yes	Yes		2	10.1016/j.jtho.2018.08.603	Untreated		Progression free survival	6	6																															4	1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Cyclophosphamide + EGF-PTI		Completed	NCT03623750	EPICAL	PCD	2020Mar26	Yes	Yes		2	10.1016/j.jtho.2021.08.117			Maximum tolerated dose/toxicity	23	23			78.3		53.6-92.5						17.4			-13.22							95.7																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Unknown	Alflutinib		Unknown	NCT03127449		ECD	2020Jun01	Yes	Yes		1	33077354	Previously-treated		Overall Response Rate	116	116			76.7																																						COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		"Active, not recruiting"	NCT03433469		ECD	2022Oct31	Yes	Yes	PaR 69%	2	10.1016/j.jtho.2021.08.383			"Complete response, Pathological complete response"	13	13																					100										6	7									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Afatinib	Required	Completed	NCT00949650	LUX-Lung 3	PCD	2012Feb09	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	Untreated		Progression free survival	345	230	115	Chemotherapy	50.4	19.11							11.1	6.9	0.58	0.43-0.78	p<0.001									28.2	28.2	0.88	0.66-1.17	0.39													COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib + Ramucirumab	Required	"Active, not recruiting"	NCT02411448	RELAY	PCD	2019Jan23	Yes	Yes	Primary outcome met	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	Untreated		Progression free survival	449	224	225	Erlotinib	76	75							19.4	12.4	0.591	0.46-0.76	<0.0001						95.1	95.6	1																		COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Osimertinib	Required	"Active, not recruiting"	NCT02511106	ADAURA	PCD	2020Jan17	Yes	Yes		2	10.1200/JCO.2020.38.18_suppl.LBA5			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	682	339	343	Placebo																															89	53	0.21	0.16-0.28	<0.0001				COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Osimertinib	Required	"Active, not recruiting"	NCT02296125	FLAURA	PCD	2017Jun19	Yes	Yes		1	29151359	Untreated		Progression free survival	556	279	277	Gefitinib					17.2	8.5	7.3-9.8		18.9	10.2	0.46	0.37-0.57	p<0.001									83	71																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Dacomitinib	Required	Completed	NCT01774721	ARCHER 1050 	PCD	2016Jul29	Yes	Yes		1	29864379	Untreated		Progression free survival	452	227	225	Gefitinib									14.7	9.2	0.59	0.47-0.74	p<0.0001									34.1	26.8	0.76	0.582-0.993	p=0.044													COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Gefitinib	Required	Completed	NCT00322452	IPASS (Study 2)	PCD	2008Apr01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	Untreated		Progression free survival	186	88	89	Chemotherapy	67	41	31-51		9.6	5.5			10.9	7.4	0.54	0.38-0.79																											COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Gefitinib	Required	Completed	NCT01203917	IFUM EURTAC (Study 1)	PCD	2012Aug01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	Untreated		Overall Response Rate	106	106			50	41-59			6		5.1-11.1																																COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib	Required	Completed	NCT00036647	BR.21 (Study 4)	PCD	2004Jan30	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	Previously-treated		Not defined	731	488	243	Placebo	8.9	0.9							2.3	1.8	0.59	0.5-0.7	p<0.001									6.7	4.7	0.73	0.61-0.86	<0.001													COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib	Required	Completed	NCT00556712	SATURN (Study 3)	PCD	2010Nov01	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	Previously-treated		Progression free survival	889	438	451	Placebo									2.8	2.6	0.71	0.62-0.82	p<0.0001									12	11	0.81	0.7-0.95	0.0088													COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib	Required	Completed	NCT00446225	EURTAC (Study 1)	PCD	2009Dec01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	Untreated		Progression free survival	175	86	88	Chemotherapy	65	16							10.4	5.2	0.34	0.23-0.49	p<0.001									22.9	19.5	0.93	0.64-1.35														COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Case study	Erlotinib		Unknown					Yes	Yes		1	15329413			Unknown	7	7																															7										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Case study	Gefitinib		Unknown					Yes	Yes		1	15329413			Unknown	4	4																															4										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Case study	Gefitinib		Unknown					Yes	Yes		1	15118073			Unknown	4	4																															4										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	21642865			Unknown	80	43	37		4.7	16.2												1.4	2.9																								COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib		Completed	NCT02228369	BLOOM	PCD	2017Aug19	Yes	Yes		1	31809241	Previously-treated		Maximum tolerated dose/toxicity	41	41			41		26-58		8.3		5.6-16.5		8.6			5.4-13.7										11			18-Aug				17	17									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	YL202		Recruiting	NCT05653752		ECD	2024Dec01	Yes	No		4	NCT05653752			Maximum tolerated dose/toxicity	80	80																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	QLH11811		Not yet recruiting	NCT05555212	Cohort 1	ECD	2024Dec03	Yes	No		4	NCT05555212	Previously-treated		Overall Response Rate	72	72																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Almonertinib + Gentuximab		Recruiting	NCT05223595		ECD	2023Sep30	Yes	No		4	NCT05223595			Maximum tolerated dose/toxicity	42	42																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Triptolide		Recruiting	NCT05166616		ECD	2024Dec15	Yes	No		4	NCT05166616			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Camrelizumab + Carboplatin + Pemetrexed		Not yet recruiting	NCT04970043		ECD	2024Jul30	Yes	No		4	NCT04970043			Progression free survival	58	58																																									COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Tegavivint		Recruiting	NCT04780568		ECD	2023Dec31	Yes	No		4	NCT04780568	Untreated		Maximum tolerated dose/toxicity	18	18																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Temozolomide		"Active, not recruiting"	NCT04541407		PCD	2022Apr25	Yes	No		4	NCT04541407			Maximum tolerated dose/toxicity	1	1																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Anlotinib + Erlotinib		Unknown	NCT03628521		ECD	2019Dec31	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.e21073	Untreated		Overall Response Rate	30	30			92.9								20.53										96.4										26										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Ribociclib		"Active, not recruiting"	NCT03333343		ECD	2023Sep08	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Naporafenib + Nazartinib		"Active, not recruiting"	NCT03333343		ECD	2023Sep08	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Trametinib		Recruiting	NCT03516214	EATON	ECD	2022Dec15	Yes	No		4	NCT03516214			Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Trametinib		"Active, not recruiting"	NCT03333343		ECD	2023Sep08	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Savolitinib		"Active, not recruiting"	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	7	7			86		42-100																										24										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	AV-412		Terminated	NCT00381654		PCD	2009Dec01	Yes	Yes	Primary outcome not met	4	NCT00381654	Previously-treated		Maximum tolerated dose/toxicity	27	27																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Selumetinib		"Active, not recruiting"	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	7	7			14		0-58																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Durvalumab + Osimertinib		"Active, not recruiting"	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	8	8			38		Sep-76																										9	9									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Gefitinib + Nazartinib		"Active, not recruiting"	NCT03333343		ECD	2023Sep08	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Capmatinib + Nazartinib		"Active, not recruiting"	NCT03333343		ECD	2023Sep08	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									COSO29915674	2022Oct12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Gefitinib + Savolitinib		Completed	NCT02374645		PCD	2018Feb18	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.e20559 	Previously-treated		Maximum tolerated dose/toxicity	11	11																															2										COSO29915674	2022Dec13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Zorifertinib		Completed	NCT02228369	BLOOM	PCD	2017Aug19	Yes	Yes	Promising efficacy	1	29056570	Previously-treated		Maximum tolerated dose/toxicity	67	67																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	DS-1205c + Gefitinib		Completed	NCT03599518		PCD	2020Apr22	Yes	Yes		2	10.1016/j.annonc.2020.08.684	Previously-treated		Maximum tolerated dose/toxicity	20																																	1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Afatinib + Xentuzumab		Completed	NCT02191891		PCD	2018Apr18	Yes	Yes		1	34590052	Previously-treated		"MTD, ORR, Toxicity"	26								3.5		0.8-12.9		2.8			1.7-3.6							73										1	18									COSO29915674	2022Dec13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Sapanisertib		"Active, not recruiting"	NCT02503722		ECD	2023Aug31	Yes	No		4	NCT02503722			Maximum tolerated dose/toxicity	36	36																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Afatinib		Completed	NCT01466660	LUX-Lung 7	PCD	2016Apr08	Yes	Yes		1	27083334	Untreated		"PFS, TTP, OS"	319	160	159	Gefitinib	72.5	56	1.32-3.40	0.0018					11	10.9	0.74	0.57-0.95	p=0.0178	13.7	5.5	0.75	0.60-0.94	p=0.0136																					COSO29915674	2023Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Amivantamab + Bevacizumab + Lazertinib		Not yet recruiting	NCT05601973	AMAZE-lung	ECD	2026Mar30	Yes	No		4	NCT05601973	Previously-treated		Overall Response Rate	60	60																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + R-(-)-gossypol acetic acid		Terminated	NCT00988169		PCD	2010May01	Yes	Yes		4	NCT00988169			Overall Response Rate	5	5																															1	3									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	EMB-01 + Osimertinib		Not yet recruiting	NCT05498389	Group 1	ECD	2024Jul01	Yes	No		4	NCT05498389	Previously-treated		Overall Response Rate	115	115																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT05334277	FOCUS-C Group B3	ECD	2025Feb28	Yes	No		4	NCT05334277	Untreated		Progression free survival	280	280																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib + Carboplatin + Pemetrexed		Recruiting	NCT05334277	FOCUS-C Group B2	ECD	2025Feb28	Yes	No		4	NCT05334277	Untreated		Progression free survival	280	280																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lazertinib + Stereotactic Body Radiation Therapy		Not yet recruiting	NCT05167851		ECD	2025Dec01	Yes	No		4	NCT05167851			Progression free survival	68			Lazertinib																																							COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	BLU-701 + Carboplatin + Pemetrexed		Recruiting	NCT05153408	HARMONY	ECD	2024Jun10	Yes	No		4	NCT05153408			Overall Response Rate	160	160																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	BLU-701 + Osimertinib		Recruiting	NCT05153408	HARMONY	ECD	2024Jun10	Yes	No		4	NCT05153408			Overall Response Rate	160	160																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	BLU-701		Recruiting	NCT05153408	HARMONY	ECD	2024Jun10	Yes	No		4	NCT05153408			Overall Response Rate	160	160																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Cisplatin + Icotinib + Pemetrexed		Not yet recruiting	NCT05132985		ECD	2024Jul01	Yes	No		4	NCT05132985			Major pathologic response	45	45																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Cisplatin + Icotinib + Pemetrexed		Recruiting	NCT05104788		ECD	2024Mar01	Yes	No		4	NCT05104788			Major pathologic response	27	27																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed		Recruiting	NCT05258279		ECD	2023Oct01	Yes	No		4	NCT05258279			Overall Response Rate	30	30																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	LY3295668 + Osimertinib		Recruiting	NCT05017025		ECD	2024May25	Yes	No		4	NCT05017025			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Amivantamab + Carboplatin + Lazertinib + Pemetrexed		Not yet recruiting	NCT05498428	PALOMA-2 Cohort 3	ECD	2024May21	Yes	No		4	NCT05498428	Untreated		Overall Response Rate	260	260																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Amivantamab + Carboplatin + Lazertinib + Pemetrexed		Not yet recruiting	NCT05299125	AMIGO-1	ECD	2024Mar01	Yes	No		4	NCT05299125	Untreated		Progression free survival	49	49																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cisplatin + Osimertinib + Pemetrexed		Recruiting	NCT05011487		ECD	2023Sep01	Yes	No		4	NCT05011487			Lymph node clearance rate	30	30																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Befotertinib + Icotinib		Recruiting	NCT05007938		ECD	2023Dec31	Yes	No		4	NCT05007938			Overall Response Rate	30	30																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Almonertinib		Not yet recruiting	NCT04922138	APPOINT	ECD	2024Apr15	Yes	No		4	NCT04922138	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	52	52																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib + Anlotinib		Recruiting	NCT04895930	FOCUS-A	ECD	2022Nov30	Yes	No		4	NCT04895930	Untreated		Overall Response Rate	40	40																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Keynatinib		Recruiting	NCT04824079		ECD	2024Apr22	Yes	No		4	NCT04824079	Previously-treated		Overall Response Rate	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Afatinib + Cisplatin + Pemetrexed + Radiotherapy		Unknown	NCT01553942	ASCENT	ECD	2020Dec01	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.8544			Response rate	13	13			69		39-91						34.6																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Almonertinib + Microwave ablation		Not yet recruiting	NCT04755738		ECD	2023Mar31	Yes	No		4	NCT04755738			Progression free survival	234			Almonertinib																																							COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lenvatinib + Pembrolizumab		Recruiting	NCT05078931		ECD	2022Oct01	Yes	No		4	NCT05078931			Progression free survival	35	35																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Pemetrexed + Platinum-based chemotherapy		Recruiting	NCT05281406	PACE-LUNG	ECD	2023Nov01	Yes	No		4	NCT05281406			Progression free survival	50	50																																									COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Amivantamab + Lazertinib		Not yet recruiting	NCT05498428	PALOMA-2 Cohort 1	ECD	2024May21	Yes	No		4	NCT05498428	Untreated		Overall Response Rate	260	260																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab		"Active, not recruiting"	NCT04099836		ECD	2023Nov10	Yes	No		4	NCT04099836	Previously-treated		Overall Response Rate	39	39																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ascorbic acid + Tyrosine Kinase Inhibitor		Recruiting	NCT03799094		ECD	2020Dec31	Yes	No		4	NCT03799094			Progression free survival	150	150																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Gefitinib		Unknown	NCT04358562		ECD	2022May01	Yes	No		4	NCT04358562			Progression free survival	240	240																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Durvalumab + Tremelimumab		Recruiting	NCT03994393	ILLUMINATE	ECD	2022Feb28	Yes	No		4	NCT03994393			Overall Response Rate	100	100																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	ZN-e4		"Active, not recruiting"	NCT03446417		PCD	2022Jan17	Yes	No		4	NCT03446417			Maximum tolerated dose/toxicity	34	34																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Chemotherapy + Icotinib		Recruiting	NCT03396185		ECD	2022Feb01	Yes	No		4	NCT03396185	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	30	30																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cisplatin + Icotinib + Pemetrexed		Completed	NCT03544814		PCD	2017Jun01	Yes	No		4	NCT03544814			Progression free survival	99	99																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pemetrexed + Toripalimab		Unknown	NCT03513666		PCD	2019Oct22	Yes	Yes		4	10.1200/JCO.2020.38.15_suppl.e21618	Previously-treated		Overall Response Rate	40	40			50				7				7										87.5										20	15									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Stereotactic radiotherapy		Recruiting	NCT03769103	LUOSICNS	ECD	2025Apr01	Yes	No		4	NCT03769103			Progression free survival	76	76																																									COSO29915674	2021Jun18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Icotinib		Completed	NCT03736837	ALTER-L004	PCD	2021Jan01	Yes	Yes		2	10.1016/j.annonc.2020.08.1656	Untreated		Progression free survival	34	34			70.6																		97.1									1	23	9									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Tyrosine Kinase Inhibitor		Unknown	NCT03720873		ECD	2021Jun01	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9030			Progression free survival	60	60			78.3								13			10.7-15.3							100																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Icotinib + Pemetrexed		Unknown	NCT02737774		PCD	2019Oct25	Yes	No		4	NCT02737774			Progression free survival	60	60																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Icotinib + Pemetrexed		Unknown	NCT03151161		ECD	2018Dec31	Yes	No		4	NCT03151161			Clinical activity	118	118																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Carboplatin + Pemetrexed		Unknown	NCT03706287		ECD	2021Mar10	Yes	Yes		2	10.1016/j.jtho.2021.01.1093			Progression free survival	10	10			60								5.8			4.04-10.09							100										6	4									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Gefitinib		Unknown					Yes	Yes		1	25695221	Untreated		Unknown	42	42			73.8								14.4			10.1-19.2																2	29										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Gefitinib		Unknown	NCT02930954		ECD	2018Dec01	Yes	No		4	NCT02930954	Untreated		Progression free survival	180	180																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Local Consolidation Therapy + Osimertinib		Recruiting	NCT03410043		ECD	2023Jan01	Yes	No		4	NCT03410043	Untreated		Progression free survival	143	143																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Selumetinib		"Active, not recruiting"	NCT03392246		ECD	2023Jun30	Yes	No		4	NCT03392246	Untreated		Best overall response	25	25																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Thalidomide		Unknown	NCT03341494		ECD	2019Nov01	Yes	No		4	NCT03341494			Progression free survival	128	128																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cyclophosphamide + Fludarabine + Interleukin-2 + Tumour infiltrating lymphocytes + Vemurafenib		Unknown	NCT00801385		ECD	2009Jun01	Comparison with wt	Yes		1	26898607			Response rate	23	8	15		62.5	6.7							11	2.93									87.5	46.7		26.1	9.17																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT04512430	Neo-DIANA	ECD	2023Dec30	Yes	No		4	NCT04512430			Major pathologic response	26	26																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cisplatin + Pemetrexed		Unknown	NCT03050437		ECD	2017Feb01	Yes	No		4	NCT03050437	Previously-treated		Progression free survival	96	96																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Ramucirumab		Recruiting	NCT03909334		ECD	2023Jun01	Yes	No		4	NCT03909334	Untreated		Progression free survival	150			Osimertinib																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Fruquintinib + Gefitinib		Completed	NCT02976116		PCD	2019Jun28	Yes	No		2	10.1093/annonc/mdz437.004	Untreated		Overall Response Rate	50	50																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Recruiting	NCT05334277	FOCUS-C Group B1	ECD	2025Feb28	Yes	No		4	NCT05334277	Untreated		Progression free survival	280	280																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Recruiting	NCT05165355	ATHEM	ECD	2024Nov01	Yes	No		4	NCT05165355	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	90	90																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Not yet recruiting	NCT05079022		ECD	2023Mar01	Yes	No		4	NCT05079022			Clearance of ctDNA	50	50																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Not yet recruiting	NCT04965831	FRONT	ECD	2023Mar01	Yes	No		4	NCT04965831			Overall Response Rate	40	40																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Recruiting	NCT04982900	TERMGGO	ECD	2022Aug01	Yes	No		4	NCT04982900			Response rate	138			Placebo																																							COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Recruiting	NCT05379803		ECD	2024Jul31	Yes	No		4	NCT05379803			Progression free survival	40	40																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Trastuzumab-emtansine		Terminated	NCT03784599	TRAEMOS	PCD	2021May17	Yes	Yes		3	https://www.onclive.com/view/tdm-1-osimertinib-combo-has-limited-efficacy-for-resistant-egfr-nsclc	Previously-treated		Maximum tolerated dose/toxicity	27	27			11								2.7			2.1-3.5							48																				COSO29915674	2022Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Nazartinib		"Active, not recruiting"	NCT03292133		ECD	2022Oct31	Yes	No		4	NCT03292133	Untreated		Progression free survival	11	11																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib + Nazartinib		Terminated	NCT02335944	Group 3	PCD	2020Nov10	Yes	Yes		2	10.1016/j.annonc.2020.08.1598	Previously-treated		Overall Response Rate	47	47			61.7		46.4-75.5		11.6		6.6-14.3		11			7.6-13.8										15.9																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib + Nazartinib		Terminated	NCT02335944	Group 1	PCD	2020Nov10	Yes	Yes		2	10.1016/j.annonc.2020.08.1598	Previously-treated		Overall Response Rate	52	52			28.8		17.1-43.1		6.3		3.7-10.8		5.6			3.7-7.4										18.8			14.9-21.7														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + Linsitinib		Completed					Yes	Yes	No benefit of treatment	1	27686971	Untreated		Unknown	88	88		Erlotinib																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Osimertinib		"Active, not recruiting"	NCT03122717		ECD	2023Apr01	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.9507	Untreated		Maximum tolerated dose/toxicity	27	27			85.2		67.5-94.1																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Olaparib		Completed	NCT01513174	GOAL	PCD	2016Jul01	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2018.36.15_suppl.9012 	Untreated		Maximum tolerated dose/toxicity	186	186		Gefitinib																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Berberine + Gefitinib		Unknown	NCT03486496	Geber	ECD	2019Jun01	Yes	No		4	NCT03486496			Progression free survival	50																																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Erlotinib		"Active, not recruiting"	NCT03126799	AvaTa	PCD	2021Dec31	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.9107			Progression free survival	127	64	63	Erlotinib	85.9	83.9		0.746					17.5	12.4	0.74	0.51-1.08	0.119																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Erlotinib		Completed	NCT01532089		PCD	2018Feb13	Yes	Yes		4	NCT01532089			Progression free survival	88	43	45	Erlotinib									17.9	13.5	0.81	0.5-1.31	0.39									32.4	50.6	1.41	0.71-2.81	0.33													COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Tegafur-gimeracil-oteracil potassium		Unknown	NCT03457337		ECD	2020Oct31	Yes	No		4	NCT03457337	Untreated		Progression free survival	200	200		Gefitinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Telaglenastat		Recruiting	NCT03831932		ECD	2023Jun01	Yes	No		4	NCT03831932	Previously-treated		Overall Response Rate	18	18		Osimertinib																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ficlatuzumab + Gefitinib		Completed	NCT01039948		PCD	2013Aug01	Yes	Yes	No benefit of treatment	1	27448761	Untreated		Overall Response Rate	188	94	94	Gefitinib																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Terminated	NCT01819428		PCD	2015Nov01	Yes	Yes	Slow accrual	4	NCT01819428	Untreated		Overall Response Rate	22	22																																									COSO29915674	2022Aug17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib		Completed	NCT00266877		PCD	2009Jan01	Comparison with wt	Yes		1	20479403	Previously-treated		Overall Response Rate	139	91	48		54	25			14	7.7																																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lapatinib		Terminated	NCT00073008	EGF20014	PCD	2008Jul01	Yes	Yes	No benefit of treatment	1	20215545			Overall Response Rate	131	131																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lazertinib		Not yet recruiting	NCT05463224		ECD	2025Mar31	Yes	No		4	NCT05463224			Progression free survival	100	100																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lazertinib		"Active, not recruiting"	NCT03046992		ECD	2022Sep01	Yes	No		4	NCT03046992	Previously-treated		Overall Response Rate	230	230																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT02444819		PCD	2017Aug01	No	No		4	NCT02444819	Untreated		Overall Response Rate	33	33																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Nazartinib		"Active, not recruiting"	NCT02108964		PCD	2018Mar22	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Phase-II-results-for-single-agent-nazartinib-EGF816-in-adult-patients-pts-with-treatment-naive-EGFR-mutant-non-small-cell-lung-cancer-NSCLC	Untreated		Overall Response Rate	45	45			64		49-78																93									1	28										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT02616393	Cohort C	PCD	2018Apr03	Yes	Yes		4	NCT02616393	Previously-treated		Overall Response Rate	3	3											8.7			4.65-14.34		8.06			7.42-8.70																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT02616393	Cohort B	PCD	2018Apr03	Yes	Yes		4	NCT02616393	Previously-treated		Overall Response Rate	20	20											2.51			1.58-3.96		1.88			1.39-8.28																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT02616393	Cohort A	PCD	2018Apr03	Yes	Yes		4	NCT02616393	Previously-treated		Overall Response Rate	13	13											2.14			0.96-6.33		4.95			0.96-6.33												6										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT00522145		PCD	2009Oct01	No	No		1	22011666	Previously-treated		Response rate	41	41			3																																						COSO29915674	2021Aug20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT00364780		PCD	2010May01	Yes	Yes		1	22722787	Untreated		Response rate	51	14	37										9.3	3.6												22.5	18.4		13.6-19.6	0.05													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Suspended	NCT04591002		ECD	2022Nov18	Yes	No		4	NCT04591002			Clinical activity	56	56																																									COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT03769103	LUOSICNS	ECD	2025Apr01	Yes	No		4	NCT03769103			Progression free survival	76	76																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT03586453		ECD	2023Mar01	Yes	No		4	NCT03586453			Biomarker discovery	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Dacomitinib		Recruiting	NCT04027647		ECD	2023Mar30	Yes	No		4	NCT04027647			Progression free survival	118	118																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Not yet recruiting	NCT05514314		ECD	2024Sep30	Yes	No		4	NCT05514314			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	90	90																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Unknown	NCT03346811	CHALLENGE	ECD	2019May10	Yes	Yes		1	35862035			Overall Response Rate	116	116			52.6		43.1-61.9						10.3			"8,3-12.2"							84.5			23.2			17.7-28.0														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Recruiting	NCT03349203		ECD	2022Feb01	Yes	No		4	NCT03349203			Overall Response Rate	60	60																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Recruiting	NCT03749213		ECD	2022Feb01	Yes	No		4	NCT03749213			Overall Response Rate	36	36																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib		Unknown	NCT03399669		ECD	2018Jun30	Yes	No		4	NCT03399669	Previously-treated		Time to progression	100	100																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib		Unknown	NCT02347839	NEGOTIATE	ECD	2020Jan01	Yes	No		4	NCT02347839			Resection rate	37	37																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib		Completed	NCT01933347	CTONG1304	PCD	2017Apr10	Yes	No		2	10.1200/JCO.2017.35.15_suppl.9035	Previously-treated		"Disease control rate, Clinical benefit rate"	46	46			4.7								4.4										69.8			8																	COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 2	Afatinib		Completed	JRCT031180136	NEJ027	PCD	2019Dec23	Yes	Yes		2	10.1186/s12885-021-07861-1	Untreated	Geriatric	Overall Response Rate	37	37			75.7		58.8-88.2						14.2			9.5-19.0										35.2			-35.2														COSO29915674	2022Feb15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Erlotinib		Completed	NCT00556712	SATURN	PCD	2010Nov01	Expression confirmed	Yes		1	20493771	Previously-treated		Progression free survival	618	307	311	Placebo									2.8	2.6	0.69	0.58-0.82	p<0.0001																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Amivantamab + Carboplatin + Pemetrexed		Recruiting	NCT04988295		ECD	2023May31	Yes	No		4	NCT04988295			Progression free survival	600			Carboplatin + Pemetrexed																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Amivantamab + Carboplatin + Lazertinib + Pemetrexed		Recruiting	NCT04988295		ECD	2023May31	Yes	No		4	NCT04988295			Progression free survival	600			Carboplatin + Pemetrexed																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib + Chemotherapy		Not yet recruiting	NCT04923906		ECD	2024Jan31	Yes	No		4	NCT04923906	Untreated		Progression free survival	624			Almonertinib																																							COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	EGFR-TKI + JY025		Not yet recruiting	NCT04874844		ECD	2022Mar30	Yes	No		4	NCT04874844	Untreated		Progression free survival	420	420																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Gefitinib or Erlotinib + Niacinamaide		Unknown	NCT02416739		ECD	2020Mar01	Yes	Yes		2	10.1016/j.jtho.2022.07.769			Progression free survival	110	55	55	Gefitinib + Placebo									12.7	10.9			0.2									31	29.4																COSO29915674	2022Dec13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Lazertinib + Placebo		"Active, not recruiting"	NCT04487080	MARIPOSA	ECD	2024Apr30	Yes	No		4	NCT04487080	Untreated		Progression free survival	1074	1074																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib + Placebo		"Active, not recruiting"	NCT04487080	MARIPOSA	ECD	2024Apr30	Yes	No		4	NCT04487080	Untreated		Progression free survival	1074	1074																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Amivantamab + Lazertinib		Recruiting	NCT05388669		ECD	2024Jan24	Yes	No		4	NCT05388669	Previously-treated		"PFS, ORR"	640			Amivantamab + Lazertinib																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Amivantamab + Lazertinib		"Active, not recruiting"	NCT04487080	MARIPOSA	ECD	2024Apr30	Yes	No		4	NCT04487080	Untreated		Progression free survival	1074	1074																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib + Carboplatin + Pemetrexed		Not yet recruiting	NCT04500717	ACROSS2	ECD	2022Oct01	Yes	No		4	NCT04500717			Progression free survival	460			Almonertinib																																							COSO29915674	2021Aug19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib + Carboplatin + Pemetrexed		Not yet recruiting	NCT04500704	ACROSS1	ECD	2021Dec01	Yes	No		4	NCT04500704			Progression free survival	166			Almonertinib																																							COSO29915674	2021Aug19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Icotinib + Stereotactic radiotherapy		Recruiting	NCT04058704	SMART	ECD	2022Dec31	Yes	No		4	NCT04058704			Overall survival	296			Icotinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Anlotinib + Gefitinib		Recruiting	NCT04028778	FL-ALTER	ECD	2020Dec01	Yes	No		4	NCT04028778			Progression free survival	310			Gefitinib + Placebo																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Chemotherapy + Osimertinib		"Active, not recruiting"	NCT03521154	LAURA	ECD	2023Jul31	Yes	No		4	NCT03521154			Progression free survival	216	216																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Patritumab deruxtecan		Recruiting	NCT05338970	HERTHENA-Lung02	ECD	2024Aug30	Yes	No		4	NCT05338970	Previously-treated		Progression free survival	560			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Chemotherapy + Erlotinib	Required	Completed	NCT00883779	FASTACT-2	PCD	2014Dec01	Yes	Yes		1	23782814	Untreated		Progression free survival	97	49	48	Chemotherapy	84	15							16.8	6.9	0.25	0.16-0.39	p<0.0001									31.4	20.6	0.48	0.27-0.84	0.0092													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Gefitinib + Yiqi-yangyin-jiedu Decoction		Unknown	NCT02929693	SHUTCM	ECD	2019Jun01	Yes	No		4	NCT02929693			Progression free survival	198			Placebo																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Apatinib + Gefitinib		Recruiting	NCT02824458		ECD	2023Dec01	Yes	Yes		1	34033974	Untreated		Progression free survival	313	157	156	Gefitinib + Placebo									13.7	10.2	0.71	0.0189																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Naquotinib		Terminated	NCT02588261	SOLAR	PCD	2017Dec21	Yes	Yes	IDMC recommended study closure	4	NCT02588261	Untreated		Progression free survival	530	267	263	Erlotinib	33	47.9		1					9.26	9.59																													COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Naquotinib		Terminated	NCT02192697		PCD	2016Jan15	Yes	Yes	Serious adverse events	4	NCT02588261	Previously-treated		Overall Response Rate	124																																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib		Recruiting	NCT04951635		ECD	2024Jul15	Yes	No		4	NCT04951635	Previously-treated		Progression free survival	150			Placebo																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib		"Active, not recruiting"	NCT03849768		PCD	2021Jan15	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9013	Untreated		Progression free survival	429	214	215	Gefitinib					18.1	8.3	0.28-0.51	<0.0001	19.3	9.9	0.46	0.36-0.60	<0.0001																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alflutinib		Recruiting	NCT04143607		ECD	2023Mar30	Yes	No		4	NCT04143607			Progression free survival	334			Gefitinib																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alflutinib		Unknown	NCT03787992	FLAG	ECD	2021Jun01	Yes	Yes		1	35662408	Untreated		Progression free survival	358	178	179	Gefitinib									20.8	11.1	0.44	0.34-0.58	<0.0001																										COSO29915674	2022Sep20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Zorifertinib		Completed	NCT03653546		PCD	2022Jul12	Yes	No		4	NCT03653546	Previously-treated		Progression free survival	492			Gefitinib																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Abivertinib		Not yet recruiting	NCT03856697		ECD	2022Mar01	Yes	No		4	NCT03856697	Untreated		Progression free survival	406			Gefitinib																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Bevacizumab + Erlotinib		"Active, not recruiting"	NCT02633189	BEVERLY	ECD	2021Dec01	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/bevacizumab-erlotinib-vs-erlotinib-alone-as-first-line-treatment-of-pts-with-egfr-mutated-advanced-non-squamous-nsclc-final-analysis-of-the-mult	Untreated		Progression free survival	159	80	79	Erlotinib									15.4	9.7	0.6	0.42-0.85	0.0039									28.4	23	0.72	0.46-1.10	0.12													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Bevacizumab + Erlotinib		Unknown	NCT02759614	Artemis	PCD	2018Jun01	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/CTONG-1509-Phase-3-study-of-bevacizumab-with-or-without-erlotinib-in-untreated-Chinese-patients-with-advanced-EGFR-mutated-NSCLC	Untreated		Progression free survival	311	157	154	Erlotinib	86.3	84.7		0.74					18	11.3	0.55	0.41-0.75	<0.001																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Afatinib + Cetuximab		"Active, not recruiting"	NCT02438722	SWOG S1403	PCD	2018Sep25	Yes	Yes	2yr OS 67 vs 70%	4	NCT02442349	Untreated		"OS, PFS"	168	83	85	Afatinib	67	74							11.9	13.4	1.01	0.72-1.43	0.94																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Cisplatin + Gefitinib + Pemetrexed		Unknown	NCT02518802		ECD	2018Jan01	Yes	No		4	NCT02518802			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	220			Cisplatin + Pemetrexed																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Cisplatin + Gefitinib + Pemetrexed		Recruiting	NCT03381066		ECD	2022Dec01	Yes	No		4	NCT03381066			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	225			Cisplatin + Vinorelbine																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Olmutinib		Unknown		ELUXA3			Yes	No		5	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-program-broadly-investigate	Untreated		Unknown																																											COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Nazartinib		Withdrawn	NCT03529084		ECD	2020Aug13	Yes	No	Changed business priorities	4	NCT03529084	Untreated		Progression free survival	0	0																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Tesevatinib		Terminated	NCT01487174		PCD	2013Jul25	No	Yes	Slow accrual	4	NCT01487174	Previously-treated		Overall survival	8	8																																									COSO29915674	2022Nov29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Recruiting	NCT05120349	ADAURA2	ECD	2027Aug02	Yes	No		4	NCT05120349			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	380			Placebo																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Recruiting	NCT04351555	NeoADAURA	ECD	2024Mar26	Yes	No		4	NCT04351555			Major pathologic response	328			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		"Active, not recruiting"	NCT04035486	FLAURA2	ECD	2023Apr03	Yes	No		4	NCT04035486			Progression free survival	587			Carboplatin + Pemetrexed																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Icotinib		"Active, not recruiting"	NCT02448797	EVIDENCE	ECD	2022Jun30	Yes	Yes		1	34280355			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	282	151	132																																47	22.1	0.36	0.24?0.55	<0.0001				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Icotinib		Completed	NCT01040780	ICOGEN	PCD	2010Mar01	No	Yes		1	23948351	Previously-treated		Progression free survival	395	200	199	Gefitinib									4.6	3.4	0.84	0.67-1.05	p=0.13																										COSO29915674	2023Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Gefitinib		Unknown	UMIN000006252	IMPACT			Yes	Yes		2	10.1200/JCO.21.01729			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	232	116	116	Cisplatin + Vinorelbine																								1.03	0.65-1.65	0.89					35.9	25.1	0.92	0.67-1.28	0.63				COSO29915674	2022Feb14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 3	Erlotinib		Completed	NCT01024413		PCD	2015Jun01	Yes	Yes	Primary outcome not met	1	28103612			Progression free survival	256	128	128	Gefitinib									13	10.4		0.62-1.05	0.11									22.9	20.1		0.63-1.13	0.25													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Phase 4	Dacomitinib		"Active, not recruiting"	NCT04511533		ECD	2022Oct18	Yes	No		4	NCT04511533			Maximum tolerated dose/toxicity	101	101																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Unknown	Apatinib + Erlotinib		Unknown	NCT03634059		ECD	2019Aug15	Yes	No		4	NCT03634059	Untreated		Progression free survival	80	80																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Unknown	Apatinib + Icotinib		Unknown	NCT03634059		ECD	2019Aug15	Yes	No		4	NCT03634059	Untreated		Progression free survival	80	80																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Unknown	Anlotinib + Gefitinib + Icotinib		Unknown	NCT03766490		ECD	2019Dec20	Yes	No		4	NCT03766490	Previously-treated		Progression free survival	66	66																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / non small cell carcinoma	1	Unknown	Gefitinib + Radiotherapy		Not yet recruiting	NCT03381430	GRAY	ECD	2023Mar01	Yes	No		4	NCT03381430			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	50	50																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib		"Active, not recruiting"	NCT02981108	APOLLO	PCD	2019Jan05	Yes	Yes		2	10.1016/j.jtho.2021.10.024	Previously-treated		Overall Response Rate	244				68.9		62.6-74.6		15.1		12.5-16.6		12.4			9.7-15.0							93.4																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib + Chemotherapy		Recruiting	NCT04952168		ECD	2022Jun02	Yes	No		4	NCT04952168			Overall survival	26	26																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib + Chemotherapy		Recruiting	NCT04905550		ECD	2024Mar01	Yes	No		4	NCT04905550			Progression free survival	50	50																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 3	Afatinib + Cetuximab		"Active, not recruiting"	NCT02438722	SWOG S1403	PCD	2018Sep25	Yes	Yes	2yr OS 67 vs 70%	4	NCT02442349	Untreated		"OS, PFS"	168	83	85	Afatinib	67	74							11.9	13.4	1.01	0.72-1.43	0.94																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 3	Almonertinib		"Active, not recruiting"	NCT04687241		ECD	2026Jan18	Yes	No		4	NCT04687241	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	192			Almonertinib + Placebo																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861 or EGFR_S768I or EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bintrafusp alfa + Carboplatin + Cisplatin + Pemetrexed		Terminated	NCT04971187		PCD	2022Feb21	Yes	Yes	PI requested termination 	4	NCT04971187	Previously-treated		Progression free survival	3	3																																									COSO29915674	2022Dec02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon20ins or ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Mobocertinib		"Active, not recruiting"	NCT02716116	Expansion Cohort 3	ECD	2023Mar13	Yes	No		4	NCT02716116			Overall Response Rate	395	395																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_19ins				lung / carcinoma / non small cell carcinoma	4	Case study	Gefitinib		Unknown					Yes	Yes		1	29483495			Unknown	1	1																															1										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Mobocertinib	Required	"Active, not recruiting"	NCT02716116		ECD	2023Mar13	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf			Overall Response Rate	114	114			28		20-37		17.5		7.4-20.3																																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Amivantamab		Recruiting	NCT02609776		ECD	2024Jan04	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761210s002lbl.pdf	Previously-treated		Overall Response Rate	81	81			40		29-51		11.1		-6.9																					3	29										COSO29915674	2023Jan20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Case study	Erlotinib		Unknown					Yes	Yes		1	24353160			Unknown	3																																2	1									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Case study	Icotinib		Unknown					Yes	Yes		3	https://www.jto.org/article/S1556-0864(17)32886-1/fulltext			Unknown	18				33.3	0							9	1.2			p<0.001						100	16.2																			COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alflutinib		Recruiting	NCT04858958	FAVOUR1 cohort 1	ECD	2021Oct01	Yes	Yes		2	10.1016/j.annonc.2021.08.1815	Untreated		Overall Response Rate	10	10																															7	3									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 1	BLU-451		Recruiting	NCT05241873		ECD	2024Aug23	Yes	No		4	NCT05241873			Overall Response Rate	150	150																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 1	JMT101		Unknown	NCT04448379		ECD	2021Dec31	Yes	No		4	NCT04448379			Maximum tolerated dose/toxicity	48	48																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alflutinib		Recruiting	NCT04858958	FAVOUR1 cohort 2/3	ECD	2021Oct01	Yes	No		4	NCT04858958	Previously-treated		Overall Response Rate	20	20																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alflutinib		Withdrawn	NCT04958967	FAVOUR1	ECD	2022May01	Yes	No		4	NCT04958967			Overall Response Rate	0	0																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Afatinib		Completed	NCT02369484	NICHE	PCD	2017Sep15	Yes	Yes		4	NCT02369484			"Disease control rate, Clinical benefit rate"	13	13			7.7								3.67			1.38-8.17							53.8			12.93																	COSO29915674	2021Dec14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	HS-10376		Recruiting	NCT05435274		ECD	2024Oct07	Yes	No		4	NCT05435274			Overall Response Rate	380	380																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	JMT101 + Osimertinib		Not yet recruiting	NCT05132777		ECD	2023Sep30	Yes	No		4	NCT05132777			Overall Response Rate	155	155																																									COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Mobocertinib + Pemetrexed		"Active, not recruiting"	NCT02716116		ECD	2023Mar13	Yes	No		4	NCT02716116			Overall Response Rate	395	395																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib + Ramucirumab		Not yet recruiting	NCT05045404		ECD	2024Dec30	Yes	No		4	NCT05045404			Progression free survival	36	36																																									COSO29915674	2021Nov15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Amivantamab + Carboplatin + Pemetrexed		Not yet recruiting	NCT05498428	PALOMA-2 Cohort 2	ECD	2024May21	Yes	No		4	NCT05498428	Untreated		Overall Response Rate	260	260																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pyrotinib		Unknown	ChiCTR1800020262				Yes	Yes		1	35101045				62	62			17.7		9.2-29.5																																				COSO29915674	2022Sep21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pyrotinib		Unknown	NCT04063462	PEER20	ECD	2021Apr01	Yes	No		4	NCT04063462	Previously-treated		Overall Response Rate	60	60																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tarloxotinib		Terminated	NCT03805841	RAIN cohort A	PCD	2021Apr09	Yes	Yes		2	10.1016/annonc/annonc325			Overall Response Rate	11	11																					55											6									COSO29915674	2022Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	CLN-081		Recruiting	NCT04036682		ECD	2024Dec31	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9077	Previously-treated		Overall Response Rate	25	25			40																												10	14									COSO29915674	2022Nov29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	DZD9008		Recruiting	NCT03974022	WU-KONG1	ECD	2022Dec01	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9008			Overall Response Rate	31	31			48.4																		90.3																				COSO29915674	2022Sep21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Mobocertinib		"Active, not recruiting"	NCT02716116	Expansion Cohort 2	ECD	2023Mar13	Yes	No		4	NCT02716116			Overall Response Rate	395	395																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Mobocertinib		Withdrawn	NCT04576208		ECD	2022Jul31	Yes	No		4	NCT04576208			Maximum tolerated dose/toxicity	0	0																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Sintilimab		"Active, not recruiting"	NCT04790409		ECD	2022Jun30	Yes	Yes		2	10.1016/j.annonc.2022.02.030			Progression free survival	11	11			36.4								4.3										90.9																				COSO29915674	2022Dec02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pirotinib		Recruiting	NCT03574402	TRUMP Arm 9	ECD	2022Dec30	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Not yet recruiting	NCT05466149		ECD	2024Apr01	Yes	No		4	NCT05466149			Overall Response Rate	100	100																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Afatinib + Cetuximab		"Active, not recruiting"	NCT03727724	AFACET	ECD	2022Dec01	Yes	Yes	Primary outcome met	2	10.1200/JCO.2021.39.15_suppl.9112			"Disease control rate, Clinical benefit rate"	37	37			47								5.5																				8	7									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + Onalespib lactate		"Active, not recruiting"	NCT02535338	Cohort B	PCD	2021Sep03	Yes	Yes		1	34140248	Previously-treated		Maximum tolerated dose/toxicity	10	10			0								5.4										40																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Recruiting	NCT03318939	ZENITH20	ECD	2023Mar01	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-targeted-anticancer-therapies-congress/safety-tolerability-and-preliminary-efficacy-of-poziotinib-with-twice-daily-strategy-in-egfr-her2-exon-20-mutant-non-small-cell-lung-cancer	Untreated		Overall Response Rate	79	79			27.8		18.4-39.1		6.5				7.2										86.1																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Recruiting	NCT04402008	SPI-POZ-104	ECD	2025Jan01	Yes	No		4	NCT04402008			Overall Response Rate	76	76																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Terminated	NCT04044170		PCD	2020Apr13	Yes	No		4	NCT04044170			Overall Response Rate	5	5																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Recruiting	NCT03318939	ZENITH20	ECD	2023Mar01	Yes	No		4	NCT03318939			Overall Response Rate	603																																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Recruiting	NCT03066206	2016-0783	ECD	2023Mar01	Yes	Yes		2	10.1016/j.jtho.2018.08.243			Overall Response Rate	40	40											5.6			-5.06																	15										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Suspended	NCT03191149		ECD	2023Jul31	Yes	No		4	NCT03191149	Previously-treated		Overall Response Rate	20	20																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Completed	NCT03414814		PCD	2021Aug03	Yes	Yes		2	10.1093/annonc/mdz260.051	Previously-treated		Overall Response Rate	3	3			0																													3									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	Poziotinib		Recruiting	NCT05378763	PINNACLE	ECD	2027Dec25	Yes	No		4	NCT05378763			Progression free survival	268			Docetaxel																																							COSO29915674	2022Oct12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	Amivantamab + Carboplatin + Pemetrexed		Recruiting	NCT04538664	PAPILLON	ECD	2023Sep30	Yes	No		4	NCT04538664			Progression free survival	300			Carboplatin + Pemetrexed																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	Pyrotinib		Recruiting	NCT04447118	PYRAMID-1	ECD	2022Oct31	Yes	No		4	NCT04447118	Previously-treated		Progression free survival	150			Docetaxel																																							COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	DZD9008		Not yet recruiting	NCT05668988		ECD		Yes	No		4	NCT05668988	Untreated		Progression free survival	320			Platinum-based chemotherapy																																							COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	Mobocertinib		Recruiting	NCT04129502		ECD	2026Feb20	Yes	No		4	NCT04129502			Progression free survival	318			Carboplatin + Pemetrexed																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	Entrectinib		Recruiting	NCT03178552	B-FAST Cohort F	ECD	2024Apr27	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alflutinib		Recruiting	NCT05607550		ECD	2025Aug15	Yes	No		4	NCT05607550	Untreated		Progression free survival	375			Platinum-based chemotherapy																																							COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Phase 4	Osimertinib		Not yet recruiting	NCT05513664		ECD	2023Jun01	Yes	No		4	NCT05513664			Overall Response Rate	80	80																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	1	Unknown	DZD9008		Recruiting	NCT05559645	WU-KONG15	ECD	2023Dec31	Yes	No		4	NCT05559645	Previously-treated		Progression free survival	110	110																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719			p.G719X	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Afatinib	Required	Unknown		Afatinib FDA			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf			Not defined	8	8			75				17.3																																		COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719			p.G719X	lung / carcinoma / non small cell carcinoma	1	Case study	Gefitinib		Unknown					Yes	Yes		1	28184913			Unknown																															50												COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719			p.G719X	lung / carcinoma / non small cell carcinoma	1	Case study	Gefitinib		Unknown					Yes	Yes		1	15118073			Unknown	1	1																															1										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719			p.G719X	lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib		Completed	NCT00266877		PCD	2009Jan01	Yes	Yes		1	20479403			Overall Response Rate	4	4																															3										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719			p.G719X	lung / carcinoma / non small cell carcinoma	1	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	18	18			77.8																																						COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719			p.G719X	lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Afatinib		Unknown					Yes	Yes		1	34540680				82	82			52.4								11.3			5.6-17.0																											COSO29915674	2021Nov23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		"Active, not recruiting"	NCT03434418		ECD	2023Jun30	Yes	No		1	NCT03434418	Untreated		Overall Response Rate	17	17																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Bevacizumab		Recruiting	NCT05267288		ECD	2022Dec01	Yes	No		4	NCT05267288			Progression free survival	30	30																																									COSO29915674	2022May16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Sutetinib		Not yet recruiting	NCT05168566		ECD	2023Feb18	Yes	No		4	NCT05168566			Overall Response Rate	99	99																																									COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Pemetrexed + Platinum-based chemotherapy		Recruiting	NCT05215951	MINOVA	ECD	2023Apr30	Yes	No		4	NCT05215951			Overall Response Rate	35	35																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Alflutinib		Recruiting	NCT05548348		ECD	2023Dec31	Yes	No		4	NCT05548348			Overall Response Rate	30	30																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Not yet recruiting	NCT05546866		ECD	2029Jun30	Yes	No		4	NCT05546866			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	50	50																																									COSO29915674	2022Dec16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9050 			Overall Response Rate	19	19																															10										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_G719 or EGFR_L861Q or EGFR_S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 3	Almonertinib		Not yet recruiting	NCT04951648		ECD	2023Oct04	Yes	No		4	NCT04951648	Untreated		Progression free survival	220			Chemotherapy																																							COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R	51765161 + 51767322 + 51801258 + 51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Osimertinib		Not yet recruiting	NCT04988607		ECD	2024Nov01	Yes	No		4	NCT04988607	Untreated		Progression free survival	90			Osimertinib																																							COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R	51765161 + 51767322 + 51801258 + 51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	Phase 2	Anlotinib + Dacomitinib		Not yet recruiting	NCT05271916		ECD	2025Jan01	Yes	No		4	NCT05271916			Progression free survival	140	140																																									COSO29915674	2022May16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R	51765161 + 51767322 + 51801258 + 51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Pemetrexed		Completed	NCT01469000		PCD	2015Apr01	Yes	Yes		1	27507876	Untreated		Progression free survival	75	52	23	Gefitinib									12.6	10.9	0.58		0.054																39	11									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R	51765161 + 51767322 + 51801258 + 51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	Phase 3	Bevacizumab + Icotinib		Recruiting	NCT05263947		ECD	2023Aug30	Yes	No		4	NCT05263947	Previously-treated		Progression free survival	284			Icotinib																																							COSO29915674	2022May16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R_Exon19del and (TP53_Exon4 or TP53_Exon7)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib or Erlotinib		Completed	NCT01024413		PCD	2015Jun01	Yes	Yes		1	33317922			Progression free survival													9.4													15.8																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R_Exon19del and EGFR_no_T790M and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Capmatinib + Osimertinib		"Active, not recruiting"	NCT04816214	GEOMETRY-E	ECD	2022Dec30	Yes	No		4	NCT04816214	Previously-treated		Progression free survival	6			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L858R_Exon19del and TP53_not_Exon4 and TP53_not_Exon7				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib or Erlotinib		Completed	NCT01024413		PCD	2015Jun01	Yes	Yes		1	33317922			Progression free survival													11													20																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Afatinib	Required	Unknown		Afatinib FDA			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf			Not defined	12	12			58.3				9.7																																		COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9050 			Overall Response Rate	9	9																															7										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	16	16			56.3																																						COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_S768I	51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Afatinib	Required	Unknown		Afatinib FDA			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf			Not defined	1	1			100				37.3																																		COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_S768I	51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9050 			Overall Response Rate	8	8																															3										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_S768I	51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	8	8			100																																						COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_S768I or EGFR_V769L	51768106 + 51811749		p.S768I + p.V769L	lung / carcinoma / non small cell carcinoma	4	Case study	Gefitinib		Unknown					Yes	Yes		1	17045698			Unknown	1	1																															1										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Osimertinib	Required	"Active, not recruiting"	NCT02151981	AURA3	PCD	2016Apr15	Yes	Yes		4	25923549	Untreated		Progression free survival	382	242	140	Chemotherapy	65	29		<0.001	11	4.2			10.1	4.4	0.3	0.23-0.41	<0.001																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Case study	Afatinib		Completed	NCT00711594	LUX-Lung 4	PCD	2013Nov01	Yes	Yes		1	22071596	Previously-treated		Unknown	1	1																																1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Afatinib		Unknown					Comparison with wt	Yes		1	24035188			Unknown	34	21	13		5	38							3.2	4.6			0.33																										COSO29915674	2022May11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Sapanisertib		"Active, not recruiting"	NCT04479306		ECD	2023Jan02	Yes	No		4	NCT04479306	Previously-treated		Maximum tolerated dose/toxicity	48	48																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	QLH11811		Not yet recruiting	NCT05555212	Cohort 3	ECD	2024Dec03	Yes	No		4	NCT05555212	Previously-treated		Overall Response Rate	72	72																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + VIC-1911		Not yet recruiting	NCT05489731	Cohort 2	ECD	2024Feb24	No	No		4	NCT05489731			Maximum tolerated dose/toxicity	72	72																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Alisertib + Osimertinib		"Active, not recruiting"	NCT04479306		ECD	2023Jan02	Yes	No		4	NCT04479306	Previously-treated		Maximum tolerated dose/toxicity	48	48																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	SH-1028		Unknown	NCT03618043		ECD	2019Dec01	Yes	No		4	NCT03618043			Maximum tolerated dose/toxicity	14	14																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	SH-1028		Unknown	NCT03603262		ECD	2019Dec01	Yes	No		4	NCT03603262	Previously-treated		Maximum tolerated dose/toxicity	85	85																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	D0316		"Active, not recruiting"	NCT03452150	100mg	PCD	2020Aug28	Yes	Yes		1	35274722	Previously-treated		Maximum tolerated dose/toxicity	33	33											9.6			-6.9																	15	16									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Avitinib		Completed	NCT03053219		PCD	2018Jul01	Yes	No		4	NCT03053219			Overall Response Rate	7	7																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Savolitinib		"Active, not recruiting"	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	8	8			25		Mar-65																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Selumetinib		"Active, not recruiting"	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	23	23			57		34-77																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Afatinib + Ruxolitinib		Completed	NCT02145637		PCD	2017Nov09	Yes	Yes		1	31319994	Previously-treated		Maximum tolerated dose/toxicity	20	20			25								4.9										100										5	15									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Durvalumab + Osimertinib		"Active, not recruiting"	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	13	13			54		25-81																										7	2									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Nivolumab		Terminated	NCT02323126		PCD	2019Sep23	Yes	No		4	NCT02323126	Previously-treated		Progression free survival	64	64																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Ramucirumab		Completed	NCT02789345		PCD	2017Oct19	Yes	Yes		1	33046516	Previously-treated		Maximum tolerated dose/toxicity	25	25			76				13.4				11										92									1	18	4									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Necitumumab + Osimertinib		Completed	NCT02789345		PCD	2017Oct19	Yes	No		4	NCT02789345	Previously-treated		Maximum tolerated dose/toxicity	74	74																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	BPI-7711		Completed	NCT03386955		PCD	2021Dec23	Yes	Yes		2	10.1093/annonc/mdz437.002	Previously-treated		Maximum tolerated dose/toxicity	119	119			61								9.92										89																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Naquotinib		Completed	NCT02113813	8273-CL-0102	PCD	2017Jul28	Yes	Yes		1	28954786	Previously-treated		Maximum tolerated dose/toxicity	110	110			30.7								6.8																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Abivertinib		"Active, not recruiting"	NCT02330367		ECD	2022Dec01	Yes	Yes		1	30032814			Overall Response Rate	16	16			60								8.12													17.62							9	5									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Afatinib + Cetuximab		Completed	NCT01090011		PCD	2013Jan01	Yes	Yes		1	29110849	Previously-treated		Maximum tolerated dose/toxicity	20	20											4.8																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Olmutinib		Terminated	NCT04510415		PCD	2018Dec11	Yes	Yes	Sponor withdrew support	4	NCT04510415	Previously-treated		Overall Response Rate	2	2																																									COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		"Active, not recruiting"	NCT01802632	AURA	PCD	2015May01	Yes	Yes		4	25923549	Previously-treated		Overall Response Rate	127	127			61	21							9.6	2.8																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	EMB-01 + Osimertinib		Not yet recruiting	NCT05498389	Group 2/3	ECD	2024Jul01	Yes	No		4	NCT05498389	Previously-treated		Overall Response Rate	115	115																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Pemetrexed + Sulfatinib + Toripalimab		Recruiting	NCT05003037		ECD	2023Apr30	Comparison with wt	No		4	NCT05003037			Progression free survival	106	106																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib + Radiotherapy		Recruiting	NCT04970693		ECD	2024Jan31	Yes	No		4	NCT04970693	Previously-treated		Progression free survival	64	64																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Almonertinib + Carboplatin + Pemetrexed		Unknown	NCT04592666	APPEAL	ECD	2021Dec31	Yes	No		4	NCT04592666			Progression free survival	226	226																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Osimertinib		Not yet recruiting	NCT04438902	TRAIN	ECD	2022Dec01	Yes	No		4	NCT04438902	Previously-treated		Progression free survival	30	30																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	ZN-e4		"Active, not recruiting"	NCT03446417		PCD	2022Jan17	Yes	No		4	NCT03446417			Maximum tolerated dose/toxicity	34	34																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	D0316		"Active, not recruiting"	NCT03861156		PCD	2021Aug15	Yes	Yes		2	10.1158/1538-7445.AM2021-CT170			Overall Response Rate	290	290			64.8		59.0-70.3																95.2										188										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Avitinib		Recruiting	NCT03574402	TRUMP Arm 1	ECD	2022Dec30	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Interleukin-2 + WT1-sensitized allogenic T cells		Recruiting	NCT04764214		ECD	2022Dec31	Yes	No		4	NCT04764214			Progression free survival	56	56																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Local Consolidation Therapy + Osimertinib		Recruiting	NCT03410043	NORTHSTAR	ECD	2023Jan01	Yes	No		4	NCT03410043	Previously-treated		Progression free survival	143	143																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		"Active, not recruiting"	NCT01449461		PCD	2015Nov01	Yes	No		4	NCT01449461	Previously-treated		Overall Response Rate	137	137																																									COSO29915674	2021May20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Emibetuzumab + Erlotinib		"Active, not recruiting"	NCT01897480		PCD	2016Mar14	No	Yes	Primary outcome not met	2	https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9019	Untreated		Progression free survival	150			Erlotinib																																							COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Emibetuzumab + Erlotinib		Completed	NCT01900652		PCD	2015Feb01	No	Yes	No benefit of treatment	3	https://meetinglibrary.asco.org/record/123487/abstract	Previously-treated		Overall Response Rate	111			Emibetuzumab																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Itacitinib + Osimertinib		"Active, not recruiting"	NCT02917993		ECD	2022Dec21	Yes	No		4	NCT02917993	Previously-treated		Overall Response Rate	59	59																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib + Erlotinib		Completed	NCT01866410	NCI 9303	PCD	2018Mar30	Yes	Yes		1	30915273	Previously-treated		Overall Response Rate	37	37			10.8								3.6																				4	21									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Lerociclib + Osimertinib		Completed	NCT03455829		PCD	2021Dec14	Yes	No		4	NCT03455829			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Aspirin + Osimertinib		Not yet recruiting	NCT03532698	COAST2	ECD	2021Dec31	No	No		4	NCT03532698	Previously-treated		Overall Response Rate	100			Osimertinib																																							COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Aspirin + Osimertinib		Not yet recruiting	NCT03543683	COAST1	ECD	2021Dec31	Yes	No		4	NCT03543683	Previously-treated		Progression free survival	330			Osimertinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Osimertinib		"Active, not recruiting"	NCT02971501		ECD	2023Jul01	Yes	No		4	NCT02971501			Progression free survival	112			Osimertinib																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Osimertinib		"Active, not recruiting"	NCT03133546	BOOSTER	ECD	2023May01	Yes	Yes		2	10.1016/j.annonc.2021.11.010	Previously-treated		Progression free survival	155	78	77	Osimertinib									15.4	12.3	0.94	0.66-1.33	0.71									24	24.3	1.03		0.91													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	BPI-7711		Completed	NCT03812809		PCD	2022Jan24	Yes	Yes		1	36049654			Overall Response Rate	226	226			64.6		58.0-70.8		12.5		10.0-13.9		12.2			9.6-13.9							89.8			23.9			-20														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Malvertinib		Terminated	NCT02349633		PCD	2020May28	Yes	Yes	Changed business priorities	3	https://www.jto.org/article/S1556-0864(16)32909-4/pdf	Previously-treated		Overall Response Rate	65	65																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Rociletinib		Terminated	NCT01526928		PCD	2018Jul03	Yes	Yes		1	25923550	Previously-treated		Overall Response Rate	46	46			59																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	BMS-690514		Completed	NCT00329004		PCD	2009Jul01	Yes	Yes		1	23490650			Maximum tolerated dose/toxicity	21	21																															1	6									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Unknown	NCT03502850		ECD	2021Jan01	Yes	Yes		2	10.1016/j.jtho.2022.05.011			Overall Response Rate	301	301			68.8		63.2-74.0		11.1		9.6-13.8		11			9.7-12.4							92.4						-19.6														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Unknown	NCT03452592		ECD	2020Jun01	Yes	Yes	Promising efficacy	2	10.1200/JCO.2020.38.15_suppl.9602			Overall Response Rate	220	220			73.6		67.3-79.3						7.6			-7																											COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + Ruxolitinib		Completed	NCT02155465		PCD	2017Oct01	Yes	Yes	No benefit of treatment	1	27613527	Previously-treated		Overall Response Rate	22	22																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Abivertinib		Unknown	NCT03300115		ECD	2019Jun17	Yes	No		4	NCT03300115			Overall Response Rate	222	222																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Terminated	NCT01819428		PCD	2015Nov01	Yes	Yes	Slow accrual	4	NCT01819428	Untreated		Overall Response Rate	22	22																																									COSO29915674	2022Aug17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Canertinib		Completed	NCT00050830				No	Yes	Primary outcome not met	1	17761977	Previously-treated		Clinical activity	163	163																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Lazertinib		"Active, not recruiting"	NCT03046992		ECD	2022Sep01	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.9037	Previously-treated		Overall Response Rate	89	89			64								9.5																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT03228277		PCD	2018Jul31	Yes	No		4	NCT03228277	Untreated		Overall Response Rate	25	25																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Terminated	NCT02485652	ELUXA 1	PCD	2020Dec08	Yes	Yes		2	10.1093/annonc/mdx671.001	Previously-treated		Overall Response Rate	115	115			44.4								6.9										87.8																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT02444819		PCD	2017Aug01	Yes	No		4	NCT02444819	Untreated		Overall Response Rate	33	33																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT01588145		PCD	2017Aug01	Yes	Yes		5	https://www.boehringer-ingelheim.com/press-release/new-data-olmutinib-bi-1482694-presented-asco-2016	Previously-treated		Maximum tolerated dose/toxicity	38	38			54				8.3																																		COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT05536505		ECD	2025Oct01	Yes	No		4	NCT05536505			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	180	180																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT04563871	BLOSSOM	ECD	2023Sep01	Yes	No		4	NCT04563871			Overall survival	80	80																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		"Active, not recruiting"	NCT02736513	Arm B	ECD	2022Dec31	No	Yes		1	35156036	Previously-treated		Overall Response Rate	20	20			66.7								7.6			-5.3							94.4																				COSO29915674	2022Sep12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT02824952		ECD	2022Dec01	Yes	No		4	NCT02824952	Untreated		Overall Response Rate	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Unknown	NCT02811354	PLASMA	ECD	2019Feb24	Yes	Yes		2	10.1016/j.jtocrr.2020.100099	Previously-treated		Overall Response Rate	15	15			53								7.3																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort G1	ECD	2023Mar01	Yes	No		1	32669708			"ORR, PFS, DOR"	10	10											15.5			8.5-32.6																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Completed	NCT03394118		PCD	2021Mar11	Yes	No		4	NCT03394118			Overall Response Rate	63	63																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		"Active, not recruiting"	NCT02094261	AURA2	PCD	2015May01	Yes	Yes		4	NCT02094261	Previously-treated		Overall Response Rate	199	199			70.9				7.8				8.6										91.5																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		"Active, not recruiting"	NCT02442349	AURA17	PCD	2016Mar04	Yes	Yes		4	NCT02442349	Previously-treated		Overall Response Rate	171	171			60.2																		88																				COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Completed	NCT02841579	AZENT	PCD	2018Dec01	Yes	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results	Untreated		Overall Response Rate	22	22			77.3			<0.025																																			COSO29915674	2021Oct29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		"Active, not recruiting"	NCT02856893	APPLE	ECD	2023Feb01	Yes	No		4	NCT02856893			Progression free survival	156	156																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Unknown	NCT02504346	TREM	ECD	2021Jan01	Comparison with wt	Yes		1	32200138	Previously-treated		Overall Response Rate	167	117	50		60	28		<0.001	11.8	10.7		0.229	10.8	5.1	0.62	0.43-0.88	0.007						91	64	<0.001	22.5	13.4	0.55	0.37-0.81	0.002													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		"Active, not recruiting"	NCT03257124	BM cohort	PCD	2019Aug31	Yes	Yes		1	32634610	Previously-treated		Overall Response Rate	40	40			55								7.6			5.0-16.6							77.5			16.9			-7.9			4	18										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Durvalumab + Osimertinib		"Active, not recruiting"	NCT02454933	CAURAL	PCD	2017Aug21	Yes	Yes	Terminated early due to adverse events in TATTON NCT02143466	1	30763730	Previously-treated		Maximum tolerated dose/toxicity	29	12	17	Osimertinib																																							COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Rociletinib		Terminated	NCT02322281	TIGER-3	PCD	2018Mar29	No	Yes	Denied regulatory approval	2	10.1093/annonc/mdw140	Previously-treated		Progression free survival	149			Chemotherapy																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib		Not yet recruiting	NCT04870190	ATTACK	ECD	2024Jun01	Yes	No		4	NCT04870190	Previously-treated		Progression free survival	232			Osimertinib																																							COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Olmutinib		Terminated		ELUXA3			Yes	Yes	Changed business priorities	3	https://www.hopkinsmedicine.org/singapore/_downloads/johns-hopkins-singapore-2016-research-report.pdf	Untreated		Unknown																																											COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Olmutinib		Terminated	2015-005079-26	ELUXA2	PCD	2016Aug01	Yes	No		5	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-program-broadly-investigate	Previously-treated		Progression free survival	0	0		Chemotherapy																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		"Active, not recruiting"	NCT03257124	LM cohort	PCD	2019Aug31	Yes	Yes		1	32634610	Previously-treated		Overall survival	40	40											8			-7.2							92.5			13.3			-9.1			5											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Completed	NCT02474355	ASTRIS	PCD	2019Apr18	Yes	Yes		4	NCT02474355			Overall survival	3014	3014											11.1			11.0-12.0										22.8			21.6-23.8														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Unknown	NCT02972333	APOLLO	ECD	2019Sep01	Yes	Yes		1	32817079	Previously-treated		Progression free survival	38	38			39.4								8.4			5.8-10.9																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Completed	NCT02959749		PCD	2017Oct01	Yes	Yes		1	29858027	Previously-treated		Progression free survival	147	74	73	Bevacizumab + Docetaxel									10.2	2.95	0.23	0.12-0.38	<0.001																										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 4	Osimertinib		Completed	NCT03853551		PCD	2020Apr15	Yes	Yes	SAE 11.67%	4	NCT03853551			Maximum tolerated dose/toxicity	60	60																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Lazertinib		Not yet recruiting	NCT05377788		ECD	2024Jun30	Yes	No		4	NCT05377788			Progression free survival	900	900																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M and MET_unspecified	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	3	Phase 1	Gefitinib + Savolitinib		Completed	NCT02374645		PCD	2018Feb18	Comparison with wt	Yes		1	33052556	Previously-treated		Maximum tolerated dose/toxicity	46	23	23		9	52																																					COSO29915674	2022Dec13	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_T790M and MET_unspecified	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Tepotinib 		Completed	NCT01982955	INSIGHT	PCD	2017Dec12	Yes	Yes		4	NCT01982955	Previously-treated		Progression free survival	15	15			0								2.63			1.38-2.73							40			25.86			13.08-39.66														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_C797S and EGFR_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	BLU-945		Recruiting	NCT04862780	Group 2	ECD	2025Jan31	Yes	No		4	NCT04862780	Previously-treated		Overall Response Rate	190	190																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_Exon19del and EGFR_no_L858R				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib		Recruiting	NCT04785742		ECD	2023Dec31	Yes	No		4	NCT04785742			Maximum tolerated dose/toxicity	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_Exon19del and EGFR_no_L858R				lung / carcinoma / non small cell carcinoma	3	Phase 2	Anlotinib + Sintilimab		"Active, not recruiting"	NCT04790409		ECD	2022Jun30	Yes	Yes		2	10.1016/j.annonc.2022.02.030			Progression free survival	19	19			36.8								6.7			2.4-11.0							84.2																				COSO29915674	2022Dec02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib		Not yet recruiting	NCT04841811		ECD	2022Oct15	Yes	No		4	NCT04841811			"ORR, EFS"	156	156																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	EMB-01 + Osimertinib		Not yet recruiting	NCT05498389	Group 4	ECD	2024Jul01	Yes	No		4	NCT05498389	Previously-treated		Overall Response Rate	115	115																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alflutinib + Cisplatin + Pemetrexed		Recruiting	NCT05430802	FORESEE	ECD	2023Mar01	Yes	No		4	NCT05430802	Untreated		Overall Response Rate	40	40																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	FWD1509		Recruiting	NCT05068024		ECD	2022Oct30	Yes	No		4	NCT05068024			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 1	Neoantigen vaccine + Tyrosine Kinase Inhibitor		Recruiting	NCT04487093		ECD	2022May17	Yes	No		4	NCT04487093			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Glumetinib		Unknown	NCT04338243		ECD	2020Dec31	Yes	No		4	NCT04338243			Overall Response Rate	70	70																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 4	Afatinib + Osimertinib		Recruiting	NCT04413201	AFAMOSI	ECD	2024Jun30	Yes	No		4	NCT04413201			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	126			Osimertinib																																							COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Unknown	DZD9008		Recruiting	NCT05559645	WU-KONG15	ECD	2023Dec31	Yes	No		4	NCT05559645	Previously-treated		Progression free survival	110	110																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_no_T790M and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib + Savolitinib		"Active, not recruiting"	NCT02143466	TATTON part D	PCD	2020Mar04	Yes	Yes	SAE 26%	1	32027846			Maximum tolerated dose/toxicity	42	42			64		46-79																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Approved FDA	Docetaxel + Ramucirumab	Not required	Completed	NCT01168973	REVEL	PCD	2016Aug01	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf			Overall survival	1253	628	625	Docetaxel + Placebo									4.5	3	0.76	0.68-0.86	<0.001									10.5	9.1	0.86	0.75-0.98	0.024													COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	21111508	Previously-treated		Unknown	156	93	63		12.9	1.59							3.9	2.3	0.677	0.485-0.943	0.021						51.6	38.1		30.8	25.8			0.439													COSO29915674	2022May11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Afatinib		Terminated	NCT03711422		PCD	2019Dec20	Yes	No		4	NCT03711422			"OS, PFS"	2	2																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Almonertinib + SHR1701		Not yet recruiting	NCT05503888		ECD	2027Jul30	Yes	No		4	NCT05503888			Progression free survival	160			Almonertinib + Placebo																																							COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Dalpiciclib + EGFR-TKI		Not yet recruiting	NCT05497076		ECD	2024Jan01	Yes	No		4	NCT05497076	Previously-treated		Overall Response Rate	9	9																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Carotuximab + Osimertinib		Not yet recruiting	NCT05401110		ECD	2025Jan01	Yes	No		4	NCT05401110	Previously-treated		Maximum tolerated dose/toxicity	60	60																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Erlotinib + Ipilimumab		Completed	NCT01998126		PCD	2017May09	Yes	Yes	Serious adverse events	2	10.1016/j.jtho.2017.09.010			Maximum tolerated dose/toxicity	11	11											17.9																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BDTX-1535		Recruiting	NCT05256290		ECD	2023Apr01	Yes	No		4	NCT05256290	Previously-treated		Maximum tolerated dose/toxicity	90	90																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Autologous personalized DC vaccine		Recruiting	NCT05195619		ECD	2024Sep01	Yes	No		4	NCT05195619			Maximum tolerated dose/toxicity	16	16																																									COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Autologous EGFR-IL13RA2 CAR-T cells + Cyclophosphamide + Fludarabine		Not yet recruiting	NCT05168423		ECD	2024Dec19	Overexpression	No		4	NCT05168423			Maximum tolerated dose/toxicity	18	18																																									COSO29915674	2022Oct24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BAY2927088_formulation A		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	250	250																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BAY2927088_formulation B_1		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	250	250																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BAY2927088_formulation B_2		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	250	250																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	CXCR5 modified EGFR CAR-T cells		Recruiting	NCT05060796		ECD	2024Nov01	Expression confirmed	No		4	NCT05060796			Maximum tolerated dose/toxicity	11	11																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	TAS2940		Recruiting	NCT04982926		ECD	2025May01	Yes	No		4	NCT04982926			Overall Response Rate	42	42																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Almonertinib + Bevacizumab		Not yet recruiting	NCT04944069	ATTRACT	ECD	2024Mar01	Yes	No		4	NCT04944069			Overall survival	69	69																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Osimertinib + Repotrectinib		Recruiting	NCT04772235	TOTEM	ECD	2026Apr01	Yes	No		4	NCT04772235			Maximum tolerated dose/toxicity	32	32																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	MRX-2843 + Osimertinib		Recruiting	NCT04762199		ECD	2024Dec27	Yes	No		4	NCT04762199			Maximum tolerated dose/toxicity	69	69																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BBP-398		Recruiting	NCT05621525	Part B	ECD	2024May01	Yes	No		4	NCT05621525			"ORR, DOR"	28	28																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BBP-398		Recruiting	NCT04528836		ECD	2023Apr01	Yes	No		4	NCT04528836			Maximum tolerated dose/toxicity	130	130																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Amivantamab + Lazertinib		Recruiting	NCT02609776		ECD	2024Jan04	Yes	No		4	NCT02609776			Overall Response Rate	780	780																																									COSO29915674	2023Jan20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BCA101		Recruiting	NCT04429542		ECD	2023Dec31	Expression confirmed	No		4	NCT04429542			Maximum tolerated dose/toxicity	292	292																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BCA101 + Pembrolizumab		Recruiting	NCT04429542		ECD	2023Dec31	Expression confirmed	No		4	NCT04429542			Maximum tolerated dose/toxicity	292	292																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Individualized neoantigen peptides vaccine		Recruiting	NCT04397926		ECD	2022May30	Yes	No		4	NCT04397926			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Alisertib + Osimertinib		Recruiting	NCT04085315		ECD	2023Dec31	Yes	No		4	NCT04085315			Maximum tolerated dose/toxicity	38	38																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	TY-9591		Recruiting	NCT04204473		ECD	2022Jun30	Yes	No		4	NCT04204473			Overall Response Rate	126	126																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Afatinib + Talcum powder		Unknown	NCT03827070	DPTA	ECD	2019Nov09	Yes	No		4	NCT03827070			Clinical activity	12	12																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Carboplatin + Pemetrexed + Zimberelimab		"Active, not recruiting"	NCT03846310		ECD	2023Jul01	Yes	No		4	NCT03846310			Maximum tolerated dose/toxicity	77	77																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Carboplatin + Etrumadenant + Pemetrexed + Zimberelimab		"Active, not recruiting"	NCT03846310		ECD	2023Jul01	Yes	No		4	NCT03846310			Maximum tolerated dose/toxicity	77	77																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Osimertinib + Palcitoclax		Recruiting	NCT04001777		ECD	2023Jun01	Yes	No		4	NCT04001777			Maximum tolerated dose/toxicity	80	80																																									COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Niraparib + Osimertinib		Recruiting	NCT03891615		ECD	2022Apr30	Yes	No		4	NCT03891615			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Ipilimumab + Osimertinib		Recruiting	NCT04141644	Osi+Ipi	ECD	2023Apr30	Yes	No		4	NCT04141644			Maximum tolerated dose/toxicity	26	26																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	JNJ-61186372 + Lazertinib		Recruiting	NCT04077463		ECD	2023Mar23	Yes	No		4	NCT04077463			"ORR, PFS, DOR"	460	460																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pembrolizumab + Stereotactic Body Radiation Therapy		Terminated	NCT03436056	PRIMING	PCD	2019Jul08	Yes	No		4	NCT03436056			Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Osimertinib + Stereotactic radiotherapy		"Active, not recruiting"	NCT03535363		ECD	2023Feb01	Yes	No		4	NCT03535363			Maximum tolerated dose/toxicity	6	6																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Gatipotuzumab + Tomuzotuximab		Completed	NCT03360734	GATTO	PCD	2020May04	Yes	Yes		2	10.1016/S0959-8049(20)31083-2			Maximum tolerated dose/toxicity	5	5											5.3																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	DV281		Completed	NCT03326752		PCD	2019Sep19	No	No		4	NCT03326752			Maximum tolerated dose/toxicity	26	26																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Cisplatin + Etoposide + Osimertinib		Recruiting	NCT03567642		ECD	2024Jun01	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2023Jan16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Abemaciclib + Necitumumab		Completed	NCT02411591		PCD	2017Jun23	No	Yes		4	NCT02411591	Previously-treated		Maximum tolerated dose/toxicity	57	57			5.3		1.1-14.6																										3	24									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Gefitinib + Savolitinib		Completed	NCT02374645		PCD	2018Feb18	Yes	No		4	NCT02374645	Previously-treated		Maximum tolerated dose/toxicity	64	64																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Cucurmin + EGFR-TKI		Unknown	NCT02321293	CURCUMIN	ECD	2016Aug01	No	Yes	No serious adverse events 	2	10.1200/JCO.2019.37.15_suppl.e20611			Maximum tolerated dose/toxicity	41	41																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Buparlisib + Gefitinib		Unknown	NCT01570296		PCD	2016Feb22	Expression confirmed	Yes		2	10.1200/jco.2013.31.15_suppl.8107			Maximum tolerated dose/toxicity	10	10											2.8			2.3-8.1																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Dasatinib + Erlotinib		Completed	NCT00903734		PCD	2015Jul01	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Bortezomib + Erlotinib		Completed	NCT00903734		PCD	2015Jul01	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Cetuximab + Erlotinib		Completed	NCT00903734		PCD	2015Jul01	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Durvalumab + Gefitinib		Completed	NCT02088112	Arm 2	PCD	2021Mar09	Yes	Yes		1	33012782	Untreated		Maximum tolerated dose/toxicity	10	10			70		34.8-93.3		12.6		5.5-20.4		12			2.7-15.6							90									0	7										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Durvalumab + Gefitinib		Completed	NCT02088112	Arms 1 + 1a	PCD	2021Mar09	Yes	Yes		1	33012782	Untreated		Maximum tolerated dose/toxicity	30	30			63.3		43.9-80.1		9.2		3.7-14.0		10.1			5.5-15.2							100									0	19										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Erlotinib + Momelotinib		Terminated	NCT02206763		PCD	2017Jan12	Yes	Yes	"Serious adverse events, no benefit of treatment"	2	10.1016/j.jtho.2017.09.1294	Previously-treated		Maximum tolerated dose/toxicity	11	11			54.5				7.1				9.2																				6	4									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pacritinib		Terminated	NCT02342353		PCD	2018Feb06	Yes	Yes	Drug unavailable	4	NCT02342353			Maximum tolerated dose/toxicity	8	8																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Crizotinib + Ipilimumab		Completed	NCT01998126		PCD	2017May09	Yes	No		4	NCT01998126			Maximum tolerated dose/toxicity	14	14																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Nivolumab + Sym004		Withdrawn	NCT02924233		PCD	2017Feb01	Expression confirmed	Yes	Changed business priorities	4	NCT02924233			Maximum tolerated dose/toxicity	0	0																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Matuzumab + Pemetrexed		Completed					Expression confirmed	Yes		1	16533873			Unknown	18																															1	3										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Binimetinib + Erlotinib		"Active, not recruiting"	NCT01859026		PCD	2019Aug22	Yes	No		4	NCT01859026			Maximum tolerated dose/toxicity	43	43																																									COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Afatinib + Necitumumab		Terminated	NCT03054038		PCD	2022Mar23	Yes	Yes	Slow accrual	4	NCT03054038	Previously-treated		Maximum tolerated dose/toxicity	22	22																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Dacomitinib + Osimertinib		"Active, not recruiting"	NCT03755102		ECD	2024Nov01	Yes	No		4	NCT03755102			Overall Response Rate	17	17																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Dacomitinib + Osimertinib		"Active, not recruiting"	NCT03810807		ECD	2023Jan01	Yes	No		4	NCT03810807	Untreated		Maximum tolerated dose/toxicity	22	22																																									COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Afatinib + Dasatinib		Completed	NCT01999985		PCD	2017Mar21	No	Yes	No benefit of treatment	1	30880334	Previously-treated		Maximum tolerated dose/toxicity	25	25			0								3.7													14.7								6									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Naquotinib		Terminated	NCT03082300		PCD	2017May12	Yes	Yes	SOLAR Study IDMC recommended closure	4	NCT03082300			Maximum tolerated dose/toxicity	3	3																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Almonertinib		Not yet recruiting	NCT04455594	ANSWER	ECD	2023Jan01	Yes	No		4	NCT04455594			Overall Response Rate	168	168																																									COSO29915674	2021Aug19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	DS-1205c + Osimertinib		Terminated	NCT03255083		PCD	2020Sep04	Yes	Yes	Changed business priorities	4	NCT03255083	Previously-treated		Maximum tolerated dose/toxicity	13	13																																									COSO29915674	2022May05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Pelitinib		Unknown					Yes	Yes		1	16364494			Unknown																																	2										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Dacomitinib		"Active, not recruiting"	NCT03755102		ECD	2024Nov01	Yes	No		4	NCT03755102			Overall Response Rate	17	17																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ipilimumab + Nivolumab		Terminated	NCT03091491		PCD	2019Nov18	Yes	Yes	Lack of efficacy	1	36426287			Overall Response Rate	31	31			3.2								1.22			1.15-1.35																											COSO29915674	2022Dec12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AK112 + AK119 + Carboplatin + Pemetrexed		Not yet recruiting	NCT05636267		ECD	2024Dec01	Yes	No		4	NCT05636267	Previously-treated		Overall Response Rate	114	114																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AK112 + AK119		Not yet recruiting	NCT05636267		ECD	2024Dec01	Yes	No		4	NCT05636267	Previously-treated		Overall Response Rate	114	114																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	H002		Recruiting	NCT05552781		ECD	2025Feb28	Yes	No		4	NCT05552781			Overall Response Rate	76	76																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	H002		Not yet recruiting	NCT05519293		ECD	2025Feb28	Yes	No		4	NCT05519293			Overall Response Rate	76	76																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + OBI-821 + OBI-833		Recruiting	NCT05442060		ECD	2024Dec31	Yes	No		4	NCT05442060			Progression free survival	60			Erlotinib																																							COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	BPI-361175		Not yet recruiting	NCT05393466		ECD	2026Jan30	Yes	No		4	NCT05393466			Overall Response Rate	30	30																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Platinum-based chemotherapy + SKB264 + Tagitanlimab		Not yet recruiting	NCT05351788	Cohort 3	ECD	2023Aug01	Yes	No		4	NCT05351788	Previously-treated		Overall Response Rate	110	110																																									COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib + Carboplatin + Osimertinib + Pemetrexed		Recruiting	NCT05298176	COMBINATION	ECD	2024Jan01	Yes	No		4	NCT05298176	Previously-treated		"Disease control rate, Clinical benefit rate"	21	21																																									COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + TQB3525		Recruiting	NCT05284994		ECD	2024Apr01	Yes	No		4	NCT05284994	Previously-treated		Overall Response Rate	160	160																																									COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	NRC-2694-A + Paclitaxel		Recruiting	NCT05283226		ECD	2024Jan31	No	No		4	NCT05283226	Previously-treated		Overall Response Rate	46	46																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Nab-paclitaxel + Sintilimab		Recruiting	NCT05244213	NEOTIDE	ECD	2023Dec01	Yes	No		4	NCT05244213			"Complete response, Pathological complete response"	30	30																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib + Thoracic surgery		Recruiting	NCT05215548		ECD	2024Jul01	Yes	No		4	NCT05215548			Progression free survival	100			Afatinib																																							COSO29915674	2022Apr29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Pemetrexed + Pimurutamab		Not yet recruiting	NCT05215925	Expt. A	ECD	2023Jul15	Overexpression	No		4	NCT05215925			Overall Response Rate	60	60																																									COSO29915674	2022Apr29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Docetaxel + Pimurutamab		Not yet recruiting	NCT05215925	Expt. B	ECD	2023Jul15	Overexpression	No		4	NCT05215925			Overall Response Rate	60	60																																									COSO29915674	2022Apr29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pimurutamab		Not yet recruiting	NCT05215925	Expt. C	ECD	2023Jul15	Overexpression	No		4	NCT05215925			Overall Response Rate	60	60																																									COSO29915674	2022Apr29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Alflutinib + Chemotherapy		Not yet recruiting	NCT05209256		ECD	2024Jan01	Yes	No		4	NCT05209256			Maximum tolerated dose/toxicity	90			Alflutinib																																							COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AFM24 + SNK01		Recruiting	NCT05099549		ECD	2025Nov01	Expression confirmed	No		4	NCT05099549			Overall Response Rate	121	121																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Radiotherapy		Recruiting	NCT05089916	ROSE	ECD	2025Sep01	Yes	No		4	NCT05089916			Maximum tolerated dose/toxicity	60	60																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	SI-B001		Recruiting	NCT05044897		ECD	2023Jul01	No	No		4	NCT05044897			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2021Nov15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed		Recruiting	NCT04989322		ECD	2024Aug01	Expression confirmed	No		4	NCT04989322			Overall Response Rate	46	46																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed		Recruiting	NCT04989322		ECD	2024Aug01	Yes	No		4	NCT04989322			Overall Response Rate	46	46																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	ERAS-007 + Osimertinib		Recruiting	NCT04959981		ECD	2023Jul01	Yes	No		4	NCT04959981			Maximum tolerated dose/toxicity	200	200																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib + Anlotinib		Recruiting	NCT04978753		ECD	2022May30	Yes	No		4	NCT04978753	Untreated		Progression free survival	54	54																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Buparlisib + Erlotinib		Completed	NCT01487265		PCD	2016May31	No	Yes	3m PFS 50.4%	4	NCT01487265			Progression free survival	37	37			5.4																																						COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Tivantinib		Completed	NCT01580735		PCD	2015Apr01	Yes	Yes	Primary outcome not met	1	27843623			Overall Response Rate	45	45			6.7		1.4-18.3						2.7			1.4-4.2							48.9			18			13.4-22.2			0	3	19									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Gemcitabine + Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2023Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Sapitinib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	5	5	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Cetuximab + Gemcitabine + SIM1803-1A + SNK01		Recruiting	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	No		4	NCT04872634	Previously-treated		Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Gemcitabine + SNK01		Recruiting	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	No		4	NCT04872634	Previously-treated		Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AK112		Not yet recruiting	NCT05636267		ECD	2024Dec01	Yes	No		4	NCT05636267	Previously-treated		Overall Response Rate	114	114																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	BBT-176 + Cetuximab		Recruiting	NCT04820023		ECD	2023Dec30	Yes	No		4	NCT04820023	Previously-treated		Overall Response Rate	168	168																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	BBT-176		Recruiting	NCT04820023		ECD	2023Dec30	Yes	No		4	NCT04820023	Previously-treated		Overall Response Rate	168	168																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	MRG003		Recruiting	NCT04838548		ECD	2022Dec01	Expression confirmed	No		4	NCT04838548			Overall Response Rate	90	90																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	APL-101 + Osimertinib		Recruiting	NCT04743505		ECD	2026Nov30	Yes	No		4	NCT04743505			Progression free survival	22	22																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Nivolumab + Pemetrexed		Completed	NCT03256136		PCD	2019Aug19	Yes	Yes		4	NCT03256136			Overall Response Rate	4	4			25								4.65										75																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Abemaciclib + Osimertinib		Recruiting	NCT04545710		ECD	2022Sep01	Yes	No		4	NCT04545710	Previously-treated		Progression free survival	18	18																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Osimertinib + Pemetrexed		Recruiting	NCT04335292	OCELOT	ECD	2024Jun01	Yes	No		4	NCT04335292	Previously-treated		Overall Response Rate	200	200																																									COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bevacizumab + Cisplatin + Durvalumab + Stereotactic Body Radiation Therapy		Not yet recruiting	NCT04517526		ECD	2022Nov01	Yes	No		4	NCT04517526			"OS, PFS"	60	60																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Necitumumab + Osimertinib + Trastuzumab		Recruiting	NCT04285671		ECD	2022Dec02	Yes	No		4	NCT04285671			Overall Response Rate	26	26																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib + Cisplatin + Pemetrexed		Not yet recruiting	NCT04470076	Neoafa	ECD	2021Dec30	Yes	No		4	NCT04470076			Overall Response Rate	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Quaratusugene ozeplasmid		Recruiting	NCT04486833	GEN-104	ECD	2024Dec01	Yes	No		4	NCT04486833	Previously-treated		Progression free survival	92	92																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Amivantamab + Lazertinib		Recruiting	NCT04965090		ECD	2024Jul01	Yes	No		4	NCT04965090			Overall Response Rate	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Osimertinib + Paclitaxel		Recruiting	NCT04410796		ECD	2023May01	Yes	No		4	NCT04410796			Progression free survival	571	571																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Pemetrexed + Tislelizumab		Recruiting	NCT04405674		ECD	2022Apr01	Yes	Yes	Promising efficacy	3	https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress/a-phase-ii-study-of-tislelizumab-plus-chemotherapy-in-egfr-mutated-advanced-non-squamous-nsclc-patients-failed-to-egfr-tki-therapies-first-analysis			Progression free survival	32	32			59.4		40.6-76.3																90.6																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Famitinb + HS-10296		Recruiting	NCT03904823		ECD	2022Dec01	Yes	No		4	NCT03904823			Overall Response Rate	58	58																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	TY-9591		Recruiting	NCT05146219		ECD	2024Jun01	Yes	No		4	NCT05146219			Intracranial Response Rate	60	60																																									COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Apatinib + Tyrosine Kinase Inhibitor		Unknown	NCT03811054		ECD	2020Dec01	Yes	No		4	NCT03811054			Overall Response Rate	60	60																																									COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	EMB-01		Recruiting	NCT03797391		ECD	2023Mar14	Yes	No		4	NCT03797391			"OS, PFS"	186	186																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Anlotinib + Osimertinib		Recruiting	NCT04770688	AUTOMAN	ECD	2022Nov30	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.e21140	Untreated		Overall Response Rate	23	23			65.2		42.7-83.6																95.7																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Anlotinib + Osimertinib		Unknown	NCT04029350	ALTN-03	ECD	2020Jan31	Yes	No		4	NCT04029350			Progression free survival	53	53																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + RMC-4630		Completed	NCT03989115		PCD	2022Feb08	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	113	113																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + RMC-4630		Completed	NCT03989115		PCD	2022Feb08	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	113	113																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Mobocertinib		Recruiting	NCT03574402	TRUMP Arm 12	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pembrolizumab + Ramucirumab		Recruiting	NCT04120454		ECD	2022Dec31	Yes	No		4	NCT04120454			Overall Response Rate	51	51																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	GC1118 + Paclitaxel		Recruiting	NCT04077255		ECD	2022Dec31	Yes	No		4	NCT04077255			Overall Response Rate	38	38																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Stereotactic Body Radiation Therapy		Recruiting	NCT04908956	STEREO	ECD	2026Mar01	Yes	No		4	NCT04908956	Untreated		Progression free survival	60	60																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Stereotactic Body Radiation Therapy		"Active, not recruiting"	NCT03667820		ECD	2024Apr01	Yes	No		4	NCT03667820			Progression free survival	41	41																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Anlotinib + Sintilimab		Unknown	NCT03765775		ECD	2019Dec31	Yes	No		4	NCT03765775			Progression free survival	20	20																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	FCN-411		Unknown	NCT03420079		ECD	2020Dec31	Yes	Yes		1	35248866			Maximum tolerated dose/toxicity	67	67			14.9		8.3-24.0						4.1			2.9-5.3							73.1										10	39									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dihydroartemisinin + Icotinib		Unknown	NCT03402464		ECD	2019Jun01	Yes	No		4	NCT03402464			"OS, PFS"	30	30																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib + Tucidinostat		Recruiting	NCT03574402	TRUMP Arm 2	ECD	2022Dec30	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	SH-1028		Unknown	NCT03823807		ECD	2020Dec01	Yes	Yes		2	10.1016/j.annonc.2022.02.016			Overall Response Rate	227	227			60.4		42.4-68.8		12.5		-11.2		12.6			9.7-15.3							92.5		88.3-95.6																		COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AZD4205 + Osimertinib		Completed	NCT03450330	JACKPOT1	PCD	2019Sep03	Yes	No		4	NCT03450330			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Stereotactic radiotherapy		Not yet recruiting	NCT04519983		ECD	2023Dec01	Yes	No		4	NCT04519983	Previously-treated		Overall Response Rate	30	30																																									COSO29915674	2021Jun18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Stereotactic radiotherapy		Recruiting	NCT03497767	OUTRUN	ECD	2023Aug01	Yes	No		4	NCT03497767			Progression free survival	80	80																																									COSO29915674	2021Jun18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Stereotactic Body Radiation Therapy + Tyrosine Kinase Inhibitor		Completed	NCT03595644		PCD	2019Jun10	Yes	Yes		2	10.1016/j.jtho.2019.08.499			Progression free survival	61	30	31	EGFR-TKI									17.4	8.9			0.042																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gefitinib + Ningetinib		"Active, not recruiting"	NCT03758287		ECD	2023Jul17	Yes	Yes	Promising efficacy	2	10.1200/JCO.2020.38.15_suppl.9583	Previously-treated		Overall Response Rate	84	84			19.1								4.4			3.7-4.6							91.7										16	61									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Apatinib + Chemotherapy		Unknown	NCT03758677		ECD	2020Nov20	Yes	No		4	NCT03758677			Progression free survival	30	30																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Autologous T-Cells with enhanced TCRs specific for NY-ESO-1/LAGE-1a + Pembrolizumab		"Active, not recruiting"	NCT03709706		ECD	2025May30	No	No		4	NCT03709706			Overall Response Rate	54	54																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Autologous T-Cells with enhanced TCRs specific for NY-ESO-1/LAGE-1a		"Active, not recruiting"	NCT03709706		ECD	2025May30	No	No		4	NCT03709706			Overall Response Rate	54	54																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Avitinib		Recruiting	NCT03574402	TRUMP Arm 13	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AVID100		Terminated	NCT03094169		PCD	2020Nov28	Yes	Yes	No benefit of treatment	4	NCT03094169			Clinical activity	49	49																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Icotinib + Stereotactic Body Radiation Therapy		Unknown	NCT03153358		ECD	2017Nov02	Yes	No		4	NCT03153358			Progression free survival	60	60																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Icotinib + Stereotactic Body Radiation Therapy		Unknown	NCT03754530		ECD	2020Jun01	Yes	No		4	NCT03754530			Progression free survival	162	162																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Cabozantinib		"Active, not recruiting"	NCT03170960	Expansion Cohort 9	ECD	2022Dec01	Yes	No		4	NCT03170960			Overall Response Rate	1732	1732																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	65	29	36	Erlotinib + Placebo									3.69	2.4	0.86		0.32																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Anlotinib + Docetaxel		Unknown	NCT04619563		ECD	2021Oct01	Yes	No		4	NCT04619563			Progression free survival	42	42																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Durvalumab + Pemetrexed		Recruiting	NCT03944772	ORCHARD	ECD	2025Nov28	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	250	250																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Tepotinib 		Recruiting	NCT03940703	INSIGHT 2	ECD	2022Nov30	Yes	No		4	NCT03940703	Previously-treated		Overall Response Rate	120	120																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Tepotinib 		Recruiting	NCT03940703	INSIGHT 2	ECD	2022Nov30	Yes	No		4	NCT03940703	Previously-treated		Overall Response Rate	120	120																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib + Savolitinib		Recruiting	NCT03944772	ORCHARD	ECD	2025Nov28	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	250	250																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cetuximab + Cilengitide + Cisplatin + Vinorelbine		Completed	NCT00842712	CERTO	PCD	2013Jul01	No	Yes		4	NCT00842712	Untreated		Progression free survival	169	85	84	Cetuximab + Cisplatin + Vinorelbine									6.2	5	0.72		0.0845																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Cetuximab + Pemetrexed + Radiotherapy		Completed	NCT00117962		PCD	2009Mar01	No	Yes		4	NCT00117962			Overall survival	109	53	48	Carboplatin + Pemetrexed																						54	48																COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Foretinib		Completed	NCT01068587		PCD	2014Mar21	No	Yes		1	29050231	Previously-treated		Overall Response Rate	3	3																															2										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cetuximab + Natural killer cell immunotherapy		Completed	NCT02845856		PCD	2017Jul01	Yes	Yes		1	29888109			Maximum tolerated dose/toxicity	54	27	27										6	4.5												9.5	7.5			<0.05													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bevacizumab + Carboplatin + Pemetrexed		Completed	NCT01344824		PCD	2016May24	Yes	Yes		1	26774201			Progression free survival	6	6											7.1													31.3																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Rociletinib + Trametinib		Terminated	NCT02580708		PCD	2016May05	Yes	Yes	Development discontinued	4	NCT02580708			Unknown	7	7																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	MP0250 + Osimertinib		Terminated	NCT03418532		PCD	2019Aug30	Yes	Yes	Changed business priorities	4	NCT03418532	Previously-treated		Overall Response Rate	8	8																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cetuximab + Chemotherapy + Radiotherapy		Completed	NCT00492206		PCD	2012Feb01	No	Yes		4	NCT00492206			Overall survival	38	38											9.3			8.5-17.2										19.4			15.4-26														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + MK2206		Completed	NCT01294306		PCD	2015Aug01	Yes	Yes		4	NCT01294306	Previously-treated		"DCR, ORR"	45	45			9								4.4										40																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Apatinib + Erlotinib		Unknown	NCT02704767		ECD	2019Jun01	Yes	No		4	NCT02704767	Untreated		Progression free survival	60	60																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Capecitabine + Cetuximab + Oxaliplatin		Completed	NCT00444678		PCD	2012Aug01	Expression confirmed	Yes		4	NCT00444678			Response rate	36	36			58.3													9.04			1.41-136.96																						COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Unknown	NCT03647956		ECD	2019Dec31	Yes	Yes	Promising efficacy	2	10.1016/annonc/annonc367	Previously-treated		Overall Response Rate	40	40			62.5								9.43			7.62-12.1																											COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		"Active, not recruiting"	NCT04245085	ABC-lung	ECD	2023Sep30	Yes	No		4	NCT04245085			Progression free survival	95			Atezolizumab + Bevacizumab + Pemetrexed																																							COSO29915674	2022Dec06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Olaparib		Recruiting	NCT04538378		ECD	2025Dec31	Yes	No		4	NCT04538378			Best overall response	14	14																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gemcitabine + Vandetanib		Completed	NCT00753714	ZELIG	PCD	2011Apr01	No	Yes	No benefit of treatment	2	10.1200/jco.2012.30.15_suppl.7550 		Geriatric	Progression free survival	124	61	63	Gemcitabine																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Fruquintinib		Unknown					No	Yes		5	https://www.chi-med.com/wp-content/uploads/2017/10/pre171031.pdf			Unknown													3.8	1.1	0.34	0.2-0.57	0.001									8.1	5.5	0.62	0.3-1.27	0.18													COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Fruquintinib		Completed	NCT02590965		PCD	2015Aug07	Yes	Yes		1	29528793	Previously-treated		Progression free survival	91			Placebo																						8.4	5.5	0.58	0.30-1.14	0.11													COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Completed	NCT00979212		PCD	2015Dec01	No	Yes	Serious adverse events	4	NCT00979212			Clinical activity	61	39	22	Carboplatin + Panitumumab									89.1	94.4																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Completed	NCT01042288		PCD	2014Dec01	No	Yes		2	10.1200/jco.2013.31.15_suppl.8062	Untreated		Time to progression	60	60																															23	18									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Suspended	NCT01088620	CHAMP	PCD	2013Jan01	No	Yes	Serious adverse events	1	26094080	Untreated		Progression free survival	134			Cisplatin + Pemetrexed																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Terminated	NCT01038037	Lung-TRIO	PCD	2013Jun01	No	Yes	Slow accrual	4	NCT01038037	Untreated		Overall Response Rate	23	23																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Fruquintinib + Gefitinib		Completed	NCT02976116	Cohort 2	PCD	2019Jun28	Yes	Yes	Serious adverse events 12.5%	3	https://www.healio.com/hematology-oncology/lung-cancer/news/online/%7B142a1200-d0db-474b-bb8b-51684d2deea7%7D/fruquintinib-gefitinib-shows-promise-for-egfr--mutated-non-small-cell-lung-cancer	Untreated		Overall Response Rate	24	25			70.8								14.7																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Matuzumab + Pemetrexed		Completed	NCT00111839		PCD	2007Jul31	Expression confirmed	Yes		1	20978446	Previously-treated		Overall Response Rate	150			Gefitinib + Tremelimumab	11	5		0.332																																			COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cisplatin + Gemcitabine + Imgatuzumab + Pemetrexed		Completed	NCT01185847	GAIN-(L)	PCD	2012Sep01	No	Yes		2	10.1200/jco.2012.30.15_suppl.7544			Progression free survival	14	14		Cisplatin + Pemetrexed																													6	7									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Carboplatin + Erlotinib + Paclitaxel		Completed	NCT00126581		PCD	2010Jun30	Yes	Yes		4	NCT00126581			Progression free survival	164	87	77	Carboplatin + Paclitaxel	73	70							17.2	14.1																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Nimotuzumab + Nivolumab		"Active, not recruiting"	NCT02947386		PCD	2021Apr15	No	No		4	NCT02947386			Overall Response Rate	7	7																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gefitinib + Metformin		Completed	NCT01864681		PCD	2017Dec01	No	No		2	10.1200/JCO.2019.37.15_suppl.9035	Untreated		Progression free survival	224			Placebo	66	67							10.3	11.4												22	27.5																COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Celecoxib + Erlotinib		Completed	NCT00499655		PCD	2016Dec01	Yes	Yes	Response not correlated with mutation status	1	26033830	Previously-treated		Progression free survival	26	12	14	Erlotinib + Placebo									9.2	9.2	0.98		0.97																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Trametinib		Completed	NCT03076164		PCD	2020Dec18	Yes	Yes		2	10.1200/PO.20.00315	Previously-treated		Overall Response Rate	23	23											1.8													21							1										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Fulvestrant + Gefitinib		Completed	NCT01556191	LADIE	PCD	2018May15	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2018.36.15_suppl.9097			Progression free survival	204	100	104										9.9	10.1												22.1	29.9																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dacomitinib + Osimertinib		Recruiting	NCT04811001	CAPLAND	ECD	2023Dec31	Yes	Yes		4	NCT04811001	Untreated		Overall survival	170	170																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Necitumumab + Osimertinib		Recruiting	NCT03944772	ORCHARD	ECD	2025Nov28	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	250	250																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bevacizumab + Osimertinib		Completed	NCT02803203		PCD	2022Mar01	Yes	Yes	"PFS 12m 76%, Primary outcome met"	1	32463456			Progression free survival	49	49			80								19			15-24																	34										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	BMS-690514		Completed					Yes	No		4	NCT01167244	Previously-treated		Overall Response Rate	11	11																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Recruiting	NCT05662813		ECD	2023Dec30	Yes	No		4	NCT05662813	Untreated		Overall Response Rate	55	55																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Not yet recruiting	NCT04882345	ACTIVE	ECD	2024Jan15	Yes	No		4	NCT04882345	Previously-treated		Maximum tolerated dose/toxicity	40	40																																									COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Not yet recruiting	NCT04423185		ECD	2022Jul01	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																									COSO29915674	2021Aug19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Recruiting	NCT04685070		ECD	2022Dec31	Yes	No		4	NCT04685070	Untreated		Overall Response Rate	56	56																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Not yet recruiting	NCT04808752	ACHIEVE	ECD	2023Mar15	Yes	No		4	NCT04808752	Untreated		Progression free survival	60	60																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Not yet recruiting	NCT04553887	AUTUMN	ECD	2023May01	Yes	No		4	NCT04553887	Untreated		Overall Response Rate	53	53																																									COSO29915674	2021Aug19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Almonertinib		Not yet recruiting	NCT04354961	ARISE	ECD	2023May01	Yes	No		4	NCT04354961	Untreated		Progression free survival	134			Carboplatin + Paclitaxel																																							COSO29915674	2021Aug19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Alflutinib		Recruiting	NCT05469022		ECD	2024May19	Yes	No		4	NCT05469022			Overall Response Rate	40	40																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Alflutinib		Recruiting	NCT05465343	iFORCE	ECD	2023Jun30	Yes	No		4	NCT05465343			"PFS, ORR"	36	36																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	AZD4635 + Oleclumab		"Active, not recruiting"	NCT03381274		PCD	2021May24	Yes	No		2	10.1158/1538-7445.AM2021-CT163	Previously-treated		Overall Response Rate	43	43																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Oleclumab + Osimertinib		"Active, not recruiting"	NCT03381274		PCD	2021May24	Yes	Yes		2	10.1158/1538-7445.AM2021-CT163	Previously-treated		Overall Response Rate	21	21			19						9.2-11.1		11			-3.7							81						-11.7			0	4	13									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gefitinib + Osimertinib		Recruiting	NCT03944772	ORCHARD	ECD	2025Nov28	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	250	250																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Zorifertinib		Recruiting	NCT03574402	TRUMP Arm 8	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib + Cetuximab		Completed	NCT02716311	ACE-LUNG	PCD	2019Feb01	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2019.37.15_suppl.9079	Untreated		Time to progression	118			Afatinib																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Hydroxychloroquine		Unknown	NCT00977470		PCD	2015May01	Yes	Yes	No benefit of treatment	2	10.1200/jco.2014.32.15_suppl.8088 	Untreated		Progression free survival	76	76																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ficlatuzumab + Gefitinib		Completed	NCT01039948		PCD	2013Aug01	No	Yes	No benefit of treatment	1	27448761			Overall Response Rate	203	203																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Canertinib		Completed	NCT00050830				No	Yes	Primary outcome not met	1	17761977	Previously-treated		Clinical activity	163																																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Lazertinib		Recruiting	NCT05338619	PLATINUM	ECD	2026Mar02	Yes	No		4	NCT05338619			Progression free survival	77	77																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Lazertinib		Not yet recruiting	NCT05277701	LU21-16	ECD	2024Dec01	Yes	No		4	NCT05277701			Overall Response Rate	36	36																																									COSO29915674	2022May16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Lazertinib		"Active, not recruiting"	NCT04075396		PCD	2021Jan08	Yes	No		4	NCT04075396			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pelitinib		Completed	NCT00067548		PCD	2005Jan01	No	No	Serious adverse events	4	NCT00067548			Not defined	44	44																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Vandetanib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	5	5	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Vandetanib		Completed	NCT00777179		PCD	2010Jan01	No	Yes		1	24075125	Previously-treated		Progression free survival	117	75	42	Placebo	18.7	2.4							2.7	1.7		0.9-2.6																											COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Docetaxel + Vandetanib		Completed	NCT00687297	PrE0501	PCD	2011Jan01	No	Yes	No benefit of treatment	1	23689430	Untreated		Progression free survival	162	80	82										4.5	4.2												9.8	9.4			0.68													COSO29915674	2021Aug16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Not yet recruiting	NCT05526755	TARGET	ECD	2029Jun19	Yes	No		4	NCT05526755			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	180	180																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		"Active, not recruiting"	NCT03804580		ECD	2023Aug31	No	No		4	NCT03804580	Untreated		Overall Response Rate	100	100																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Recruiting	NCT03865511	MELROSE	ECD	2024Apr01	Yes	No		4	NCT03865511			Biomarker discovery	66	66																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Unknown	NCT03460275		ECD	2020Dec01	Yes	No		4	NCT03460275			Clinical activity	100	100																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		"Active, not recruiting"	NCT02736513	Arm A	ECD	2022Dec31	No	Yes		1	35156036	Untreated		Overall Response Rate	20	20			84.2								11.8			-7.7							94.7																				COSO29915674	2022Sep12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		"Active, not recruiting"	NCT03239340	ELIOS	ECD	2024Oct31	Yes	No		4	NCT03239340	Untreated		Unknown	154	154																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dacomitinib		Completed	NCT00818441		PCD	2012Apr27	Yes	Yes		4	NCT00818441			Progression free survival	89	89							12.9		9.6-18.4		11.5			9.0-12.9										29.5			22.8-35.6														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dacomitinib		Not yet recruiting	NCT04423185		ECD	2022Jul01	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																									COSO29915674	2021Jun16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dacomitinib		Not yet recruiting	NCT04339829	CTONG2001	ECD	2022Jul01	Yes	No		4	NCT04339829			Progression free survival	50	50																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Dacomitinib		Recruiting	NCT04504071		ECD	2022Oct31	Yes	No		4	NCT04504071			Overall Response Rate	30	30																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gefitinib		Completed	NCT00344773		PCD	2007Dec01	Yes	Yes		4	NCT00344773			Overall Response Rate	46	46			0																																						COSO29915674	2021Jun17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gefitinib		Completed	NCT00411047		PCD	2007Jan01	Yes	No		4	NCT00411047	Untreated		Overall Response Rate	34	34																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Gefitinib		Completed	NCT02804776	ECRU-LUNG	PCD	2018Feb21	Yes	No		4	NCT02804776			Tumour volume	15	15																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib		"Active, not recruiting"	NCT01306045	Arm 1	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	15	15																																									COSO29915674	2022Dec15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib		Completed	NCT00087412		PCD	2007Jul01	No	No		4	NCT00087412			Overall survival	65	65																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib		"Active, not recruiting"	NCT02183883	DARWIN1	ECD	2023Nov01	Yes	No		4	NCT02183883			Progression free survival	48	48																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib		Recruiting	NCT04201756		ECD	2022Apr30	Yes	No		4	NCT04201756			Overall Response Rate	47	47																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ipilimumab + Nivolumab		Completed	NCT03256136		PCD	2019Aug19	Yes	Yes		4	NCT03256136			Overall Response Rate	3	3			0								1.3										0																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib		"Active, not recruiting"	NCT02193282		ECD	2026Oct10	No	No		4	NCT02193282			Overall survival	450			Placebo																																							COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	EGFR-TKI + Metformin		Recruiting	NCT05445791	METLUNG	ECD	2024Jul14	Yes	No		4	NCT05445791			Progression free survival	312			EGFR-TKI + Placebo																																							COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Osimertinib + TY-9591		Not yet recruiting	NCT05382728	FLETEO	ECD	2025May01	Yes	No		4	NCT05382728			Progression free survival	680			Placebo + TY-9591																																							COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed		"Active, not recruiting"	NCT04194203	IMpower151	ECD	2023Feb03	Yes	No		4	NCT04194203			Progression free survival	304			Bevacizumab + Carboplatin + Paclitaxel or Pemetrexed + Placebo																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Pemetrexed + Placebo + Platinum-based chemotherapy + SHR1701		Not yet recruiting	NCT05132413		ECD	2024Dec30	Yes	No		4	NCT05132413			Progression free survival	561			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Bevacizumab + Pemetrexed + Platinum-based chemotherapy + SHR1701		Not yet recruiting	NCT05132413		ECD	2024Dec30	Yes	No		4	NCT05132413			Progression free survival	561			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Almonertinib + Chemotherapy		Recruiting	NCT05493501		ECD	2027May01	Yes	No		4	NCT05493501			Progression free survival	420			Osimertinib																																							COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	AK112		Recruiting	NCT05184712		ECD	2024Jan01	Yes	No		4	NCT05184712	Previously-treated		Progression free survival	320			Placebo																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Almonertinib + Cisplatin + Pemetrexed		Recruiting	NCT04762459	APEX	ECD	2026May01	Yes	No		4	NCT04762459	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	606			Cisplatin + Pemetrexed																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Osimertinib + Pemetrexed + Platinum-based chemotherapy		Recruiting	NCT04765059	COMPEL	ECD	2024Jun12	Yes	No		4	NCT04765059	Previously-treated		Progression free survival	204			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Osimertinib + Pemetrexed + Platinum-based chemotherapy		Recruiting	NCT04351555	NeoADAURA	ECD	2024Mar26	Yes	No		4	NCT04351555			Major pathologic response	328			Pemetrexed + Platinum-based chemotherapy																																							COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Pemetrexed + Toripalimab		Unknown	NCT03924050		ECD	2021Jul06	Yes	Yes	Promising efficacy	2	10.1038/s41392-021-00751-9	Previously-treated		Overall Response Rate	40	40			50								7										87.5			23.5																	COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Cisplatin + Pemetrexed + Placebo + Sintilimab		Recruiting	NCT03802240		ECD	2023Apr30	Yes	Yes		2	10.1016/j.annonc.2021.10.007	Previously-treated		Progression free survival	296	145	151	Cisplatin + Pemetrexed	33.1	25.2							5.6	4.3	0.75	0.555-1.013	0.0584																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Cisplatin + IBI305  + Pemetrexed + Sintilimab		Recruiting	NCT03802240		ECD	2023Apr30	Yes	Yes		2	10.1016/j.annonc.2021.10.007	Previously-treated		Progression free survival	299	148	151	Cisplatin + Pemetrexed	43.9	25.2							6.9	4.3	0.464	0.337-0.639	<0.0001																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	SH-1028		Not yet recruiting	NCT04239833		ECD	2022Jan31	Yes	No		4	NCT04239833			Progression free survival	240			Gefitinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	D0316		"Active, not recruiting"	NCT04206072		ECD	2021Dec30	Yes	No		4	NCT04206072			Progression free survival	362			Icotinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Pembrolizumab + Pemetrexed		"Active, not recruiting"	NCT03515837		ECD	2023Jun15	Yes	No		4	NCT03515837			"OS, PFS"	492			Carboplatin + Pemetrexed																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Stereotactic Body Radiation Therapy + Tyrosine Kinase Inhibitor		Unknown	NCT03727867		ECD	2021Jun01	Yes	No		4	NCT03727867			Progression free survival	300			Stereotactic Body Radiation Therapy																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Anlotinib + Icotinib		Recruiting	NCT04797806	SAINT	ECD	2022Apr30	Yes	No		4	NCT04797806			Progression free survival	206			Icotinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Endostatin + Tyrosine Kinase Inhibitor		Unknown	NCT03008109		ECD	2017Nov01	Yes	No		4	NCT03008109			Progression free survival	80	80																																									COSO29915674	2021Aug20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Vinorelbine		Not yet recruiting	NCT03203590		ECD	2026Jan01	Yes	No		4	NCT03203590			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	590			Gefitinib																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib + Sunitinib		Completed	NCT00558103		PCD	2011May01	Overexpression	Yes		4	NCT00558103			Overall Response Rate	74	38	36	Lapatinib + Placebo	57.9	47.2							3.7	2.63																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib + Sunitinib		Completed	NCT00558103		PCD	2011May01	Overexpression	Yes		4	NCT00558103			Overall Response Rate	76	38	38	Lapatinib + Placebo	44.7	29							3.3	3.7																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib + Stereotactic Body Radiation Therapy		Unknown	NCT02882984		ECD	2020Mar01	No	No		4	NCT02882984			Progression free survival	325			Erlotinib + Radiotherapy																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Gefitinib + Stereotactic Body Radiation Therapy		Unknown	NCT02882984		ECD	2020Mar01	No	No		4	NCT02882984			Progression free survival	325			Gefitinib + Radiotherapy																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Gefitinib + Thalidomide		Unknown	NCT02387086	GELI	ECD	2017May01	Yes	No		4	NCT02387086	Untreated		Progression free survival	380			Placebo																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Chemotherapy + Gefitinib		Completed	NCT01544179		PCD	2014May05	Yes	Yes		1	26159065	Previously-treated		Progression free survival	265	133	132	Placebo	31.6	34.1		0.76					5.4	5.4												14.8	17.2	1.62	1.05-2.52	0.029													COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Fruquintinib		Completed	NCT02691299	FALUCA	PCD	2018Sep21	No	Yes		2	10.1016/j.lungcan.2020.06.016	Previously-treated		Overall survival	527	354	173	Placebo	13.8	0.6							3.7	1	0.34	0.28?0.43	<0.001						66.7	24.9		8.9	10.4	1.2	0.82?1.28	0.841													COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib + Onartuzumab		Completed	NCT02031744		PCD	2016Jan06	No	No		4	NCT02031744	Previously-treated		Overall survival	530			Erlotinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Carboplatin + Erlotinib + Paclitaxel		Completed		TRIBUTE			No	Yes	No benefit of treatment	1	16043829			Unknown	1059	526	533	Carboplatin + Paclitaxel																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Bevacizumab + Osimertinib		Recruiting	NCT05104281		ECD	2022Dec31	Yes	No		4	NCT05104281			Progression free survival	60	60																																									COSO29915674	2021Nov16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	BPI-7711		"Active, not recruiting"	NCT03866499		ECD	2022Oct01	Yes	No		4	NCT03866499			Progression free survival	369																																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Rociletinib		Terminated	NCT02186301	TIGER 1	PCD	2017Jun28	Yes	Yes	Development discontinued	4	NCT02186301			Progression free survival	80	30	50	Erlotinib	40	78																																					COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Almonertinib		Recruiting	NCT05493501		ECD	2027May01	Yes	No		4	NCT05493501			Progression free survival	420			Osimertinib																																							COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Almonertinib		Recruiting	NCT04762459	APEX	ECD	2026May01	Yes	No		4	NCT04762459	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	606			Cisplatin + Pemetrexed																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Alflutinib		Not yet recruiting	NCT04853342	FORWARD	ECD	2023Dec01	Yes	No		4	NCT04853342	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	318			Placebo																																							COSO29915674	2021Aug24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Bevacizumab + Erlotinib		"Active, not recruiting"	UMIN000017069	NEJ026			Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9006 			Progression free survival	228	112	114	Erlotinib									16.9	13.3	0.61	0.42-0.88	0.016																										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Lazertinib		"Active, not recruiting"	NCT04248829	LASER301	ECD	2022Dec01	Yes	No		4	NCT04248829			Progression free survival	393			Gefitinib																																							COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Docetaxel + Vandetanib		Completed	NCT00312377	ZODIAC	PCD	2008Aug01	Yes	Yes	Regulatory submissions withdrawn 6/2009	1	25057173	Previously-treated		Progression free survival	50	32	18	Docetaxel	56.3	27.8	0.8-13.89	0.058					7.6	5.9	0.51	0.25-1.06	p=0.038										18.6	0.46	0.14-1.57	p=0.155													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Gefitinib		Unknown	NCT03656393	RCTACSCNSCLC	ECD	2020Jul31	Yes	No		4	NCT03656393			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	48			Carboplatin + Vinorelbine																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Gefitinib		Unknown	NCT01066195		ECD	2010Oct01	Yes	Yes		1	22674612	Previously-treated		Progression free survival	33	16	17	Pemetrexed									15.7	2.9	0.3	0.13-0.72	0.005																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Gefitinib		Completed	NCT00252707				No	Yes		1	18779611	Previously-treated		Overall survival	484			Docetaxel									2	2	0.81	0.65-1.02	0.077									11.5	14	1.12															COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Gefitinib		Unknown	NCT01405079	ADJUVANT/CTONG1104	PCD	2017Mar01	Yes	Yes		1	33332190			Progression free survival	222	111	111	Cisplatin + Vinorelbine																						75.5	62.8	0.92	0.62-1.36	0.674					28.7	18	0.6	0.42-0.87	0.0054				COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 4	Beta-elemene + Tyrosine Kinase Inhibitor		Recruiting	NCT04401059	SELECT-2	ECD	2025Sep30	Yes	No		4	NCT04401059			Progression free survival	744																																										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Osimertinib		"Active, not recruiting"	NCT03969823		ECD	2023Sep30	Yes	No		4	NCT03969823			Progression free survival	148	148																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Carboplatin + Pemetrexed + Tyrosine Kinase Inhibitor		Recruiting	NCT04552613		ECD	2023Jul01	Yes	No		4	NCT04552613	Previously-treated		"OS, PFS"	110	110																																									COSO29915674	2021Aug20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Chemotherapy + Icotinib		Not yet recruiting	NCT03983811		ECD	2021Oct31	Yes	No		4	NCT03983811			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	174			Chemotherapy + Placebo																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	DZD9008		Recruiting	NCT05559645	WU-KONG15	ECD	2023Dec31	Yes	No		4	NCT05559645	Previously-treated		Progression free survival	110	110																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Anlotinib + Tyrosine Kinase Inhibitor		Unknown	NCT04007835		ECD	2021Jul01	Yes	No		4	NCT04007835			Progression free survival	120	120																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Radiotherapy + Tyrosine Kinase Inhibitor		Recruiting	NCT03916913		ECD	2022Jan01	Yes	No		4	NCT03916913	Previously-treated		Progression free survival	85	85																																									COSO29915674	2021Aug20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Metformin + Tyrosine Kinase Inhibitor		Unknown	NCT03071705		ECD	2017Apr01	Yes	Yes		1	31486833			Progression free survival	139	69	70	Tyrosine Kinase Inhibitor	71	54.3		0.04					13.1	9.9	0.6	0.4-0.94	0.03									31.7	17.5	0.5	0.28-0.90	0.02													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Almonertinib		Recruiting	NCT04778800	ARTISTRY	ECD	2023Feb20	Yes	No		4	NCT04778800			Progression free survival	60	60																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	2	Unknown	Osimertinib		Recruiting	NCT04737382	OSIRIS	ECD	2023Aug22	No	No		4	NCT04737382			Biomarker discovery	200	200																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Gemcitabine + Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2023Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Gemcitabine + Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2023Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Capmatinib + Erlotinib		Completed	NCT01911507		PCD	2020Aug26	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.2587	Previously-treated		Maximum tolerated dose/toxicity	8	8			50																		50																				COSO29915674	2022Dec14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib + Tepotinib		Not yet recruiting	NCT05120960		ECD	2023Dec31	Yes	No		4	NCT05120960			Maximum tolerated dose/toxicity	60	60																																									COSO29915674	2021Nov19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Savolitinib		Recruiting	NCT03778229	SAVANNAH	ECD	2024May27	Yes	No		4	NCT03778229	Previously-treated		Overall Response Rate	360	360																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capmatinib + Osimertinib + Ramucirumab		Not yet recruiting	NCT05642572	Arm A	ECD	2026May31	Expression confirmed	No		4	NCT05642572			Progression free survival	66	66																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Tepotinib		Recruiting	NCT03940703	INSIGHT 2	ECD	2022Nov30	Yes	No		4	NCT03940703	Previously-treated		Overall Response Rate	120	120																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capmatinib + Gefitinib		Completed	NCT01610336		PCD	2016Jun10	Expression confirmed	Yes		1	30156984				78	78			32																												25	33									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capmatinib + Osimertinib		Not yet recruiting	NCT05642572	Arm B	ECD	2026May31	Expression confirmed	No		4	NCT05642572			Progression free survival	66	66																																									COSO29915674	2023Jan09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Tepotinib 		Recruiting	NCT03940703	INSIGHT 2	ECD	2022Nov30	Yes	No		4	NCT03940703	Previously-treated		Overall Response Rate	120	120																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Savolitinib		Not yet recruiting	NCT05163249	FLOWERS	ECD	2023Dec01	Yes	No		4	NCT05163249	Untreated		Overall Response Rate	44			Osimertinib																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Savolitinib		"Active, not recruiting"	NCT04606771	CoC	ECD	2022Dec21	Yes	No		4	NCT04606771	Previously-treated		Overall Response Rate	30			Placebo + Savolitinib																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Onartuzumab		Completed	NCT01456325	METLung	PCD	2016Jan01	No	Yes	Response not correlated with mutation or expression status	1	27937096	Previously-treated		Overall survival	499	249	250	Erlotinib	8.4	9.6							2.7	2.6	0.99	0.81-1.2	0.92									6.8	9.1	1.27	0.98-1.65	0.067													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Osimertinib + Savolitinib		Recruiting	NCT05015608	SACHI	ECD	2024Sep15	Yes	No		4	NCT05015608			Progression free survival	250			Cisplatin + Pemetrexed																																							COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Onartuzumab		Completed	NCT01887886		PCD	2015Feb01	Yes	Yes	Sponsor withdrew support	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000868-29/results	Untreated		Progression free survival	10	5	5	Erlotinib + Placebo																																							COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and MUC1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	M1231		Recruiting	NCT04695847		ECD	2023Jul15	Expression confirmed	No		4	NCT04695847	Previously-treated		"ORR, DOR"	84	84																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Gemcitabine + Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2023Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified and TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Carboplatin + Osimertinib + Pemetrexed		Recruiting	NCT05507606		ECD	2023Aug01	Yes	No		4	NCT05507606			Overall Response Rate	50	50																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified or ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Neratinib		Completed	NCT00146172		PCD	2007Jan01	Expression confirmed	Yes		1	19318484			Maximum tolerated dose/toxicity	14	14																																6									COSO29915674	2022Nov29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified or ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	PLB1004		Recruiting	NCT05347628		ECD	2022May01	Yes	No		4	NCT05347628			Maximum tolerated dose/toxicity	91	91																																									COSO29915674	2022May17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified or ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Mobocertinib		"Active, not recruiting"	NCT03807778		PCD	2021Nov08	Yes	No		4	NCT03807778			Overall Response Rate	33	33																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified or ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Alflutinib		Recruiting	NCT05364073		ECD	2025Sep01	Yes	No		4	NCT05364073			Maximum tolerated dose/toxicity	170	170																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified or ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	DZD9008		Recruiting	NCT03974022	WU-KONG1	ECD	2022Dec01	Yes	No		4	NCT03974022			Overall Response Rate	336	336																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	EML4-ALK_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Crizotinib		Terminated	NCT01822496		PCD	2018Jun04	Yes	Yes	Slow accrual	4	NCT01822496			Progression free survival	59			Chemotherapy																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	EML4-ALK_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Camrelizumab		Unknown	NCT03083041		ECD	2018Dec27	No	No		4	NCT03083041			Overall Response Rate	118	118																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	EML4-ALK_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Luminespib		Completed	NCT01124864		PCD	2014Aug01	Yes	Yes		4	NCT01124864	Previously-treated		Overall Response Rate	22	22			31.8																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_A775_G776insYVMA or ERBB2_M774_A775insAYVM				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Unknown	NCT02834936		ECD	2017Dec01	Yes	Yes		1	32614698			Overall Response Rate	44	44			27.3		15.0-42.8																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20				lung / carcinoma / non small cell carcinoma	3	Phase 2	Poziotinib		Recruiting	NCT05378763	PINNACLE	ECD	2027Dec25	Yes	No		4	NCT05378763	Previously-treated			268			Docetaxel																																							COSO29915674	2022Sep26	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20				lung / carcinoma / non small cell carcinoma	3	Phase 2	ABT-101		Recruiting	NCT05532696		ECD	2023Apr01	Yes	No		4	NCT05532696			Overall Response Rate	121	121																																									COSO29915674	2022Oct06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Poziotinib		Terminated	NCT04044170		PCD	2020Apr13	Expression confirmed	No		4	NCT04044170			Overall Response Rate	5	5																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib + Thalidomide		Recruiting	NCT04382300		ECD	2022Oct01	Expression confirmed	No		4	NCT04382300			Overall Response Rate	39	39																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Unknown	NCT04063462	PEER20 Cohort 2	ECD	2021Apr01	Yes	No		4	NCT04063462			Overall Response Rate	60	60																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capecitabine + Pyrotinib		Unknown	NCT02535507		ECD	2016Dec01	No	Yes		1	30596880	Previously-treated		Overall Response Rate	15	15			53.3								6.4																														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Poziotinib		Recruiting	NCT04402008		ECD	2025Jan01	Yes	No		4	NCT04402008			Overall Response Rate	76	76																																									COSO29915674	2022Jan17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Poziotinib		Recruiting	NCT03066206	2016-0783	ECD	2023Mar01	Yes	No		4	NCT03066206			Overall Response Rate	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Poziotinib		Recruiting	NCT03318939	ZENITH20	ECD	2023Mar01	Yes	Yes		3	https://www.cancernetwork.com/view/zenith20-trial-shows-positive-results-with-poziotinib-in-untreated-her2-exon-20-mutant-nsclc	Untreated		Overall Response Rate	43	43			43.8		29.5-58.8		5.4		-2.8		5.6																			1	20	15									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_G776_V777insVC or ERBB2_G776R or ERBB2_G776C	54064203 + 54064477 + 54077015 + 99507093 + 54082404		p.G776C + p.G776delinsVC	lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Unknown	NCT02834936		ECD	2017Dec01	Yes	Yes		1	32614698			Overall Response Rate	6	6			16.7		0.4-64.1																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_L755P	54069116		p.L755P	lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Unknown	NCT02834936		ECD	2017Dec01	Yes	Yes		1	32614698			Overall Response Rate	4	4			25		0.6-80.6																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_P780_Y781insGSP			p.P780_Y781insGSP	lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Unknown	NCT02834936		ECD	2017Dec01	Yes	Yes		1	32614698			Overall Response Rate	5	5			60		14.7-94.7																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_V777L	54062385 + 54062767		p.V777L	lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Unknown	NCT02834936		ECD	2017Dec01	Yes	Yes		1	32614698			Overall Response Rate	1	1			100		2.5-100																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04644237	DESTINY-LUNG02	ECD	2023Mar01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s024lbl.pdf			Overall Response Rate	52	52			57.7		43.2-71.3		8.7		-7.1																																COSO29915674	2023Jan20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Trastuzumab + Vinorelbine		Completed	NCT00014430		PCD	2002Sep01	Overexpression	No		4	NCT00014430				13	13																																									COSO29915674	2021Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	ELVN-002 + Trastuzumab deruxtecan		Not yet recruiting	NCT05650879		ECD	2026Jul01	Yes	No		4	NCT05650879	Previously-treated		Maximum tolerated dose/toxicity	178	178																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	ELVN-002		Not yet recruiting	NCT05650879		ECD	2026Jul01	Yes	No		4	NCT05650879	Previously-treated		Maximum tolerated dose/toxicity	178	178																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Durvalumab + Pemetrexed + Trastuzumab deruxtecan		Recruiting	NCT04686305	DESTINY-Lung03	ECD	2024Sep26	Expression confirmed	No		4	NCT04686305			Maximum tolerated dose/toxicity	136	136																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Carboplatin + Durvalumab + Trastuzumab deruxtecan		Recruiting	NCT04686305	DESTINY-Lung03	ECD	2024Sep26	Expression confirmed	No		4	NCT04686305			Maximum tolerated dose/toxicity	136	136																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Durvalumab + Trastuzumab deruxtecan		Recruiting	NCT04686305	DESTINY-Lung03	ECD	2024Sep26	Expression confirmed	No		4	NCT04686305			Maximum tolerated dose/toxicity	136	136																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Pembrolizumab + Trastuzumab deruxtecan		Recruiting	NCT04042701		ECD	2023Mar01	Yes	No		4	NCT04042701			Overall Response Rate	115	115																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Pembrolizumab + Trastuzumab deruxtecan		Recruiting	NCT04042701		ECD	2023Mar01	Expression confirmed	No		4	NCT04042701			Overall Response Rate	115	115																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	BAY2927088_formulation A		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	250	250																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	BAY2927088_formulation B_1		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	250	250																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	BAY2927088_formulation B_2		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	250	250																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	HER2 peptide vaccine + Sargramostim		Completed	NCT00003002		PCD	2004Jan01	Expression confirmed	No		4	NCT00003002				60	60																																									COSO29915674	2021Sep29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	TAS2940		Recruiting	NCT04982926		ECD	2025May01	Yes	No		4	NCT04982926			Overall Response Rate	42	42																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Disitamab vedotin		"Active, not recruiting"	NCT04311034		PCD	2021Aug19	Overexpression	No		4	NCT04311034			"ORR, PFS, OS"	37	37																																									COSO29915674	2022Oct06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT02564900		PCD	2019Feb01	Expression confirmed	Yes		4	NCT02564900			Overall Response Rate	18	18			55.6		30.8-78.5		10.7		6.9-11.5		11.3			7.2-14.3							83.3						-17.3														COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Trastuzumab Deruxtecan		Recruiting	NCT04686305	DESTINY-Lung03	ECD	2024Sep26	Expression confirmed	No		4	NCT04686305			Maximum tolerated dose/toxicity	136	136																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Pyrotinib		"Active, not recruiting"	NCT02500199		ECD	2021May01	Expression confirmed	Yes		2	10.1200/JCO.2020.38.15_suppl.3510			Maximum tolerated dose/toxicity	24	24																														1	3										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Afatinib		Completed	NCT02597946		PCD	2018Jul22	Expression confirmed	Yes		4	NCT02597946	Previously-treated		Overall Response Rate	18	18			0								2.76			1.87-4.60		2.76			1.87-4.60		61.1			10.02			8.47-10/08														COSO29915674	2021Dec14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Pemetrexed + Pyrotinib		Recruiting	NCT04706949		ECD	2021Dec31	Overexpression	No		4	NCT04706949	Untreated		Progression free survival	26	26																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Inetetamab + Pyrotinib		Recruiting	NCT05016544		ECD	2023Aug01	Overexpression	No		4	NCT05016544			Maximum tolerated dose/toxicity	48	48																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	SHR-A1811		Recruiting	NCT04818333		ECD	2023Jan30	Expression confirmed	No		4	NCT04818333	Previously-treated		Overall Response Rate	120	120																																									COSO29915674	2022Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	MRG002		Not yet recruiting	NCT05141786		ECD	2023Dec01	Expression confirmed	No		4	NCT05141786	Previously-treated		Overall Response Rate	100	100																																									COSO29915674	2022Feb14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	PD-1 + Pyrotinib		Recruiting	NCT04144569		ECD	2023Dec30	Yes	No		4	NCT04144569	Previously-treated		Progression free survival	30	30																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	ARX788		Withdrawn	NCT05041972	ACE-Pan Tumor-02	PCD	2022Apr20	Yes	Yes	Changed business priorities	4	NCT05041972			Overall Response Rate	0	0																																									COSO29915674	2022May05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib + Temsirolimus		Completed	NCT01827267		PCD	2016Sep20	Yes	Yes		2	10.1016/j.jtho.2016.11.398			Overall Response Rate	43	43			0								3			1.4-6.9							35			10			1.4-6.9														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cisplatin + Gemcitabine + Trastuzumab		Completed	NCT00016367		PCD	2004Dec14	Overexpression	No		4	NCT00016367			Clinical activity	22	22																																									COSO29915674	2021Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Paclitaxel + Trastuzumab		Completed	NCT00003881				Expression confirmed	No		1	14981103					53			24.5		13.8-38.3						3.25													10.1			6.7-14.6														COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Sapitinib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	5	5	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Almonertinib + Pyrotinib		Recruiting	NCT04785729	APPEAR	ECD	2023Dec01	Overexpression	No		4	NCT04785729	Previously-treated		Maximum tolerated dose/toxicity	36	36																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Docetaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03845270	R2D2	PCD	2021Feb01	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9015			Overall Response Rate	44	44			29								6.8			4.0-8.5							85											26									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT03505710	DESTINY-Lung01 Cohort 1a	PCD	2021May03	Overexpression	Yes		4	NCT03505710			Overall Response Rate	41	41			31.7		18.1-48.1																																				COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT03505710	DESTINY-Lung01 Cohort 1	PCD	2021May03	Overexpression	Yes		4	NCT03505710			Overall Response Rate	49	49			28.6		16.6-43.3																																				COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT03505710	DESTINY-Lung01	PCD	2021May03	Yes	Yes		1	34534430			Overall Response Rate	91	91			55		44-65		9.3		5.7-14.7		8.2			6.0-11.9										17.8			13.8-22.1			1	49										COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab Deruxtecan		Recruiting	NCT05246514	DESTINY-Lung05	ECD	2023Dec08	Yes	No		4	NCT05246514			Overall Response Rate	66	66																																									COSO29915674	2023Jan12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pertuzumab + Trastuzumab		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Expression confirmed	Yes		3	https://www.asco.org/sites/new-www.asco.org/files/content-files/ESMO-2022-Pert-Trast-Lung-ERBB23-TAPUR-Poster.pdf	Previously-treated		"Disease control rate, Clinical benefit rate"	28	28			11		28-Feb						3.71			1.99-5.4							37			12.55			8.45-23.4														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pyrotinib		Unknown	ChiCTR1800020262				Yes	Yes	PFS 6m 49.5% 95%CI 39.2-60.8	1	35101045			Progression free survival	78	78			19.2		11.2-30.0		9.9		6.2-13.6		5.6			2.8-8.4							74.4			10.5			8.7-12.3				15										COSO29915674	2022Sep21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pyrotinib		Recruiting	NCT03574402	TRUMP Arm 7	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tarloxotinib		Terminated	NCT03805841	RAIN cohort B	PCD	2021Apr09	Yes	Yes		2	10.1016/annonc/annonc325			Overall Response Rate	11	11																															2	4									COSO29915674	2022Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab-emtansine		Completed	NCT02289833	Cohort IHC3+	PCD	2016Oct25	Expression confirmed	Yes		4	NCT02289833	Previously-treated		Overall Response Rate	20	20			20				7.3				2.7			1.4-8.3							30			13.7			4.1-33.0														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab-emtansine		Completed	NCT02289833	Cohort IHC2+	PCD	2016Oct25	Expression confirmed	Yes		4	NCT02289833	Previously-treated		Overall Response Rate	29	29			0								2.6			1.4-2.8							6.9			12.2			3.8-23.6														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab-emtansine		Recruiting	NCT02675829	Cohort 2	ECD	2024Feb01	Overexpression	No		4	NCT02675829			Overall Response Rate	140	140																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab-emtansine		Recruiting	NCT02675829	Cohort 1	ECD	2024Feb01	Yes	No		4	NCT02675829			Overall Response Rate	140	140																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab		Completed	NCT00004883		PCD	2005Aug01	Overexpression	No		4	NCT00004883			Response rate	84	84																																									COSO29915674	2021Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab		Terminated	NCT00758134		PCD	2010Jun01	Expression confirmed	Yes	Slow accrual	4	NCT00758134			Response rate	9	9																																									COSO29915674	2021Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Trastuzumab		Terminated	NCT00758134		PCD	2010Jun01	Yes	Yes	Slow accrual	4	NCT00758134			Response rate	9	9																																									COSO29915674	2021Dec08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib		Completed	NCT01827267		PCD	2016Sep20	Yes	Yes		2	10.1016/j.jtho.2016.11.398			Overall Response Rate	17	17			19								4.1			2.9-5.6							51			15.8			10.8-19.5														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lapatinib		"Active, not recruiting"	NCT01306045	Arm 10	PCD	2014Feb12	Expression confirmed	Yes		1	25667274			Response rate	6	6																																									COSO29915674	2022Dec15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT03865511	MELROSE	ECD	2024Apr01	Yes	No		4	NCT03865511			Biomarker discovery	66	66																																									COSO29915674	2021Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Dacomitinib		Completed	NCT00818441		PCD	2012Apr27	Expression confirmed	Yes		4	NCT00818441			Progression free survival	30	30							12.4		11.0-13.9		2.6			1.8-3.7										9.3			6.6-20.8														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ERBB3	ERBB3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	SI-B001		Recruiting	NCT05044897		ECD	2023Jul01	No	No		4	NCT05044897			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2021Nov15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGF1	FGF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGF1	FGF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	20	7	13	Erlotinib + Placebo									2.7	1.78	0.45	0.05-4.10	0.23																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Regorafenib		Terminated	NCT01187615		PCD	2012Jun01	No	Yes	Slow accrual	1	26003007			Maximum tolerated dose/toxicity	9	9																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Nintedanib + Pembrolizumab		Recruiting	NCT02856425	PEMBIB	ECD	2021Jul01	No	Yes	Serious adverse events	4	NCT02856425			Maximum tolerated dose/toxicity	18	18																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pazopanib		Terminated	NCT02193152		PCD	2019Dec24	No	Yes		4	NCT02193152			Overall Response Rate	12	12			16.7								3.1			0.81-11.0																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2020.38.15_suppl.e21694 			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4547		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	No		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	8	8	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ponatinib		Unknown					Expression confirmed	Yes	Serious adverse events	1	30297175			Unknown	4	4																																2									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4547 + Docetaxel		Completed	NCT01824901		PCD	2014Jul09	Expression confirmed	Yes	Serious adverse events	4	NCT01824901	Previously-treated		Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Methotrexate + Regorafenib		"Active, not recruiting"	NCT03520842		ECD	2023Jan01	Yes	Yes		4	NCT03520842			Progression free survival	18	18																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pazopanib		Completed	NCT00367679		PCD	2008Apr01	No	Yes		4	NCT00367679	Untreated		Tumour volume	35	35																															3	31									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Nintedanib		Completed	NCT01948141		PCD	2016Aug16	Expression confirmed	Yes		4	NCT01948141	Previously-treated		Progression free survival	2	2											0													10.2			4-16.4														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dovitinib		Unknown	NCT01861197		ECD	2015Jan01	No	Yes		1	27315356			Response rate	27	27			11.5																		50										3	10									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dovitinib		Completed	NCT01676714		PCD	2016Jan01	No	Yes	"Serious adverse events, no benefit of treatment"	2	10.1200/jco.2016.34.4_suppl.616	Previously-treated		Unknown	1	1																																1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Docetaxel + Nintedanib		Terminated	NCT02231164	LUME-Columbus	PCD	2015Dec01	No	Yes	Slow accrual	4	NCT02231164			"Disease control rate, Clinical benefit rate"	12	6	6	Placebo																			66.7	50																			COSO29915674	2021Aug16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Pazopanib		Terminated	NCT01208064		PCD	2015Jun01	No	Yes	No benefit of treatment	1	26074395			Overall survival	102	50	52										4.3	3.2	0.67	0.43-1.03	0.068									17.4	12.3	0.72	0.4-1.28	0.257													COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erdafitinib		"Active, not recruiting"	NCT02699606		PCD	2021Oct12	Yes	No		4	NCT02699606			Overall Response Rate	35	35																																									COSO29915674	2023Jan04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pemigatinib		Recruiting	NCT05287386		ECD	2024Jan21	Yes	No		4	NCT05287386	Previously-treated		Overall Response Rate	20	20																																									COSO29915674	2022May20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pemigatinib		Recruiting	NCT05253807	FIGHT-210	ECD	2026Jan19	Yes	No		4	NCT05253807	Previously-treated		Overall Response Rate	125	125																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Rogaratinib		Terminated	NCT03762122		PCD	2021Aug13	Expression confirmed	Yes		2	10.1200/JCO.2019.37.15_suppl.e20661	Previously-treated		Progression free survival	15	15			5.6																		64										2										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Pemigatinib		Recruiting	NCT05210946		ECD	2023Dec06	Yes	No		4	NCT05210946	Previously-treated		Overall Response Rate	20	20																																									COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR2	FGFR2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Bemarituzumab		Recruiting	NCT05267470	FORTITUDE-201	ECD	2024Feb16	Overexpression	No		4	NCT05267470			Maximum tolerated dose/toxicity	108	108																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR2	FGFR2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Bemarituzumab + Docetaxel		Recruiting	NCT05267470	FORTITUDE-201	ECD	2024Feb16	Overexpression	No		4	NCT05267470			Maximum tolerated dose/toxicity	108	108																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR2	FGFR2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR2	FGFR2_unspecified or FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4547		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort A1	ECD	2023Mar01	No	Yes		1	32669708			"ORR, PFS, DOR"	5	5											5.6			2.4-19.0																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FGFR3	FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT1	FLT1_unspecified (VEGFR1_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT1	FLT1_unspecified (VEGFR1_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	53	23	30	Erlotinib + Placebo									2.89	2.59	1.1		0.56																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT1	FLT1_unspecified (VEGFR1_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT3	FLT3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT3	FLT3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	30	17	13	Erlotinib + Placebo									3.69	2.79	1.46	0.25-7.96	0.65																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT4	FLT4_unspecified (VEGFR3_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
FLT4	FLT4_unspecified (VEGFR3_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
JAK2	JAK2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Pemetrexed + Ruxolitinib		Terminated	NCT02119650		PCD	2016Feb11	No	Yes	No benefit of treatment	1	27479177			Overall survival	76	76		Placebo																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	62	30	32	Erlotinib + Placebo									3.92	2.84	0.92		0.44																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KEAP1	KEAP1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat		Terminated	NCT04265534	KEAPSAKE	PCD	2021Nov05	Yes	No		4	NCT04265534	Untreated		Progression free survival	40			Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KEAP1	KEAP1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sirpiglenastat		Recruiting	NCT04471415		ECD	2023Mar01	Yes	No		4	NCT04471415			Maximum tolerated dose/toxicity	246	246																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KEAP1	KEAP1_unspecified or STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 4	Atezolizumab		Unknown					Yes	Yes		1	33537171			Overall survival	157	83	74	Docetaxel																						7.3	5.8	0.7	0.49-0.99	0.042													COSO29915674	2021Nov24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	KIF5B-RET_fusion COSF1231				lung / carcinoma / non small cell carcinoma	1	Case study	Vandetanib		Unknown					Yes	Yes		1	23584301			Unknown																																1											COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	KIF5B-RET_fusion COSF1231				lung / carcinoma / non small cell carcinoma	1	Case study	Everolimus + Vandetanib		Recruiting	NCT01582191		ECD	2026May31	Yes	Yes		1	25982012			Maximum tolerated dose/toxicity	174	174																															1										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	KIF5B-RET_fusion COSF1231				lung / carcinoma / non small cell carcinoma	1	Phase 1	Sitravatinib		"Active, not recruiting"	NCT02219711		PCD	2022Apr27	Expression confirmed	Yes		1	35767205			Maximum tolerated dose/toxicity	13	13			7.7				10.2				5.7			1.5-13.5										27.2			10.9-33.8				1	6									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	KIF5B-RET_fusion COSF1231				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lenvatinib		Completed	NCT01877083		PCD	2016Feb03	Yes	Yes		4	NCT01877083			Overall Response Rate	25	25			16		4.5-36.1						7.3			3.6-10.2																											COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KIT	KIT_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KIT	KIT_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	46	26	20	Erlotinib + Placebo									4.5	2.33	1.34	0.42-4.30	0.69																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KIT	KIT_unspecified or PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		"Active, not recruiting"	NCT01306045	Arm 13	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	2	2																																									COSO29915674	2022Dec15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS G12C and STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sotorasib		"Active, not recruiting"	NCT04933695	CodeBreaK201	ECD	2023Dec29	Yes	No		4	NCT04933695	Untreated		Overall Response Rate	170	170																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	lung / carcinoma / non small cell carcinoma	3	Phase 1	Cetuximab + Selumetinib		Completed	NCT01217450		PCD	2012Dec01	Yes	Yes		1	26666244			Maximum tolerated dose/toxicity	1	1																																1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	lung / carcinoma / non small cell carcinoma	3	Phase 1	Ipilimumab + KRAS peptide vaccine + Nivolumab + poly ICLC		Not yet recruiting	NCT05254184		ECD	2024Apr01	Yes	No		4	NCT05254184			Maximum tolerated dose/toxicity	12	12																																									COSO29915674	2022May23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12 or KRAS_G13 or KRAS_Q61				lung / carcinoma / non small cell carcinoma	3	Phase 3	Sorafenib		Completed	NCT00411671	BATTLE	PCD	2012Nov01	Yes	Yes		2	10.1200/jco.2010.28.15_suppl.7609	Previously-treated		Unknown	18	18																					61																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Sotorasib	Required	"Active, not recruiting"	NCT03600883	CodeBreaK 100	ECD	2025Nov21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214665s002lbl.pdf	Untreated		Overall Response Rate	124	124			36		28-45		10		1.3-11.1																																COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Adagrasib		Recruiting	NCT03785249	KRYSTAL-1	ECD	2022Dec01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf			Maximum tolerated dose/toxicity	112	112			43		34-53		8.5		6.2-13.8																																COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	Sotorasib		"Active, not recruiting"	NCT04380753	CodeBreak 105	PCD	2021Dec31	Yes	No		4	NCT04380753			Maximum tolerated dose/toxicity	12	12																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	GFH925 + Sintilimab		Not yet recruiting	NCT05504278		ECD	2023May12	Yes	No		4	NCT05504278			Overall Response Rate	144	144																																									COSO29915674	2022Oct03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	Cisplatin or carboplatin + GFH925 + Pemetrexed + Sintilimab		Not yet recruiting	NCT05504278		ECD	2023May12	Yes	No		4	NCT05504278			Overall Response Rate	144	144																																									COSO29915674	2022Oct03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	GFH925 + Pemetrexed + Sintilimab		Not yet recruiting	NCT05504278		ECD	2023May12	Yes	No		4	NCT05504278			Overall Response Rate	144	144																																									COSO29915674	2022Oct03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	Cetuximab + GFH925		Not yet recruiting	NCT05504278		ECD	2023May12	Yes	No		4	NCT05504278			Overall Response Rate	144	144																																									COSO29915674	2022Oct03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	Sotorasib + VIC-1911		Not yet recruiting	NCT05374538		ECD	2025May01	Yes	No		4	NCT05374538			"ORR, PFS, OS"	140	140																																									COSO29915674	2022May23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	VIC-1911		Not yet recruiting	NCT05374538		ECD	2025May01	Yes	No		4	NCT05374538			"ORR, PFS, OS"	140	140																																									COSO29915674	2022May23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 1	Midazolam + Sotorasib		"Active, not recruiting"	NCT03600883	CodeBreaK 100	ECD	2025Nov21	Yes	No		4	NCT03600883	Untreated		Overall Response Rate	6	6																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib		Recruiting	NCT04625647		ECD	2026Dec31	Yes	No		4	NCT04625647	Previously-treated		Overall Response Rate	116	116																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	D-1553 + Physician's choice		Not yet recruiting	NCT05492045		ECD	2023Apr01	Yes	No		4	NCT05492045			Overall Response Rate	144	144																																									COSO29915674	2022Oct03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Adagrasib + VS-6766		Recruiting	NCT05375994	RAMP204	ECD	2024Jul24	Yes	No		4	NCT05375994			Overall Response Rate	85	85																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	HS-10370		Not yet recruiting	NCT05367778		ECD	2025Apr30	Yes	No		4	NCT05367778			Overall Response Rate	176	176																																									COSO29915674	2022May23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib + Tarloxotinib		Recruiting	NCT05313009		ECD	2023Dec01	Yes	No		4	NCT05313009	Previously-treated		Overall Response Rate	30	30																																									COSO29915674	2022May23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab biosimilar Mvasi + Sotorasib		Recruiting	NCT05180422		ECD	2026Dec31	Yes	No		4	NCT05180422			Intracranial Response Rate	43	43																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Pemetrexed + Platinum-based chemotherapy + Sotorasib		Recruiting	NCT05118854		ECD	2023Oct20	Yes	No		4	NCT05118854	Untreated		Major pathologic response	27	27																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib + VS-6766		Recruiting	NCT05074810	RAMP203	ECD	2023Dec01	Yes	No		4	NCT05074810	Previously-treated		Clinical activity	53	53																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	RMC-4630 + Sotorasib		Recruiting	NCT05054725		ECD	2023Mar31	Yes	No		4	NCT05054725			Overall Response Rate	46	46																																									COSO29915674	2022Nov09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	JDQ443		Not yet recruiting	NCT05445843	Cohort A	ECD	2026Nov02	Yes	No		4	NCT05445843			Overall Response Rate	120	120																																									COSO29915674	2022Sep30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Adagrasib + Pembrolizumab		Recruiting	NCT04613596	KRYSTAL-7	ECD	2023Oct30	Yes	No		4	NCT04613596			Overall Response Rate	250	250																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Adagrasib		Not yet recruiting	NCT05472623	Arm A	ECD	2025Nov20	Yes	No		4	NCT05472623			"Complete response, Pathological complete response"	42	42																																									COSO29915674	2022Sep30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib		Not yet recruiting	NCT05451056		ECD	2026Jan01	Yes	No		4	NCT05451056			"ORR, PFS, OS"	37	37																																									COSO29915674	2022Sep30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib		Recruiting	NCT05400577		ECD	2024Jan01	Yes	No		4	NCT05400577			Major pathologic response	25	25																																									COSO29915674	2022Sep30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib		Recruiting	NCT05398094	MERIT-lung	ECD	2027Dec30	Yes	No		4	NCT05398094			Progression free survival	43	43																																									COSO29915674	2022Sep30	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib		Recruiting	NCT05631249	CODEBREAK-IGR	ECD	2023May13	Yes	No		4	NCT05631249			Response rate	40	40																																									COSO29915674	2023Jan05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 2	Sotorasib		Recruiting	NCT05311709	SOLUCOM	ECD	2024Oct01	Yes	No		4	NCT05311709			Overall Response Rate	100	100																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 3	Adagrasib		Recruiting	NCT04685135	KRYSTAL-12	ECD	2023Aug01	Yes	No		4	NCT04685135	Previously-treated		"OS, PFS"	340			Docetaxel																																							COSO29915674	2022Jan25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 3	JDQ443		Recruiting	NCT05132075	KontRASt-02	ECD	2024Aug09	Yes	No		4	NCT05132075	Previously-treated		Progression free survival	360			Docetaxel																																							COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	lung / carcinoma / non small cell carcinoma	1	Phase 3	Docetaxel + Sotorasib		"Active, not recruiting"	NCT04303780	CodeBreak 200	PCD	2022Aug02	Yes	No		4	NCT04303780			Progression free survival	345			Docetaxel																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C and STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sotorasib		"Active, not recruiting"	NCT04933695		ECD	2023Dec29	Yes	No		4	NCT04933695	Untreated		Overall Response Rate	170	170																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_G12C and STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	JAB-21822		Recruiting	NCT05276726		ECD	2023Dec01	Yes	No		4	NCT05276726			Overall Response Rate	104	104																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	VS-6766		"Active, not recruiting"	NCT03681483		ECD	2023Sep01	Yes	No		4	NCT03681483			Overall Response Rate	15	15																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	RMC-4630		"Active, not recruiting"	NCT03634982		ECD	2023Mar31	Yes	No		4	NCT03634982			Maximum tolerated dose/toxicity	133	133																																									COSO29915674	2022Nov09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	HL-085 + Vemurafenib		Terminated	NCT03990077		PCD	2021Jul20	Yes	Yes	Changed business priorities	4	NCT03990077			Maximum tolerated dose/toxicity	2	2																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	BBP-398 + Nivolumab		Recruiting	NCT05375084		ECD	2024Jul01	Yes	No		4	NCT05375084	Previously-treated		Overall Response Rate	45	45																																									COSO29915674	2022May23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Anlotinib + Trametinib		Recruiting	NCT04967079		ECD	2023Jan01	Yes	No		4	NCT04967079			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pembrolizumab + Trametinib		"Active, not recruiting"	NCT03299088		PCD	2021Jan28	Yes	No		4	NCT03299088			Maximum tolerated dose/toxicity	15	15																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	RO4987655		Unknown					Yes	No		1	24947927			Unknown	18	18																															2										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Docetaxel		Withdrawn	NCT02451865		ECD	2018Jun01	No	No		4	NCT02451865			Maximum tolerated dose/toxicity	0	0																																									COSO29915674	2021Aug16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	ERAS-007		Completed	NCT03415126	ASN007-101 Group 4	PCD	2020Jun30	No	No		4	NCT03415126			Overall Response Rate	49	49																																									COSO29915674	2022Jul12	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LTT462 + Naporafenib		"Active, not recruiting"	NCT02974725		ECD	2023Apr25	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	241	241																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Naporafenib + Trametinib		"Active, not recruiting"	NCT02974725		ECD	2023Apr25	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	241	241																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Naporafenib + Ribociclib		"Active, not recruiting"	NCT02974725		ECD	2023Apr25	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	241	241																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Momelotinib + Trametinib		Terminated	NCT02258607		PCD	2016Jul19	Yes	Yes	Primary outcome met	1	30087028	Previously-treated		Maximum tolerated dose/toxicity	21	21			0								3.6													7.4																	COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Atezolizumab + Cobimetinib		Completed	NCT01988896		PCD	2019Nov04	Comparison with wt	Yes		1	30918950				24	12	12		8	33																																					COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Erlotinib		"Active, not recruiting"	NCT01859026		PCD	2019Aug22	Yes	No		4	NCT01859026			Maximum tolerated dose/toxicity	43	43																																									COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Trametinib		Completed	NCT01362296		PCD	2012Sep01	Yes	Yes	Response not correlated with mutation status	1	25722381			Progression free survival	129	86	43	Docetaxel									11.7	11.4	1.14		0.52																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	IMM-1-104		Recruiting	NCT05585320		ECD	2026Jun01	Yes	No		4	NCT05585320	Previously-treated		Overall Response Rate	156	156																																									COSO29915674	2023Jan05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	BGB-3245 + Mirdametinib		Recruiting	NCT05580770	Dose expansion B	ECD	2026Oct31	Yes	No		4	NCT05580770			Overall Response Rate	136	136																																									COSO29915674	2023Jan05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Defactinib + VS-6766		Recruiting	NCT04620330		ECD	2023Mar01	Yes	No		4	NCT04620330	Previously-treated		Overall Response Rate	100	100																																									COSO29915674	2021Nov19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Selumetinib		Completed	NCT01229150		PCD	2013Sep30	Yes	Yes		4	NCT01229150				41	30	11	Selumetinib	10	0							2.3	4			0.24						43	89		21.8	10.5			0.81													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Nivolumab + Rigosertib		Recruiting	NCT04263090		ECD	2022Dec01	Yes	No		4	NCT04263090			Overall Response Rate	20	20																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Defactinib		Recruiting	NCT04620330		ECD	2023Mar01	Yes	No		4	NCT04620330			Overall Response Rate	100	100																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lifirafenib + Mirdametinib		Recruiting	NCT03905148		ECD	2024Mar30	Yes	No		4	NCT03905148			Maximum tolerated dose/toxicity	105	105																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Binimetinib + Hydroxychloroquine		Recruiting	NCT04735068	LIMIT	ECD	2023Apr01	Yes	No		4	NCT04735068			Overall Response Rate	29	29																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ponatinib + Trametinib		Completed	NCT03704688		PCD	2022Feb04	Yes	Yes	SAE 41.7%	2	10.1016/j.jtocrr.2021.100256	Previously-treated		Maximum tolerated dose/toxicity	12	12			0		0-25																																				COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Camrelizumab		Unknown	NCT03777124		ECD	2020Apr01	Yes	No		4	NCT03777124			Progression free survival	230	230																																									COSO29915674	2022Jun06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Yes	Yes		4	NCT00265317			Progression free survival	133	65	67	Erlotinib + Placebo									4.64	1.73																													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort C6	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	30	30											5.3			3.8-7.9																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Spartalizumab		Unknown	NCT03693326		ECD	2020Jun30	Yes	No		4	NCT03693326			Overall Response Rate	70	70																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Durvalumab + Pemetrexed		Withdrawn	NCT04470674		PCD	2021Jun08	Yes	Yes	Slow accrual	4	NCT04470674			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	0	0																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Foretinib		Completed	NCT01068587		PCD	2014Mar21	No	Yes		1	29050231	Previously-treated		Overall Response Rate	4	4																																4									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Durvalumab		Withdrawn	NCT04470674		PCD	2021Jun08	Yes	Yes	Slow accrual	4	NCT04470674			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	0	0																																									COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Methotrexate		"Active, not recruiting"	NCT03520842		ECD	2023Jan01	Yes	No		4	NCT03520842			Progression free survival	18	18																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Tivantinib		Completed	NCT00777309		PCD	2011May01	No	Yes		1	21768463			Progression free survival	167	84	83	Erlotinib + Placebo									3.8	2.3	0.81	0.57-1.16	0.24																										COSO29915674	2021Jun01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Tivantinib		Completed	NCT01395758		PCD	2016Aug01	Yes	Yes	No benefit of treatment - OS and ORR were greater with control	4	NCT01395758	Previously-treated		Progression free survival	96			Placebo																																							COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Selumetinib		Unknown	NCT02450656		ECD	2019May01	No	No		4	NCT02450656			Progression free survival	320	320																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT00861627	REO 016	PCD	2015Sep01	No	Yes		1	29748010	Previously-treated		Overall Response Rate	37	37											4			2.9-6.1										13.1			9.2-21.6														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Docetaxel + Pelareorep		Completed	NCT01708993	IND211	PCD	2016Jan26	No	Yes	No benefit of treatment	1	29748010	Previously-treated		Progression free survival	166	166																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pelareorep + Pemetrexed		Completed	NCT01708993	IND211	PCD	2016Jan26	No	Yes	No benefit of treatment	1	29748010	Previously-treated		Progression free survival	166	166											3	2.8	0.9	0.65-1.25	0.53																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Docetaxel + Selinexor		"Active, not recruiting"	NCT03095612		PCD	2022Nov08	No	Yes		4	NCT03095612	Previously-treated		Maximum tolerated dose/toxicity	59	59																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Salirasib		Completed	NCT00531401		PCD	2009Nov01	Yes	Yes	No benefit of treatment	1	21847063			Unknown	30	30																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dasatinib		Terminated	NCT00787267	TOP0801	PCD	2013Jun01	Yes	Yes	Slow accrual	4	NCT00787267			"Disease control rate, Clinical benefit rate"	37	37																																									COSO29915674	2022Jul11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	TVB2640		Recruiting	NCT03808558		ECD	2022Dec01	Yes	No		4	NCT03808558			Overall Response Rate	12	12																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	VS-6766		Recruiting	NCT04620330		ECD	2023Mar01	Yes	No		4	NCT04620330	Previously-treated		Overall Response Rate	100	100																																									COSO29915674	2021Nov19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Sorafenib		Unknown		BATTLE-2			No	Yes	Response not correlated with mutation or expression status	1	27480147	Previously-treated		Unknown																																											COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Abemaciclib		"Active, not recruiting"	NCT02152631	JUNIPER	PCD	2017Sep15	No	Yes	Primary outcome not met	3	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9025	Previously-treated		Overall survival	453	270	183	Erlotinib	8.9	2.7		0.01					3.6	1.9	0.58	0.47-0.72	p < 0.001																										COSO29915674	2021Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Sorafenib		Completed	NCT00863746	MISSION	PCD	2012Mar01	No	Yes	Response not correlated with mutation or expression status	1	26743856	Previously-treated		Overall survival	703	350	353	Placebo									2.8	1.4	0.61	0.51-0.72	p<0.0001	2.9	1.4	0.54	0.45-0.65	<0.0001																					COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified and CD274_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Abemaciclib + Pembrolizumab		"Active, not recruiting"	NCT02779751	Cohort A	PCD	2020Feb03	Expression confirmed	Yes	SAE 80%	1	34746886	Untreated		Maximum tolerated dose/toxicity	25	25			24								7.6			-1.6							56			27.8			-9.9														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified and TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sintilimab		Recruiting	NCT03574402	TRUMP Arm 16	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified or STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vistusertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort B2D	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	25	25											2.9			2.0-4.6																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified or STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Palbociclib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort C5	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	12	12											2.6			1.5-5.0																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MAP2K1	MAP2K1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	65	65	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Capmatinib	Required	"Active, not recruiting"	NCT02414139	Geometry Mono-1	ECD	2023Feb07	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf	Previously-treated		Overall Response Rate	100	100			44		34-54		9.7		5.6-13.0																					0	44										COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Tepotinib	Required	"Active, not recruiting"	NCT02864992	VISION cohort A	PCD	2022May16	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf	Previously-treated		Overall Response Rate	83	83			43		33-55		11.1		9.5-18.5																																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Tepotinib	Required	"Active, not recruiting"	NCT02864992	VISION cohort A	PCD	2022May16	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf	Untreated		Overall Response Rate	69	69			43		32-56		10.8		-6.9																																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Capmatinib	Required	"Active, not recruiting"	NCT02414139	Geometry Mono-1	ECD	2023Feb07	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf	Untreated		Overall Response Rate	60	60			68		55-80		16.6		8.4-22.1																					3	38										COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 1	PF-07265807		Recruiting	NCT04458259	"Part 4, Cohort 1"	ECD	2024Jun02	Expression confirmed	No		4	NCT04458259	Previously-treated		Overall Response Rate	161	161																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Capmatinib + Trametinib		Recruiting	NCT05435846		ECD	2026Jun30	Yes	No		4	NCT05435846			Maximum tolerated dose/toxicity	33	33																																									COSO29915674	2022Oct04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Unknown	NCT03911193		ECD	2020Sep01	Yes	No		4	NCT03911193			Overall Response Rate	25	25																																									COSO29915674	2021Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Amivantamab + Capmatinib		Not yet recruiting	NCT05488314	METalmark	ECD	2024Dec27	Expression confirmed	No		4	NCT05488314			Overall Response Rate	161	161																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	REGN5093		Recruiting	NCT04077099		ECD	2024Oct20	Yes	No		4	NCT04077099			Overall Response Rate	111	111																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib + Spartalizumab		"Active, not recruiting"	NCT04323436		ECD	2022Dec16	Yes	No		4	NCT04323436			"PFS, ORR"	31			Capmatinib + Placebo																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	APL-101		Recruiting	NCT03175224	Cohort A	ECD	2026Mar30	Yes	No		4	NCT03175224			Response rate	344	344																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Sym015		Completed	NCT02648724		PCD	2020Dec01	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.9510 			Overall Response Rate	12	12			25								5.5																				3	5									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Savolitinib		"Active, not recruiting"	NCT02897479		ECD	2021Dec30	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.9519			Overall Response Rate	76	76			47.5		34.6-60.7						6.8			4.2-13.8							93.4																				COSO29915674	2022Jan21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Glumetinib		Recruiting	NCT04270591		ECD	2023Oct25	Expression confirmed	Yes		2	10.1200/PO.20.00098			Overall Response Rate	54	54			31		18-45						5.8			3.7-20.0										13.7			10.8-22.9														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ningetinib		Not yet recruiting	NCT04992858		ECD	2024Sep09	Yes	No		4	NCT04992858			Overall Response Rate	80	80																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib		Recruiting	NCT04926831	Cohort A	ECD	2023Sep21	Yes	No		4	NCT04926831			Major pathologic response	38	38																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib		Recruiting	NCT04677595	GeoMETry-C	ECD	2023Dec12	Yes	No		4	NCT04677595			Overall Response Rate	35	35																																									COSO29915674	2021Nov25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib		Withdrawn	NCT04460729		ECD	2023Nov17	Yes	No		4	NCT04460729			Overall Response Rate	0	0																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib		Unknown	NCT03693339		ECD	2020Jun30	Yes	No		4	NCT03693339			Overall Response Rate	27	27																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib		Completed	NCT02750215		PCD	2021May01	Yes	Yes		4	NCT02750215			Overall Response Rate	20	20			50								5.5			1.3-11.0							80			11.3			-5.5														COSO29915674	2022May05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib		Recruiting	NCT04677595	GeoMETry-C	ECD	2023Dec12	Yes	No		4	NCT04677595			Overall Response Rate	35	35																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort D3	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	13	13											12.5			6.4-29.7																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Capmatinib		"Active, not recruiting"	NCT04427072	GeoMETry-III	ECD	2023Sep15	Yes	No		4	NCT04427072			Progression free survival	22	22																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Savolitinib		Recruiting	NCT04923945		ECD	2024Jul01	Yes	No		4	NCT04923945			Overall Response Rate	163	163																																									COSO29915674	2021Nov02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del				lung / carcinoma / non small cell carcinoma	1	Phase 4	Capmatinib		Recruiting	NCT05110196		ECD	2024Jul01	Yes	No		4	NCT05110196			Maximum tolerated dose/toxicity	50	50																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del or MET_D1228N				lung / carcinoma / non small cell carcinoma	4	Case study	Cabozantinib		Unknown					Yes	Yes		2	10.1200/PO.21.00076	Previously-treated		Unknown	1	1																															1										COSO29915674	2021May21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_Exon14del or NTRK1_unspecified or NTRK2_unspecified or NTRK3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Merestinib		"Active, not recruiting"	NCT02920996		PCD	2021Oct01	Yes	No		4	NCT02920996			Overall Response Rate	12	12																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_no_Exon14del				lung / carcinoma / non small cell carcinoma	3	Retrospective/Meta-analysis	Glumetinib		Unknown					Overexpression	Yes	Promising activity	6	https://www.haihepharma.com/en/news/details/358	Untreated			32	32			37.5		21.1-56.3		8.3		-2.8		6.9			3.6-9.7										16.2			-10.3														COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Case study	Crizotinib		Completed	NCT00585195	PROFILE 1001	PCD	2020Jul30	Expression confirmed	Yes		1	21623265			Clinical activity	65	65																															1										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Capmatinib + Erlotinib		Completed	NCT01911507		PCD	2020Aug26	Expression confirmed	Yes		2	10.1200/jco.2015.33.15_suppl.2587	Previously-treated		Maximum tolerated dose/toxicity	4	4			75																		75																				COSO29915674	2022Dec14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	MYTX-011		Not yet recruiting	NCT05652868		ECD	2025Dec01	No	No		4	NCT05652868			Overall Response Rate	150	150																																									COSO29915674	2023Jan10	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	ABBV-400		Recruiting	NCT05029882		ECD	2025Jun22	Expression confirmed	No		4	NCT05029882			Overall Response Rate	220	220																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Capmatinib + Nivolumab		Terminated	NCT02323126		PCD	2019Sep23	Expression confirmed	Yes	PFS 6m 60.7%	4	NCT02323126	Previously-treated		Progression free survival	16	16																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	BPI-9016M		Recruiting	NCT02929290		ECD	2024Nov01	Expression confirmed	No		4	NCT02929290			"DCR, ORR"	80	80																																									COSO29915674	2021Oct29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Apatinib + HS-10241		Unknown	NCT03243643		ECD	2019Jul01	Expression confirmed	No		4	NCT03243643			Maximum tolerated dose/toxicity	80	80																																									COSO29915674	2021Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	HS-10241		Unknown	NCT02977364		ECD	2018Nov01	Expression confirmed	No		4	NCT02977364			Maximum tolerated dose/toxicity	50	50																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Bozitinib		Completed	NCT02896231		PCD	2019Oct01	Expression confirmed	Yes		3	https://cancerres.aacrjournals.org/content/80/16_Supplement/CT127			Maximum tolerated dose/toxicity	37	37			30.6																		94.4																				COSO29915674	2021Jun14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Erlotinib + Telisotuzumab vedotin		Recruiting	NCT02099058	Arm A	ECD	2023Dec08	Expression confirmed	Yes	PFS 6m 0.43	2	10.1200/JCO.2019.37.15_suppl.3011			Maximum tolerated dose/toxicity	7	7			28.6		3.7-71.0						5.9			-1.2																0											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	SAR125844		Completed	NCT01391533		PCD	2016Apr01	Expression confirmed	Yes		1	29145039			Clinical activity	22	22																															4										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Glumetinib		Unknown	NCT03457532		ECD	2021Jul30	Expression confirmed	No		4	NCT03457532				75	75																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Crizotinib		Completed	NCT00585195	PROFILE 1001	PCD	2020Jul30	Expression confirmed	Yes		4	NCT00585195			Immune response	38	38			31.6		17.5-48.7						4			1.9-6.9										10.1			7.1-12.9														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 1	Crizotinib		Completed	NCT00585195	PROFILE 1001	PCD	2020Jul30	Yes	Yes		4	NCT00585195			Maximum tolerated dose/toxicity	65	65			32.3		21.2-45.1		1.56		0.65-3.09		7.6			5.6-9.1										20			13.2-25.7														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Recruiting	NCT03865511	MELROSE	ECD	2024Apr01	Yes	No		4	NCT03865511			Biomarker discovery	66	66																																									COSO29915674	2021Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Tepotinib + Tyrosine Kinase Inhibitor		Recruiting	NCT04739358		ECD	2025Jun30	Yes	No		4	NCT04739358			Overall Response Rate	65	65																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	REGN5093		Recruiting	NCT04077099		ECD	2024Oct20	Expression confirmed	No		4	NCT04077099			Overall Response Rate	111	111																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Glumetinib + Osimertinib		Unknown	NCT04338243		ECD	2020Dec31	Expression confirmed	No		4	NCT04338243			Overall Response Rate	70	70																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Durvalumab + Savolitinib		Not yet recruiting	NCT05374603	SOUND	ECD	2023Oct31	Expression confirmed	No		4	NCT05374603			Progression free survival	60	60																																									COSO29915674	2022May24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	OMO-1		Terminated	NCT03138083		PCD	2020May25	Expression confirmed	Yes	Changed business priorities	4	NCT03138083			Maximum tolerated dose/toxicity	40	40																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bozitinib		Recruiting	NCT04258033		ECD	2022Dec31	Expression confirmed	No		4	NCT04258033			Overall Response Rate	185	185																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Sym015		Completed	NCT02648724		PCD	2020Dec01	Expression confirmed	Yes		2	10.1200/JCO.2020.38.15_suppl.9510 			Overall Response Rate	8	8			25								5.5																				2	6									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Tepotinib		Recruiting	NCT04739358		ECD	2025Jun30	Yes	No		4	NCT04739358			Overall Response Rate	65	65																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Tepotinib		"Active, not recruiting"	NCT02864992	VISION cohort B	PCD	2022May16	Expression confirmed	No		4	NCT02864992			Overall Response Rate	337	337																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Telisotuzumab vedotin		Recruiting	NCT05513703		ECD	2025Nov15	Expression confirmed	No		4	NCT05513703			Overall Response Rate	70	70																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Telisotuzumab vedotin		Recruiting	NCT03539536		ECD	2025Sep24	Expression confirmed	No		4	NCT03539536	Previously-treated		Overall Response Rate	270	270																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Savolitinib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	1	1	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Onartuzumab + Paclitaxel + Platinum-based chemotherapy		Completed	NCT01519804		PCD	2014Jan01	Expression confirmed	No		4	NCT01519804	Untreated		Progression free survival	108			Paclitaxel + Placebo + Platinum-based chemotherapy																																							COSO29915674	2022Jan28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Onartuzumab + Pemetrexed + Platinum-based chemotherapy		Completed	NCT01496742		PCD	2015Nov01	Expression confirmed	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003719-42/results	Untreated		Progression free survival	73	36	37	Pemetrexed + Placebo + Platinum-based chemotherapy									5	5	1.25	0.72-2.15	0.4271																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Bevacizumab + Onartuzumab + Paclitaxel + Platinum-based chemotherapy		Completed	NCT01496742		PCD	2015Nov01	Expression confirmed	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003719-42/results	Untreated		Progression free survival	89	45	44	Bevacizumab + Paclitaxel + Placebo + Platinum-based chemotherapy									4.8	6.9	1.71	0.97-3.02	0.0576																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	SAR125844		Completed	NCT02435121		PCD	2016Jan01	Expression confirmed	No		4	NCT02435121			Overall Response Rate	1	1																																									COSO29915674	2021Jun11	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Glesatinib		Completed	NCT02544633		PCD	2018Apr30	Expression confirmed	Yes		4	NCT02544633			Overall Response Rate	20	20			15		3.21-37.89	0.79	5.58				4.84			1.35-5.53										7.04			1.84-14.93														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Glesatinib		Completed	NCT02544633		PCD	2018Apr30	Yes	Yes		4	NCT02544633			Overall Response Rate	28	28			10.7		2.27-28.23	0.94	2.79				3.95			2.11-4.18										16.32			-4.01														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Glumetinib		Recruiting	NCT04270591		ECD	2023Oct25	Expression confirmed	No		4	NCT04270591			Overall Response Rate	210	210																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Capmatinib		Not yet recruiting	NCT05567055		ECD	2025Dec01	Yes	No		4	NCT05567055			CNS ORR	35	35																																									COSO29915674	2023Jan10	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Capmatinib		Recruiting	NCT04926831	Cohort B	ECD	2023Sep21	Expression confirmed	No		4	NCT04926831			Major pathologic response	38	38																																									COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Capmatinib		Withdrawn	NCT03240393		ECD	2021Oct26	Yes	No		4	NCT03240393	Previously-treated		Overall Response Rate	0	0																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Capmatinib		"Active, not recruiting"	NCT02414139	Geometry Mono-1	ECD	2023Feb07	Yes	No		4	NCT02414139			Overall Response Rate	373	373																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	TQ-B3139		Unknown	NCT04398940		ECD	2022Jan31	Expression confirmed	No		4	NCT04398940			Overall Response Rate	71	71																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 4	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Ceritinib		Completed	NCT02276027		PCD	2019Oct15	Yes	Yes		4	NCT02276027			Overall Response Rate	16	16			18.8																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		Unknown	NCT02499614	METROS cohort B	ECD	2018Jun01	Yes	Yes		1	31416808			Response rate	26	26			27		Nov-47		3.7		1.1-6.3		4.4			3.0-5.8							69			5.4			4.2-6.5														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		Recruiting	NCT04084717	CROME	ECD	2024Dec01	Yes	No		4	NCT04084717			Response rate	50	50																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		"Active, not recruiting"	NCT03737994		ECD	2025Dec13	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																									COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Yes	Yes		1	31584608			Overall Response Rate	28	28			10.7																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Expression confirmed	Yes		1	31584608			Overall Response Rate	25	25			16																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		Recruiting	NCT03574402	TRUMP Arm 3	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Crizotinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort D1	ECD	2023Mar01	Expression confirmed	Yes		1	32669708			"ORR, PFS, DOR"	16	16											3.8			2.3-7.2																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cabozantinib		Unknown	NCT03911193		ECD	2020Sep01	Expression confirmed	No		4	NCT03911193			Overall Response Rate	25	25																																									COSO29915674	2021Jun15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cabozantinib		Terminated	NCT02132598		PCD	2019Aug09	Expression confirmed	Yes	Slow accrual	4	NCT02132598	Previously-treated		Overall Response Rate	5	5																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Cabozantinib		"Active, not recruiting"	NCT03468985		PCD	2022May09	Yes	No		4	NCT03468985			Progression free survival	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Emibetuzumab + Erlotinib		Completed	NCT01900652		PCD	2015Feb01	Expression confirmed	Yes		4	NCT01900652	Previously-treated		Overall Response Rate	53	53			3.8																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Erlotinib + Onartuzumab		Completed	NCT00854308		PCD	2010Nov01	Expression confirmed	Yes		4	NCT00854308			Progression free survival	66	35	31	Erlotinib + Placebo	8.6	3.2		0.3671					2.9	1.5	0.53	0.28-0.99	0.04									12.6	3.8	0.37		0.002													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 2	Emibetuzumab		Completed	NCT01900652		PCD	2015Feb01	Expression confirmed	Yes		4	NCT01900652	Previously-treated		Overall Response Rate	21	21			4.8																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib + Onartuzumab		Completed	NCT01456325	METLung	PCD	2016Jan01	No	Yes	Response not correlated with expression status	1	27937096	Previously-treated		Overall survival	499	249	250	Erlotinib	8.4	9.6							2.7	2.6	0.99	0.81-1.2	0.92									6.8	9.1	1.27	0.98-1.65	0.067													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Telisotuzumab vedotin		Recruiting	NCT04928846		ECD	2025Jun07	Yes	No		4	NCT04928846			Progression free survival	698			Docetaxel																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Telisotuzumab vedotin		Recruiting	NCT04928846		ECD	2025Jun07	Yes	No		4	NCT04928846	Previously-treated		Progression free survival	698			Docetaxel																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	2	Phase 3	Erlotinib + Onartuzumab		Completed	NCT02031744		PCD	2016Jan06	Expression confirmed	No		4	NCT02031744	Previously-treated		Overall survival	530			Erlotinib + Placebo																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
MTOR	MTOR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vistusertib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	18	18	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NF1	NF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Trametinib		Terminated	NCT03232892		PCD	2019Sep11	Yes	Yes	Slow accrual	4	NCT03232892			Overall Response Rate	1	1																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NF1	NF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort E2	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	14	14											5.3			3.2-10.0																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NFE2L2	NFE2L2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat		Terminated	NCT04265534	KEAPSAKE	PCD	2021Nov05	Yes	No		4	NCT04265534	Untreated		Progression free survival	40			Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NFE2L2	NFE2L2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sirpiglenastat		Recruiting	NCT04471415		ECD	2023Mar01	Yes	No		4	NCT04471415			Maximum tolerated dose/toxicity	246	246																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NRAS	NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Docetaxel		Withdrawn	NCT02451865		ECD	2018Jun01	No	No		4	NCT02451865			Maximum tolerated dose/toxicity	0	0																																									COSO29915674	2021Aug16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NRAS	NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort E3	ECD	2023Mar01	Yes	No		1	32669708			"ORR, PFS, DOR"	423	423																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NRAS	NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Spartalizumab		Unknown	NCT03693326		ECD	2020Jun30	Yes	No		4	NCT03693326			Overall Response Rate	70	70																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Entrectinib	Required	Unknown		Entrectinib NTRK			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212725s006lbl.pdf			"ORR, DOR"	54	54			57		43-71																									4	29										COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 6	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Larotrectinib		Recruiting	NCT02576431	NAVIGATE Arm 1	ECD	2023Aug15	Yes	No		4	NCT02576431			Best overall response	204	204																																									COSO29915674	2022Jul15	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Entrectinib		"Active, not recruiting"	NCT02568267	STARTRK-2	ECD	2024Dec31	Yes	No		4	NCT02568267			Overall Response Rate	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK1	NTRK1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Entrectinib + Resection		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK2	NTRK2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Entrectinib + Resection		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
NTRK3	NTRK3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Entrectinib + Resection		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PDGFRA	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PDGFRA	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	61	29	32	Erlotinib + Placebo									2.84	2.7	0.82	0.27-2.49	0.37																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PDGFRA	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PDGFRB	PDGFRB_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PDGFRB	PDGFRB_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	58	29	29	Erlotinib + Placebo									2.84	12	2.69	0.79-9.14	0.95																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PDGFRB	PDGFRB_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	2014Feb01	No	Yes	"Serious adverse events, no benefit of treatment"	1	26899759			Maximum tolerated dose/toxicity	70	70																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alpelisib		Completed	NCT02276027		PCD	2019Oct15	Yes	Yes		4	NCT02276027			Overall Response Rate	2	2			0																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Carboplatin + Paclitaxel + Pictilisib		Completed	NCT01493843	FIGARO	PCD	2016Mar30	No	Yes	No benefit of treatment	1	28992562	Untreated		Progression free survival	501																																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pictilisib		Completed	NCT01493843	FIGARO	PCD	2016Mar30	No	Yes	No benefit of treatment	1	28992562	Untreated		Progression free survival	501																																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RB1	RB1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Etoposide + Osimertinib		Recruiting	NCT03567642		ECD	2024Jun01	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2023Jan16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Pralsetinib	Required	"Active, not recruiting"	NCT03037385	ARROW	ECD	2023Dec31	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf	Untreated		Overall Response Rate	27	27			70		50-86		9																																		COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	2024Mar21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	Untreated		Overall Response Rate	69	69			84		73-92		20.2		-13																																COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	2024Mar21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	Previously-treated		Overall Response Rate	247	247			61		55-67		28.6		-20																																COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Pralsetinib	Required	"Active, not recruiting"	NCT03037385	ARROW	ECD	2023Dec31	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf	Previously-treated		Overall Response Rate	87	87			57		46-68																																				COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 1	Sitravatinib		"Active, not recruiting"	NCT02219711		PCD	2022Apr27	Expression confirmed	Yes		1	35767205			Maximum tolerated dose/toxicity	23	23			17.4				2.3		1.8-10.2		5.7			3.0-13.5										27.2			-10.9				4	13									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Recruiting	NCT01639508	Group A	ECD	2023Jul01	Yes	No		4	NCT01639508	Untreated		Overall survival	86	86			33																												2										COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Pemetrexed + Selpercatinib		Recruiting	NCT05364645		ECD	2028May01	Yes	No		4	NCT05364645			Progression free survival	74			Carboplatin + Pemetrexed																																							COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	HA121-28		Recruiting	NCT05117658		ECD	2023Oct01	Yes	No		4	NCT05117658			Overall Response Rate	83	83																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Sitravatinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort H1	ECD	2023Mar01	Yes	No		1	32669708			"ORR, PFS, DOR"	423	423																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Selpercatinib		"Active, not recruiting"	NCT04280081	LIBRETTO-321	PCD	2021Mar25	Yes	Yes		4	NCT04280081	Previously-treated		Overall Response Rate	34	34			58.8		40.7-75.4																									0	20	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Selpercatinib		"Active, not recruiting"	NCT04280081	LIBRETTO-321	PCD	2021Mar25	Yes	Yes		4	NCT04280081	Untreated		Overall Response Rate	11	11			90.9		58.7-99.8																									2	8	1									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Recruiting	NCT01639508	Group D	ECD	2023Jul01	Yes	No		4	NCT01639508	Previously-treated		Overall Response Rate	86	86			20																												3										COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 3	Durvalumab		Recruiting	NCT05170204		ECD	2029Jun17	Yes	No		4	NCT05170204	Previously-treated		Progression free survival	320	320																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Out of trials human study	Alectinib		Unknown					Yes	Yes		1	27544060			Unknown	4	4																															1	1									COSO29915674	2022Mar02	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Agerafenib		Completed	NCT03784378		PCD	2020Sep30	Yes	No		4	NCT03784378			Clinical activity	3	3																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	DS-5010 		"Active, not recruiting"	NCT03780517		ECD	2023Apr30	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.3008			Maximum tolerated dose/toxicity	30	30			33																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Alectinib		Terminated	NCT03131206		PCD	2018Nov08	Yes	Yes	"Slow accrual, Lack of efficacy"	4	NCT03131206			Overall Response Rate	5	5																																									COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Agerafenib		Completed	NCT01877811		PCD	2018Dec01	Yes	Yes		2	10.1158/2159-8290.CD-18-0839			Maximum tolerated dose/toxicity	31	31			19																												6	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vandetanib		Completed	NCT01823068		PCD	2014Dec29	Yes	Yes		1	27803005			Overall Response Rate	17	17			18																		65										3	8									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Pralsetinib + Resection		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	27	7	20	Erlotinib + Placebo									2.4	2.33	0.69	0.071-6.765	0.376																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib		Unknown	NCT02540824		ECD	2016Dec01	Yes	No		4	NCT02540824			Overall Response Rate	40	40																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Selpercatinib		"Active, not recruiting"	NCT04268550		ECD	2023Apr01	Yes	No		4	NCT04268550			Overall Response Rate	124	124																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ponatinib		Completed	NCT01813734		PCD	2018Jun01	Yes	Yes		4	NCT01813734			Overall Response Rate	9	9			0								3.8										55.6											5									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		Terminated	NCT03445000	ALERT-lung	PCD	2021Mar31	Yes	Yes	Slow accrual	4	NCT03445000			Best overall response	14	14																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cabozantinib		"Active, not recruiting"	NCT03468985		PCD	2022May09	Yes	No		4	NCT03468985			Progression free survival	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cabozantinib		Unknown	NCT04131543	CRETA	ECD	2020Aug07	Yes	No		4	NCT04131543			"Disease control rate, Clinical benefit rate"	25	25																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vandetanib		Unknown	UMIN000010095	LURET			Yes	Yes		1	27825616			Unknown	19	19			47								4.7																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Alectinib		Recruiting	NCT03178552	B-FAST Cohort B	ECD	2024Apr27	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Selpercatinib		Recruiting	NCT04819100	LIBRETTO-432	ECD	2028Aug31	Yes	No		4	NCT04819100			Event free survival	170			Placebo																																							COSO29915674	2022Jan24	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Selpercatinib		Recruiting	NCT04194944	LIBRETTO-431	ECD	2023Jan15	Yes	No		4	NCT04194944			Progression free survival	250																																										COSO29915674	2021Nov01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Pralsetinib		Recruiting	NCT05170204		ECD	2029Jun17	Yes	No		4	NCT05170204	Previously-treated		Progression free survival	320	320																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Pralsetinib		Recruiting	NCT04222972	AcceleRET	ECD	2023Sep30	Yes	No		4	NCT04222972	Untreated		Progression free survival	226			Best supportive care																																							COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_G2032R	63851612 + 105924630		p.G2032R	lung / carcinoma / non small cell carcinoma	4	Case study	Repotrectinib		Recruiting	NCT03093116	TRIDENT-1	ECD	2022Dec31	Yes	Yes		1	30093503			Overall Response Rate	1	1																															1										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_L2086F	105924633		p.L2086F	lung / carcinoma / non small cell carcinoma	4	Case study	Cabozantinib		Unknown					Yes	Yes		1	33685866			Not defined	1	1																																1									COSO29915674	2021Nov25	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Crizotinib	Required	Completed	NCT00585195	PROFILE 1001	PCD	2020Jul30	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf			Overall Response Rate	50	50			66		51-79		18.3		-12.7																					1	32										COSO29915674	2023Jan23	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 1	Taletrectinib		Completed	NCT02675491		PCD	2021Dec27	Yes	Yes		1	29805770			Maximum tolerated dose/toxicity	15	15			58.3																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 1	Autologous personalized DC vaccine		Recruiting	NCT05195619		ECD	2024Sep01	Yes	No		4	NCT05195619			Maximum tolerated dose/toxicity	16	16																																									COSO29915674	2022Jan31	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 1	XZP-3621		Recruiting	NCT05055232		ECD	2023Mar12	Yes	No		4	NCT05055232			Maximum tolerated dose/toxicity	120	120																																									COSO29915674	2021Nov17	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 1	Taletrectinib		Completed	NCT02279433		PCD	2019Mar01	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.2514	Previously-treated		Clinical activity	6	6																															2	2									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Recruiting	NCT01639508	Group C	ECD	2023Jul01	Yes	No		4	NCT01639508			Overall Response Rate	86	86																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Taletrectinib		Recruiting	NCT04395677	Crizotinib naive cohort	ECD	2023Dec30	Yes	Yes	Promising efficacy	5	https://www.prnewswire.com/news-releases/innovent-and-anheart-announce-interim-data-from-phase-2-trial-of-taletrectinib-in-ros1-positive-nsclc-at-the-csco-2021-annual-meeting-301385147.html			Overall Response Rate	21	21			43.8																		90.5																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Taletrectinib		Recruiting	NCT04919811	TRUST-II	ECD	2025Jun01	Yes	No		4	NCT04919811			Overall Response Rate	119	119																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Taletrectinib		Recruiting	NCT04395677	Crizotinib treated cohort	ECD	2023Dec30	Yes	Yes	Promising efficacy	5	https://www.prnewswire.com/news-releases/innovent-and-anheart-announce-interim-data-from-phase-2-trial-of-taletrectinib-in-ros1-positive-nsclc-at-the-csco-2021-annual-meeting-301385147.html			Overall Response Rate	16	16			43.8																		75																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Unknown	JapicCTI-194851	Barossa study cohort 1			Yes	No		2	10.1200/JCO.2021.39.15_suppl.9040			Overall Response Rate	52	52																																									COSO29915674	2022Feb16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Unknown	JapicCTI-194851	Barossa study cohort 2			Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9040	Previously-treated		Overall Response Rate	19	19			26.3		11.0-47.6						7.3			1.3-9.3							57.9										5	6									COSO29915674	2022Feb16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT05297890		ECD	2023Dec01	Yes	No		4	NCT05297890			Overall Response Rate	70	70																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort D2	ECD	2023Mar01	No	Yes		1	32669708			"ORR, PFS, DOR"	8	8											44.6			16.5-192.7																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 3	Entrectinib		Recruiting	NCT04603807		ECD	2027Dec01	Yes	No		4	NCT04603807			Progression free survival	220			Crizotinib																																							COSO29915674	2022Oct04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 4	Crizotinib		Recruiting	NCT03646994		ECD	2022Dec31	Yes	Yes		1	34511132	Untreated		Progression free survival	235	168	67	Chemotherapy	85.7	44		0.003					18	7			<0.001						97.1	91	0.164																		COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 4	Taletrectinib		Unknown					Yes	Yes		1	34589973	Untreated		Overall Response Rate	9	9			66.7		35.4-87.9						29.1										100																				COSO29915674	2022May06	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Phase 4	Entrectinib		Unknown					Yes	Yes		1	33646820				108	108			67.1		59.3-74.3		15.7				15.7																														COSO29915674	2022Oct04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_fusions				lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Taletrectinib		Unknown					Yes	Yes		1	34589973	Previously-treated		Overall Response Rate	6	6			33.3		9.7-70.0						14.2										88.3																				COSO29915674	2022Jun20	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Entrectinib	Required	Unknown		Entrectinib ROS1			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212725s006lbl.pdf			Unknown	92	92			74		64-83																																				COSO29915674	2023Jan19	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Case study	Cabozantinib		Unknown					Yes	Yes		1	30217491			Unknown	4	4			25																												1	3									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	2014Feb01	Yes	Yes		1	26899759	Previously-treated		Maximum tolerated dose/toxicity	34	34											2.1			1.4-3.5																	1	11									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Binimetinib + Cetuximab + Encorafenib + Lorlatinib + PF-07284892		Recruiting	NCT04800822		ECD	2026Feb04	Expression confirmed	No		4	NCT04800822			Overall Response Rate	211	211																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Brigatinib + Midazolam		Completed	NCT03420742		PCD	2020Mar25	Yes	No		4	NCT03420742			Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Everolimus		"Active, not recruiting"	NCT02321501		ECD	2023Jun30	Yes	No		4	NCT02321501			Maximum tolerated dose/toxicity	37	37																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alkotinib		Recruiting	NCT03607188		ECD	2022Feb28	Yes	No		4	NCT03607188	Previously-treated		Maximum tolerated dose/toxicity	18	18																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Binimetinib + Brigatinib		Terminated	NCT04005144		PCD	2022Oct01	Yes	No		4	NCT04005144			Maximum tolerated dose/toxicity	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Trametinib		Terminated	NCT03087448		PCD	2022Apr30	Yes	Yes	Slow accrual	4	NCT03087448			Maximum tolerated dose/toxicity	9	9																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Yes	Yes		1	31584608			Overall Response Rate	37	37			47.2																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Chemotherapy + Entrectinib + Resection		Recruiting	NCT04302025		ECD	2024Mar07	Yes	No		4	NCT04302025			Major pathologic response	80	80																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Foritinib		Recruiting	NCT04237805		ECD	2022Dec31	Yes	No		4	NCT04237805			Overall Response Rate	280	280																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed		Recruiting	NCT04989322		ECD	2024Aug01	Yes	No		4	NCT04989322			Overall Response Rate	46	46																																									COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib + TNO155		Recruiting	NCT04292119		ECD	2022Dec01	Yes	No		4	NCT04292119			Overall Response Rate	96	96																																									COSO29915674	2021Jun21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Binimetinib + Lorlatinib		Recruiting	NCT04292119		ECD	2022Dec01	Yes	No		4	NCT04292119			Overall Response Rate	96	96																																									COSO29915674	2021Jun21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Cetuximab + Gemcitabine + SIM1803-1A + SNK01		Recruiting	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	No		4	NCT04872634	Previously-treated		Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Gemcitabine + SNK01		Recruiting	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	No		4	NCT04872634	Previously-treated		Maximum tolerated dose/toxicity	24	24																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pembrolizumab + Recombinant EphB4-HSA fusion protein		"Active, not recruiting"	NCT03049618		ECD	2024Mar10	Yes	No		4	NCT03049618			Overall Response Rate	42	42																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib + Ipilimumab + Nivolumab		"Active, not recruiting"	NCT03468985		PCD	2022May09	Yes	No		4	NCT03468985			Progression free survival	3	3																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Nivolumab + Plinabulin		Terminated	NCT02846792		PCD	2018Jul12	Yes	Yes	Changed business priorities	4	NCT02846792			Overall Response Rate	5	5																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Foretinib		Withdrawn	NCT02034097		PCD	2014Apr01	Yes	Yes	Development discontinued	4	NCT02034097			Unknown	0	0																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Pemetrexed		Unknown	NCT03778138	ALTER-L025	ECD	2019Dec31	Yes	No		4	NCT03778138			Progression free survival	51	51																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Avelumab + Axitinib + Palbociclib		"Active, not recruiting"	NCT03386929	SPRING	ECD	2023Oct01	Yes	No		4	NCT03386929			Progression free survival	130	130																																									COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Docetaxel + Sintilimab		Completed	NCT03798743	Success	PCD	2021Dec30	Yes	No		4	NCT03798743			Overall Response Rate	30	30																																									COSO29915674	2022Sep27	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Radiotherapy		Unknown	NCT04193007	BRATR	ECD	2021Dec30	Yes	No		4	NCT04193007			Progression free survival	100	100																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Iruplinalkib		Unknown	NCT04641754		ECD	2020Dec01	Expression confirmed	No		4	NCT04641754			Overall Response Rate	176	176																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Iruplinalkib		Unknown	NCT03389815		ECD	2020Jun01	Yes	Yes		2	10.1093/annonc/mdz260.007			Maximum tolerated dose/toxicity	10	10			30																																						COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Lorlatinib		Recruiting	NCT04292119		ECD	2022Dec01	Yes	No		4	NCT04292119			Overall Response Rate	96	96																																									COSO29915674	2021Jun21	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Lorlatinib		"Active, not recruiting"	NCT03439215	PFROST	ECD	2022Jun01	Yes	No		4	NCT03439215	Previously-treated		Response rate	20	20																																									COSO29915674	2021Aug05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Repotrectinib		Recruiting	NCT03093116	TRIDENT-1 Exp-4	ECD	2022Dec31	Yes	Yes		2	10.1016/j.jtho.2021.01.251	Previously-treated		Overall Response Rate	6	6			67		22-96																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Repotrectinib		Recruiting	NCT03093116	TRIDENT-1 Exp-2	ECD	2022Dec31	Yes	Yes		2	10.1016/j.jtho.2021.01.251	Previously-treated		Overall Response Rate	5	5			40		May-85																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Repotrectinib		Recruiting	NCT03093116	TRIDENT-1 Exp-1	ECD	2022Dec31	Yes	Yes		2	10.1016/j.jtho.2021.01.251	Previously-treated		Overall Response Rate	7	7			86		42-100																																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Entrectinib		"Active, not recruiting"	NCT02568267	STARTRK-2	ECD	2024Dec31	Yes	No		4	NCT02568267			Overall Response Rate	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Stereotactic Body Radiation Therapy		"Active, not recruiting"	NCT02314364		PCD	2021Nov01	Yes	No		4	NCT02314364			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	30	30																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT04042558		ECD	2022Jun01	Yes	No		4	NCT04042558	Previously-treated		Overall Response Rate	149	149																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									COSO29915674	2021Oct08	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Onalespib lactate		Completed	NCT01712217		PCD	2016Dec01	Yes	No		4	NCT01712217			Overall Response Rate	220																																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 5	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Unknown	NCT03608007		ECD	2020Mar01	Yes	Yes		1	34265433			Overall Response Rate	59	59			27		13.8-44.1		4.8		1.8-10.8		4.6			4.0-6.4																	10										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		"Active, not recruiting"	NCT01449461		PCD	2015Nov01	Yes	No		4	NCT01449461			Overall Response Rate	137	137																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT04621188	ALBATROS	ECD	2023Jul01	Yes	No		4	NCT04621188	Previously-treated		Overall Response Rate	84	84																																									COSO29915674	2021Aug10	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT02927340		ECD	2022Jan01	Yes	No		1	35584349			"Disease control rate, Clinical benefit rate"	30	30																																									COSO29915674	2022Sep14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT03612154		ECD	2022Dec31	Yes	No		4	NCT03612154			Overall Response Rate	35	35																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		"Active, not recruiting"	NCT01970865	B7461001	PCD	2017Mar15	Yes	Yes		1	31669155	Previously-treated		Overall Response Rate	40	40			35				13.8																																		COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		"Active, not recruiting"	NCT01970865	B7461001	PCD	2017Mar15	Yes	Yes		1	31669155	Untreated		Overall Response Rate	21	21			62				25.3																																		COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Terminated	NCT02186821	SIGNATURE	PCD	2017Dec13	Yes	Yes	Slow accrual	4	NCT02186821			"Disease control rate, Clinical benefit rate"	47	47																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Unknown	NCT03399487		ECD	2020May01	Yes	No		4	NCT03399487			Overall Response Rate	46	46																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Unknown	NCT01964157		ECD	2019Dec01	Yes	Yes		1	28520527			Overall Response Rate	32	32			62		45-77		21		17-25		9.3										81			24			May-43														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Yes	No		4	NCT02693535			Overall Response Rate	3581	3581																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Recruiting	NCT04084717	CROME	ECD	2024Dec01	Yes	No		4	NCT04084717			Response rate	50	50																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Unknown	NCT02499614	METROS cohort A	ECD	2018Jun01	Yes	Yes		1	31416808			Response rate	26	26			65				21.4		12.7-30.1		22.8			15.2-30.3							85									1	16										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Completed	NCT02183870	EUCROSS	PCD	2018Jul24	Yes	Yes		1	30978502			Overall Response Rate	30	30			73		54-88																83																				COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Unknown	NCT01964157		ECD	2019Dec01	Yes	No		4	NCT01964157			Overall Response Rate	32	32																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Completed	NCT01945021		PCD	2015Jul31	Yes	Yes		1	29596029			Overall Response Rate	129	129			71.7		63-79		19.7		14.1-NR		15.9			12.9-24																17	74										COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Durvalumab		Recruiting	NCT05170204		ECD	2029Jun17	Expression confirmed	No		4	NCT05170204	Previously-treated		Progression free survival	320	320																																									COSO29915674	2022Aug04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Entrectinib		Recruiting	NCT05170204		ECD	2029Jun17	Expression confirmed	No		4	NCT05170204	Previously-treated		Progression free survival	320	320																																									COSO29915674	2022Oct04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Entrectinib		Recruiting	NCT03178552	B-FAST Cohort D	ECD	2024Apr27	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 4	Crizotinib		"Active, not recruiting"	NCT03672643		ECD	2023Jun30	Yes	No		4	NCT03672643	Previously-treated		Maximum tolerated dose/toxicity	41	41																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 4	Lorlatinib		Recruiting	NCT05144997		ECD	2026Dec28	Yes	No		4	NCT05144997	Previously-treated		Maximum tolerated dose/toxicity	200	200																																									COSO29915674	2022Feb01	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Crizotinib		Unknown		EUROS1			Yes	Yes		1	25667280			Unknown	29	29			80								9.1										86.6																				COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Entrectinib		Unknown					Yes	Yes		1	33646820				108	108			67.1		59.3-74.3						15.7																														COSO29915674	2022Oct04	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
SMO	SMO_P641A	50852667		p.P641A	lung / carcinoma / non small cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes		2	10.1200/PO.17.00149	Previously-treated		Unknown	1	1																															1										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_S69*	58822317		p.S69*	lung / carcinoma / non small cell carcinoma	4	Case study	Nivolumab		Unknown					Yes	Yes		1	31401029			Unknown	1	1																															1										COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Nivolumab + PBF-1129		Recruiting	NCT05234307		ECD	2024Dec31	No	No		4	NCT05234307			Maximum tolerated dose/toxicity	30	30																																									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vistusertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort B2S	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	17	17											2.3			1.5-3.8																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed		Not yet recruiting	NCT05469178		ECD	2025Aug11	Yes	No		4	NCT05469178	Untreated		Overall Response Rate	64	64																																									COSO29915674	2022Oct05	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bemcentinib + Pembrolizumab		Recruiting	NCT03184571		ECD	2022Sep01	Yes	Yes		1	35492873			Overall Response Rate	3	3											6.6													17.67							1	2									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sirpiglenastat		Recruiting	NCT04471415		ECD	2023Mar01	Yes	No		4	NCT04471415			Maximum tolerated dose/toxicity	246	246																																									COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed + Telaglenastat		Terminated	NCT04265534	KEAPSAKE	PCD	2021Nov05	Yes	No		4	NCT04265534	Untreated		Progression free survival	40			Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed																																							COSO29915674	2022Jul29	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
STK11	STK11_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Avelumab + Talazoparib		"Active, not recruiting"	NCT04173507		ECD	2023Jan31	Yes	No		4	NCT04173507			"DCR, ORR"	47	47																																									COSO29915674	2022Dec09	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TERT	TERT_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vx-001		Completed	NCT01935154		PCD	2017Jan01	Expression confirmed	Yes	Primary outcome not met	1	32210365			Overall survival	190	101	89	Placebo																						14.3	11.3			0.86													COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Etoposide + Osimertinib		Recruiting	NCT03567642		ECD	2024Jun01	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	20	20																																									COSO29915674	2023Jan16	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Docetaxel + Radiotherapy		Terminated	NCT00378404		PCD	2009Jun01	No	Yes	Slow accrual	4	NCT00378404			Maximum tolerated dose/toxicity	10	10																																									COSO29915674	2022Oct28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Ad5CMV-p53 gene + Radiotherapy		Completed	NCT00004225				No	No		4	NCT00004225			Unknown																																											COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Cisplatin + Olaparib + Paclitaxel		Recruiting	NCT04318938		ECD	2025Dec31	No	No		4	NCT04318938			Progression free survival	116	116																																									COSO29915674	2022May03	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	rAD-p53		Unknown	NCT01574729	rAd-p53	ECD	2015Aug01	No	Yes	"PFS 3y 71.9 v 46.9% p=0.0165, OS 3y 88.4 v 67.0% p=0.01991"	1	29291013			Overall survival	163	82	81	Surgery																																							COSO29915674	2022Dec14	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		"Active, not recruiting"	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11							3	12									COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
TSC1	TSC1_unspecified or TSC2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vistusertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort B1	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	5	5											2.1			1.0-6.2																											COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
VEGFA	VEGFA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vandetanib		"Active, not recruiting"	NCT02117167	SAFIR02_Lung	PCD	2018Dec22	No	Yes		2	10.1200/JCO.2021.39.15_suppl.9095			Progression free survival	5	5	59	Pemetrexed									2.7	2.7			0.98									14.3	14.1																COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
VEGFA	VEGFA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	52	25	27	Erlotinib + Placebo									3.69	2.33	0.91		0.44																										COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
VEGFA	VEGFA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														COSO29915674	2021May18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
WT1	WT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	WT2725		Completed	NCT01621542		PCD	2017May17	Expression confirmed	Yes		1	34785698			Maximum tolerated dose/toxicity	7	7											1.91													9			3.85-11.54														COSO29915674	2022Nov28	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
WT1	WT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cyclophosphamide + Interleukin-2 + WT1-TCRc4 gene-transduced autologous CD8-positive Tcm/Tn lymphocytes		Terminated	NCT02408016		PCD	2020Jun30	Expression confirmed	Yes	Lack of funding	4	NCT02408016			Maximum tolerated dose/toxicity	11	11																																									COSO29915674	2022Nov18	COSO29915674	lung	NS	NS	NS	carcinoma	non_small_cell_carcinoma	NS	NS	lung
ALK	ALK_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Crizotinib		Unknown	NCT02946359	CAMAR	ECD	2017Oct01	Yes	No		4	NCT02946359	Untreated		Progression free survival	60	60																																									COSO29914826	2021May18	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ALK	ALK_unspecified or EGFR_unspecified or MET_Exon14 or NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				lung / carcinoma / adenocarcinoma	3	Phase 2	Carboplatin + LP-300 + Pemetrexed		Recruiting	NCT05456256	HARMONIC	ECD	2024Nov01	Yes	No		4	NCT05456256			"OS, PFS"	90			Carboplatin + Pemetrexed																																							COSO29914826	2022Nov28	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ATM	ATM_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	2025Nov26	Expression confirmed	No		4	NCT02264678			Maximum tolerated dose/toxicity	330	330																																									COSO29914826	2022Nov28	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
BCL2	BCL2_unspecified and EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 1	Icotinib		Completed	NCT02044328	ICAPE	PCD	2018Jan01	No	No		4	NCT02044328			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	79	79																																									COSO29914826	2022Oct31	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / adenocarcinoma	3	Unknown	Dabrafenib + Trametinib		Recruiting	NCT05099068	PLANET	ECD	2025Sep15	Yes	No		4	NCT05099068			"PFS, ORR"	500	500																																									COSO29914826	2022Jan24	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Apatinib + Camrelizumab + Cryoablation		Not yet recruiting	NCT04201990		ECD	2021Dec01	No	No		4	NCT04201990			Maximum tolerated dose/toxicity	20	20																																									COSO29914826	2022Jun27	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ERBB2	EGFR_A859T and ERBB2_G776L	51833668		p.A859T + p.G776L	lung / carcinoma / adenocarcinoma	4	Case study	Afatinib		Completed	NCT00730925		PCD	2012Jan01	Yes	Yes		1	22325357			Overall Response Rate	1	1																4								14							1										COSO29914826	2022Nov28	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 1	Icotinib		Completed	NCT02044328	ICAPE	PCD	2018Jan01	Yes	No		4	NCT02044328			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	79	79																																									COSO29914826	2022Oct31	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Erlotinib + Ruxolitinib		Completed	NCT02155465		PCD	2017Oct01	Yes	Yes	No benefit of treatment	1	27613527	Previously-treated		Maximum tolerated dose/toxicity	22	22																															1										COSO29914826	2021May18	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Alflutinib + Bevacizumab		Recruiting	NCT05503667		ECD	2023Oct01	Yes	No		4	NCT05503667			Overall Response Rate	96			Alflutinib																																							COSO29914826	2022Sep27	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	EGFR-TKI + Nimotuzumab		Recruiting	NCT04833205		ECD	2022Apr19	Expression confirmed	No		4	NCT04833205			Progression free survival	30	30																																									COSO29914826	2022May03	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Cisplatin + Nimotuzumab + Pemetrexed		Recruiting	NCT03574402	TRUMP Arm 11	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									COSO29914826	2022May03	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ERBB2	ERBB2_G778_P780dup	54064411 + 54065275 + 54070170 + 54085695		p.G778_P780dup	lung / carcinoma / adenocarcinoma	4	Case study	Afatinib		Completed	NCT00730925		PCD	2012Jan01	Yes	Yes		1	22325357			Overall Response Rate	1	1																4								32								1									COSO29914826	2022Nov28	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ERBB2	ERBB2_Y772_A775dup	54062164 + 54062409		p.Y772_A775dup	lung / carcinoma / adenocarcinoma	4	Case study	Afatinib		Completed	NCT00730925		PCD	2012Jan01	Yes	Yes		1	22325357			Overall Response Rate	1	1																3								12							1										COSO29914826	2022Nov28	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Poziotinib		Completed	NCT02979821	KASTT001	PCD	2017Dec01	Yes	No		4	NCT02979821			Overall Response Rate	6	6																																									COSO29914826	2021Dec15	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ERBB2	ERBB2_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Loperamide + Neratinib		"Active, not recruiting"	NCT01953926	SUMMIT	ECD	2022Oct31	Yes	Yes		1	29420467			Overall Response Rate	26	26			3.8		0.1?19.6						5.5										42.3	23.4?63.1																			COSO29914826	2022Nov28	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 1	Docetaxel + Nintedanib		Completed	NCT02668393		PCD	2019Nov27	No	Yes	Slow accrual	4	NCT02668393	Previously-treated		Maximum tolerated dose/toxicity	14	14																																									COSO29914826	2022May03	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Lucitanib		Terminated	NCT02109016	US Breast	PCD	2016Apr01	Yes	Yes	No benefit of treatment	1	30684019			Overall Response Rate	18	18																																									COSO29914826	2021Aug13	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Crizotinib		Unknown	NCT02946359	CAMAR	ECD	2017Oct01	Yes	No		4	NCT02946359	Untreated		Progression free survival	60	60																																									COSO29914826	2021Aug17	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
NTRK1	NTRK1_fusions or NTRK3_fusions				lung / carcinoma / adenocarcinoma	3	Retrospective/Meta-analysis	Larotrectinib		Unknown					Yes	Yes		1	35085007	Previously-treated		Overall Response Rate	15	15			73		45-92		33.9		5.6-33.9		35.4			5.3-35.4										40.7			-17.2			1	10	3									COSO29914826	2022Jul14	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / adenocarcinoma	3	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	23788756			Unknown	76	5	71		60	8.5		0.01						3.3			0.008																										COSO29914826	2021May18	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ROS1	ROS1_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Crizotinib		Unknown	NCT02946359	CAMAR	ECD	2017Oct01	Yes	No		4	NCT02946359	Untreated		Progression free survival	60	60																																									COSO29914826	2021Aug17	COSO29914826	lung	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	lung
ATM	ATM_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Avelumab + Berzosertib + Carboplatin + Gemcitabine		Recruiting	NCT04216316		ECD	2023Aug15	Expression confirmed	No		4	NCT04216316			Progression free survival	106			Avelumab + Carboplatin + Gemcitabine																																							COSO29914830	2022Dec09	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
ATM	ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCF_unspecified or FANCM_unspecified or NBN_unspecified or PALB2_unspecified or RAD51_unspecified or RAD51B_unspecified or RAD54L_unspecified or RPA1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Talazoparib		Completed	NCT03377556		PCD	2021Jan10	No	Yes		4	NCT03377556			Overall Response Rate	24	24			4								2.4			1.5-2.8										5.2			10-Apr														COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
CCND1	CCND1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	Palbociclib		Completed	NCT02154490	Lung-MAP	PCD	2022Apr01	Expression confirmed	Yes	OS not correlated with expression status	1	33358401	Previously-treated		"PFS, ORR"	43	14	29		14	7							2.3													10.7							2										COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
CCND1	CCND1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	Palbociclib		Completed	NCT02154490	Lung-MAP	PCD	2022Apr01	Expression confirmed	Yes		1	31302234	Previously-treated		"PFS, ORR"	26	26																															2										COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
CDKN2A	CDKN2A_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Palbociclib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort C1	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	25	25											4.2			2.7-7.2																											COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
DDR2	DDR2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Dasatinib		Terminated	NCT01491633		PCD	2013Jan01	No	Yes	Toxicity issues	4	NCT01491633			Overall Response Rate	5	5																																									COSO29914830	2022Nov18	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
EGFR	EGFR_Exon19del or EGFR_L858R				lung / carcinoma / squamous cell carcinoma	3	Approved FDA	Afatinib	Required	Completed	NCT01523587	LUX-Lung 8	PCD	2013Oct21	No	Yes		1	26156651	Previously-treated		Progression free survival	795	398	397	Erlotinib									2.4	1.9	0.82	0.68-1.0	0.043									7.9	6.8	0.81	0.61-0.95	0.008													COSO29914830	2022May03	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Approved FDA	Cisplatin + Gemcitabine + Necitumumab	Not required	"Active, not recruiting"	NCT00981058	SQUIRE	PCD	2013Jun17	No	Yes		1	27668058	Untreated		Overall survival	1093	545	548	Cisplatin + Gemcitabine									5.7	5.5	0.85	0.74-0.98	0.02									11.5	9.9	0.84	0.74-0.96	0.01													COSO29914830	2023Jan17	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	Afatinib		Unknown	NCT04132102		ECD	2021Apr30	Yes	No		4	NCT04132102			Progression free survival	20	20																																									COSO29914830	2022May03	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib + Cisplatin + Gemcitabine		Not yet recruiting	NCT04470076	Neoafa	ECD	2021Dec30	Yes	No		4	NCT04470076			Overall Response Rate	30	30																																									COSO29914830	2022May03	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Carboplatin + Gemcitabine + Nimotuzumab		Recruiting	NCT03574402	TRUMP Arm 10	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									COSO29914830	2022May03	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	AZD4547		Terminated	NCT00979134		PCD	2014Feb12	Expression confirmed	Yes		1	28615371	Previously-treated		Maximum tolerated dose/toxicity	15	15			8																					4.9							1										COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	Infigratinib		Completed	NCT01004224		PCD	2018Oct08	Expression confirmed	Yes		1	27870574			Maximum tolerated dose/toxicity	36	36																					50										4	14									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	AZD4547		Unknown	NCT01795768		ECD	2014Sep01	Yes	No		4	NCT01795768	Previously-treated		Tumour volume	48	48																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Erdafitinib		Terminated	NCT00979134		PCD	2014Feb12	Yes	No		4	NCT03827850	Previously-treated		Maximum tolerated dose/toxicity	15	15			8																					4.9							1										COSO29914830	2023Jan04	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Completed	NCT02965378	SWOG S1400D	PCD	2017Jan01	Yes	Yes		1	31195180	Previously-treated		Overall Response Rate	1	1																															1										COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Completed	NCT02154490	Lung-MAP	PCD	2022Apr01	Yes	No		4	NCT02154490	Previously-treated		"PFS, ORR"	1864	1864																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR2	FGFR2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Completed	NCT02154490	Lung-MAP	PCD	2022Apr01	No	No		4	NCT02154490	Previously-treated		"PFS, ORR"	1864	1864																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR2	FGFR2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Completed	NCT02965378	SWOG S1400D	PCD	2017Jan01	No	No		4	NCT02965378	Previously-treated		Overall Response Rate	42	42																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR3	FGFR3_S249C	53390026		p.S249C	lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Completed	NCT02965378	SWOG S1400D	PCD	2017Jan01	Yes	Yes		1	31195180	Previously-treated		Overall Response Rate	1	1																															1										COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
FGFR3	FGFR3_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Completed	NCT02154490	Lung-MAP	PCD	2022Apr01	No	No		4	NCT02154490	Previously-treated		"PFS, ORR"	1864	1864																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
HRAS	HRAS_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Tipifarnib		"Active, not recruiting"	NCT03496766		ECD	2023Jan30	Yes	No		4	NCT03496766			Overall Response Rate	9	9																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT00998192	REO 021	PCD	2013Sep01	No	Yes		3	http://mct.aacrjournals.org/content/12/11_Supplement/C70	Previously-treated		Overall Response Rate	25	25																															12	10									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified and CD274_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	Abemaciclib + Pembrolizumab		"Active, not recruiting"	NCT02779751	Cohort B	PCD	2020Feb03	Expression confirmed	Yes	SAE 76%	1	34746886	Untreated		Maximum tolerated dose/toxicity	25	25			8								3.3			1.4-5.2							64			6			3.7-13.1														COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified and CD274_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Ipilimumab + Nivolumab		Unknown	NCT03823625	SQUINT	ECD	2021Feb28	No	No		4	NCT03823625			Overall survival	112	112																																									COSO29914830	2022Aug01	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified and CD274_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Nivolumab + Platinum-doublet chemotherapy		Unknown	NCT03823625	SQUINT	ECD	2021Feb28	No	No		4	NCT03823625			Overall survival	112	112																																									COSO29914830	2022Aug01	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
KRAS	KRAS_unspecified and CD274_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	Docetaxel + Finotonlimab		"Active, not recruiting"	NCT04171284		ECD	2022Oct22	No	No		4	NCT04171284			Overall survival	360			Docetaxel + Placebo																																							COSO29914830	2022Aug04	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
MET	MET_N375S	59260365		p.N375S	lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib		Not yet recruiting	NCT04533321		ECD	2023Sep01	Yes	No		4	NCT04533321	Previously-treated		Unknown	20	20																																									COSO29914830	2021May18	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib		Not yet recruiting	NCT04533321		ECD	2023Sep01	Yes	No		4	NCT04533321	Previously-treated		Unknown	20	20																																									COSO29914830	2021May18	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Telisotuzumab vedotin		Completed	NCT03574753	Cohort 2	PCD	2019Dec21	Expression confirmed	Yes	"Primary outcome not met, Lack of efficacy"	1	33221175	Previously-treated		Response rate	13	13																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Telisotuzumab vedotin		Completed	NCT03574753	Cohort 1	PCD	2019Dec21	Expression confirmed	Yes	"Primary outcome not met, Lack of efficacy"	1	33221175			Response rate	15	15											2.4													5.6						1	1	10									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	Erlotinib + Rilotumumab		Terminated	NCT02926638		PCD	2015Jan12	Expression confirmed	Yes	Company terminated all studies involving rilotumumab	4	NCT02926638	Previously-treated		Progression free survival	9	9		Erlotinib																																							COSO29914830	2022May03	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
NF1	NF1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort E1	ECD	2023Mar01	Yes	No		1	32669708			"ORR, PFS, DOR"	423	423																																									COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
PIK3CA	PIK3CA_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Capivasertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort F1	ECD	2023Mar01	No	Yes		1	32669708			"ORR, PFS, DOR"	4	4											1.9			0.8-6.3																											COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
PIK3CA	PIK3CA_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Capivasertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort F2	ECD	2023Mar01	Overexpression	Yes		1	32669708			"ORR, PFS, DOR"	12	12											2.1			1.2-4.1																											COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
PTEN	PTEN_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Capivasertib		"Active, not recruiting"	NCT02664935	National Lung Matrix Trial Cohort F4	ECD	2023Mar01	Yes	Yes		1	32669708			"ORR, PFS, DOR"	4	4											4.6			1.4-31.6																											COSO29914830	2022Nov28	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib		Not yet recruiting	NCT04533321		ECD	2023Sep01	Yes	No		4	NCT04533321	Previously-treated		Unknown	20	20																																									COSO29914830	2021May18	COSO29914830	lung	NS	NS	NS	carcinoma	squamous_cell_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / large cell neuroendocrine carcinoma	3	Phase 2	Cisplatin or carboplatin + Durvalumab + Etoposide		Recruiting	NCT05262985		ECD	2024Jan01	No	No		4	NCT05262985			Progression free survival	22	22																																									COSO299110404	2023Jan16	COSO299110404	lung	NS	NS	NS	carcinoma	large_cell_neuroendocrine_carcinoma	NS	NS	lung
CD274	CD274_unspecified				lung / carcinoma / sarcomatoid carcinoma	3	Phase 2	Durvalumab + Ifosfamide + doxorubicin hydrochloride		Unknown	NCT04224337		ECD	2021Dec31	Expression confirmed	No		4	NCT04224337			Response rate	34	34																																									COSO299111567	2022Nov28	COSO299111567	lung	NS	NS	NS	carcinoma	sarcomatoid_carcinoma	NS	NS	lung
MET	MET_unspecified				lung / carcinoma / sarcomatoid carcinoma	3	Phase 2	Durvalumab + Ifosfamide + doxorubicin hydrochloride		Unknown	NCT04224337		ECD	2021Dec31	Yes	No		4	NCT04224337			Response rate	34	34																																									COSO299111567	2022Nov28	COSO299111567	lung	NS	NS	NS	carcinoma	sarcomatoid_carcinoma	NS	NS	lung
EGFR	EGFR_unspecified				lung / carcinoma / bronchioloalveolar adenocarcinoma	3	Phase 2	Gefitinib		Completed	NCT00029003		PCD	2004Dec01	No	No		4	NCT00029003			Overall survival	90	90																																									COSO29915645	2021May18	COSO29915645	lung	NS	NS	NS	carcinoma	bronchioloalveolar_adenocarcinoma	NS	NS	lung
TP53	TP53_unspecified				lung / carcinoma / bronchioloalveolar adenocarcinoma	3	Phase 1	Ad5CMV-p53 gene		Completed	NCT00003649				No	No		4	NCT00003649			Unknown																																											COSO30015645	2022May03	COSO30015645	lung	right_upper_lobe	NS	NS	carcinoma	bronchioloalveolar_adenocarcinoma	NS	NS	lung
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Case study	Ipatasertib		Unknown					Yes	Yes		1	33177006			Unknown	1	1																															1										COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	Capivasertib		"Active, not recruiting"	NCT01226316		PCD	2019Apr26	Yes	Yes		1	32312891	Untreated		Maximum tolerated dose/toxicity	20	20				20							5.4																				4										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	BAY1125976		Completed	NCT01915576		PCD	2016Jul01	Yes	Yes		4	NCT01915576			Maximum tolerated dose/toxicity	6	6																																3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	Capivasertib + Fulvestrant		"Active, not recruiting"	NCT01226316		PCD	2019Apr26	Yes	Yes		1	32312891	Untreated		Maximum tolerated dose/toxicity	15	15				20							5.6																				3										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	Capivasertib + Fulvestrant		"Active, not recruiting"	NCT01226316		PCD	2019Apr26	Yes	Yes		1	32312891	Previously-treated		Maximum tolerated dose/toxicity	28	28				36							5																				10										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 2	Capivasertib		Unknown					Yes	Yes		1	33377972			Overall Response Rate	15	15																															7										COSO28394862	2021Nov24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 2	Ipatasertib + Paclitaxel		Completed	NCT02162719	LOTUS	PCD	2016Jun07	Yes	Yes		1	28800861	Untreated		Unknown	32	26	16		50	44			11.2	6.1			9	4.9	0.44	0.20-0.99	0.041						54	44																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 2	Fulvestrant + Ipatasertib + Palbociclib		Not yet recruiting	NCT04920708		ECD	2023Aug01	No	No		4	NCT04920708			Progression free survival	324			Fulvestrant + Palbociclib																																							COSO28394862	2021Aug24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 2	Capivasertib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Paclitaxel + Placebo		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Capivasertib + Fulvestrant + Palbociclib		Recruiting	NCT04862663	CAPItello-292	ECD	2025Oct07	Yes	No		4	NCT04862663			Progression free survival	700			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Ipatasertib + Paclitaxel + Placebo		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Atezolizumab + Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Capivasertib + Fulvestrant		Recruiting	NCT04305496	CAPItello-291	PCD	2022Aug15	No	No		4	NCT04305496			Progression free survival	834			Fulvestrant + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Fulvestrant + Ipatasertib		Recruiting	NCT04650581	FINER	ECD	2024Jun30	No	No		4	NCT04650581			Progression free survival	250			Fulvestrant + Placebo																																							COSO28394862	2021Nov02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified				breast / carcinoma / NS	3	Phase 3	Fulvestrant + Ipatasertib + Palbociclib		"Active, not recruiting"	NCT04060862		ECD	2023Apr30	No	No		4	NCT04060862			Progression free survival	20			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	AKT1_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified or PIK3CA_unspecified or PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	MK2206		Completed	NCT01277757		PCD	2014Aug01	No	Yes		4	NCT01277757			Overall Response Rate	21	21																														0	1	0									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified or PIK3CA_unspecified or PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT03337724	IPATunity130 Cohort A	ECD	2022Dec22	Yes	Yes	No benefit of treatment	5	https://www.cancernetwork.com/view/ipatasertib-paclitaxel-combo-does-not-improve-pfs-in-pik3ca-akt1-pten-altered-tnbc			Progression free survival	255			Paclitaxel + Placebo	39	35							7.4	6.1	1.02	0.71-1.45	0.924						47	45																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified or PIK3CA_unspecified or PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT03337724	IPATunity130 Cohort B	ECD	2022Dec22	Yes	Yes		1	34860318			Progression free survival	222	146	76	Paclitaxel + Placebo	47	47							9.3	9.3	1	0.71-1.40																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ALK	ALK_unspecified				breast / carcinoma / NS	3	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 1	Prasterone		Terminated	NCT00972023		PCD	2010Mar01	Expression confirmed	No		4	NCT00972023			Change in Ki-67 expression	1	1																																									COSO28394862	2022Sep08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 1	Proxalutamide		Completed	NCT04103853		PCD	2019May22	Expression confirmed	Yes	PFS 6m 19.6%	1	36182805	Previously-treated		"Disease control rate, Clinical benefit rate"	39	39																					25.6																				COSO28394862	2022Dec05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Bicalutamide		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	EP0062		Not yet recruiting	NCT05573126		ECD	2024Dec01	Expression confirmed	No		4	NCT05573126	Previously-treated		Maximum tolerated dose/toxicity	128	128																																									COSO28394862	2023Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	SHR2554 + SHR3680		Recruiting	NCT04355858	MULAN	ECD	2023May01	Yes	No		4	NCT04355858			Overall Response Rate	319	319																																									COSO28394862	2022Jul08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Letrozole + Megestrol		Recruiting	NCT03306472	PIONEER	ECD	2021Oct31	No	No		4	NCT03306472			Change in Ki-67 expression	189			Letrozole																																							COSO28394862	2022Jul08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Enzalutamide + Fulvestrant		"Active, not recruiting"	NCT02955394		PCD	2022Feb17	No	No		4	NCT02955394			Pathologic Response	61			Fulvestrant																																							COSO28394862	2022Jul07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Bicalutamide + Palbociclib		"Active, not recruiting"	NCT02605486		ECD	2024Nov01	Expression confirmed	No		4	NCT02605486			Progression free survival	46	46																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Enobosarm		Completed	NCT02463032	18 mg arm	PCD	2019Mar01	Expression confirmed	Yes		4	NCT02463032			"Disease control rate, Clinical benefit rate"	52	52																					28.9																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Enobosarm		Completed	NCT02463032	9 mg arm	PCD	2019Mar01	Expression confirmed	Yes		4	NCT02463032			"Disease control rate, Clinical benefit rate"	50	50																					32																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Transdermal 4-hydroxytestosterone		"Active, not recruiting"	NCT02067741		PCD	2018Aug02	Expression confirmed	Yes	"Primary outcome not met, Lack of efficacy, DCR 24w 24%"	2	10.1093/annonc/mdz100.014			"Disease control rate, Clinical benefit rate"	21	21											5.1			2.5-5.6										24.6			-22.9														COSO28394862	2022Sep08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Orteronel		Completed	NCT01990209		PCD	2021May01	Expression confirmed	Yes		4	NCT01990209			"DCR, ORR"	21	21			4.8		0.1-23.82																4.8																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Diindolylmethane		Withdrawn	NCT01612910		PCD	2014Feb01	Expression confirmed	No		4	NCT01612910			Progression free survival	0	0																																									COSO28394862	2022Jul06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / NS	3	Phase 2	Prasterone		Terminated	NCT02000375		PCD	2016Feb01	Expression confirmed	Yes	"Slow accrual, published data"	4	NCT02000375			"Disease control rate, Clinical benefit rate"	20	20																																									COSO28394862	2022Jul07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Enzalutamide + Trastuzumab		"Active, not recruiting"	NCT02091960		PCD	2017Feb28	Expression confirmed	Yes		4	NCT02091960			"Disease control rate, Clinical benefit rate"	103	103																					23.6																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Orteronel		Completed	NCT01990209		PCD	2021May01	Expression confirmed	Yes		4	NCT01990209			"DCR, ORR"	23	23			0		0-14.82																8.7																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Enzalutamide + Trastuzumab		"Active, not recruiting"	NCT02099864		PCD	2019Oct01	No	Yes	"PSA >= 50% decline 86.4%, efficacy not correlated with mutation status p=0.055"	4	NCT02091960			Prostate Specific Antigen (PSA) response rate 	22	22																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AR	AR_unspecified or PTEN_unspecified				breast / carcinoma / NS	3	Phase 1	Alpelisib + Enzalutamide		Recruiting	NCT03207529		ECD	2020Dec31	No	No		4	NCT03207529	Previously-treated		Maximum tolerated dose/toxicity	28	28																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 1	BAY1895344 + Pembrolizumab		"Active, not recruiting"	NCT04095273	cohort 1a	ECD	2023Mar16	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	56	56																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified or ATR_unspecified or BAP1_unspecified or BARD1_unspecified or BLM_unspecified or BRIP1_unspecified or CHEK1_unspecified or CDK12_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified MRE11_unspecified or NBN_unspecified or PTEN_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified or WRN_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib + Trastuzumab		Recruiting	NCT04508803	CHANGEABLE	ECD	2022Nov20	Yes	No		4	NCT04508803			Overall Response Rate	37	37																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965	Olaparib Expanded Cohort 2	ECD	2022Dec30	Yes	Yes	Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations	2	10.1200/JCO.2020.38.15_suppl.1002			Overall Response Rate	26	26			38.5		22.5-56.4																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCG_unspecified or FANCL_unspecified or MRE11_unspecified or NBN_unspecified or PALB2_unspecified or PTEN_unspecified or RAD50_unspecified or RAD51C_unspecified RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		"Active, not recruiting"	NCT02401347		PCD	2019Dec23	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3006			Overall Response Rate	12	12			25																		50										3	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ATM	ATM_unspecified or BARD1_unspecified or CHEK2_unspecified or FANCC_unspecified or PALB2_unspecified or RAD51C_unspecified or RAD51D_unspecified or SLX4_unspecified or XRCC2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT05033756	COMPRENDO cohort 2	ECD	2024Jan01	Yes	No		4	NCT05033756			Overall Response Rate	89	89																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BARD1	BARD1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BCL2	BCL2_unspecified				breast / carcinoma / NS	3	Phase 1	Letrozole + Palbociclib + Venetoclax		Recruiting	NCT03900884		ECD	2023Mar01	Expression confirmed	No		4	NCT03900884			Maximum tolerated dose/toxicity	36	36																																									COSO28394862	2022Oct31	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 1	Onalespib lactate + Talazoparib		Withdrawn	NCT02627430		ECD	2019Mar01	No	No		4	NCT02627430			Unknown	0	0																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Completed	NCT00679783		PCD	2010Mar26	Yes	Yes		1	21862407	Previously-treated		Overall Response Rate	3	3			0																											0	0	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Cisplatin		Unknown	NCT01630226		ECD	2013Dec01	Yes	Yes	pCR 61%	1	25129345			"Complete response, Pathological complete response"	107	107																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Paclitaxel + Veliparib		"Active, not recruiting"	NCT01149083		ECD	2022Dec31	Yes	Yes		1	28356425	Previously-treated		Response rate	22	22			14																		23																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Rucaparib		Completed	NCT00664781		PCD	2015Jan01	Yes	Yes		1	27002934			Tumour volume	4	4			0																											0	0	0									COSO28394862	2022Dec02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Rucaparib		Completed	NCT00664781		PCD	2015Jan01	Yes	Yes		1	27002934			Tumour volume	9	9			0																											0	0	4									COSO28394862	2022Dec02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Terminated	NCT02034916	ABRAZO	PCD	2016Sep01	Yes	Yes		1	30563931			Overall Response Rate	41	41			23																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 3	Denosumab		Recruiting	NCT04711109	BRCA-P	ECD	2027Jul01	Yes	No		4	NCT04711109			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	300			Placebo																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib + Trastuzumab		Terminated	NCT03931551	OPHELIA	PCD	2022Mar02	Yes	Yes	Slow accrual	4	NCT03931551			"OS, PFS"	5	20																																									COSO28394862	2022May12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Approved FDA	Olaparib	Required	"Active, not recruiting"	NCT02000622	OlympiAD	PCD	2016Dec09	No	Yes		1	28578601			Progression free survival	302	205	97	Chemotherapy	59.9	28.8							7	4.2	0.58	0.43-0.80	<0.001									19.3	17.1	0.9															COSO28394862	2022Feb21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Approved FDA	Talazoparib	Required	Completed	NCT01945775	EMBRACA	PCD	2017Sep15	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211651s008lbl.pdf	Previously-treated		Progression free survival	431	287	144	Chemotherapy	50.2	18.4			6.4	3.9			8.6	5.6	0.54	0.41-0.71	<0.0001									19.3	19.5	0.85	0.67-1.07	0.1693													COSO28394862	2023Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Approved FDA	Olaparib	Required	"Active, not recruiting"	NCT02032823	OlympiA	PCD	2020Mar27	Yes	Yes	EFS 3y 93 v 89%	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1836	921	915	Placebo																								0.68	0.50-0.91	0.0091					88	80	0.58	0.46-0.74	<0.0001				COSO28394862	2022Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Doxorubicin hydrochloride liposome + Veliparib		Completed	NCT01145430		PCD	2017May23	No	No		1	32055930	Previously-treated		Maximum tolerated dose/toxicity	11	11																														2											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	2025Nov26	Yes	Yes		2	10.1158/1538-7445.SABCS20-PS11-18			Progression free survival	37	37			35								11.5																			1	12	17									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Capivasertib + Olaparib		"Active, not recruiting"	NCT02208375		ECD	2023Jun30	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Olaparib + Vistusertib		"Active, not recruiting"	NCT02208375		ECD	2023Jun30	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Carboplatin + Olaparib		Terminated	NCT02561832		PCD	2016Sep30	Yes	Yes	Changed business priorities	4	NCT02561832			Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Niraparib		Completed	NCT03329937		PCD	2020Jan02	Yes	Yes	Promising activity - 90.5% tumour response rate	2	10.1158/1538-7445.SABCS19-P3-11-03			Tumour volume	21	21																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Cyclophosphamide + Veliparib		"Active, not recruiting"	NCT01351909		PCD	2016Nov25	No	No		4	NCT01351909			Maximum tolerated dose/toxicity	35	35																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Cisplatin + Veliparib + Vinorelbine		Completed	NCT01104259		PCD	2015Feb01	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.2569			Maximum tolerated dose/toxicity	11	11			73																											2	6										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 1	Carboplatin + Paclitaxel + Veliparib		Completed	NCT01251874		PCD	2017Apr12	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.1074			Maximum tolerated dose/toxicity	16	16																															4	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel		Unknown	NCT04499118		ECD	2021Aug01	No	No		4	NCT04499118			"Complete response, Pathological complete response"	100	100																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Capecitabine + Niraparib		Not yet recruiting	NCT05519670	CAPRICE	ECD	2027Sep01	Yes	No		4	NCT05519670			Overall Response Rate	72	72																																									COSO28394862	2022Sep26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	TSL-1502		Not yet recruiting	NCT05420779		ECD	2024Dec31	Yes	No		4	NCT05420779			Overall Response Rate	125			Chemotherapy																																							COSO28394862	2022Sep26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Lurbinectedin		Completed	NCT02454972		PCD	2020Sep18	Yes	Yes	Primary outcome met	2	10.1200/JCO.2022.40.16_suppl.1092	Previously-treated		Overall Response Rate	21	21			28.6		11.3-52.2		8.6				4.1										76.2			16.1							6	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Dalpiciclib + Fluzoparib		Recruiting	NCT04355858	MULAN	ECD	2023May01	Yes	No		4	NCT04355858			Overall Response Rate	319	319																																									COSO28394862	2022Jul04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Cisplatin + Rucaparib		Completed	NCT01074970	BRE09-146	PCD	2018Dec15	No	Yes	"DFS 2yr 63.1 v 58.3, p=0.43, Efficacy not correlated with mutation status"	2	10.1200/jco.2015.33.15_suppl.1082	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	128			Cisplatin																																							COSO28394862	2022Dec02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Dexamethasone + Trabectedin		Completed	NCT00580112		PCD	2011Aug01	Yes	Yes		1	24692579	Previously-treated		Overall Response Rate	35	35			17		Jul-34						3.9			1.6-5.5																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Chemotherapy + Durvalumab + Olaparib + Stereotactic radiotherapy		Recruiting	NCT04711824		ECD	2023Nov01	Yes	No		4	NCT04711824			"Disease control rate, Clinical benefit rate"	41	41																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Mercaptopurine + Methotrexate		Completed	NCT01432145		PCD	2014Dec01	Yes	Yes		1	31813938			Overall Response Rate	10	10																														0	0	4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Cyclophosphamide + Docetaxel + doxorubicin hydrochloride		Recruiting	NCT04664972		ECD	2022Nov23	No	No		4	NCT04664972			"Complete response, Pathological complete response"	166			Cisplatin + Docetaxel																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	M4344 + Niraparib		Withdrawn	NCT04655183		ECD	2023Sep01	Yes	No		4	NCT04655183			Overall Response Rate	0	0																																									COSO28394862	2021Aug10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Avelumab + Talazoparib		"Active, not recruiting"	NCT03330405	JAVELIN PARP Medley	PCD	2022Feb22	Yes	Yes		2	10.1158/1538-7445.SABCS19-P1-19-03			Overall Response Rate	12	12																															1	6									COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Famitinb + Fluzoparib		Recruiting	NCT03805399	FUTURE group D	ECD	2022Dec01	Yes	Yes		1	32719455			Overall Response Rate	4	4																																									COSO28394862	2022Dec01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	SC10914		Unknown	NCT04556292		ECD	2022Mar30	Yes	No		4	NCT04556292			Overall Response Rate	78	78																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Aromatase inhibitors + Niraparib		Recruiting	NCT04240106	LUZERN	ECD	2022Nov01	No	No		4	NCT04240106			"Disease control rate, Clinical benefit rate"	23	23																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Docetaxel + Epirubicin hydrochloride		Unknown	NCT04499118		ECD	2021Aug01	No	No		4	NCT04499118			"Complete response, Pathological complete response"	100	100																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Docetaxel + doxorubicin hydrochloride		Unknown	NCT04499118		ECD	2021Aug01	No	No		4	NCT04499118			"Complete response, Pathological complete response"	100	100																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Fulvestrant + Olaparib		Recruiting	NCT04053322	DOLAF	ECD	2023Aug15	Yes	No		4	NCT04053322			Progression free survival	158	158																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Pamiparib		Completed	NCT03575065	HR+ cohort	PCD	2020Oct09	Yes	Yes	Promising efficacy	2	10.1200/JCO.2021.39.15_suppl.1087			Overall Response Rate	21	21			61.9		38.4-81.9		7.49		5.55-14.75		9.2			7.39-11.39																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Pamiparib		Completed	NCT03575065	TNBC cohort	PCD	2020Oct09	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.1087			Overall Response Rate	55	55			38.2		25.4-52.3		6.97		-3.94		5.49			3.65-7.33										17.08			-13.7														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT05033756	COMPRENDO cohort 1	ECD	2024Jan01	Yes	No		4	NCT05033756			Overall Response Rate	89	89																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT03025035		ECD	2023Nov01	Yes	No		4	NCT03025035			Overall Response Rate	20	20																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Recruiting	NCT04090567		ECD	2023Mar31	Yes	No		4	NCT04090567			Overall Response Rate	60	60																																									COSO28394862	2022Jan25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Sapacitabine		"Active, not recruiting"	NCT03641755		PCD	2022Apr27	Yes	No		4	NCT03641755			Overall Response Rate	10	10																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Adavosertib + Olaparib		"Active, not recruiting"	NCT03330847	VIOLETTE	PCD	2020Nov13	Yes	Yes		4	NCT03330847			Progression free survival	56	13	43	Olaparib									3.8	7.3	1.01		0.93																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Ceralasertib + Olaparib		"Active, not recruiting"	NCT03330847	VIOLETTE	PCD	2020Nov13	Yes	Yes		4	NCT03330847			Progression free survival	83	40	43	Olaparib									7.4	7.3	1.02		0.94																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Chemotherapy + Olaparib		Recruiting	NCT05629429		ECD	2025Dec31	No	No		4	NCT05629429			Progression free survival	300	300																																									COSO28394862	2023Jan05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib		Not yet recruiting	NCT05209529		ECD	2027Sep06	No	No		4	NCT05209529	Untreated		"Complete response, Pathological complete response"	152			Olaparib																																							COSO28394862	2022Feb03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib		Recruiting	NCT05498155	OlympiaN Cohort B	ECD	2024May17	Yes	No		4	NCT05498155			"Complete response, Pathological complete response"	80	80																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib		Recruiting	NCT02484404		ECD	2023Jan30	No	No		4	NCT02484404			Overall Response Rate	384	384																																									COSO28394862	2022Feb22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Olaparib + Palbociclib		Recruiting	NCT03685331		ECD	2024Apr01	Yes	No		4	NCT03685331			Progression free survival	54	54																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Niraparib		Terminated	NCT02826512		PCD	2022Jul01	Yes	No		4	NCT02826512			Progression free survival	9	9																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Temozolomide + Veliparib		"Active, not recruiting"	NCT01009788		PCD	2021May01	Comparison with wt	Yes		1	34417675			Overall Response Rate	41	30	11		23	0							3.3	1.8	0.48	0.006																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Temozolomide + Veliparib		Completed	NCT01506609		PCD	2018Dec13	Yes	Yes		1	29045554			Progression free survival	193	94	99	Carboplatin + Paclitaxel	28.6	61.3							7.4	12.3	1.86	1.28-2.70	0.001									19.1	25.9	1.48	1.03-2.13	0.032													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Cyclophosphamide + Veliparib		Completed	NCT01306032		PCD	2014Dec31	Yes	Yes		4	NCT01306032	Previously-treated		Overall Response Rate	39	21	18	Cyclophosphamide	9.5	5.6																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Cisplatin + Veliparib		"Active, not recruiting"	NCT02595905		ECD	2023Oct31	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.1001			Progression free survival	37												5.7	4.3	0.64		0.26																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Veliparib		Completed	NCT01506609		PCD	2018Dec13	Yes	Yes		1	29045554			Progression free survival	196	97	99	Carboplatin + Paclitaxel	77.8	61.3		0.027					14.1	12.3	0.79	0.54-1.16	0.227									28.3	25.9	0.75	0.50-1.12	0.156													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Rucaparib		Completed	NCT02505048	RUBY	PCD	2019Feb01	Yes	Yes		1	34837859			"Disease control rate, Clinical benefit rate"	5	5			20																												1	1									COSO28394862	2022Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Not yet recruiting	NCT04755868		ECD	2024Mar01	Yes	No		4	NCT04755868	Previously-treated		Progression free survival	206			Placebo																																							COSO28394862	2022Feb22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Recruiting	NCT03990896		ECD	2023Dec31	Yes	No		4	NCT03990896			Progression free survival	30	30																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Terminated	NCT03499353		PCD	2020Sep23	Yes	Yes	Changed business priorities	4	NCT03499353			"Complete response, Pathological complete response"	61	61																																									COSO28394862	2022Feb22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Completed	NCT02282345		PCD	2018Apr26	Yes	Yes	PaR 52.6%	1	31461380	Untreated		Maximum tolerated dose/toxicity	19	19																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Not yet recruiting	NCT05332561	COGNITION-GUIDE Arm 4	ECD	2029Apr01	Yes	No		4	NCT05332561			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	240	240																																									COSO28394862	2022Apr25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT05498155	OlympiaN Cohort A	ECD	2024May17	Yes	No		4	NCT05498155			"Complete response, Pathological complete response"	80	80																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Unknown	NCT02681562	OLTRE	ECD	2018Jan01	Yes	No		4	NCT02681562			Unknown	45																																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Withdrawn	NCT01661868		PCD	2012Aug01	Yes	Yes	Drug unavailable	4	NCT01661868			Response rate	0																																										COSO28394862	2022Feb21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		"Active, not recruiting"	NCT02849496		ECD	2023Aug31	No	No		4	NCT02849496			Progression free survival	81	81																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Olaparib		Completed	NCT03286842	LUCY	PCD	2021Oct08	Yes	Yes		1	34087573				256	256											8.11			6.93?8.67																											COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Apatinib + Fluzoparib		Recruiting	NCT04296370		ECD	2022Jun30	Yes	No		4	NCT04296370			Progression free survival	474			Fluzoparib																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Chemotherapy + Olaparib		Recruiting	NCT03150576	PARTNER	ECD	2024Jun01	No	No		4	NCT03150576			"Complete response, Pathological complete response"	780	780																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Niraparib		Recruiting	NCT04915755	ZEST	ECD	2025Mar12	Yes	No		4	NCT04915755			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	800			Placebo																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Niraparib		Terminated	NCT01905592	BRAVO	PCD	2018May23	Yes	Yes		4	NCT01905592	Previously-treated		Progression free survival	206	135	71	Best supportive care									4.1	3.1				4.3	2.6							14.5	14.8																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Atezolizumab + Chemotherapy + Niraparib		"Active, not recruiting"	NCT03598270	ANITA	ECD	2024Aug01	No	No		4	NCT03598270	Previously-treated		Progression free survival	414																																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Chemotherapy + Niraparib		"Active, not recruiting"	NCT03598270	ANITA	ECD	2024Aug01	No	No		4	NCT03598270	Previously-treated		Progression free survival	414			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Carboplatin + Cyclophosphamide + Paclitaxel + Veliparib + doxorubicin hydrochloride		Completed	NCT02032277		PCD	2016Mar18	No	Yes	Primary outcome not met	1	29501363			"Complete response, Pathological complete response"	474	316	158	Carboplatin + Cyclophosphamide + Paclitaxel																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Carboplatin + Paclitaxel + Veliparib		"Active, not recruiting"	NCT02163694	BROCADE3	PCD	2019Apr05	Yes	Yes		4	NCT02163694			Progression free survival	509	337	172	Carboplatin + Paclitaxel									14.5	12.6			0.002																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 4	Olaparib		Completed	NCT04330040	SOLI	PCD	2022Sep30	Yes	No		4	NCT04330040	Previously-treated		Maximum tolerated dose/toxicity	162	162																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / NS	1	Phase 4	Choriogonadotropin alfa		Completed	NCT03495609		PCD	2018Dec18	No	No		4	NCT03495609			Altered genomic signature	33	33																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified or CHEK2_unspecified or PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Recruiting	NCT04508803	CHANGEABLE	ECD	2022Nov20	Yes	No		4	NCT04508803			Overall Response Rate	37	37																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified or PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Dostarlimab + Niraparib		Recruiting	NCT04584255		ECD	2024Jul17	Yes	No		4	NCT04584255			"Complete response, Pathological complete response"	62	62																																									COSO28394862	2022Feb22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified or PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Dalpiciclib + Fluzoparib		Not yet recruiting	NCT05594095	SNF3 3	ECD	2025Dec01	Yes	No		4	NCT05594095			Overall Response Rate	140	140																																									COSO28394862	2022Nov07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified or PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Prophylactic contralateral breast irradiation		Recruiting	NCT04960839		ECD	2029Dec01	Yes	No		4	NCT04960839			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	323	323																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified or PALB2_unspecified or RAD51C_unspecified or RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	AZD9574		Recruiting	NCT05417594	CERTIS1 Module 1 Cohort B1	ECD	2024Apr11	Yes	No		4	NCT05417594			Maximum tolerated dose/toxicity	195	195																																									COSO28394862	2022Sep30	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Completed	NCT00679783		PCD	2010Mar26	Yes	Yes		1	21862407	Previously-treated		Overall Response Rate	5	5			0																											0	0	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT03025035		ECD	2023Nov01	Yes	No		4	NCT03025035			Overall Response Rate	20	20																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Paclitaxel + Veliparib		"Active, not recruiting"	NCT01149083		ECD	2022Dec31	Yes	Yes		1	28356425	Previously-treated		Response rate	22	22			36																		64																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Rucaparib		Completed	NCT00664781		PCD	2015Jan01	Yes	Yes		1	27002934			Tumour volume	1	1			0																											0	0	1									COSO28394862	2022Dec02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Rucaparib		Completed	NCT00664781		PCD	2015Jan01	Yes	Yes		1	27002934			Tumour volume	9	9			0																											0	0	4									COSO28394862	2022Dec02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Terminated	NCT02034916	ABRAZO	PCD	2016Sep01	Yes	Yes		1	30563931			Overall Response Rate	42	42			33																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRCA2	BRCA2_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib + Trastuzumab		Terminated	NCT03931551	OPHELIA	PCD	2022Mar02	Yes	Yes	Slow accrual	4	NCT03931551			"OS, PFS"	5	20																																									COSO28394862	2022May12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
BRIP1	BRIP1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CCND1	CCND1_unspecified or CCND2_unspecified				breast / carcinoma / NS	3	Phase 1	Erdafitinib + Fulvestrant + Palbociclib		"Active, not recruiting"	NCT03238196		ECD	2022Dec31	No	No		4	NCT03238196			Maximum tolerated dose/toxicity	35	35											3																					8									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CCND1	CCND1_unspecified or CDKN2A_unspecified or CDK4_unspecified or CDK6_unspecified				breast / carcinoma / NS	3	Phase 3	Letrozole + Palbociclib		"Active, not recruiting"	NCT01740427	PALOMA-2 Asian	PCD	2016Feb26	No	Yes		1	31125276			Progression free survival	95	65	30	Letrozole + Placebo									25.7	13.9	0.49	0.27-0.87	0.007																										COSO28394862	2022Nov09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CCND1	CCND1_unspecified or CDKN2A_unspecified or CDK4_unspecified or CDK6_unspecified				breast / carcinoma / NS	3	Phase 3	Letrozole + Palbociclib		"Active, not recruiting"	NCT01740427	PALOMA-2 Non-Asian	PCD	2016Feb26	No	Yes		1	31125276			Progression free survival	571	379	192	Letrozole + Placebo									24.8	15.9	0.58	0.46-0.73	<0.001																										COSO28394862	2022Nov09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CCND1	CCND1_unspecified or CDKN2A_unspecified or ESR1_unspecified or PIK3CA_unspecified or PTEN_unspecified or TP53_unspecified or RB1_unspecified				breast / carcinoma / NS	3	Phase 3	Alpelisib + Fulvestrant		"Active, not recruiting"	NCT03439046	BioItaLEE	ECD	2024Jul01	Yes	No		4	NCT03439046			Biomarker discovery	287	287																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CCND1	CCND1_unspecified or ERBB2_unspecified or ERBB4_unspecified or PIK3CA_unspecified or TP53_unspecified				breast / carcinoma / NS	4	Observational	Eribulin		Recruiting	NCT04683445		ECD	2022Dec31	Yes	No		4	NCT04683445			Progression free survival	80	80																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CCND1	CCND1_unspecified or ESR1_unspecified or PGR_unspecified				breast / carcinoma / NS	3	Phase 3	Letrozole + Palbociclib + Trastuzumab		Recruiting	NCT05429684	Experimental E	ECD	2024Feb28	Yes	No		4	NCT05429684	Previously-treated		Overall Response Rate	120	120																																									COSO28394862	2022Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 1	Radiotherapy + Sintilimab		Completed	NCT03812549		PCD	2022Jan31	Expression confirmed	Yes		2	10.1200/JCO.2022.40.16_suppl.e21174			Maximum tolerated dose/toxicity	28	28			57.1		37.2-75.5		13.6		59.1-91.7		8.6			5.7-11.5							78.6																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	PGG beta-glucan + Pembrolizumab		Recruiting	NCT05159778		ECD	2025Jan15	No	No		4	NCT05159778	Previously-treated		Overall Response Rate	50	50																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Pembrolizumab + Sacituzumab govitecan		Recruiting	NCT04448886		ECD	2025Jun01	No	No		2	NCT04448886			Progression free survival	110			Sacituzumab govitecan																																							COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Ipilimumab + Nivolumab		"Active, not recruiting"	NCT03409198		PCD	2022May11	No	No		4	NCT03409198			Progression free survival	82	82																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Durvalumab + Exemstane + Tremelimumab		Completed	NCT02997995		PCD	2019Jul15	No	No		4	NCT02997995			"Complete response, Pathological complete response"	61	61																																									COSO28394862	2022Jul20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Tesetaxel		Terminated	NCT03952325	CONTESSA TRIO	PCD	2021Jun23	No	Yes		4	NCT03952325			"OS, PFS"	294																																										COSO28394862	2022Jun23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Atezolizumab + Tesetaxel		Terminated	NCT03952325	CONTESSA TRIO	PCD	2021Jun23	No	Yes		4	NCT03952325			"OS, PFS"	294																																										COSO28394862	2022Jun23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Pembrolizumab + Tesetaxel		Terminated	NCT03952325	CONTESSA TRIO	PCD	2021Jun23	No	Yes		4	NCT03952325			"OS, PFS"	294																																										COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Nivolumab + Tesetaxel		Terminated	NCT03952325	CONTESSA TRIO	PCD	2021Jun23	No	Yes		4	NCT03952325			"OS, PFS"	294																																										COSO28394862	2022Jun23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Paclitaxel + Pembrolizumab		"Active, not recruiting"	NCT04251169	TATEN	ECD	2022Dec01	No	No		4	NCT04251169	Previously-treated		Overall Response Rate	46	46																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Paclitaxel + Pembrolizumab		Not yet recruiting	NCT03841747	PELICAN	ECD	2023Apr01	No	No		4	NCT03841747			"OS, PFS"	87			Paclitaxel																																							COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab		"Active, not recruiting"	NCT02957968		ECD	2025Feb28	No	No		4	NCT02957968			Immune cell infiltration	47	47																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 3	Chemotherapy + Pembrolizumab		Recruiting	NCT04895358	KEYNOTE-B49	ECD	2027Oct21	Expression confirmed	No		4	NCT04895358			"OS, PFS"	800			Chemotherapy + Placebo																																							COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 3	Sintilimab + Trastuzumab		Recruiting	NCT05429684	Experimental F	ECD	2024Feb28	Yes	No		4	NCT05429684	Previously-treated		Overall Response Rate	120	120																																									COSO28394862	2022Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / NS	3	Phase 3	Cyclophosphamide + Doxorubicin or Epirubicin + Paclitaxel + Pembrolizumab		"Active, not recruiting"	NCT03725059	KEYNOTE-756	ECD	2031Jan24	No	No		4	NCT03725059			"EFS, pCR"	1240			Cyclophosphamide + Doxorubicin or Epirubicin + Paclitaxel + Placebo																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Pembrolizumab + Trastuzumab		Completed	NCT02129556	PANACEA	PCD	2017Aug04	Expression confirmed	Yes		4	NCT02129556			Overall Response Rate	40	40			15		29-Jul						2.7			2.6-4.0		2.7			2.6-4.9		25																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Pembrolizumab + Trastuzumab		Recruiting	NCT03095352		ECD	2023Sep30	No	No		4	NCT03095352	Previously-treated		"PFS, DCR"	84			Carboplatin + Pembrolizumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Atezolizumab + Trastuzumab + Vinorelbine		Recruiting	NCT04759248	ATREZZO	ECD	2023Feb24	Expression confirmed	No		4	NCT04759248	Previously-treated		Overall Response Rate	110	110																																									COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Pembrolizumab + Trastuzumab + Tucatinib		Not yet recruiting	NCT04789096	TUGETHER	ECD	2024Jun01	Expression confirmed	No		4	NCT04789096	Previously-treated		Overall Response Rate	50	50																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Atezolizumab + Carboplatin + Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab		Terminated	NCT03894007	PREDIXIIHER2	PCD	2021Jun30	Overexpression	Yes	Toxicities in other studies	4	NCT03894007			"Complete response, Pathological complete response"	6			Carboplatin + Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Durvalumab + Pertuzumab + Trastuzumab		Recruiting	NCT03820141	DTP Trial	ECD	2023Mar01	Expression confirmed	No		4	NCT03820141			"Complete response, Pathological complete response"	39	39																																									COSO28394862	2022Aug01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 3	Atezolizumab + Cyclophosphamide + Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride		"Active, not recruiting"	NCT03726879	IMpassion050 PD-L1+	PCD	2021Feb05	Expression confirmed	Yes	"pCR 64.2 v 72.5%, p=0.185"	2	10.1016/j.annonc.2021.05.800			"Complete response, Pathological complete response"	218	109	109	Cyclophosphamide + Paclitaxel + Pertuzumab + Placebo + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CD274	CD274_unspecified and ERBB2_unspecified				breast / carcinoma / NS	3	Phase 3	Atezolizumab + Trastuzumab-emtansine		Recruiting	NCT04740918	KATE3	ECD	2026Aug09	Expression confirmed	No		4	NCT04740918			"OS, PFS"	320			Atezolizumab + Placebo + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CDK12	CDK12_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CDK4	CDK4_unspecified				breast / carcinoma / NS	3	Phase 1	Erdafitinib + Fulvestrant + Palbociclib		"Active, not recruiting"	NCT03238196		ECD	2022Dec31	No	No		4	NCT03238196			Maximum tolerated dose/toxicity	35	35																																									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CDK6	CDK6_unspecified				breast / carcinoma / NS	3	Phase 1	Erdafitinib + Fulvestrant + Palbociclib		"Active, not recruiting"	NCT03238196		ECD	2022Dec31	No	No		4	NCT03238196			Maximum tolerated dose/toxicity	35	35																																									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	CDKN2A_deletion and PDCD4_unspecified				breast / carcinoma / NS	3	Phase 2	Pemrametostat		Completed	NCT04676516	OTT-19-06	PCD	2022Aug15	No	No		4	NCT04676516			Change in Ki-67 expression	40	40																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CHEK1	CHEK1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CHEK2	CHEK2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CHEK2	CHEK2_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
CTAG1B	CTAG1B_unspecified				breast / carcinoma / NS	3	Phase 1	CHP-NY-ESO-1 vaccine + Picibanil		Completed	NCT00291473		PCD	2008Aug01	Expression confirmed	No		4	NCT00291473			Maximum tolerated dose/toxicity	9	9																																									COSO28394862	2021Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Vandetanib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Lapatinib + Paclitaxel		Completed	NCT00111787		PCD	2006Nov01	Overexpression	No		4	NCT00111787			"Complete response, Pathological complete response"	49	49																																									COSO28394862	2021Oct04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Doxorubicin-loaded anti-EGFR immunoliposomes		Terminated	NCT02833766		PCD	2020Oct31	Expression confirmed	Yes		1	23153506			Progression free survival	48	48																														1	1	10									COSO28394862	2021Oct29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Sapitinib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT01688609		PCD	2013Dec01	No	Yes		4	NCT01688609			"Complete response, Pathological complete response"	18	18																														8											COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Gemcitabine + Panitumumab		Completed	NCT00894504		PCD	2014Sep01	No	Yes	"No benefit of treatment, Response not correlated with mutation status"	1	27340049			Progression free survival	71	71			42								4.4													11.6						1	29										COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Capecitabine + Pyrotinib		Completed					No	Yes		3	http://cancerres.aacrjournals.org/content/78/4_Supplement/PD3-08			Unknown	128	65	63	Capecitabine + Lapatinib	78.5	57.1		0.01					18.1	7	0.363	0.228-0.579	<0.0001																										COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Poziotinib		Completed	NCT02544997		PCD	2020Feb01	Yes	No		4	NCT02544997	Previously-treated		Progression free survival	5	5																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Canertinib		Completed	NCT00051051				No	Yes	Primary outcome not met	1	19294387	Previously-treated		Clinical activity	168																																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Pyrotinib		Unknown	NCT03080805	PHOEBE	PCD	2019Mar31	No	Yes		2	10.1200/JCO.2020.38.15_suppl.1003	Previously-treated		Progression free survival	267	134	132	Capecitabine + Lapatinib	67.2	51.5	4.0-27.3	0.0091	11.1	7			12.5	6.8	0.39	0.27-0.56	<0.0001						73.1	59.1																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 3	Docetaxel + Pyrotinib + Trastuzumab		"Active, not recruiting"	NCT03588091		PCD	2021Apr30	No	No		4	NCT03588091			"Complete response, Pathological complete response"	355			Docetaxel + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified and ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Unknown	NCT02226757		ECD	2016Aug01	Expression confirmed	Yes	Primary outcome met	2	10.1200/JCO.2017.35.15_suppl.9042	Previously-treated		Overall Response Rate	17	17																															7	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
EGFR	EGFR_unspecified or ERBB2_unspecified				breast / carcinoma / NS	3	Phase 1	Neratinib		Completed	NCT00146172		PCD	2007Jan01	Expression confirmed	Yes		1	19318484			Maximum tolerated dose/toxicity	25	25			32																												3	1									COSO28394862	2022Nov29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	"ERBB2_Exon19,Exon20"				breast / carcinoma / NS	3	Phase 3	Trastuzumab Deruxtecan		Recruiting	NCT05048797	DESTINY-Lung04	ECD	2025Jan17	Yes	No		4	NCT05048797			Progression free survival	264			Pembrolizumab + Pemetrexed + Platinum-based chemotherapy																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Neratinib		Completed	NCT00878709	ExteNET	PCD	2014Aug21	Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2840	1420	1420	Placebo																															94.2	91.9	0.66	0.49-0.90	0.008				COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab and hyaluronidase	Required	Unknown		H0648g			Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf	Untreated			469	235	234	Chemotherapy	45	29		<0.001	8.3	5.8								7.2	4.5			<0.0001				25.1	20.3			0.05													COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab and hyaluronidase	Required	Completed	NCT00021255	BCIRG 006	PCD	2014Dec01	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1075	1075																																			0.67	0.54-0.84	<0.0006				COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab and hyaluronidase	Required	Unknown		HERA			Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf				3386	1693	1693	Observation																								0.75									0.54	0.44-0.67	<0.0001				COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab and hyaluronidase		Completed	NCT01566721	SafeHER	PCD	2015Mar10	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf			Maximum tolerated dose/toxicity	1867	1867																																	93								COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab and hyaluronidase		Unknown		NSABP B31 + NCCTG N9831			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3752	1872	1880	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel																								0.64	0.55-0.74								0.48	0.39-0.59	<0.0001				COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab and hyaluronidase	Required	Unknown		H0649g			Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf	Previously-treated		Overall Response Rate	222	222			14																																						COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab and hyaluronidase		Completed	NCT00950300	HannaH	PCD	2011Jul12	Expression confirmed	Yes	"IV v subcutaneous, pCR 40.7 v 45.4%"	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf	Untreated		"Complete response, Pathological complete response"	523	263	260	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab																																							COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Lapatinib + Taxane	Required	Unknown					Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf			Progression free survival	652			Taxane + Trastuzumab									9	11.3	1.37	1.13-1.65																											COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Capecitabine + Eribulin + Gemcitabine + Margetuximab + Vinorelbine		Completed	NCT02492711	SOPHIA	PCD	2021Aug11	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf	Previously-treated		Progression free survival	536	266	270	Capecitabine + Eribulin + Gemcitabine + Trastuzumab + Vinorelbine	22	16			6.1	6			5.8	4.9	0.76	0.59-0.98	0.03																										COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Aromatase inhibitors + Trastuzumab	Required	Unknown					Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf	Previously-treated		Progression free survival	235	117	118	Aromatase inhibitors + Lapatinib	8.5	12.7							5.6	8.3	0.85	0.62-1.17	0.292																										COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Aromatase inhibitors + Lapatinib + Trastuzumab	Required	Unknown					Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf	Previously-treated		Progression free survival	237	120	117	Aromatase inhibitors + Trastuzumab	22.5	8.5							11	5.6	0.62	0.45-0.88	0.004																										COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Capecitabine + Neratinib		Completed	NCT01808573	NALA	PCD	2018Sep28	Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	Previously-treated		"OS, PFS"	621	307	314	Capecitabine + Lapatinib	32.8	26.7			8.5	5.6			5.6	5.5	0.76	0.63-0.93	0.0059									21	18.7	0.88	0.72-1.07	0.2086													COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Lapatinib + Letrozole	Required	Unknown		HER2+			Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf			Progression free survival	219	111	108	Letrozole + Placebo	27.9	14.8							8.17	3	0.71	0.53-0.96																											COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab		Unknown		Study 5			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	Untreated		Time to progression	469	235	234	Chemotherapy	45	29		<0.001	8.3	5.8		0.05						7.2	4.5			<0.0001																					COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Chemotherapy + Trastuzumab		Unknown		Study 3			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3386	1693	1693	Chemotherapy																								0.75									0.54	0.44-0.67	<0.00001				COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Paclitaxel + Trastuzumab		Unknown		"Study 1,2"			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3725	1872	1880	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel																								0.64	0.55-0.74	<0.0001							0.48	0.39-0.59	<0.0001				COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Carboplatin + Docetaxel + Trastuzumab		Unknown		Study 4 TCH v ACT			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2148	1075	1073	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride																																	0.67	0.54-0.84	0.0006				COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Capecitabine + Trastuzumab + Tucatinib		Completed	NCT02614794	HER2CLIMB	PCD	2019Sep04	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf			Progression free survival	480	320	160	Capecitabine + Placebo + Trastuzumab	40.6	22.8		0.00008	8.3	6.3			7.6	5.4	0.48	0.34-0.69	<0.00001									21.9	17.4	0.66	0.50-0.87	0.0048													COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab Deruxtecan	Required	"Active, not recruiting"	NCT03248492	DESTINY-Breast01	PCD	2019Mar21	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s024lbl.pdf	Previously-treated		Overall Response Rate	184	184			60.3		52.9-67.4		14.8		13.8-16.9												97.3																				COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab Deruxtecan	Required	"Active, not recruiting"	NCT03529110	DESTINY-Breast03	PCD	2021May21	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s017s020lbl.pdf	Previously-treated		Progression free survival	524	261	263	Trastuzumab-emtansine	82.7	36.1								6.8	0.28	0.22-0.37	<0.0001																										COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT03734029	DESTINY-Breast04	ECD	2023Jan01	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s024lbl.pdf	Previously-treated		Progression free survival	557	373	184	Physician's choice	52.3	16.3			10.7	6.8			9.9	5.1	0.5	0.4-0.63	<0.0001									23.4	16.8	0.64	0.49-0.84	0.001													COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab-emtansine		"Active, not recruiting"	NCT01772472	KATHERINE	PCD	2018Jul25	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1486	743	743	Trastuzumab																															88.3	77	0.5	0.39-0.64	<0.0001				COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab-emtansine	Required	Completed	NCT00829166	EMILIA	PCD	2012Jul01	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf			"OS, PFS"	961	495	496	Capecitabine + Lapatinib	43.6	30.8	6.0-19.4	0.0002		12.6	6.5		9.6	6.4	0.65	0.55-0.77	<0.0001						58.2	44.2		30.9	25.1	0.68	0.55-0.85	0.0006													COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab	Required	Unknown		Study 6			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	Previously-treated		Overall Response Rate	222	222			14																																						COSO28394862	2023Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Trastuzumab	Required	Completed	NCT00045032	HERA (Study 3)	PCD	2005Mar01	Overexpression	Yes		1	21354370			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3401	1703	1698	Observation																															78.6	72.2	0.76	0.66-0.87	<0.0001				COSO28394862	2023Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Docetaxel + Trastuzumab		Unknown		Study 4 ACTH v ACT			Overexpression	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2147	1074	1073	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride																																	0.6	0.48-0.76	0.0001				COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Capecitabine + Lapatinib	Required	Unknown					Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf				540			Capecitabine + Trastuzumab									6.6	8	1.3	1.04-1.64												1.34	0.95-1.92														COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Approved FDA	Capecitabine + Lapatinib	Required	Completed	NCT00078572	100151	PCD	2006Apr01	Expression confirmed	Yes		1	18188694	Previously-treated		Time to progression	399	198	201	Capecitabine	23.7	13.9												6.23	4.29	0.57	0.43-0.77	0.00013				17.3	15.2	0.89	0.71-1.10	0.276													COSO28394862	2023Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Experimental	Gefitinib + Tamoxifen		Terminated	NCT00206492		PCD	2006Oct01	Overexpression	No		4	NCT00206492			Clinical activity	3	3																																									COSO28394862	2021Oct04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib		Completed	NCT00462956		PCD	2006Dec20	Overexpression	No		4	NCT00462956			Response rate	59	59																																									COSO28394862	2021Oct15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	ELVN-002 + Trastuzumab-emtansine		Not yet recruiting	NCT05650879		ECD	2026Jul01	Expression confirmed	No		4	NCT05650879	Previously-treated		Maximum tolerated dose/toxicity	178	178																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab deruxtecan + Valemetostat tosylate		Not yet recruiting	NCT05633979		ECD	2030Dec31	Expression confirmed	No		4	NCT05633979	Previously-treated		Overall Response Rate	37	37																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cyclophosphamide + Fludarabine + Interleukin-2 + Pembrolizumab + TBio-4101		Not yet recruiting	NCT05576077	STARLING	ECD	2023Dec31	No	No		4	NCT05576077			Maximum tolerated dose/toxicity	30	30																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Stereotactic radiotherapy + Trastuzumab + Tucatinib		Not yet recruiting	NCT05553522		ECD	2024Jul01	Expression confirmed	No		4	NCT05553522			Maximum tolerated dose/toxicity	40	40																																									COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2-pulsed DC1 vaccine + IL-15 expanded CD4 T cells + IL-7 expanded CD4 T cells + Pepinemab + Trastuzumab		Recruiting	NCT05378464		ECD	2024May01	Expression confirmed	No		4	NCT05378464			Maximum tolerated dose/toxicity	28	28																																									COSO28394862	2022Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Allogenic NK cells + Cyclophosphamide + Interleukin-2 + Pertuzumab + Trastuzumab		Recruiting	NCT05385705		ECD	2024Sep11	Expression confirmed	No		4	NCT05385705			Maximum tolerated dose/toxicity	20	20																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Ribociclib + Trastuzumab + Tucatinib		Recruiting	NCT05319873		ECD	2023Apr01	Overexpression	No		4	NCT05319873			Maximum tolerated dose/toxicity	18	18																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Loperamide + Pyrotinib		Not yet recruiting	NCT05252546		ECD	2022Mar18	Expression confirmed	No		4	NCT05252546			Maximum tolerated dose/toxicity	36	36																																									COSO28394862	2022Sep22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Montmorillonite  + Pyrotinib		Not yet recruiting	NCT05252546		ECD	2022Mar18	Expression confirmed	No		4	NCT05252546			Maximum tolerated dose/toxicity	36	36																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	MSC2363318A + Trastuzumab		Completed	NCT01971515	Cohort 2	PCD	2018Aug09	Expression confirmed	Yes		1	34407844	Previously-treated		Maximum tolerated dose/toxicity	13	13											2.8			-1.4																	1	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Bintrafusp alfa + Brachyury-TRICOM + Trastuzumab-emtansine		Terminated	NCT04296942	BrEAsT	PCD	2021Oct22	Expression confirmed	Yes	"Slow accrual, safety issues"	4	NCT04296942			Overall Response Rate	1	1																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Brachyury-TRICOM + Trastuzumab-emtansine		Terminated	NCT04296942	BrEAsT	PCD	2021Oct22	Expression confirmed	Yes	"Slow accrual, safety issues"	4	NCT04296942			Overall Response Rate	1	1																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	DZD1516 + Trastuzumab-emtansine		"Active, not recruiting"	NCT04509596		ECD	2024Jan01	Expression confirmed	No		4	NCT04509596	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + DZD1516 + Trastuzumab		"Active, not recruiting"	NCT04509596		ECD	2024Jan01	Expression confirmed	No		4	NCT04509596	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + DZD1516		"Active, not recruiting"	NCT04509596		ECD	2024Jan01	Expression confirmed	No		4	NCT04509596	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	DZD1516 + Trastuzumab		"Active, not recruiting"	NCT04509596		ECD	2024Jan01	Expression confirmed	No		4	NCT04509596	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	DZD1516		"Active, not recruiting"	NCT04509596		ECD	2024Jan01	Expression confirmed	No		4	NCT04509596	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	B002		Recruiting	NCT04382352		ECD	2022Dec30	Expression confirmed	No		4	NCT04382352			Maximum tolerated dose/toxicity	19	19																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pelareorep + Trastuzumab		Terminated	NCT04102618	AWARE-1	PCD	2022Apr20	Expression confirmed	No		4	NCT04102618			CelTIL score	26	26																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Atezolizumab + Pelareorep + Trastuzumab		Terminated	NCT04102618	AWARE-1	PCD	2022Apr20	Expression confirmed	No		4	NCT04102618			CelTIL score	26	26																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	huMNC2-CAR44 CAR T cells		Recruiting	NCT04020575	HER2+ cohort	ECD	2023Jan01	Expression confirmed	No		4	NCT04020575	Previously-treated		Maximum tolerated dose/toxicity	69	69																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	RBX7455		Recruiting	NCT04139993	Cohort 2	ECD	2023Mar31	Overexpression	No		4	NCT04139993			"ORR, DOR"	30	30																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pembrolizumab + Trastuzumab deruxtecan		Recruiting	NCT04042701		ECD	2023Mar01	Expression confirmed	No		4	NCT04042701			Overall Response Rate	115	115																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab monomethyl auristatin F		Recruiting	NCT03944499		ECD	2023Sep01	Overexpression	No		4	NCT03944499			Overall Response Rate	92	92																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Chemotherapy + Margetuximab		Completed	NCT04398108		PCD	2021Apr27	Expression confirmed	Yes		4	NCT04398108	Previously-treated		Maximum tolerated dose/toxicity	16	16																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Copanlisib + Trastuzumab-emtansine		Terminated	NCT04042051	Panthera	PCD	2020Nov02	Expression confirmed	Yes	Slow accrual	4	NCT04042051	Previously-treated		Maximum tolerated dose/toxicity	2	2																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab + alpha-tocopheryloxyacetic acid		Recruiting	NCT04120246		ECD	2024Feb01	Expression confirmed	No		4	NCT04120246			"OS, PFS"	24	24																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	ZW49		Recruiting	NCT03821233		ECD	2023Aug01	Expression confirmed	No		4	NCT03821233			Maximum tolerated dose/toxicity	174	174																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	BAY2701439		Recruiting	NCT04147819		ECD	2026Jul24	Overexpression	No		4	NCT04147819			Overall Response Rate	213	213																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	B003		Recruiting	NCT03953833		ECD	2022Dec30	Expression confirmed	No		4	NCT03953833	Previously-treated		Overall Response Rate	45	45																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	DHES0815A		Completed	NCT03451162		PCD	2021Jul16	Expression confirmed	Yes	Safety issues	2	10.1158/1538-7445.SABCS21-P2-13-25	Previously-treated		Maximum tolerated dose/toxicity	14	14																														1		10									COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Nivolumab + Trastuzumab deruxtecan		"Active, not recruiting"	NCT03523572		PCD	2021Jul22	Expression confirmed	Yes		2	10.1158/1538-7445.SABCS20-PD3-07	Previously-treated		Overall Response Rate	32	32			59.4								8.6			-5.4																	18										COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Poziotinib + Trastuzumab-emtansine		Terminated	NCT03429101		PCD	2019Apr17	Expression confirmed	Yes	Toxicity issues	4	NCT03429101			Maximum tolerated dose/toxicity	6	6																																									COSO28394862	2022Jan07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pembrolizumab + Trastuzumab-emtansine		"Active, not recruiting"	NCT03032107		PCD	2020Oct29	Expression confirmed	Yes		2	10.1200/JCO.2020.38.15_suppl.1046			Maximum tolerated dose/toxicity	26	26			20		8.1-41.6		10.1		-3.1		9.6			-2.9							50																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	GP2 peptide/GM-CSF vaccine + Trastuzumab		Completed	NCT03014076		PCD	2016Jan01	Overexpression	Yes	Primary outcome met	1	28315060			Maximum tolerated dose/toxicity	17	17		Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	NK-92/5.28.z		Recruiting	NCT03383978		ECD	2023Oct31	Expression confirmed	No		4	NCT03383978			Maximum tolerated dose/toxicity	42	42																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	BI-CON-02		Terminated	NCT03062007		PCD	2017Jun05	Expression confirmed	No		4	NCT03062007			Maximum tolerated dose/toxicity	6	6																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	MP0274		Completed	NCT03084926		PCD	2021Dec13	Expression confirmed	No		4	NCT03084926			Maximum tolerated dose/toxicity	22	22																																									COSO28394862	2022Jan24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Fulvestrant + Hemay022		Recruiting	NCT03308201		ECD	2022May28	Overexpression	No		4	NCT03308201			Maximum tolerated dose/toxicity	48	48																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Hemay022 + Letrozole		Recruiting	NCT03308201		ECD	2022May28	Overexpression	No		4	NCT03308201			Maximum tolerated dose/toxicity	48	48																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Exemstane + Hemay022		Recruiting	NCT03308201		ECD	2022May28	Overexpression	No		4	NCT03308201			Maximum tolerated dose/toxicity	48	48																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab-emtansine + Utomilumab		Completed	NCT03364348		PCD	2021Feb15	Expression confirmed	No		4	NCT03364348			Maximum tolerated dose/toxicity	18	18																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab + Utomilumab		Completed	NCT03364348		PCD	2021Feb15	Expression confirmed	No		4	NCT03364348			Maximum tolerated dose/toxicity	18	18																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pertuzumab + Tocilizumab + Trastuzumab		Completed	NCT03135171		PCD	2020Mar16	Expression confirmed	No		4	NCT03135171	Previously-treated		Maximum tolerated dose/toxicity	11	11																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	ALT-P7		Completed	NCT03281824		PCD	2020Mar12	Expression confirmed	Yes	DCR 6w 77.3	2	10.1200/JCO.2020.38.15_suppl.3551	Previously-treated		Maximum tolerated dose/toxicity	22	22											6.2			2.5-9.9																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	WOKVAC vaccine		Recruiting	NCT03384914		ECD	2023Mar01	Expression confirmed	No		4	NCT03384914			Immune response	110	110																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2-pulsed DC1 vaccine		Recruiting	NCT03387553		ECD	2023Aug01	Expression confirmed	No		4	NCT03387553			"Complete response, Pathological complete response"	32	32																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2-pulsed DC1 vaccine		Recruiting	NCT03384914		ECD	2023Mar01	Expression confirmed	No		4	NCT03384914			Immune response	110	110																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	TAS-116		Completed	NCT02965885		PCD	2019May03	Expression confirmed	No		4	NCT02965885			Overall Response Rate	31	31																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Durvalumab + Trastuzumab		Completed	NCT02649686		PCD	2017Sep25	Expression confirmed	Yes		2	10.1200/JCO.2018.36.15_suppl.1029	Previously-treated			14	14			0																													4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Tucatinib + Zanidatamab		"Active, not recruiting"	NCT02892123		ECD	2023Jun01	Expression confirmed	No		4	NCT02892123			Maximum tolerated dose/toxicity	279	279																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Vinorelbine + Zanidatamab		"Active, not recruiting"	NCT02892123		ECD	2023Jun01	Expression confirmed	No		4	NCT02892123			Maximum tolerated dose/toxicity	279	279																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Zanidatamab		"Active, not recruiting"	NCT02892123		ECD	2023Jun01	Expression confirmed	No		4	NCT02892123			Maximum tolerated dose/toxicity	279	279																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Paclitaxel + Zanidatamab		"Active, not recruiting"	NCT02892123		ECD	2023Jun01	Expression confirmed	No		4	NCT02892123			Maximum tolerated dose/toxicity	279	279																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Zanidatamab		"Active, not recruiting"	NCT02892123		ECD	2023Jun01	Expression confirmed	No		4	NCT02892123			Maximum tolerated dose/toxicity	279	279																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	ETBX-021		Unknown	NCT02751528	QUILT-3.013	ECD	2020Jul01	Expression confirmed	No		4	NCT02751528			Maximum tolerated dose/toxicity	3	3																																									COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Non-pegylated liposome-encapsulated doxorubicin + Trastuzumab-emtansine		Completed	NCT02562378	Thelma	PCD	2018Dec01	Expression confirmed	Yes		1	33255658			Maximum tolerated dose/toxicity	15	15			40				8.3		5.9-10.7		7.2			6.6-7.8							66.7										6	4									COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Paclitaxel + Pertuzumab + Taselisib + Trastuzumab		"Active, not recruiting"	NCT02390427		PCD	2020Dec01	Expression confirmed	No		4	NCT02390427			Maximum tolerated dose/toxicity	68	68																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pertuzumab + Taselisib + Trastuzumab		"Active, not recruiting"	NCT02390427		PCD	2020Dec01	Expression confirmed	No		4	NCT02390427			Maximum tolerated dose/toxicity	68	68																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pertuzumab + Taselisib + Trastuzumab-emtansine		"Active, not recruiting"	NCT02390427		PCD	2020Dec01	Expression confirmed	No		4	NCT02390427			Maximum tolerated dose/toxicity	68	68																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Taselisib + Trastuzumab-emtansine		"Active, not recruiting"	NCT02390427		PCD	2020Dec01	Expression confirmed	Yes		2	10.1200/JCO.2017.35.15_suppl.1030			Maximum tolerated dose/toxicity	24	24											7.6			-2.9																1	7	12									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Hemay022		Unknown	NCT02476539		ECD	2018Dec01	Overexpression	No		4	NCT02476539			Maximum tolerated dose/toxicity	57	57																																									COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab duocarmazine		Completed	NCT02277717		PCD	2019Jan01	Expression confirmed	Yes		1	31257177			Maximum tolerated dose/toxicity	48	48			33		20.4-48.4																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Ganetespib + Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT02060253		PCD	2018Jun01	Expression confirmed	Yes	Primary outcome met	1	28764748	Previously-treated		Maximum tolerated dose/toxicity	9	9			22								4.62										44																				COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + Nab-paclitaxel + Trastuzumab-emtansine		Completed	NCT02073916		PCD	2018Dec01	Overexpression	Yes		2	10.1200/JCO.2018.36.15_suppl.1035			Maximum tolerated dose/toxicity	14	14			85.7																											6	2										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Radiotherapy + Trastuzumab-emtansine		Completed	NCT02135159		PCD	2017Feb01	Expression confirmed	No		4	NCT02135159			Clinical activity	36	36																																									COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	MV-NIS		"Active, not recruiting"	NCT01846091		PCD	2019Sep18	No	Yes		2	10.1158/1538-7445.SABCS18-P6-21-03			Maximum tolerated dose/toxicity	6	6																															1	4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Palbociclib + Trastuzumab-emtansine		Completed	NCT01976169		PCD	2021May19	Expression confirmed	Yes		2	10.1093/annonc/mdx137.002			Maximum tolerated dose/toxicity	16	16																															3	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	VM206Ad + VM206RY		Completed	NCT01895491		PCD	2013Jul01	Expression confirmed	No	SAE 66.7%	1	26445724			Maximum tolerated dose/toxicity	9	9			11.1																		88.9										1	7									COSO28394862	2021Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Tucatinib		Completed	NCT02025192		PCD	2017Oct03	Expression confirmed	No		1	29804905	Previously-treated		Maximum tolerated dose/toxicity	6	6			83																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Doxorubicin hydrochloride liposome + Lapatinib		Terminated	NCT02131506		PCD	2016Jan01	Overexpression	Yes	Toxicity issues	4	NCT02131506			Maximum tolerated dose/toxicity	11	11																																									COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Elgemtumab + Trastuzumab		Completed	NCT01602406		PCD	2017Aug02	Overexpression	Yes		2	10.1200/jco.2014.32.15_suppl.2519	Previously-treated		Maximum tolerated dose/toxicity	29	29																															2										COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	AVX901 + Trastuzumab or Pertuzumab or Lapatinib or Trastuzumab-emtansine		Completed	NCT01526473		PCD	2016Mar01	Expression confirmed	Yes		2	10.1200/jco.2015.33.15_suppl.3081			Maximum tolerated dose/toxicity	10	10											1.9																				1	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	AVX901		Completed	NCT01526473		PCD	2016Mar01	Expression confirmed	Yes		2	10.1200/jco.2015.33.15_suppl.3081			Maximum tolerated dose/toxicity	4	4											1.9																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Degenerate HLA class II HER2 epitope vaccine		Completed	NCT01632332		PCD	2014Mar24	Expression confirmed	Yes	IR 68-88%	1	31757875	Previously-treated		Immune response	22	22																																									COSO28394862	2021Dec01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Z-endoxifen hydrochloride		"Active, not recruiting"	NCT01327781		PCD	2017Mar05	No	Yes	Acceptable toxicity	2	10.1158/1538-7445.SABCS15-PD2-03			Maximum tolerated dose/toxicity	38	38																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Dactolisib + Paclitaxel + Trastuzumab		Completed	NCT01285466		PCD	2014Oct01	Expression confirmed	Yes		5	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14187			Maximum tolerated dose/toxicity	11	11			54.5																		81.8									2	4	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cyclophosphamide + Gancotamab + Trastuzumab		Unknown	NCT01304797		PCD	2016Aug01	Expression confirmed	Yes		1	30361524				13	13			13								7.4																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Gancotamab + Trastuzumab		Unknown	NCT01304797		PCD	2016Aug01	Expression confirmed	Yes		1	30361524				22	22			13								7.4																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Gancotamab		Unknown	NCT01304797		PCD	2016Aug01	Expression confirmed	Yes		1	30361524				27	27			13								7.4																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Entinostat + Lapatinib		Completed	NCT01434303	Group 1	PCD	2016Feb16	Expression confirmed	Yes		2	10.1200/JCO.2016.34.15_suppl.609	Previously-treated		Maximum tolerated dose/toxicity	15																															1		4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Entinostat + Lapatinib + Trastuzumab		Completed	NCT01434303	Group 2	PCD	2016Feb16	Expression confirmed	Yes		2	10.1200/JCO.2016.34.15_suppl.609	Previously-treated		Maximum tolerated dose/toxicity	22																															2	3	6									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Neratinib + Paclitaxel + Trastuzumab		Completed	NCT01423123		PCD	2012Aug01	Expression confirmed	Yes		1	24077916	Previously-treated		Maximum tolerated dose/toxicity	21	21			38													3.7					52																				COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cipatinib		Terminated	NCT01301911		PCD	2012Nov01	Expression confirmed	No		4	NCT01301911			Maximum tolerated dose/toxicity	26	26																																									COSO28394862	2021Nov29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Eribulin + Trastuzumab		Completed	NCT01432886		PCD	2013Aug01	Expression confirmed	Yes	SAE 0%	4	NCT01432886			Maximum tolerated dose/toxicity	12	12																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03716180	DAPHNe	PCD	2020Oct08	Expression confirmed	Yes		1	35538105			"Treatment rate, Treatment completion, Compliance, Adherence to protocol"	100	100																																									COSO28394862	2022Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Paclitaxel + Seribantumab		Completed	NCT01209195		PCD	2014May01	Expression confirmed	No		4	NCT01209195			Maximum tolerated dose/toxicity	41	41																																									COSO28394862	2021Oct25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	KW-2450 + Lapatinib + Letrozole		Terminated	NCT01199367		PCD	2012Dec01	Overexpression	Yes	Toxicity issues	4	NCT01199367			Maximum tolerated dose/toxicity	11	11																																									COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Lapatinib + Vinorelbine		Terminated	NCT01238029		PCD	2014Jul01	Expression confirmed	Yes	Slow accrual	4	NCT01238029			Maximum tolerated dose/toxicity	12	12																																									COSO28394862	2021Oct22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	MM-111 + Trastuzumab		Completed	NCT01097460		PCD	2013Jul01	Overexpression	Yes	SAE 12.5%	4	NCT01097460	Untreated		Maximum tolerated dose/toxicity	16	16																																									COSO28394862	2022May06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + MK2206		Terminated	NCT01281163		PCD	2013Dec01	Expression confirmed	No		4	NCT01281163			Maximum tolerated dose/toxicity	4	4																																									COSO28394862	2021Nov30	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Gemcitabine + Lapatinib + Paclitaxel		Completed	NCT01133912		PCD	2010Jun01	Overexpression	Yes	clinical PR 91.6%	3	https://bionlp.nlm.nih.gov/trec2017precisionmedicine/extra_abstracts_web/ASCO_102/ASCO_78594-102.html				12	12																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Imetelstat + Trastuzumab		Completed	NCT01265927		PCD	2012Aug01	Expression confirmed	Yes		2	10.1158/0008-5472.SABCS12-P5-18-13	Previously-treated		Overall Response Rate	10	10																																2									COSO28394862	2022Aug24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	MVA-BN-HER2 vaccine		Completed	NCT01152398		PCD	2012Sep01	Expression confirmed	No		4	NCT01152398	Previously-treated		Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2021Oct21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Afatinib + Trastuzumab		Completed	NCT00950742		PCD	2013Oct01	Overexpression	Yes		4	NCT00950742			Maximum tolerated dose/toxicity	16	16			12.5								3.72			3.32-12.76																0	2	4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pictilisib + Trastuzumab		Completed	NCT00928330		PCD	2014Jan01	Expression confirmed	No		4	NCT00928330	Previously-treated		Maximum tolerated dose/toxicity	57	57																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pictilisib + Trastuzumab-emtansine		Completed	NCT00928330		PCD	2014Jan01	Expression confirmed	No		4	NCT00928330	Previously-treated		Maximum tolerated dose/toxicity	57	57																																									COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Nelipepimut-S + Sargramostim		Completed	NCT00841399		PCD	2012Sep01	Expression confirmed	No		1	16157940			Maximum tolerated dose/toxicity	100	24	29	Observation																															85.7	59.8			0.19				COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Nelipepimut-S + Sargramostim		Completed	NCT00854789		PCD	2012May01	Expression confirmed	No		1	NCT00854789			Maximum tolerated dose/toxicity	95	95																																									COSO28394862	2021Oct20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Epirubicin hydrochloride + Lapatinib		Completed	NCT00753207	ICORG 06-30	PCD	2008Nov01	No	No		4	NCT00753207			Maximum tolerated dose/toxicity	10	10																																									COSO28394862	2021Oct19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + Panobinostat		Completed	NCT00632489		PCD	2009Jan01	Overexpression	Yes	SAE 60%	4	NCT00632489			Maximum tolerated dose/toxicity	5	5																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Panobinostat		Completed	NCT00632489		PCD	2009Jan01	Overexpression	Yes	SAE 40%	4	NCT00632489			Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Lapatinib + Panobinostat		Completed	NCT00632489		PCD	2009Jan01	Overexpression	Yes		4	NCT00632489			Maximum tolerated dose/toxicity	0	0																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Alvespimycin + Trastuzumab		Completed	NCT00803556		PCD	2009Aug01	Overexpression	No		4	NCT00803556	Previously-treated		Maximum tolerated dose/toxicity	29	29																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Alvespimycin + Paclitaxel + Trastuzumab		Completed	NCT00803556		PCD	2009Aug01	Overexpression	No		4	NCT00803556	Previously-treated		Maximum tolerated dose/toxicity	29	29																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Ixabepilone + Lapatinib		Terminated	NCT00634088		PCD	2010Jun01	Expression confirmed	Yes		4	NCT00634088			Maximum tolerated dose/toxicity	13	13																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Ixabepilone + Lapatinib		Terminated	NCT00634088		PCD	2010Jun01	Expression confirmed	Yes		4	NCT00634088			Maximum tolerated dose/toxicity	13	13																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Lapatinib + Trebananib		Completed	NCT00807859		PCD	2014Feb27	Expression confirmed	No		4	NCT00807859			Maximum tolerated dose/toxicity	65	65																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Paclitaxel + Trastuzumab + Trebananib		Completed	NCT00807859		PCD	2014Feb27	Expression confirmed	Yes		2	10.1200/jco.2014.32.15_suppl.502			Maximum tolerated dose/toxicity	37	37			80				14.7				16.6																			3	28										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab		Unknown	NCT01880385	Beva	ECD	2013Sep01	Expression confirmed	No		4	NCT01880385			"Complete response, Pathological complete response"	30	30																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Paclitaxel + Panobinostat + Trastuzumab		Completed	NCT00788931		PCD	2010Aug01	Overexpression	Yes	Primary outcome not met	5	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4342	Previously-treated			15	15																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Tucatinib		Completed	NCT00650572		PCD	2013Mar01	Expression confirmed	Yes		1	28053022			Maximum tolerated dose/toxicity	22	22			14																		27									0	3	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + Temozolomide		Completed	NCT00614978	LAPTEM	PCD	2011Jun01	Overexpression	Yes		1	24013582	Previously-treated		Maximum tolerated dose/toxicity	16	16											2.6			1.78-3.42										10.94			1.09-20.79				5	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Sargramostim + pNGVL3-hICD vaccine		"Active, not recruiting"	NCT00436254		PCD	2010Mar01	Overexpression	Yes	Primary outcome met	2	10.1200/JCO.2021.39.15_suppl.2619	Previously-treated		Immune response	66	66																																									COSO28394862	2022Jan25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + Radiotherapy		Completed	NCT00470847		PCD	2009Dec01	Overexpression	Yes		4	NCT00470847			Maximum tolerated dose/toxicity	35	35											4.8			0 to 58.3																											COSO28394862	2021Oct11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	MVA-BN-HER2 vaccine + Trastuzumab		Completed	NCT00485277		PCD	2010Sep01	Expression confirmed	No		4	NCT00485277	Previously-treated		Maximum tolerated dose/toxicity	9	9																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + Nab-paclitaxel		Completed	NCT00331630		PCD	2006Nov10	Expression confirmed	Yes		4	NCT00331630			Overall Response Rate	29	29																														6	18	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Carboplatin + Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT00367471		PCD	2010Dec22	Expression confirmed	No		4	NCT00367471			Maximum tolerated dose/toxicity	31	31																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Bevacizumab + Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00949247		PCD	2013Jan01	Overexpression	No		4	NCT00949247			"Complete response, Pathological complete response"	20	20																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cetuximab + Trastuzumab		Unknown	NCT00367250		ECD	2011Jun01	Overexpression	No		4	NCT00367250			Maximum tolerated dose/toxicity	32	32																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	CNF2024 + Trastuzumab		Completed	NCT00412412		PCD	2011Apr01	Expression confirmed	No		4	NCT00412412			Maximum tolerated dose/toxicity	34	34																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Docetaxel + Sunitinib + Trastuzumab		Completed	NCT00372424		PCD	2011Sep01	Expression confirmed	Yes		4	NCT00372424			Maximum tolerated dose/toxicity	25	25			72.7		49.8-89.3		11.8		7.4-13.9		13.5			8.6-15.3																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Adenoviral vector encoding rat Her2		Completed	NCT00307229		PCD	2009Jul01	Expression confirmed	No		4	NCT00307229			Response rate	8	8																																									COSO28394862	2021Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	CHP-HER2 vaccine + Picibanil		Completed	NCT00291473		PCD	2008Aug01	Expression confirmed	Yes	Primary outcome met	1	17189412			Maximum tolerated dose/toxicity	9	9																																									COSO28394862	2021Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Rat HER2 DNA		"Active, not recruiting"	NCT00393783		ECD	2023May01	Overexpression	No		4	NCT00393783			Maximum tolerated dose/toxicity	13	13																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Bortezomib + Trastuzumab		Completed	NCT00199212		PCD	2007Dec01	Overexpression	No		4	NCT00199212			Time to progression	19	19																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2 transduced autologous DCs		Completed	NCT00162929	AdHERe	PCD	2009Jul01	Expression confirmed	No		4	NCT00162929			Maximum tolerated dose/toxicity	5	5																																									COSO28394862	2021Oct04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2 transduced autologous DCs		Completed	NCT00197522		PCD	2012May01	Expression confirmed	No		4	NCT00197522			Maximum tolerated dose/toxicity	5	5																																									COSO28394862	2021Oct04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Denileukin diftitox + Ex vivo-expanded HER2-specific T cells 		Completed	NCT00228358		PCD	2011May01	Overexpression	Yes	Drug unavailable	1	24162107			Maximum tolerated dose/toxicity	8	3	5	Cyclophosphamide + Ex vivo-expanded HER2-specific T cells 																																							COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib + Trastuzumab		Completed	NCT00085020		PCD	2004Dec01	Overexpression	No		4	NCT00085020			Maximum tolerated dose/toxicity	13	13																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Tamoxifen + Trastuzumab		Completed	NCT00009997		PCD	2004Jan01	Overexpression	No		4	NCT00009997			Response rate		15																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Tamoxifen + Trastuzumab		Completed	NCT00003992		PCD	2007Jan01	Overexpression	No		4	NCT00003992				200	200																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2 peptide vaccine + Sargramostim		Completed	NCT00003002		PCD	2004Jan01	Expression confirmed	No		4	NCT00003002				60	60																																									COSO28394862	2021Sep29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	"CP-724,714"		Completed	NCT00055926		PCD	2004Dec01	Overexpression	No		4	NCT00055926				9	9																																									COSO28394862	2021Sep28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Alvocidib + Trastuzumab		Terminated	NCT00039455		PCD	2004Dec01	Overexpression	No		4	NCT00039455			Maximum tolerated dose/toxicity	50	50																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	SB-AS15 + SB719125		Completed	NCT00058526		PCD	2006Sep06	Overexpression	Yes	Primary outcome met	1	26993131			Maximum tolerated dose/toxicity	61	61																																									COSO28394862	2021Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lonafarnib + Paclitaxel + Trastuzumab		Completed	NCT00068757		PCD	2007Nov01	Overexpression	No		4	NCT00068757			Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Completed	NCT00003992		PCD	2007Jan01	Overexpression	No		4	NCT00003992				200	200																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	HER2 ICD-pulsed autologous DCs		"Active, not recruiting"	NCT02063724		PCD	2017Sep01	Expression confirmed	Yes	TR 93.3%	4	NCT02063724	Previously-treated		"Treatment rate, Treatment completion, Compliance, Adherence to protocol"	15	15																																									COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	AutoVac		Completed	NCT00068614		PCD	2005Oct01	Expression confirmed	No		4	NCT00068614																																														COSO28394862	2021Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Bintrafusp alfa + Carboplatin + Cisplatin + Pemetrexed		"Active, not recruiting"	NCT03620201		ECD	2024Dec31	Expression confirmed	No		4	NCT03620201			Maximum tolerated dose/toxicity	20	20																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Valemetostat tosylate		Not yet recruiting	NCT05633979		ECD	2030Dec31	Expression confirmed	No		4	NCT05633979			Overall Response Rate	37	37																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Recruiting	NCT05319873		ECD	2023Apr01	Overexpression	No		4	NCT05319873			"Complete response, Pathological complete response"	18	18																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Trastuzumab + Tucatinib		"Active, not recruiting"	NCT01921335	Cohort B	PCD	2018Mar01	Expression confirmed	Yes	CBR 16w 53%	1	32461105	Previously-treated		Maximum tolerated dose/toxicity	9	9																																									COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Trastuzumab + Tucatinib		"Active, not recruiting"	NCT01921335	Cohort A	PCD	2018Mar01	Expression confirmed	Yes	CBR 16w 35%	1	32461105	Previously-treated		Maximum tolerated dose/toxicity	6	6																																									COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Trastuzumab + Tucatinib		Completed	NCT02025192		PCD	2017Oct03	Expression confirmed	Yes		1	29804905	Previously-treated		Maximum tolerated dose/toxicity	23	23			61																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Trastuzumab + Tucatinib		Completed	NCT02025192		PCD	2017Oct03	Expression confirmed	Yes		1	29804905	Previously-treated		Maximum tolerated dose/toxicity	15	15			40																																						COSO28394862	2023Jan20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Disitamab vedotin		Completed	NCT02881138		PCD	2020Apr30	Expression confirmed	Yes		2	10.1200/JCO.2018.36.15_suppl.1030			Maximum tolerated dose/toxicity	14	14																															8	4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT02564900		PCD	2019Feb01	Expression confirmed	Yes		4	NCT02564900			Overall Response Rate	33	33			39.4		22.9-57.9		10.4		-3.4		11.1			-5							87.9			19.7			12.5-29.4														COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT02564900		PCD	2019Feb01	Expression confirmed	Yes		4	NCT02564900			Overall Response Rate	21	21			33.3		14.6-57.0									-2.7							85.7																				COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT02564900		PCD	2019Feb01	Overexpression	Yes		4	NCT02564900			Overall Response Rate	67	67			53.7		41.1-66.0		13.6		-7.3		14.1			-8.5							95.5						-26.4														COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT02564900		PCD	2019Feb01	Overexpression	Yes		4	NCT02564900			Overall Response Rate	51	51			51		36.6-65.2		12.7		-6.7		13.7			8.5-19.6							88.2																				COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab-emtansine + Tucatinib		Completed	NCT01983501		PCD	2017Oct10	Expression confirmed	Yes	SAE 37%	1	29955792	Previously-treated		Maximum tolerated dose/toxicity	57	57											8.2			4.8-10.3																											COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pertuzumab + Trastuzumab		Terminated	NCT02598427		PCD	2018Feb22	Expression confirmed	Yes	Slow accrual	4	NCT02598427			Progression free survival	1	1																																									COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pyrotinib		Completed	NCT01937689		PCD	2016Jul01	Expression confirmed	Yes		2	10.1158/1538-7445.SABCS15-P4-14-18			Maximum tolerated dose/toxicity	36	36			52.8								8.19			5.45-9.21							80.6																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab-emtansine		Completed	NCT03153163		PCD	2018Sep27	Expression confirmed	Yes	SAE 36.4%	1	33126339	Previously-treated		Maximum tolerated dose/toxicity	11	11																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab-emtansine		Completed	NCT00932373		PCD	2009Jun01	Expression confirmed	Yes		1	22648179			Maximum tolerated dose/toxicity	28	28							18.6														57										13	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab + Vinorelbine		Completed	NCT00014430		PCD	2002Sep01	Overexpression	No		4	NCT00014430				13	13																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pembrolizumab		Completed	NCT03197389	Cohort B2	PCD	2020Mar31	Expression confirmed	Yes	SAE 0%	4	NCT03197389			Reduced target expression level	1	1																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Pembrolizumab		Completed	NCT03197389	Cohort A2	PCD	2020Mar31	Expression confirmed	Yes	SAE 0%	4	NCT03197389			Reduced target expression level	4	4																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Trastuzumab		Terminated	NCT02571530		PCD	2021Jun01	Yes	Yes	Slow accrual	4	NCT02571530			Maximum tolerated dose/toxicity	2	2																																									COSO28394862	2022Oct17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Alpelisib + Trastuzumab-emtansine		Completed	NCT02038010		PCD	2015Apr15	Expression confirmed	Yes	SAE 27.2-50%	4	NCT02038010	Previously-treated		Maximum tolerated dose/toxicity	14	14											8.1			3.9-10.8																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Buparlisib + Paclitaxel + Trastuzumab		Completed	NCT01285466		PCD	2014Oct01	Expression confirmed	Yes		5	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14187			Maximum tolerated dose/toxicity	11	11			27.3																		72.7									0	3	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Docetaxel + Pyrotinib + Trastuzumab		"Active, not recruiting"	NCT04367090		ECD	2022Jun30	Expression confirmed	No		4	NCT04367090			Maximum tolerated dose/toxicity	97	97																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Nimotuzumab		Completed	NCT00513058		PCD	2010May01	Overexpression	No		4	NCT00513058			Maximum tolerated dose/toxicity	33	33																																									COSO28394862	2021Oct11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Lapatinib		Completed	NCT02650752		PCD	2021Jan22	Overexpression	Yes		1	30988080			Maximum tolerated dose/toxicity	11	11																																2									COSO28394862	2022Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Capecitabine + Pyrotinib		Completed	NCT02361112	BLTN-Ic	PCD	2016Aug01	Expression confirmed	Yes	Promising efficacy	2	10.1200/JCO.2019.37.15_suppl.1035	Previously-treated		Maximum tolerated dose/toxicity	28	28			78.6		59.0-91.7						22.1			9.0-26.2							96.4																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 1	Lapatinib		Completed	NCT00544804		PCD	2013Jun01	Overexpression	Yes		1	24711549	Previously-treated		Maximum tolerated dose/toxicity	30	30																														2	4										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib		Completed	NCT00431067		PCD	2009Aug01	Expression confirmed	Yes		4	NCT00431067	Previously-treated		Overall Response Rate	41	41			9.8								3.49			1.87-3.85										14																	COSO28394862	2021Oct11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AB-201 + Cyclophosphamide + Fludarabine		Not yet recruiting	NCT05678205		ECD	2027Apr01	Overexpression	No		4	NCT05678205	Previously-treated		Overall Response Rate	133	133																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AB-201 + Cyclophosphamide + Fludarabine		Not yet recruiting	NCT05678205		ECD	2027Apr01	Overexpression	No		4	NCT05678205	Previously-treated		Overall Response Rate	133	133																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Tucatinib + Vinorelbine		Not yet recruiting	NCT05583110	TrasTUCAN	ECD	2026Aug01	Expression confirmed	No		4	NCT05583110	Previously-treated		Overall Response Rate	49	49																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Endocrine therapy + Pyrotinib + Trastuzumab		Not yet recruiting	NCT05577442		ECD	2023Oct20	Expression confirmed	No		4	NCT05577442			Overall Response Rate	52	52																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Fulvestrant + Pyrotinib + Trastuzumab		Not yet recruiting	NCT05577923	T-sunflower	ECD	2024Sep01	Expression confirmed	No		4	NCT05577923	Untreated		Progression free survival	126	126																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Fulvestrant + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT05574881		ECD		Expression confirmed	No		4	NCT05574881			Progression free survival	72	72																																									COSO28394862	2023Jan11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	GQ1001 + Pyrotinib		"Active, not recruiting"	NCT05575804	GRACE	ECD	2024Jan01	Yes	No		4	NCT05575804	Previously-treated		Overall Response Rate	75			Capecitabine + Pyrotinib																																							COSO28394862	2023Jan11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Trastuzumab-emtansine		Not yet recruiting	NCT05560308		ECD	2024Aug31	Expression confirmed	No		4	NCT05560308	Previously-treated		Overall Response Rate	50	50																																									COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Physician's choice + Stereotactic Body Radiation Therapy		Recruiting	NCT05534438		ECD	2025Sep06	No	No		4	NCT05534438			Progression free survival	40	40																																									COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Eribulin + Samfenet		Recruiting	NCT05530057		ECD	2024Feb28	Expression confirmed	No		4	NCT05530057	Previously-treated		Progression free survival	180			Eribulin																																							COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	YH32367		Recruiting	NCT05523947		ECD	2024Jan31	Expression confirmed	No		4	NCT05523947			Overall Response Rate	110	110																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Pertuzumab		Completed	NCT00545688		PCD	2014Sep22	Expression confirmed	Yes	pCR 24.0	4	NCT00545688			"Complete response, Pathological complete response"	96	96																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Utidelone 		Recruiting	NCT05357417		ECD	2024May01	Expression confirmed	No		4	NCT05357417			Intracranial Response Rate	100	100																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + SHR-A1811		Not yet recruiting	NCT05353361		ECD	2025Dec31	Expression confirmed	No		4	NCT05353361			Overall Response Rate	402	402																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Adebrelimab + SHR-A1811		Not yet recruiting	NCT05353361		ECD	2025Dec31	Expression confirmed	No		4	NCT05353361			Overall Response Rate	402	402																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + SHR-A1811		Not yet recruiting	NCT05353361		ECD	2025Dec31	Expression confirmed	No		4	NCT05353361			Overall Response Rate	402	402																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + SHR-A1811		Not yet recruiting	NCT05635487		ECD	2023Nov30	Expression confirmed	No		4	NCT05635487			"Complete response, Pathological complete response"	61	61																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + SHR-A1811		Not yet recruiting	NCT05582499	FASCINATE-N H1-1	ECD	2024Sep01	Expression confirmed	No		4	NCT05582499			"Complete response, Pathological complete response"	716			Chemotherapy + Nab-paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + SHR-A1811		Not yet recruiting	NCT05353361		ECD	2025Dec31	Expression confirmed	No		4	NCT05353361			Overall Response Rate	402	402																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Nab-paclitaxel + Pertuzumab + Trastuzumab		Recruiting	NCT05346107	Brecan	ECD	2022Dec31	Expression confirmed	No		4	NCT05346107			"Complete response, Pathological complete response"	100	100																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Inetetamab + Pyrotinib		Recruiting	NCT05328440	DAP-Her-02 Arm B	ECD	2024Jun01	Expression confirmed	No		4	NCT05328440	Untreated		Progression free survival	120	120																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Fulvestrant + Pyrotinib		Recruiting	NCT05328440	DAP-Her-02 Arm A	ECD	2024Jun01	Expression confirmed	No		4	NCT05328440	Untreated		Progression free survival	120	120																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Ribociclib + Trastuzumab + Tucatinib		Recruiting	NCT05319873		ECD	2023Apr01	Overexpression	No		4	NCT05319873			"Complete response, Pathological complete response"	18	18																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ribociclib + Trastuzumab + Tucatinib		Recruiting	NCT05319873		ECD	2023Apr01	Overexpression	No		4	NCT05319873			"Complete response, Pathological complete response"	18	18																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib + Trastuzumab		Recruiting	NCT05292742		ECD	2026Oct01	Expression confirmed	No		4	NCT05292742			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	206			Pertuzumab + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Colesevelam + Loperamide + Neratinib		Not yet recruiting	NCT05252988	DIANER	ECD	2023Dec01	Expression confirmed	No		4	NCT05252988			Maximum tolerated dose/toxicity	315			Loperamide + Neratinib																																							COSO28394862	2022May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Margetuximab + Tucatinib		Withdrawn	NCT05227131	MARGARET	ECD	2024Oct01	Expression confirmed	No		4	NCT05227131	Previously-treated		Overall Response Rate	0	0																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2-pulsed DC1 vaccine + Paclitaxel + Pertuzumab + Trastuzumab		Recruiting	NCT05325632		ECD	2024Oct27	Expression confirmed	No		4	NCT05325632			"Complete response, Pathological complete response"	34	34																																									COSO28394862	2022May17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fluorothymidine F-18 + LRP-1-targeted peptide-drug conjugate GRN1005		Completed	NCT01480583	GRABM-B	PCD	2015Jun01	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.2552			Overall Response Rate	8	8																															2	6									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Loperamide + Neratinib		"Active, not recruiting"	NCT01953926	SUMMIT	ECD	2022Oct31	Yes	Yes		1	29420467			Overall Response Rate	25	25			24		9.4-45.1						3.5										40	21.1?61.3																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Pyrotinib		Recruiting	NCT05165225		ECD	2023May19	Expression confirmed	No		4	NCT05165225			"Complete response, Pathological complete response"	46	46																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AST-301 + Capecitabine + Pembrolizumab + Sargramostim		Recruiting	NCT05163223	Cornerstone001	ECD	2025Aug01	Expression confirmed	No		4	NCT05163223			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	146			Capecitabine + Pembrolizumab + Sargramostim																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab + Tucatinib		Recruiting	NCT05323955		ECD	2024Apr01	Expression confirmed	No		4	NCT05323955			Progression free survival	48	48																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Palbociclib + Pyrotinib + Trastuzumab		Recruiting	NCT05076695	NeoTPPF	ECD	2023Oct15	Expression confirmed	No		4	NCT05076695	Untreated		"Complete response, Pathological complete response"	37	37																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Pertuzumab + Trastuzumab + Tucatinib		Recruiting	NCT05041842	InTTercePT	ECD	2024Dec30	Expression confirmed	No		4	NCT05041842			Progression free survival	55	55																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib + Stereotactic radiotherapy		Recruiting	NCT05042791		ECD	2023Sep30	Expression confirmed	No		4	NCT05042791			Intracranial Response Rate	362			Capecitabine + Pyrotinib + Radiotherapy																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AGuIX  + Stereotactic radiotherapy		Recruiting	NCT04899908		ECD	2025Feb01	No	No		4	NCT04899908			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	112			Placebo + Stereotactic radiotherapy																																							COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Neratinib + Trastuzumab		Recruiting	NCT04886531		ECD	2023Aug01	Expression confirmed	No		4	NCT04886531			"Complete response, Pathological complete response"	48	48																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib		Not yet recruiting	NCT04789096	TUGETHER	ECD	2024Jun01	Expression confirmed	No		4	NCT04789096	Previously-treated		Overall Response Rate	50	50																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Inetetamab + Pyrotinib + Vinorelbine		Not yet recruiting	NCT04963595		ECD	2023Jan31	Expression confirmed	No		4	NCT04963595	Untreated		Progression free survival	100	100		Pyrotinib + Vinorelbine																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aromatase inhibitors + Cyclophosphamide + Inetetamab		Recruiting	NCT04941885		ECD	2023Jul01	Expression confirmed	No		4	NCT04941885			Overall Response Rate	78	78																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + TQB3616		Recruiting	NCT04796623		ECD	2023Jan31	No	No		4	NCT04796623			Overall Response Rate	120	120																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Tucatinib + Vinorelbine or Gemcitabine		Recruiting	NCT04896320		ECD	2030Dec01	Expression confirmed	No		4	NCT04896320			Maximum tolerated dose/toxicity	40	40																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Physician's choice + Trastuzumab-emtansine		Recruiting	NCT04733118	PHERGAIN-2	ECD	2025Sep01	Expression confirmed	No		4	NCT04733118	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	393	393																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	ARX788 + Pyrotinib		Recruiting	NCT04983121		ECD	2027Aug15	Expression confirmed	No		4	NCT04983121	Previously-treated		"Residual disease, Residual cancer burden"	30	30																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Letrozole + Pyrotinib + Trastuzumab		Not yet recruiting	NCT05638594		ECD	2025Dec10	Expression confirmed	No		4	NCT05638594			"Complete response, Pathological complete response"	236			Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Letrozole + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04997798		ECD	2023Jul01	Expression confirmed	No		4	NCT04997798	Untreated		"Complete response, Pathological complete response"	40	40																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Letrozole + Pyrotinib + Trastuzumab		Recruiting	NCT05228951		ECD	2022Dec31	Expression confirmed	No		4	NCT05228951			"Complete response, Pathological complete response"	12	12																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Exemstane + Palbociclib + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04858516		ECD	2024Apr30	Expression confirmed	No		4	NCT04858516			"Complete response, Pathological complete response"	57	57																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Zanidatamab		Recruiting	NCT05035836		ECD	2024Dec29	Expression confirmed	No		4	NCT05035836			"Complete response, Pathological complete response"	17	17																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anbenitamab + Palbociclib		Recruiting	NCT04778982		ECD	2023Aug30	Expression confirmed	No		4	NCT04778982			Overall Response Rate	36	36																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anbenitamab + Fulvestrant + Palbociclib		Recruiting	NCT04778982		ECD	2023Aug30	Expression confirmed	No		4	NCT04778982			Overall Response Rate	36	36																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine or Vinorelbine + Trastuzumab		Unknown	NCT04296162	ORCHID	ECD	2021May30	Expression confirmed	No		4	NCT04296162			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	178	178																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib + Radiotherapy		Unknown	NCT04582968		ECD	2021Nov30	Expression confirmed	No		4	NCT04582968			Intracranial Response Rate	47	47																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Nab-paclitaxel + Pertuzumab + Pyrotinib + Trastuzumab		"Active, not recruiting"	NCT04398914		ECD	2022Dec30	Expression confirmed	No		4	NCT04398914			"Complete response, Pathological complete response"	216			Chemotherapy + Nab-paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine + Venetoclax		Terminated	NCT04298918		PCD	2021Feb04	Expression confirmed	Yes	Changed business priorities	4	NCT04298918	Previously-treated		Overall Response Rate	1	1																																									COSO28394862	2022Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Lapatinib + Palbociclib + Trastuzumab		Recruiting	NCT04334330		ECD	2023Dec30	Expression confirmed	No		4	NCT04334330			Overall Response Rate	34	34																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Neratinib		Terminated	NCT04460430	NEREA	PCD	2021Nov29	No	No		4	NCT04460430			Progression free survival	12	12																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Margetuximab + Pertuzumab + Trastuzumab		Recruiting	NCT04425018	MARGOT	ECD	2024Jul01	Expression confirmed	No		4	NCT04425018			"Complete response, Pathological complete response"	171	171		Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	SHR-A1811		Not yet recruiting	NCT05582499	FASCINATE-N H2-1	ECD	2024Sep01	Expression confirmed	No		4	NCT05582499			"Complete response, Pathological complete response"	716			Chemotherapy + Nab-paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Zanidatamab		"Active, not recruiting"	NCT04276493		PCD	2022Mar29	Expression confirmed	Yes		2	10.1200/JCO.2022.40.16_suppl.1031			Overall Response Rate	22	22			86.4		65.1-97.1																90.9									1	18	1									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Pyrotinib		Recruiting	NCT04407988		ECD	2021Dec31	Expression confirmed	No		4	NCT04407988			"Disease control rate, Clinical benefit rate"	86	86																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Durvalumab + Paclitaxel + Trastuzumab deruxtecan		Recruiting	NCT04538742	DESTINY-Breast07	ECD	2025Apr30	Expression confirmed	No		4	NCT04538742			Maximum tolerated dose/toxicity	450	450																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	MRG002		Recruiting	NCT04924699		ECD	2023Sep01	Expression confirmed	No		4	NCT04924699	Previously-treated		Overall Response Rate	60	60																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	MRG002		Recruiting	NCT05263869		ECD	2022Dec01	Expression confirmed	No		4	NCT05263869			Overall Response Rate	99	99																																									COSO28394862	2022May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab duocarmazine		Recruiting	NCT04538742	DESTINY-Breast07	ECD	2025Apr30	Expression confirmed	No		4	NCT04538742			Maximum tolerated dose/toxicity	450	450																																									COSO28394862	2022Jan25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Durvalumab + Trastuzumab deruxtecan		Recruiting	NCT04538742	DESTINY-Breast07	ECD	2025Apr30	Expression confirmed	No		4	NCT04538742			Maximum tolerated dose/toxicity	450	450																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Palbociclib + Zanidatamab		"Active, not recruiting"	NCT04224272		ECD	2022Dec30	Expression confirmed	No		4	NCT04224272			Progression free survival	86	86																																									COSO28394862	2023Jan25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Monalizumab + Trastuzumab		"Active, not recruiting"	NCT04307329		ECD	2023May01	Expression confirmed	No		4	NCT04307329			Overall Response Rate	38	38																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Abemaciclib + Trastuzumab-emtansine		Withdrawn	NCT04351230		PCD	2022Feb16	Expression confirmed	No		4	NCT04351230			Progression free survival	0	0		Trastuzumab-emtansine																																							COSO28394862	2022May05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Temozolomide		Unknown	NCT04303988	Cohort HR+/HER2+	ECD	2021Dec30	Expression confirmed	No		4	NCT04303988			Intracranial Response Rate	59	59																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pembrolizumab + Trastuzumab + Tucatinib		Withdrawn	NCT04512261	TOPAZ	ECD	2024Jun01	Expression confirmed	No		4	NCT04512261			"Disease control rate, Clinical benefit rate"	0	0																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anastrozole + Dalpiciclib + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04236310		ECD	2022Dec31	Expression confirmed	No		4	NCT04236310			Change in Ki-67 expression	37	37																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AIP-303		Not yet recruiting	NCT04469127		ECD	2024Aug30	Expression confirmed	No		4	NCT04469127	Previously-treated		Maximum tolerated dose/toxicity	100	100																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab + WOKVAC vaccine		Recruiting	NCT04329065		ECD	2023Jun30	Expression confirmed	No		4	NCT04329065			Immune response	16	16																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anti-HER2/HER3 Dendritic Cell Vaccine + Celecoxib + Interferon alpha-2B + Pembrolizumab + Rintatolimod		Recruiting	NCT04348747		ECD	2024Apr15	No	No		4	NCT04348747			Intracranial Response Rate	23	23																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Inetetamab + PD-1 inhibitor 		Recruiting	NCT04681287		PCD	2021Nov04	Expression confirmed	Yes	PFS 3m 75%	2	10.1200/JCO.2022.40.16_suppl.e13030	Previously-treated		Progression free survival	20	20			30																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Pyrotinib + Trastuzumab		Recruiting	NCT04481932		ECD	2022Jun01	Expression confirmed	No		4	NCT04481932			"Complete response, Pathological complete response"	104	104																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine		Not yet recruiting	NCT04419181		ECD	2025Jun01	Expression confirmed	No		4	NCT04419181			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	20	20																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab deruxtecan + Tucatinib		Recruiting	NCT04539938	HER2CLIMB-04	ECD	2023Jul31	Expression confirmed	No		4	NCT04539938	Previously-treated		Overall Response Rate	70	70																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab deruxtecan + Tucatinib		Recruiting	NCT04538742	DESTINY-Breast07	ECD	2025Apr30	Expression confirmed	No		4	NCT04538742			Maximum tolerated dose/toxicity	450	450																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fractionated stereotactic radiotherapy		Unknown	NCT04061408		ECD	2021Jul01	Overexpression	No		4	NCT04061408			Intracranial Response Rate	170	170																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	DF1001		Recruiting	NCT04143711		ECD	2022Apr01	Expression confirmed	No		4	NCT04143711			Overall Response Rate	220	220																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anbenitamab + Docetaxel		"Active, not recruiting"	NCT04165993	Cohort 1	ECD	2023Jun30	Expression confirmed	No		4	NCT04165993			"ORR, DOR"	68	68																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anbenitamab + Docetaxel		Recruiting	NCT04881929		ECD	2022Nov15	Expression confirmed	No		4	NCT04881929	Untreated		"Complete response, Pathological complete response"	30	30																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Doxorubicin hydrochloride liposome + Nab-paclitaxel + Trastuzumab		Unknown	NCT03994107		ECD	2021Jan01	Expression confirmed	No		4	NCT03994107			"Complete response, Pathological complete response"	40	40																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cisplatin + Paclitaxel + Pyrotinib + Trastuzumab		"Active, not recruiting"	NCT04126525		PCD	2021Oct28	Expression confirmed	Yes	pCR 69.81%	2	10.1158/1078-0432.CCR-22-0446			"Complete response, Pathological complete response"	53	53																																									COSO28394862	2022Sep21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	DP303c		Not yet recruiting	NCT05334810		ECD	2023Dec31	Expression confirmed	No		4	NCT05334810			Overall Response Rate	191	191																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Etoposide + Pyrotinib		Unknown	NCT03923179		ECD	2021Apr01	Expression confirmed	No		4	NCT03923179			Overall Response Rate	32	32																																									COSO28394862	2023Jan16	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride liposome + Trastuzumab		Unknown	NCT04172259		ECD	2021Apr01	Expression confirmed	No		4	NCT04172259			"Complete response, Pathological complete response"	180			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	ISB 1302		Terminated	NCT03983395		PCD	2020Jul24	Expression confirmed	Yes	Changed business priorities	4	NCT03983395			Maximum tolerated dose/toxicity	1	1																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib + Trastuzumab		Not yet recruiting	NCT05659056		ECD	2024Apr01	Overexpression	No		4	NCT05659056			"Complete response, Pathological complete response"	65	65																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib + Trastuzumab		Unknown	NCT04639271		ECD	2022Jan01	Expression confirmed	No		4	NCT04639271			"PFS, ORR"	100	100																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib + Trastuzumab		Recruiting	NCT04917900		ECD	2023Aug30	Expression confirmed	No		4	NCT04917900	Untreated		"Complete response, Pathological complete response"	216	216																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04900311	Pyramid	ECD	2023Dec01	Expression confirmed	No		4	NCT04900311			"Complete response, Pathological complete response"	490			Nab-paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib + Trastuzumab		Unknown	NCT04152057		ECD	2020Apr01	Expression confirmed	Yes	pCR 57.1	2	10.1016/j.annonc.2020.08.346			"Complete response, Pathological complete response"	21	21			100																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Placebo + Sargramostim + Trastuzumab-emtansine		Recruiting	NCT04197687		ECD	2025Jan15	Expression confirmed	No		4	NCT04197687			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	480	480																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Sargramostim + TPIV100 + Trastuzumab-emtansine		Recruiting	NCT04197687		ECD	2025Jan15	Expression confirmed	No		4	NCT04197687			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	480	480																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Vinorelbine		Recruiting	NCT04605575		ECD	2023Aug01	Expression confirmed	No		4	NCT04605575			Progression free survival	208	208																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Vinorelbine		Completed	NCT04903652		PCD	2022Feb01	Expression confirmed	Yes		2	10.1200/JCO.2022.40.16_suppl.1033	Previously-treated		Progression free survival	36	36			38.9								14.23			8.13-20.33							83.3																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Vinorelbine		Unknown	NCT03997539		ECD	2021Jun30	Expression confirmed	No		4	NCT03997539			Progression free survival	256			Physician's choice																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Vinorelbine		Unknown	NCT03933982		ECD	2021Dec22	Expression confirmed	No		4	NCT03933982	Previously-treated		Overall Response Rate	30	30																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Ribociclib + Trastuzumab		Recruiting	NCT03913234		ECD	2023Oct30	Expression confirmed	No		4	NCT03913234		Postmenopausal	Progression free survival	95	95																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aromatase inhibitors + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04088110		ECD	2021Nov01	Expression confirmed	No		4	NCT04088110			Progression free survival	77	77																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aromatase inhibitors + Pyrotinib + Trastuzumab		Not yet recruiting	NCT03910712		ECD	2022Jun01	Expression confirmed	No		4	NCT03910712	Untreated		Progression free survival	250	250																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Margetuximab		Unknown	NCT04262804		ECD	2021Sep01	Expression confirmed	No		4	NCT04262804	Previously-treated		Progression free survival	120			Chemotherapy + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Pyrotinib		Recruiting	NCT04034589		ECD	2021Jul06	Expression confirmed	No		4	NCT04034589			Progression free survival	46	46																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Pyrotinib		Unknown	NCT04033172		ECD	2021Mar01	Expression confirmed	No		4	NCT04033172			Progression free survival	40	40																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Dalpiciclib + Pyrotinib		Unknown	NCT04095390	INPHASE	ECD	2021Nov30	Expression confirmed	No		4	NCT04095390	Previously-treated		Overall Response Rate	60	60																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib		Not yet recruiting	NCT04659499		ECD	2022Jun01	Expression confirmed	No		4	NCT04659499			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	261	261																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pyrotinib		Unknown	NCT03919253		ECD	2020Apr30	Expression confirmed	No		4	NCT03919253			Progression free survival	80	80																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Trastuzumab		Not yet recruiting	NCT05020964		ECD	2022Sep01	Overexpression	No		4	NCT05020964			Overall Response Rate	68	68																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Trastuzumab		Not yet recruiting	NCT04158856	SHERO	ECD	2023May31	Expression confirmed	No		4	NCT04158856			Maximum tolerated dose/toxicity	60	60																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib + Trastuzumab		Not yet recruiting	NCT05255523		ECD	2023Nov05	Expression confirmed	No		4	NCT05255523	Previously-treated		Time to progression	60	60																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pembrolizumab + Pertuzumab + Trastuzumab		Unknown	NCT03988036	Keyriched-1	ECD	2021Aug01	Expression confirmed	Yes	pCR 52% 95%CI 0.37-0.67 p=0.06	2	10.1158/1538-7445.SABCS21-PD10-11	Untreated		"Complete response, Pathological complete response"	46	46																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Durvalumab + Pertuzumab + Trastuzumab		Recruiting	NCT03820141		ECD	2023Mar01	Overexpression	No		4	NCT03820141			"Complete response, Pathological complete response"	39	39																																									COSO28394862	2022Jan11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Atezolizumab + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Pertuzumab + Trastuzumab		Not yet recruiting	NCT03881878		ECD	2022Oct31	Expression confirmed	No		2	10.1001/jamaoncol.2022.2310			"Complete response, Pathological complete response"	67	67																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Atezolizumab + Docetaxel + Pertuzumab + Trastuzumab		Not yet recruiting	NCT03881878		ECD	2022Oct31	Expression confirmed	Yes	pCR 61%	2	10.1001/jamaoncol.2022.2310			"Complete response, Pathological complete response"	67	67																																									COSO28394862	2022Sep21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Envafolimab + Trastuzumab		Unknown	NCT04034823		ECD	2021Jan01	Expression confirmed	No		4	NCT04034823	Untreated		Overall Response Rate	59	59																																									COSO28394862	2022Jan11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib + Trastuzumab-emtansine		Recruiting	NCT04158947	HER2BAT	ECD	2023Dec31	Expression confirmed	No		4	NCT04158947	Previously-treated		Overall Response Rate	130			Trastuzumab-emtansine																																							COSO28394862	2022Jan11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Nivolumab + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03742986	Cohort 2	ECD	2023May01	Expression confirmed	Yes	pCR 75.0%	4	NCT03742986			"Complete response, Pathological complete response"	4	4																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Avelumab + Trastuzumab + Utomilumab		Recruiting	NCT03414658		ECD	2023Jul01	Expression confirmed	No		4	NCT03414658	Previously-treated		Progression free survival	100	100																																									COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Avelumab + Trastuzumab + Utomilumab + Vinorelbine		Recruiting	NCT03414658		ECD	2023Jul01	Expression confirmed	No		4	NCT03414658	Previously-treated		Progression free survival	100	100																																									COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Avelumab + Trastuzumab + Vinorelbine		Recruiting	NCT03414658		ECD	2023Jul01	Expression confirmed	No		4	NCT03414658	Previously-treated		Progression free survival	100	100																																									COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gedatolisib + Trastuzumab		Recruiting	NCT03698383		ECD	2021Oct01	Expression confirmed	No		4	NCT03698383			Overall Response Rate	15	15																																									COSO28394862	2022Sep20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paxalisib + Trastuzumab		Recruiting	NCT01494662	Cohort 3A	ECD	2022Dec01	Expression confirmed	Yes		1	30860945	Previously-treated		Overall Response Rate	12	12			33		Oct-65						3.1													15.1																	COSO28394862	2022Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paxalisib + Trastuzumab		Recruiting	NCT03765983		ECD	2022Nov30	Expression confirmed	Yes		1	30860945			Overall Response Rate	47	47																																									COSO28394862	2022Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pembrolizumab + Trastuzumab		Recruiting	NCT03747120		ECD	2024Jul01	Expression confirmed	No		4	NCT03747120			"Complete response, Pathological complete response"	174	174																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab		Recruiting	NCT03747120		ECD	2024Jul01	Expression confirmed	No		4	NCT03747120			"Complete response, Pathological complete response"	174	174																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Pyrotinib		"Active, not recruiting"	NCT04293276		ECD	2022Aug31	Expression confirmed	Yes	Priary outcome met	3	https://www.cancernetwork.com/view/dalpiciclib-plus-pyrotinib-may-be-a-potential-chemo-free-treatment-option-in-her2-positive-advanced-breast-cancer			Overall Response Rate	40	40			70																											1	27										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Pyrotinib		Unknown	NCT03993964		ECD	2020Oct30	Expression confirmed	No		4	NCT03993964			Overall Response Rate	20	20																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Pyrotinib		Unknown	NCT04095390	INPHASE	ECD	2021Nov30	Expression confirmed	No		4	NCT04095390	Previously-treated		Overall Response Rate	60	60																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Palbociclib + Trastuzumab-emtansine		"Active, not recruiting"	NCT03709082		PCD	2020Mar12	Expression confirmed	No		4	NCT03709082	Previously-treated		Overall Response Rate	3	3																																									COSO28394862	2022Jan10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pegfilgrastim + Trastuzumab		Recruiting	NCT03571633	BREASTIMMU02	ECD	2024Apr01	Expression confirmed	No		4	NCT03571633			"Complete response, Pathological complete response"	90			Paclitaxel + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	A166		Not yet recruiting	NCT05346328		ECD	2023Dec31	Expression confirmed	No		4	NCT05346328	Previously-treated		Overall Response Rate	48	48																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	A166		"Active, not recruiting"	NCT03602079		PCD	2022Mar31	Overexpression	No		4	NCT03602079	Previously-treated		Overall Response Rate	82	82																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Letrozole + Pyrotinib		Recruiting	NCT03772353	LORDSHIPS	PCD	2020Dec21	Expression confirmed	Yes	Promising activity	1	35321427			Progression free survival	15	15			66.7		38.4-88.2						11.3			-5.3																											COSO28394862	2022Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dalpiciclib + Letrozole + Pyrotinib		Unknown	NCT04095390	INPHASE	ECD	2021Nov30	Expression confirmed	No		4	NCT04095390	Previously-treated		Overall Response Rate	60	60																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pyrotinib + Trastuzumab		Recruiting	NCT03735966		ECD	2020Oct20	Expression confirmed	Yes	pCR 51.6%	3	https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/neoadjuvant-pyrotinib-plus-trastuzumab-docetaxel-and-carboplatin-in-patients-with-her2-positive-early-breast-cancer-a-single-group-multicenter			"Complete response, Pathological complete response"	16	16																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pyrotinib + Trastuzumab		Unknown	NCT03847818		ECD	2020Mar01	Expression confirmed	No		4	NCT03847818			"Complete response, Pathological complete response"	268			Carboplatin + Docetaxel + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Palbociclib + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03644186	TOUCH	ECD	2023Mar01	Expression confirmed	No		4	NCT03644186		Postmenopausal	"Complete response, Pathological complete response"	144	144		Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AVX901 + Pembrolizumab		Recruiting	NCT03632941		ECD	2022Dec01	Expression confirmed	No		4	NCT03632941	Previously-treated		Immune cell infiltration	39	39																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Neratinib + Paclitaxel		"Active, not recruiting"	NCT03101748		ECD	2026Jan01	Expression confirmed	No		4	NCT03101748			"Complete response, Pathological complete response"	43	43																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Neratinib + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03101748		ECD	2026Jan01	Expression confirmed	No		4	NCT03101748			"Complete response, Pathological complete response"	43	43																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Temozolomide + Trastuzumab-emtansine		"Active, not recruiting"	NCT03190967		ECD	2023Jun30	Expression confirmed	No		4	NCT03190967			Progression free survival	12	12		Trastuzumab-emtansine																																							COSO28394862	2022Oct12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Palbociclib + Tucatinib		"Active, not recruiting"	NCT03054363		ECD	2023Mar18	Expression confirmed	No		4	NCT03054363			Progression free survival	42	42																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + TVB2640 + Trastuzumab		Recruiting	NCT03179904		ECD	2023Jul30	Expression confirmed	No		4	NCT03179904	Previously-treated		Overall Response Rate	80	80																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + TVB2640 + Trastuzumab		Recruiting	NCT03179904		ECD	2023Jul30	Expression confirmed	No		4	NCT03179904	Previously-treated		Overall Response Rate	80	80																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Zenocutuzumab		"Active, not recruiting"	NCT03321981		ECD	2023Dec31	Expression confirmed	No		4	NCT03321981	Previously-treated		"Disease control rate, Clinical benefit rate"	101	101																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinorelbine + Zenocutuzumab		"Active, not recruiting"	NCT03321981		ECD	2023Dec31	Expression confirmed	Yes		2	10.1200/JCO.2020.38.15_suppl.3093	Previously-treated		"Disease control rate, Clinical benefit rate"	26	26																					77									1	4										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Zenocutuzumab		"Active, not recruiting"	NCT03321981		ECD	2023Dec31	Expression confirmed	No		4	NCT03321981	Previously-treated		"Disease control rate, Clinical benefit rate"	101	101																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Interferon gamma-1b + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03112590		PCD	2021Mar31	Expression confirmed	Yes	pCR 52%	4	NCT03112590			"Complete response, Pathological complete response"	23	23																					100																				COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab		Suspended	NCT03125928		ECD	2022Dec01	Overexpression	No		4	NCT03125928			Response rate	50	50																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Simvastatin		Recruiting	NCT03324425	SIMPHONY	ECD	2028Dec01	Expression confirmed	No		4	NCT03324425	Previously-treated		Overall Response Rate	34	34																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ibrutinib + Trastuzumab		Recruiting	NCT03379428		ECD	2023Dec31	Overexpression	No		4	NCT03379428	Previously-treated		"Disease control rate, Clinical benefit rate"	51	51																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anastrozole + Palbociclib + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03304080		ECD	2023Jul01	Expression confirmed	No		4	NCT03304080			"Disease control rate, Clinical benefit rate"	36	36																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Neratinib		Completed	NCT01670877	Fulvestrant naive ER+	PCD	2021Feb11	Yes	Yes		4	NCT01670877			"Disease control rate, Clinical benefit rate"	10	10			30								4.6			-1.9							30																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Neratinib		"Active, not recruiting"	NCT03289039	MutHER study FUL-naive	ECD	2022Oct31	Expression confirmed	Yes	Primary outcome not met	3	https://www.targetedonc.com/view/neratinib-fulvestrant-shows-modest-anti-tumor-activity-in-her2-breast-cancer	Previously-treated		"Disease control rate, Clinical benefit rate"	11	11											4.61			-1.85							30										3										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Neratinib		"Active, not recruiting"	NCT03289039	MutHER study FUL-treated	ECD	2022Oct31	Expression confirmed	Yes	Primary outcome not met	3	https://www.targetedonc.com/view/neratinib-fulvestrant-shows-modest-anti-tumor-activity-in-her2-breast-cancer	Previously-treated		"Disease control rate, Clinical benefit rate"	24	24											5.55			3.62-7.15							38									1	4										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Metformin + Pertuzumab + Trastuzumab		Recruiting	NCT03238495	HERMET	ECD	2022Jun01	Expression confirmed	No		4	NCT03238495			"Complete response, Pathological complete response"	100	100		Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Jan05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aromatase inhibitors + Pertuzumab + Trastuzumab		Unknown	NCT02689921	NEOADAPT	ECD	2018Dec01	Expression confirmed	No		4	NCT02689921			"Complete response, Pathological complete response"	7	7																																									COSO28394862	2022Jan05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Tocotrienol + Trastuzumab		Completed	NCT02909751	NeoToc	PCD	2019Jan21	Expression confirmed	Yes	pCR 39.5 v 43.9%	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000080-16/results			"Complete response, Pathological complete response"	80	39	41	Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Denosumab		Completed	NCT02682693		PCD	2019Dec31	Expression confirmed	Yes	"pCR 43.3% v 69.6, Primary outcome not met"	2	10.1200/JCO.2020.38.15_suppl.580			"Complete response, Pathological complete response"				Chemotherapy																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Goserelin + Letrozole + Palbociclib + Trastuzumab		Terminated	NCT02907918	PALTAN	PCD	2020Aug24	Expression confirmed	Yes	No benefit of treatment	4	NCT02907918			"Complete response, Pathological complete response"	26	26																																									COSO28394862	2022Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Ribociclib + Trastuzumab		Completed	NCT02657343	Cohort C	PCD	2020Aug27	Expression confirmed	No		4	NCT02657343	Previously-treated		"Disease control rate, Clinical benefit rate"	26	26																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ribociclib + Trastuzumab		Completed	NCT02657343	Cohort B	PCD	2020Aug27	Expression confirmed	Yes		1	31235441	Previously-treated		"Disease control rate, Clinical benefit rate"	12	12			0								13.3			0.92-2.57																		1									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ribociclib + Trastuzumab-emtansine		Completed	NCT02657343	Cohort A	PCD	2020Aug27	Expression confirmed	Yes		1	34349115	Previously-treated		"Disease control rate, Clinical benefit rate"	12	12			16.7		Mar-44						10.4			2.7-19.3																1	1	9									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Paclitaxel + Trastuzumab		"Active, not recruiting"	NCT02654119		ECD	2025Nov20	Expression confirmed	No		4	NCT02654119	Previously-treated		Maximum tolerated dose/toxicity	20	20																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Abemaciclib + Fulvestrant + Trastuzumab		"Active, not recruiting"	NCT02675231	monarcHER	PCD	2019Apr08	Expression confirmed	Yes		4	NCT02675231	Previously-treated		Progression free survival	158	79	79	Chemotherapy + Trastuzumab									8.3	5.7			0.0506						78.5	67.1																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine + Vinorelbine		Terminated	NCT02658084		PCD	2018Oct11	Expression confirmed	Yes	Slow accrual	4	NCT02658084	Previously-treated		Progression free survival	2	2																																									COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Zanidatamab		Recruiting	NCT05035836		ECD	2024Dec29	Expression confirmed	No		4	NCT05035836			"Complete response, Pathological complete response"	17	17																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Durvalumab + Ibrutinib		Completed	NCT02403271		PCD	2017Aug01	No	Yes		4	NCT02403271			Overall Response Rate	105	105			1.9																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ad-RTS-hIL-12 + Veledimex		Completed	NCT02423902		PCD	2016Jul01	No	No		4	NCT02423902	Previously-treated		Maximum tolerated dose/toxicity	9	9																																									COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine or Vinorelbine + Lapatinib		Completed	NCT02362958		PCD	2020May31	Expression confirmed	Yes		1	35291977			Progression free survival	159	159			29.6		22.6-37.3						8.5			7.2-9.8							61.7			29.7			21.9-37.5				47	51									COSO28394862	2022May06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Pertuzumab + Trastuzumab		Completed	NCT02411344	PerELISA	PCD	2018Jan12	Expression confirmed	Yes	pCR 20.5%	4	NCT02411344			"Complete response, Pathological complete response"	64	64																																									COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Fulvestrant + Pertuzumab + Trastuzumab		Terminated	NCT02345772		PCD	2015Nov01	Expression confirmed	Yes	PI departure	4	NCT02345772			"Complete response, Pathological complete response"	4	4																																									COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03101748		ECD	2026Jan01	Expression confirmed	No		4	NCT03101748			"Complete response, Pathological complete response"	43	43																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Varlitinib		Unknown	NCT02396108		ECD	2018Mar01	Expression confirmed	Yes		2	10.1200/JCO.2018.36.15_suppl.2588			"Complete response, Pathological complete response"	20	20																															7	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Palbociclib + Trastuzumab		Recruiting	NCT02448420	PATRICIA II	ECD	2023Aug01	Expression confirmed	No		4	NCT02448420	Previously-treated		Progression free survival	102	102																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Palbociclib + Trastuzumab		Recruiting	NCT02448420	PATRICIA II	ECD	2023Aug01	Expression confirmed	No		4	NCT02448420	Previously-treated		Progression free survival	102	102																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	ARX788		Recruiting	NCT05018702		ECD	2022Dec30	Expression confirmed	No		4	NCT05018702	Previously-treated		Intracranial Response Rate	32	32																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	ARX788		"Active, not recruiting"	NCT04829604	ACE-Breast03	ECD	2024Jun01	Expression confirmed	No		4	NCT04829604	Previously-treated		Overall Response Rate	31	31																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	ARX788		Withdrawn	NCT05041972	ACE-Pan Tumor-02	PCD	2022Apr20	Yes	Yes	Changed business priorities	4	NCT05041972			Overall Response Rate	0	0																																									COSO28394862	2022May05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Doxorubicin hydrochloride liposome + Metformin + Trastuzumab		Completed	NCT02488564	met-HEReMYTA	PCD	2018Oct01	Overexpression	Yes		1	33613693			"Complete response, Pathological complete response"	41	41			78		62.4-89.4																									18	14	9									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Pyrotinib		Unknown	NCT03876587		ECD	2019Oct01	Expression confirmed	Yes		2	10.1016/j.annonc.2022.07.278			Overall Response Rate	79	79			77.2		66.4-85.9						15.03			10.54-19.53																3	58										COSO28394862	2022Sep21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Abemaciclib + Trastuzumab		Completed	NCT02308020		PCD	2018Nov08	Expression confirmed	Yes		4	NCT02308020			Overall Response Rate	23	23			0																		52.2																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Abemaciclib + Trastuzumab		"Active, not recruiting"	NCT02675231	monarcHER	PCD	2019Apr08	Expression confirmed	Yes		4	NCT02675231	Previously-treated		Progression free survival	158	79	79	Chemotherapy + Trastuzumab									5.7	5.7			0.7695						74.7	67.1																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cisplatin + Paclitaxel + Trastuzumab		Completed	NCT02199418		PCD	2015Nov01	No	No		4	NCT02199418			"Complete response, Pathological complete response"	132	132																																									COSO28394862	2021Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cabozantinib + Trastuzumab		Completed	NCT02260531	Cohort 1	PCD	2019Jan04	Expression confirmed	Yes		4	NCT02260531			Overall Response Rate	21	21			5								4.1			2.8-6.2																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT02229149		ECD	2022Jun01	Overexpression	No		4	NCT02229149	Previously-treated			33			Chemotherapy + Trastuzumab																																							COSO28394862	2021Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Autologous activated NK cells + Trastuzumab		Completed	NCT02843126		PCD	2017Jul01	Expression confirmed	No		4	NCT02843126			Clinical activity	30			Trastuzumab																																							COSO28394862	2022Jan05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Radiotherapy + Trastuzumab		Recruiting	NCT04588545		ECD	2023Nov01	Expression confirmed	No		4	NCT04588545			Overall survival	39	39																																									COSO28394862	2022Jan14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ruxolitinib + Trastuzumab		Completed	NCT02066532		PCD	2020Oct14	Expression confirmed	Yes	Primary outcome not met	1	34169393	Previously-treated		Maximum tolerated dose/toxicity	26	26			4								1.92			1.6-3.21																	1	4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Enzalutamide + Trastuzumab		"Active, not recruiting"	NCT02091960		PCD	2017Feb28	Expression confirmed	Yes		4	NCT02091960			"Disease control rate, Clinical benefit rate"	89	89											3.45			2.0-3.8		3.55			2.0-3.8		23.6																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Nab-paclitaxel + Trastuzumab-emtansine		Completed	NCT02073487	TEAL	PCD	2019Jan01	Overexpression	Yes	"pCR 100 v 62.5%, p <0.01"	4	NCT02073487			"Complete response, Pathological complete response"	30	14	16	Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gemcitabine + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT02252887		ECD	2023Sep01	Expression confirmed	Yes	PFS 3m 73.3%	1	31774522	Previously-treated		Progression free survival	45	45											5.5			5.4-8.2																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gemcitabine + Pertuzumab + Trastuzumab		Completed	NCT02139358		PCD	2018Apr24	Expression confirmed	Yes		4	NCT02139358	Previously-treated			10	10			20																		100									1	1	8									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Tesevatinib + Trastuzumab		Terminated	NCT02154529		PCD	2015Sep13	Expression confirmed	Yes	Lack of efficacy	4	NCT02154529			Maximum tolerated dose/toxicity	17	17																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Radiotherapy + Trastuzumab-emtansine		Not yet recruiting	NCT05288777	Breast53	ECD	2024Dec01	Expression confirmed	No		4	NCT05288777			Maximum tolerated dose/toxicity	45	45																																									COSO28394862	2022May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Nab-paclitaxel + Trastuzumab		Unknown	NCT01830244	Neonab	PCD	2015Sep01	No	Yes	pCR 80%	1	30763338	Untreated		"Complete response, Pathological complete response"	12	12																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Enzalutamide + Exemstane		"Active, not recruiting"	NCT02007512	Cohort 2	PCD	2016Sep23	Expression confirmed	Yes		4	NCT02007512	Previously-treated		Progression free survival	120	60	60	Exemstane + Placebo									3.6	3.9	1.02	0.659-1.586	0.921																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Enzalutamide + Exemstane		"Active, not recruiting"	NCT02007512	Cohort 1	PCD	2016Sep23	Expression confirmed	Yes		4	NCT02007512	Untreated		Progression free survival	127	63	64	Exemstane + Placebo									11.8	5.8	0.82	0.535-1.257	0.363																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Palbociclib + Trastuzumab-emtansine		"Active, not recruiting"	NCT03530696		ECD	2022Dec22	Expression confirmed	No		4	NCT03530696			Progression free survival	46	46																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cabazitaxel + Lapatinib		Terminated	NCT01934894		PCD	2016Feb01	Expression confirmed	Yes	Lack of efficacy	4	NCT01934894			Overall Response Rate	11	11																																									COSO28394862	2021Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Everolimus + Lapatinib		Completed	NCT01783756		PCD	2019May10	Expression confirmed	Yes		1	30542377			Overall Response Rate	11	11			27								6.2										64			24.4																	COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	SNX-5422		Terminated	NCT01848756		PCD	2015Feb01	Overexpression	Yes	Changed business priorities	4	NCT01848756			"ORR, PFS, OS"	15	15																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT01855828	HR-	PCD	2018Aug01	Overexpression	Yes	pCR 80%	4	NCT01855828			"Complete response, Pathological complete response"	25	25																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT01855828	HR+	PCD	2018Aug01	Overexpression	Yes	pCR 26%	4	NCT01855828			"Complete response, Pathological complete response"	23	23																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab		Terminated	NCT01873833		PCD	2021Mar02	Overexpression	Yes	Slow accrual	4	NCT01873833	Previously-treated		Progression free survival	10	10																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Eribulin + Pertuzumab + Trastuzumab		Terminated	NCT01912963		PCD	2016Dec01	Overexpression	Yes	Slow accrual	4	NCT01912963				32	32																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab		Recruiting	NCT02436993		ECD	2021Dec01	Expression confirmed	No		4	NCT02436993			Progression free survival	120	120																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 peptide vaccine + Polysaccharide-K + Trastuzumab		Unknown	NCT01922921		ECD	2018Mar31	Overexpression	No		4	NCT01922921			Maximum tolerated dose/toxicity	31			Placebo + Trastuzumab																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 peptide vaccine + Pertuzumab + Polysaccharide-K + Trastuzumab		Unknown	NCT01922921		ECD	2018Mar31	Overexpression	No		4	NCT01922921			Maximum tolerated dose/toxicity	31			Pertuzumab + Placebo + Trastuzumab																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Paclitaxel + Radiotherapy + Trastuzumab		"Active, not recruiting"	NCT01750073		PCD	2021Sep01	No	No		4	NCT01750073			"Complete response, Pathological complete response"	99	99																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Docetaxel + Epirubicin hydrochloride		Terminated	NCT01690325		PCD	2016Nov01	Expression confirmed	Yes	Slow accrual	4	NCT01690325			"Complete response, Pathological complete response"	21	21																																									COSO28394862	2021Dec06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Patritumab + Trastuzumab		Terminated	NCT01512199		PCD	2015Jan28	Expression confirmed	Yes	Changed treatment landscape	4	NCT01512199			Progression free survival	29	29		Paclitaxel + Placebo + Trastuzumab																																							COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Capecitabine + Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Unknown	NCT01641406		ECD	2013Jan01	Expression confirmed	No		4	NCT01641406			"Residual disease, Residual cancer burden"	60	60																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab + Vinorelbine		Completed	NCT01565083	VELVET Single Infusion	PCD	2015Oct01	Expression confirmed	Yes		4	NCT01565083			Overall Response Rate	91	91			63.7				11.8		7.5-17.9																																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab + Vinorelbine		Completed	NCT01565083	VELVET Separate Infusion	PCD	2015Oct01	Expression confirmed	Yes		4	NCT01565083			Overall Response Rate	89	89			74.2				13.3		10.6-16.2																																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Doxorubicin hydrochloride liposome + Lapatinib		Terminated	NCT01658358		ECD	2014Sep01	Overexpression	No		4	NCT01658358			Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Pertuzumab + Trastuzumab + Trastuzumab-emtansine		Completed	NCT01597414	EORTC 75111-10114	PCD	2017Mar01	Expression confirmed	Yes	PFS 6m 43.9 v 55.5%	1	29433963		Geriatric	Progression free survival	29	15	14	Pertuzumab + Trastuzumab + Trastuzumab-emtansine									5	6.7																													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Pertuzumab + Trastuzumab		Completed	NCT01597414	EORTC 75111-10114	PCD	2017Mar01	Expression confirmed	Yes	PFS 6m 73.4 v 46.2 HR 0.65 95% CI 0.37-1.12 p=0.12	1	29433963		Geriatric	Progression free survival	80	41	39	Pertuzumab + Trastuzumab									12.7	5.6																													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT01730833		ECD	2023Oct25	Overexpression	No		4	NCT01730833			Progression free survival	65	65																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab-emtansine		Terminated	NCT01702558	TRAXHER2	PCD	2017May31	Expression confirmed	Yes		1	32584367	Previously-treated		Overall Response Rate	161	81	80	Trastuzumab-emtansine	44	36		0.34																																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Taxane + Trastuzumab		Not yet recruiting	NCT04760431	HER2BRAIN	ECD	2024Sep30	Expression confirmed	No		4	NCT04760431	Untreated		Overall Response Rate	120			Taxane + Trastuzumab + Tyrosine Kinase Inhibitor																																							COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Liposome-encapsulated doxorubicin citrate + Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT01669239	Opti-HER HEART	PCD	2016Jan01	Expression confirmed	Yes	pCR 56.6%	1	30621698			Maximum tolerated dose/toxicity	83	83																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nelipepimut-S + Sargramostim + Trastuzumab		Completed	NCT02297698		PCD	2021Dec01	Expression confirmed	No		4	NCT02297698	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	100			Sargramostim + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nelipepimut-S + Sargramostim + Trastuzumab		Completed	NCT01570036		PCD	2018Sep28	Expression confirmed	Yes		4	NCT01570036			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	275	136	139	Nelipepimut-S + Sargramostim																															89.8	83.8	0.62	0.31-1.25	0.18				COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Trastuzumab		Not yet recruiting	NCT04383275		ECD	2025May15	Expression confirmed	No		4	NCT04383275			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	356	356																																									COSO28394862	2022Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Trastuzumab-emtansine		Unknown	NCT01745965		PCD	2015Feb01	Expression confirmed	Yes	"pCR 41.5 v 15.1, p<0.001"	1	28682681			"Complete response, Pathological complete response"	256	127	129	Endocrine therapy + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Trastuzumab-emtansine		Recruiting	NCT04733118	PHERGAIN-2	ECD	2025Sep01	Expression confirmed	No		4	NCT04733118	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	393	393																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 peptide vaccine		Terminated	NCT01729884		PCD	2013Jun01	Expression confirmed	Yes		4	NCT01729884	Previously-treated		Immune response	3	3																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Eribulin		Completed	NCT01439282		PCD	2012Nov01	Expression confirmed	Yes	SAE <21%	4	NCT01439282			Maximum tolerated dose/toxicity	77	77																																									COSO28394862	2021Nov30	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fluorothymidine F-18 + LRP-1-targeted peptide-drug conjugate GRN1005 + Trastuzumab		Completed	NCT01480583	GRABM-B	PCD	2015Jun01	Expression confirmed	No		4	NCT01480583			Overall Response Rate	85	85																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Glutathione pegylated liposomal doxorubicin hydrochloride formulation 2B3-101 + Trastuzumab		Completed	NCT01386580		PCD	2014Dec01	Expression confirmed	Yes		2	10.1093/annonc/mdu331.32			Maximum tolerated dose/toxicity	19	19																															2	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Everolimus + Lapatinib + Letrozole		Terminated	NCT01499160		PCD	2014Nov01	Expression confirmed	Yes	Slow accrual	4	NCT01499160			"Disease control rate, Clinical benefit rate"	7	7																																									COSO28394862	2021Nov30	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ganitumumab + Trastuzumab		Withdrawn	NCT01479179		ECD	2015Nov01	Overexpression	Yes	Sponor withdrew support	4	NCT01479179				0	0																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Radiotherapy + Trastuzumab		Terminated	NCT01363986		PCD	2012Jun01	Overexpression	Yes	Slow accrual	4	NCT01363986			Overall Response Rate	3	3																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Cyclophosphamide + Liposome-encapsulated doxorubicin citrate + Paclitaxel + Trastuzumab		Unknown	NCT01321775		ECD	2013Feb01	Expression confirmed	Yes	pCR 44.4%	2	10.1200/jco.2012.30.15_suppl.602	Untreated		Pathologic Response	44	44																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Eribulin		Completed	NCT01328249		PCD	2014Oct27	Expression confirmed	No		4	NCT01328249			Maximum tolerated dose/toxicity	81	81																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Trastuzumab + Zoledronic acid		Completed	NCT01472146	Zo-NAnTax	PCD	2016Jul01	Expression confirmed	Yes	pCR 42%	1	31210800			"Complete response, Pathological complete response"	58	58																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anthracycline + Nab-paclitaxel + Trastuzumab		Completed	NCT01432223		PCD	2013Nov01	Expression confirmed	Yes	pCR 49%	1	25579459			"Complete response, Pathological complete response"	44	44																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Everolimus + Lapatinib		Unknown	NCT01283789		PCD	2016Apr01	Expression confirmed	No		4	NCT01283789			Overall Response Rate	23	23																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Lapatinib + Paclitaxel		Unknown	NCT01309607		ECD	2014Dec01	Expression confirmed	Yes	pCR 11.1%	2	10.1200/jco.2014.32.15_suppl.619			"Complete response, Pathological complete response"	36	36																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dasatinib + Paclitaxel + Trastuzumab		Completed	NCT01306942		PCD	2013Dec01	Expression confirmed	Yes		4	NCT01306942	Untreated		Overall Response Rate	29	29			79.3				18.4				23.9					29.3					82.8																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib + Paclitaxel or Vinorelbine		Completed	NCT01271725	LUX-Breast 2	PCD	2017Mar13	Overexpression	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results	Previously-treated			39	39			31		17-48		4.11		2.40-16.60		4.44			3.12-7.36																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dactolisib + Trastuzumab		Completed	NCT01471847		PCD	2012Jun01	Expression confirmed	No		4	NCT01471847			Progression free survival	5			Capecitabine + Lapatinib																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Non-pegylated liposome-encapsulated doxorubicin		Terminated	NCT01495884		PCD	2014Oct01	Expression confirmed	Yes	Slow accrual	4	NCT01495884	Previously-treated		Maximum tolerated dose/toxicity	11	11																																									COSO28394862	2021Nov29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Pegfilgrastim + Trastuzumab		Completed	NCT01367028	ABCSG 32 cohort A	PCD	2014Apr01	Expression confirmed	Yes	pCR 36%	2	10.1158/1538-7445.SABCS14-P3-11-06			Maximum tolerated dose/toxicity	100	100																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Docetaxel + Pegfilgrastim + Trastuzumab		Completed	NCT01367028	ABCSG 32 cohort B	PCD	2014Apr01	Expression confirmed	Yes	pCR 51%	2	10.1158/1538-7445.SABCS14-P3-11-06			Maximum tolerated dose/toxicity	100	100																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Non-pegylated liposome-encapsulated doxorubicin + Pegfilgrastim + Trastuzumab		Completed	NCT01367028	ABCSG 32 cohort C	PCD	2014Apr01	Expression confirmed	Yes	pCR 63%	2	10.1158/1538-7445.SABCS14-P3-11-06			Maximum tolerated dose/toxicity	100	100																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Non-pegylated liposome-encapsulated doxorubicin + Pegfilgrastim + Trastuzumab		Completed	NCT01367028	ABCSG 32 cohort D	PCD	2014Apr01	Expression confirmed	Yes	pCR 62%	2	10.1158/1538-7445.SABCS14-P3-11-06			Maximum tolerated dose/toxicity	100	100																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aromatase inhibitors + Docetaxel or Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT01491737	PERTAIN	PCD	2016Mar17	Expression confirmed	Yes		4	NCT01491737			Progression free survival	258	129	129	Aromatase inhibitors + Docetaxel or Paclitaxel + Trastuzumab	63.3	55.7		0.2537	27.4	16.36		0.0205	20.63	15.8	0.67	0.50-0.89	0.0059						68.8	67	0.7743	60.16	57.17	1.05	0.73-1.52	0.7833													COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Eribulin + Trastuzumab		Completed	NCT01401959	Cohort C	PCD	2017Apr03	Expression confirmed	Yes	"DFS 2y 73%, 95% CI 53-86"	4	NCT01401959	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	31	31																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Eribulin + Trastuzumab		Completed	NCT01269346		PCD	2013Mar01	Expression confirmed	Yes		4	NCT01269346			Overall Response Rate	52	52			71.2		56.92-82.87		11.1		6.7-17.77		11.6			9.13-13.93																											COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Trastuzumab-emtansine		Not yet recruiting	NCT05388149		ECD	2025Jul01	Expression confirmed	No		4	NCT05388149			Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2022Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Trastuzumab-emtansine		Unknown	NCT02236000	NSABP FB-10	ECD	2020Nov01	Expression confirmed	Yes		1	31442103	Previously-treated		Overall Response Rate	19	19			63																											3	9	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Trastuzumab-emtansine		"Active, not recruiting"	NCT01494662	Cohort 4	ECD	2022Dec01	Expression confirmed	No		4	NCT01494662			Overall Response Rate	140	140																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT01276041		PCD	2019Aug07	Expression confirmed	Yes	PFS 6m 86%	4	NCT01276041			Progression free survival	70	70																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab		Unknown	NCT01817452	ADAPT	PCD	2015Aug01	Expression confirmed	Yes	pCR 78.6 v 24.4	3	https://www.targetedonc.com/view/triplet-regimen-of-trastuzumab-pertuzumab-and-paclitaxel-improves-pcr-survival-in-her2-breast-cancer			"Complete response, Pathological complete response"				Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab		Recruiting	NCT03747120		ECD	2024Jul01	Expression confirmed	No		4	NCT03747120			"Complete response, Pathological complete response"	174	174																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03272477		PCD	2020Jul14	Expression confirmed	Yes	pCR 57 v 24% p<0.001	2	10.1200/JCO.2020.38.15_suppl.515			"Complete response, Pathological complete response"	198	102	96	Endocrine therapy + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT01796197		PCD	2018Jun01	Expression confirmed	Yes	"pCR 48%, Primary outcome met"	4	NCT01796197	Untreated		"Complete response, Pathological complete response"	23	23																																									COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Eribulin + Trastuzumab		Terminated	NCT01388647		PCD	2014Jun01	Expression confirmed	Yes	Toxicity issues	4	NCT01388647			Pathologic Response	12	12																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Letrozole + Luminespib		Withdrawn	NCT01361945		PCD	2012Aug01	Expression confirmed	Yes	Slow accrual	4	NCT01361945			Overall Response Rate	0	0																																									COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Luminespib + Trastuzumab		Completed	NCT01271920		PCD	2013Oct01	Expression confirmed	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015628-27/results	Previously-treated		Overall Response Rate	45	45			22		10.6-37.6						3.94			3.48-6.47										12.65			11.7-17.22														COSO28394862	2022Jan26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Inetetamab		Completed	NCT01439191		PCD	2007Feb01	Expression confirmed	No		4	NCT01439191			Overall Response Rate	109	109																																									COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Inetetamab + Vinorelbine		Completed	NCT01439191		PCD	2007Feb01	Expression confirmed	No		4	NCT01439191			Overall Response Rate	109	109																																									COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Neratinib + Trastuzumab		Completed	NCT01670877	Fulvestrant treated ER+	PCD	2021Feb11	Yes	Yes		4	NCT01670877	Previously-treated		"Disease control rate, Clinical benefit rate"	21	21			23.8								5.5			3.6-7.2							38.1																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Neratinib + Trastuzumab		"Active, not recruiting"	NCT01953926	SUMMIT	ECD	2022Oct31	Yes	Yes		3	https://www.targetedonc.com/view/neratinib-displays-encouraging-efficacy-in-her2-mutant-metastatic-breast-cancers	Previously-treated		Overall Response Rate	33	33			42.4				14.4		-6.4		7			4.2-12.7							51.5									1	13										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT02132949	BERENICE	PCD	2016Mar03	Expression confirmed	Yes	"CE 1.5 v 0%, SAE 28.4 v 33.3%"	4	NCT02132949	Untreated		Cardiac event	397	199	198	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pertuzumab + Trastuzumab		Terminated	NCT03329378		PCD	2020May29	Expression confirmed	No		4	NCT03329378			"Complete response, Pathological complete response"	7	7		Carboplatin + Docetaxel + Pegfilgrastim + Pertuzumab + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Lapatinib		Unknown	NCT00842998	HERLAP	ECD	2011Dec01	Overexpression	Yes		1	24075779			Clinical activity	8	8											7.3			1.6-38.8										43			14.0-81.0														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 peptide vaccine + Rintatolimod + Sargramostim		Completed	NCT01355393		PCD	2013Nov01	Expression confirmed	No		4	NCT01355393			Immune response	50	50																																									COSO28394862	2021Oct25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 peptide vaccine + Rintatolimod		Completed	NCT01355393		PCD	2013Nov01	Expression confirmed	No		4	NCT01355393			Immune response	50	50																																									COSO28394862	2021Oct25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Alisertib		Completed	NCT01045421		PCD	2013May01	Expression confirmed	Yes		1	25728526			Overall Response Rate	9	9			22				11.2				4.1			0.95-15.0																	2	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Dostarlimab + Doxorubicin hydrochloride + Encequidar + Paclitaxel + Trastuzumab		Recruiting	NCT01042379	I-SPY	ECD	2030Dec01	Expression confirmed	No		4	NCT01042379	Untreated		"Complete response, Pathological complete response"	5000	5000																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Cyclophosphamide + Dostarlimab + Doxorubicin hydrochloride + Encequidar + Paclitaxel + Trastuzumab		Recruiting	NCT01042379	I-SPY	ECD	2030Dec01	Expression confirmed	No		4	NCT01042379	Untreated		"Complete response, Pathological complete response"	5000	5000																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab + Trilaciclib		Recruiting	NCT01042379	I-SPY	ECD	2030Dec01	Expression confirmed	No		4	NCT01042379	Untreated		"Complete response, Pathological complete response"	5000	5000																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	BMS-690514 + Letrozole		Completed	NCT01068704		PCD	2010Dec01	Expression confirmed	No		4	NCT01068704			"Disease control rate, Clinical benefit rate"	4			Lapatinib + Letrozole																																							COSO28394862	2021Oct25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Foretinib + Lapatinib		Completed	NCT01138384		PCD	2014May14	Overexpression	Yes		1	28464908	Previously-treated		Maximum tolerated dose/toxicity	19	19											3.2			1.6-4.3																											COSO28394862	2021Oct25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gemcitabine + Lapatinib		Completed	NCT01050322	GLICO-0801 arm C	PCD	2010Dec01	Expression confirmed	Yes	No unexpected toxicities	2	10.1200/jco.2012.30.15_suppl.e11087	Previously-treated		"Disease control rate, Clinical benefit rate"	26	26																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anthracycline + Trastuzumab		Completed	NCT01196052		PCD	2013Jun01	Expression confirmed	Yes	pCR 56.0%	4	NCT01196052			Maximum tolerated dose/toxicity	50	50																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Lapatinib		Completed	NCT01044485		PCD	2011Nov01	Expression confirmed	No		4	NCT01044485			Maximum tolerated dose/toxicity	17	17																																									COSO28394862	2021Oct22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aderbasib + Trastuzumab + Vinorelbine		Terminated	NCT01254136		PCD	2011Sep01	Overexpression	Yes	Aderbasib development suspended	4	NCT01254136			Maximum tolerated dose/toxicity	20	20																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + HER2Bi-armed activated T cells + Paclitaxel		Unknown	NCT01147016		PCD	2017Jul01	Expression confirmed	No	Results submitted	4	NCT01147016			"Complete response, Pathological complete response"	8	8																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Liposome-encapsulated doxorubicin citrate + Paclitaxel		Completed	NCT01172223	LAPADO	PCD	2013Jan01	Overexpression	Yes	Prematurely Ended	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000924-42/DE			Response rate	81	81																																									COSO28394862	2021Oct21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Temsirolimus		Completed	NCT01111825	Dose Esc cohort	PCD	2016Jul01	Overexpression	Yes		4	NCT01111825	Previously-treated		Overall Response Rate	48	48			29.2								6			3.7-8.3							39.6			17.8			-13.4														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Temsirolimus		Completed	NCT01111825		PCD	2016Jul01	Overexpression	Yes		4	NCT01111825	Previously-treated		Overall Response Rate	37	37			13.5								4.8			2.7-8.4							21.6																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Margetuximab		Completed	NCT01828021		PCD	2016Dec07	Expression confirmed	Yes		4	NCT01828021			Overall Response Rate	22	22																														0	0	6									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Buparlisib + Capecitabine + Trastuzumab		Completed	NCT02000882		PCD	2019Mar29	No	Yes		4	NCT02000882			"Disease control rate, Clinical benefit rate"	10	10																					10																				COSO28394862	2022May05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Buparlisib + Capecitabine + Trastuzumab		Terminated	NCT01132664		PCD	2014Aug01	Overexpression	Yes	Slow accrual	4	NCT01132664	Previously-treated		Overall Response Rate	72	72																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Robatumumab + Trastuzumab		Terminated	NCT00954512		PCD	2011Jun07	Expression confirmed	Yes	Changed business priorities	4	NCT00954512			Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Sapitinib		Completed	NCT00900627	THYME	PCD	2012Apr01	Expression confirmed	Yes		4	NCT00900627			Progression free survival	190	94	96	Paclitaxel + Placebo	59	41.2		0.026					8.7	8.1	1.08	0.76-1.52	0.679																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Agatolimod + Trastuzumab		Terminated	NCT00824733		PCD	2013Feb01	Overexpression	Yes	Inaccurate patient accrual 	4	NCT00824733			Immune response	6	6																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Carboplatin + Trastuzumab		Completed	NCT01004172		PCD	2013Dec01	Expression confirmed	Yes		1	33256829			CNS ORR	29	29			66																											0	19	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + SB-AS15 + SB719125		Completed	NCT00952692		PCD	2011Jul01	Overexpression	Yes		1	22325452	Previously-treated		Maximum tolerated dose/toxicity	12	12			0								1.8																														COSO28394862	2021Oct21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Nab-paclitaxel + Trastuzumab		Completed	NCT00944047		PCD	2014May01	Expression confirmed	Yes	pCR 26%	4	NCT00944047			"Complete response, Pathological complete response"	32	32																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aderbasib + Trastuzumab		Terminated	NCT00864175		PCD	2011Jun01	Expression confirmed	Yes	Changed business priorities	4	NCT00864175	Untreated		Overall Response Rate	68	68																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Capecitabine + Docetaxel + Trastuzumab		Withdrawn	NCT00964704		ECD	2013Aug01	Expression confirmed	Yes	Slow accrual	4	NCT00964704	Previously-treated			0	0																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Neratinib + Paclitaxel + Trastuzumab		Completed	NCT01008150		PCD	2015Sep01	Expression confirmed	Yes	pCR 41.7%	4	NCT01008150			"Complete response, Pathological complete response"	12	12																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Neratinib + Paclitaxel + Trastuzumab		Completed	NCT01008150		PCD	2015Sep01	Expression confirmed	Yes	pCR 50.0%	4	NCT01008150			"Complete response, Pathological complete response"	42	42																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Neratinib + Paclitaxel		Completed	NCT01008150		PCD	2015Sep01	Expression confirmed	Yes	pCR 33.3%	4	NCT01008150			"Complete response, Pathological complete response"	42	42																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Pertuzumab + Trastuzumab		Completed	NCT00976989		PCD	2011Jun01	Expression confirmed	Yes	pCR 61.6 v 66.2%	4	NCT00976989	Untreated		Maximum tolerated dose/toxicity	150	73	77	Carboplatin + Pertuzumab + Trastuzumab																			91.8	89.6																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pertuzumab + Trastuzumab-emtansine		Completed	NCT00951665		PCD	2012Feb01	Expression confirmed	Yes		1	26979312	Previously-treated		Maximum tolerated dose/toxicity	21	21			52.4		29.8-72.4																59.1									1	15	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab-emtansine		"Active, not recruiting"	NCT02326974		PCD	2018Jun01	Expression confirmed	Yes	pCR 49.0%	4	NCT02326974			"Complete response, Pathological complete response"	157	157			80.3																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab-emtansine		Completed	NCT00875979		PCD	2011Aug01	Expression confirmed	Yes		4	NCT00875979	Previously-treated		Overall Response Rate	64	64			40.6		28.5-52.6		13.9		-6.93		6.6			4.21-9.46																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Retaspimycin + Trastuzumab		Terminated	NCT00817362		PCD	2010Aug01	Expression confirmed	Yes	Lack of efficacy	4	NCT00817362			Overall Response Rate	29	29																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Hydroxychloroquine + Ixabepilone		Terminated	NCT00765765		PCD	2011Dec01	No	Yes	Slow accrual	4	NCT00765765			Overall Response Rate	6	6																																									COSO28394862	2021Oct19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Erlotinib + Letrozole		Terminated	NCT00611715		PCD	2008Dec01	No	Yes	Slow accrual	4	NCT00611715			"Complete response, Pathological complete response"	48	48																																									COSO28394862	2021Oct19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Vinorelbine		Completed	NCT00706030		PCD	2009Oct01	Expression confirmed	Yes	Prior lapatinib	4	NCT00706030	Previously-treated		Overall Response Rate	15	15			13.3		1.7-40.5						5.2			2.8-9.5							40																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Vinorelbine		Completed	NCT00706030		PCD	2009Oct01	Expression confirmed	Yes	No prior lapatinib	4	NCT00706030	Previously-treated		Overall Response Rate	64	64			35.9		24.3-48.9						11.1			7.1-15.0							64.1																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Tanespimycin + Trastuzumab		Completed	NCT00773344		PCD	2009May01	Expression confirmed	Yes		1	21558407	Previously-treated		Overall Response Rate	27	27			22				4.83		3.58-6.67		6			4.0-9.0										17			16-28				6	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Neratinib		"Active, not recruiting"	NCT01494662	Cohort 3A	ECD	2022Dec01	Expression confirmed	No		4	NCT01494662			Overall Response Rate	37	37			49		32-66						5.5													13.3																	COSO28394862	2022Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Neratinib		Completed	NCT00741260		PCD	2010Nov01	Expression confirmed	Yes		4	NCT00741260			Maximum tolerated dose/toxicity	63	63			63.5		50.4-75.3		10.69														73																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Lapatinib + Trastuzumab		Completed	NCT01485926		PCD	2014Sep01	Expression confirmed	Yes	pCR 44 v 48%	2	10.1158/0008-5472.SABCS13-P4-12-25			"Complete response, Pathological complete response"	49	16	33	Carboplatin + Docetaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Radiotherapy + Trastuzumab		Completed	NCT00943410		PCD	2006Jan01	Overexpression	Yes	"pCR 28.6%, Primary outcome met"	2	10.1016/j.ijrobp.2009.03.027	Previously-treated		"Complete response, Pathological complete response"	7	7			43		Oct-82																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Alvespimycin		Terminated	NCT00780000		PCD	2008Jun01	Overexpression	No		4	NCT00780000			Overall Response Rate	4	4																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Nab-paclitaxel + Trastuzumab		Completed	NCT00629499		PCD	2008Oct01	No	Yes	RFS 18m 100%	4	NCT00629499			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	63	63																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ridaforalimus + Trastuzumab		Completed	NCT00736970	8669-009	PCD	2011Jan01	Expression confirmed	Yes		1	25239224	Previously-treated		Overall Response Rate	34	34			15				4.41		3.67-18.49		5.4			0-20.3							34.3			17.7			0-25.9				5	14									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Trastuzumab + Vinorelbine		Completed	NCT00670982		PCD	2011Dec01	Expression confirmed	Yes		4	NCT00670982	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	7	7			71								7.8			3.5-22.0																			29			Apr-71					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Trastuzumab + Vinorelbine		Completed	NCT00670982		PCD	2011Dec01	Expression confirmed	Yes		4	NCT00670982	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	22	22			73								9.9			1.6-22.3																			36			17-59					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Capecitabine + Trastuzumab		Completed	NCT00811135		PCD	2015Dec01	Expression confirmed	Yes		4	NCT00811135	Untreated		Overall Response Rate	88	88			75				12.7		10.2-17.7		14.2			10.5-14.9		14.5			11.0-17.0					31.8			26.3-38.2														COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Chemotherapy + Trastuzumab		Completed	NCT00717405		PCD	2010Apr01	Expression confirmed	Yes	pCR 63.5%	4	NCT00717405			"Complete response, Pathological complete response"	52	52																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	BMS-754807 + Trastuzumab		Completed	NCT00788333		PCD	2011Nov01	Expression confirmed	Yes	No benefit of treatment	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013766-78/results	Previously-treated		Maximum tolerated dose/toxicity	15	15																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Apricoxib + Capecitabine + Lapatinib		Terminated	NCT00657137	APRiCOT-B	PCD	2009Sep01	Expression confirmed	Yes	Slow accrual	4	NCT00657137			Clinical activity	12	12																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Cixutumumab + Lapatinib		Completed	NCT00684983		PCD	2014Jan07	Expression confirmed	Yes		4	NCT00684983	Previously-treated		Progression free survival	56	37	19	Capecitabine + Lapatinib	29	43.8			6.9	4.8	0.09-1.53	0.26	4.9	6	1.04	0.58-1.89	0.89	4.4	4.6	1.01	0.53-1.92	0.66				14.7	16.8	1.22	0.5-3.0	0.93													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Etoposide + Trastuzumab		Terminated	NCT00810017		PCD	2010May01	Overexpression	Yes	Slow accrual	4	NCT00810017			Overall Response Rate	2	2																																									COSO28394862	2023Jan16	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Ex vivo-expanded HER2-specific T cells + HER2 peptide vaccine + Sargramostim		Completed	NCT00791037		PCD	2013Jul01	Overexpression	Yes	SAE 4.35% 	4	NCT00791037	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Paclitaxel		Completed	NCT00915018		PCD	2013Aug01	Expression confirmed	Yes		4	NCT00915018	Untreated		Progression free survival	515	242	273		74.8	77.6		0.52	13.1	12.9		0.84	12.9	12.9	1	0.81-1.27	0.89						88.4	85.2	0.24																		COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Paclitaxel		Completed	NCT00445458	Arm B	PCD	2011May01	Expression confirmed	Yes		4	NCT00445458	Previously-treated		Overall Response Rate	31	31			77.4		58.9-90.4																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Paclitaxel		Completed	NCT00445458	Arm A	PCD	2011May01	Expression confirmed	Yes		4	NCT00445458	Previously-treated		Overall Response Rate	68	68			70.6		58.3-81.0																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Lapatinib		Completed	NCT00841828		PCD	2011Dec01	Expression confirmed	Yes	"pCR 23.5 V 47.9%, "	4	NCT00841828			"Complete response, Pathological complete response"	99	51	48	Capecitabine + Docetaxel + Epirubicin hydrochloride + Trastuzumab	62.7	77.1																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Lapatinib		Completed	NCT00450892	EORTC 10054	PCD	2013Jul01	Expression confirmed	Yes	pCR 46 v 52%	1	25467016			"Complete response, Pathological complete response"	74	22	52	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Trastuzumab		Completed	NCT00450892	EORTC 10054	PCD	2013Jul01	Expression confirmed	Yes	pCR 60 v 52%	1	25467016			"Complete response, Pathological complete response"	100	48	52	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab	88	94																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Docetaxel + Lapatinib + Nab-paclitaxel		Terminated	NCT00479856		PCD	2009Sep01	Overexpression	Yes	Slow accrual	4	NCT00479856			Overall Response Rate	9	9																																									COSO28394862	2021Oct14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Lapatinib + Trastuzumab		Completed	NCT00548184		PCD	2011Jan01	Overexpression	Yes	pCR 27%	1	23569315			"Complete response, Pathological complete response"	64	64																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Lapatinib		Completed	NCT00444535		PCD	2008Jul22	Overexpression	Yes	PFS 3m 69.2%	4	NCT00444535			Progression free survival	52	52											5.7			4.82-7.64																											COSO28394862	2021Oct14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Doxorubicin hydrochloride liposome + Paclitaxel + Trastuzumab		Unknown	NCT00518583		ECD	2009Jan01	Overexpression	No		4	NCT00518583			"Complete response, Pathological complete response"	30	30																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dexamethasone + Trabectedin		Completed	NCT00580112		PCD	2011Aug01	Overexpression	No		4	NCT00580112	Previously-treated		Overall Response Rate	127	127																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel		Terminated	NCT00756470		PCD	2013Oct01	Overexpression	Yes	Slow accrual	4	NCT00756470			"Complete response, Pathological complete response"	15	15																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel		Completed	NCT00524303	Arm2	PCD	2010Oct01	Overexpression	Yes	pCR 45 v 54	4	NCT00524303			"Complete response, Pathological complete response"	55	29	26	Epirubicin hydrochloride																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel		Completed	NCT00524303	Arm2	PCD	2010Oct01	Overexpression	Yes	cCR 61 v 61 p=1.0	4	NCT00524303			"Complete response, Pathological complete response"	66	33	33	Epirubicin hydrochloride																															67	90							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel		Completed	NCT00429299	CHERLOB	PCD	2012Jun01	Overexpression	Yes	pCR 26.3 v 25.0	4	NCT00429299			"Complete response, Pathological complete response"	74	38	36																																								COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT00524303	Arm 3	PCD	2010Oct01	Overexpression	Yes	pCR 74 v 54	4	NCT00524303			"Complete response, Pathological complete response"	49	23	26	Epirubicin hydrochloride																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT00524303	Arm 3	PCD	2010Oct01	Overexpression	Yes	cCR 68 v 61 p=0.627	4	NCT00524303			"Complete response, Pathological complete response"	67	34	33	Epirubicin hydrochloride																															66	90							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT00429299	CHERLOB	PCD	2012Jun01	Overexpression	Yes	"pCR 46.7 v 25.0, p=0.019"	4	NCT00429299			"Complete response, Pathological complete response"	81	45	36																																								COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anthracycline + Cyclophosphamide + Larotaxel + Trastuzumab		Completed	NCT00485979	SATIN	PCD	2010Aug01	Expression confirmed	Yes	pCR 24.4 v 41.3	8	https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2006-006473-24/1/8094			"Complete response, Pathological complete response"	93	45	48	Anthracycline + Cyclophosphamide + Docetaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	AE37 peptide/GM-CSF vaccine		Completed	NCT00524277		PCD	2014Dec31	Expression confirmed	Yes		2	10.1200/JCO.2017.35.15_suppl.3088			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	198	153	145	Sargramostim																															82	67	0.48		0.06				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	GP2 peptide/GM-CSF vaccine		Completed	NCT00524277		PCD	2014Dec31	Expression confirmed	Yes	No serious adverse events	2	10.1200/JCO.2021.39.15_suppl.542			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	167	81	86	Sargramostim																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bicalutamide		Completed	NCT00418080				No	No		4	NCT00418080			Prostate Specific Antigen (PSA) response rate 	86	86																																									COSO28394862	2021Oct13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Taxane + Trastuzumab		Completed	NCT00475670		PCD	2012Jun01	Expression confirmed	Yes		4	NCT00475670	Untreated		Overall Response Rate	41	41			61		48.7-80.4																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Sargramostim + Trastuzumab		Completed	NCT00429104		PCD	2009Nov01	Overexpression	Yes		4	NCT00429104			"Disease control rate, Clinical benefit rate"	17	17																					29.4																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib + Topotecan		Terminated	NCT00437073		PCD	2009Jan01	Overexpression	Yes	Operational issues	4	NCT00437073	Previously-treated		Overall Response Rate	22	22																																									COSO28394862	2021Oct13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Paclitaxel + Trastuzumab + Vorinostat		Completed	NCT00574587	Stratum A	PCD	2014May01	Expression confirmed	Yes	pCR 54.2%	4	NCT00574587	Untreated		Maximum tolerated dose/toxicity	24	24																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gemcitabine + Paclitaxel + Trastuzumab		Completed	NCT00532857		PCD	2008Feb01	Overexpression	Yes	pCR 58.5%	4	NCT00532857	Untreated		"Complete response, Pathological complete response"	53	53		Trastuzumab																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cisplatin + Docetaxel + Trastuzumab		Completed	NCT00535509		PCD	2013Jun01	Overexpression	No		4	NCT00535509			Clinical activity	285	285																																									COSO28394862	2022Jan25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Trastuzumab		Terminated	NCT02598310		PCD	2018Nov30	Expression confirmed	Yes	pCR 66.7%	1	30963212			"Complete response, Pathological complete response"	30	30																																									COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Nab-paclitaxel + Trastuzumab		Completed	NCT00503750		PCD	2011Jul01	Overexpression	Yes	pCR 48.2%	4	NCT00503750			"Complete response, Pathological complete response"	27	27																														20	7	0									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Completed	NCT00912275		PCD	2015Mar31	Overexpression	Yes		1	29315394			Maximum tolerated dose/toxicity	31	31			19.4								5.6			5.2-5.9							38.7										6	6									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Completed	NCT01013740	VITAL	PCD	2012Aug21	Overexpression	Yes		4	NCT01013740			Progression free survival	112	75	37		20	35.1			6.7	10.8			6.2	6.2	0.84	0.53-1.35							38.7	48.7		24.3	19.4																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Completed	NCT01128543		PCD	2012Mar01	Overexpression	Yes	DCR 24w 56%	4	NCT01128543			"Disease control rate, Clinical benefit rate"	25	25							4.6		4.0-8.0		87.7																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Completed	NCT01050322	GLICO-0801 arm B	PCD	2010Dec01	Expression confirmed	Yes	No unexpected toxicities	2	10.1200/jco.2012.30.15_suppl.e11087	Previously-treated		"Disease control rate, Clinical benefit rate"	28	28																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Terminated	NCT01161368		PCD	2014May01	Expression confirmed	Yes	Slow accrual	4	NCT01161368	Previously-treated		Progression free survival	9	9																																									COSO28394862	2022May06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Terminated	NCT00754702		PCD	2011Mar01	Overexpression	Yes	Slow accrual	4	NCT00754702			"OS, PFS"	16	16																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Terminated	NCT00709618		PCD	2012May01	Overexpression	Yes	Slow accrual	4	NCT00709618			Overall Response Rate	44	44																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Vinorelbine		Unknown	NCT01730677		ECD	2017Dec01	Expression confirmed	Yes	"Primary outcome not met, PFS 18w 45.9 v 38.9, p=0.4 "	1	31690831			Progression free survival	149	75	74	Vinorelbine																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Paclitaxel + Trastuzumab		Completed	NCT01008150		PCD	2015Sep01	Expression confirmed	Yes	pCR 38.1%	4	NCT01008150			"Complete response, Pathological complete response"	42	42																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Paclitaxel + Trastuzumab		Completed	NCT00550771		PCD	2010Aug23	Expression confirmed	Yes	SAE 16.67%	4	NCT00550771			Maximum tolerated dose/toxicity	120	120																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Trastuzumab + Vinorelbine		"Active, not recruiting"	NCT00431704		ECD	2021Dec01	Overexpression	No		4	NCT00431704			Overall Response Rate	39	39																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Panobinostat + Trastuzumab		Terminated	NCT00567879		PCD	2011May01	Overexpression	Yes	No benefit of treatment	4	NCT00567879				56	56																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Radiotherapy		Completed	NCT01622868		PCD	2019Dec30	Expression confirmed	Yes	"CR 0 v 5.8%, p=0.97"	4	NCT01622868			"Complete response, Pathological complete response"	116	64	52	Radiotherapy																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT00436566		PCD	2009Apr01	Expression confirmed	No		4	NCT00436566			Maximum tolerated dose/toxicity	122	122																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT00482391		PCD	2011Jul01	Overexpression	Yes	"Primary outcome not met, Toxicity issues"	1	20479410			Maximum tolerated dose/toxicity	92	92																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Trastuzumab		Completed	NCT00493649		PCD	2013Apr01	Expression confirmed	Yes	DFS 24m 97.9%	4	NCT00493649			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	248	248																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Nab-paclitaxel		Completed	NCT00709761	LPT 111111	PCD	2011Jan05	Overexpression	Yes		4	NCT00709761	Previously-treated		Overall Response Rate	60	60			53				11.24		7.32-13.18		9.16					9.46			9.02-14.91																						COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Trastuzumab		"Active, not recruiting"	NCT03457896		PCD	2021Sep30	Overexpression	Yes	Slow accrual	2	10.1200/JCO.2022.40.16_suppl.3564	Previously-treated		Progression free survival	4	4																																									COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Trastuzumab		Completed	NCT00398567		PCD	2009Jul31	Expression confirmed	Yes	PFS 16w 44.8%	4	NCT00398567			Progression free survival					28.6		13.2-48.7		10.2		-5.56		3.67			3.49-7.22							35.7																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib + Trastuzumab		"Active, not recruiting"	NCT01953926	SUMMIT	ECD	2022Oct31	Yes	No		4	NCT01953926			Overall Response Rate	650	650																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Exemstane		Completed	NCT00291798				No	No		4	NCT00291798			Complete remission	98	98																																									COSO28394862	2021Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Gefitinib		Completed	NCT00319618				No	Yes	Toxicity issues	1	NCT00319618			Overall Response Rate	18	9	9	Docetaxel + Placebo																													1	4									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Aflibercept		Completed	NCT00369655		PCD	2008Mar01	Overexpression	Yes		4	NCT00369655			Overall Response Rate	21	21							4.6		4.6-4.6		2.7			1.8-5.0										12.7			6.7-31.1				1										COSO28394862	2021Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00365365		PCD	2011Oct01	Expression confirmed	Yes	DFS 36m 90.4%	4	NCT00365365			Maximum tolerated dose/toxicity	59	59																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00446030		PCD	2010Aug01	Expression confirmed	Yes	Efficacy endpoints not evaluated	1	24860718			Maximum tolerated dose/toxicity	34	34																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Pazopanib		Completed	NCT00347919		PCD	2008Aug01	Expression confirmed	Yes		4	NCT00347919			"Disease control rate, Clinical benefit rate"	141	69	72	Lapatinib																			63.8	61.1	0.37																		COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Liposome-encapsulated doxorubicin citrate + Paclitaxel + Trastuzumab		Completed	NCT02015676		PCD	2009Sep01	Overexpression	Yes		4	NCT02015676			Overall Response Rate	54	54			98.2																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Oxaliplatin + Trastuzumab		Completed	NCT00297596		PCD	2008Oct01	Overexpression	Yes		4	NCT00297596			Overall Response Rate	25	25			20		4.3-35.7																																				COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Anastrozole + Bevacizumab + Trastuzumab		Completed	NCT00405938		PCD	2010Jun01	Expression confirmed	Yes	RR 66 v 0%	1	21665134			Progression free survival	5	3	2	Bevacizumab + Fulvestrant + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim + Nab-paclitaxel + Trastuzumab		Completed	NCT00407888		PCD	2009May01	Expression confirmed	Yes	DFS 2yr 93.3%	4	NCT00407888			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	60	60																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cetuximab + Trastuzumab		"Active, not recruiting"	NCT03457896		PCD	2021Sep30	Overexpression	Yes		2	10.1200/JCO.2022.40.16_suppl.3564	Previously-treated		Progression free survival	2	2																															1										COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ertumaxomab		Terminated	NCT00351858				Expression confirmed	Yes	Changed business priorities	4	NCT00351858			Clinical activity	40	40																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ertumaxomab		Terminated	NCT00452140				Overexpression	Yes	Changed business priorities	4	NCT00452140	Previously-treated		Overall Response Rate	40	40																																									COSO28394862	2021Oct13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ertumaxomab		Terminated	NCT00522457		PCD	2009Dec01	Overexpression	Yes	Changed business priorities	4	NCT00522457	Previously-treated		Overall Response Rate	19	19																																									COSO28394862	2021Oct13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Everolimus + Trastuzumab		Completed	NCT00458237		PCD	2010Apr01	Overexpression	Yes		4	NCT00458237			Maximum tolerated dose/toxicity	5	5																					80																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Everolimus + Trastuzumab		Terminated	NCT00674414		PCD	2013Jan01	Expression confirmed	Yes	Slow accrual	4	NCT00674414			Clinical activity	82	82																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Patupilone + Trastuzumab		Completed	NCT00337649		PCD	2008Apr01	Overexpression	No		4	NCT00337649			Response rate	27	27																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Dexamethasone + Docetaxel + Doxorubicin hydrochloride + Filgrastim + Lapatinib + Pegfilgrastim + Trastuzumab		Completed	NCT00404066		PCD	2010Dec01	Overexpression	Yes	pCR 38.9%	4	NCT00404066			"Complete response, Pathological complete response"	18	18																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Larotaxel + Trastuzumab		Completed	NCT00386685		PCD	2008Oct01	Overexpression	No		4	NCT00386685			Response rate	51	51																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Larotaxel + Trastuzumab		Completed	NCT00387907		PCD	2008Mar01	Expression confirmed	Yes		5	https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/TCD10037_summary.pdf			Response rate	6	6			50																											1	2	1									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Docetaxel + Trastuzumab		Completed	NCT00364611		PCD	2011Jun01	Expression confirmed	Yes	PFS 1yr 81%	4	NCT00364611			Progression free survival	21	21							12																							4	13	1									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Carboplatin + Nab-paclitaxel + Trastuzumab		Completed	NCT00392392		PCD	2008Apr01	Overexpression	Yes	pCR 56%	4	NCT00392392			"Complete response, Pathological complete response"	27	27																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Sirolimus + Trastuzumab		Completed	NCT00411788		PCD	2010May01	Overexpression	Yes		4	NCT00411788			"Disease control rate, Clinical benefit rate"	9	9			11.1																		44.4																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Allogeneic GM-CSF-secreting breast cancer vaccine + Cyclophosphamide + Trastuzumab		Completed	NCT00847171		PCD	2013Jun01	Overexpression	Yes	DTH response 25%	4	NCT00847171			Immune response	20	20																					90																				COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Allogeneic GM-CSF-secreting breast cancer vaccine + Cyclophosphamide + Trastuzumab		Completed	NCT00399529		PCD	2010Feb01	Overexpression	Yes	DCR 1yr 40%	4	NCT00399529			"Disease control rate, Clinical benefit rate"	20	20																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinflunine		Completed	NCT00284180		PCD	2008Feb01	Overexpression	Yes		4	NCT00284180			Overall Response Rate	21	21			33		14.6-57.0																																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Doxorubicin hydrochloride liposome + Trastuzumab		Completed	NCT00303108		PCD	2010Mar01	Expression confirmed	Yes		4	NCT00303108			Overall Response Rate	45	45			55.6		40.0-70.4		11.8		2.3-16.8		10.1			0.2-18.5																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 ICD peptide vaccine + Sargramostim		Completed	NCT00343109		PCD	2015Jun01	Expression confirmed	No		4	NCT00343109			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	38	38																																									COSO28394862	2021Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Radiotherapy + Trastuzumab		Terminated	NCT02297230		PCD	2014Dec02	Expression confirmed	Yes	PI departure	4	NCT02297230			Clinical activity	44	44																																									COSO28394862	2021Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Epirubicin hydrochloride + Pegfilgrastim		Completed	NCT00253500		PCD	2005Sep01	No	No		4	NCT00253500			"Complete response, Pathological complete response"	15	15																																									COSO28394862	2021Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Autologous Dendritic Cells vaccine + Sargramostim + Trastuzumab + Vinorelbine		Completed	NCT00266110		PCD	2013Feb01	Overexpression	Yes		4	NCT00266110			Overall Response Rate	17	17			0																																						COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vorinostat		Completed	NCT00258349		PCD	2010Aug01	Overexpression	Yes		4	NCT00258349			Response rate	10	10			0													1.5			1.3-5.7					9.3			5.1-24.7														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant + Trastuzumab		Terminated	NCT00138125		PCD	2009Sep01	Overexpression	Yes	Slow accrual	4	NCT00138125				2	2																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gefitinib + Tamoxifen		Completed	NCT00229697	Stratum 1	PCD	2006Dec01	Expression confirmed	Yes		1	21220480			Overall Response Rate	37	22	15	Tamoxifen									6.7	5.8	0.54	 0.25?1.15	0.111																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Nab-paclitaxel + Sargramostim + Trastuzumab		Completed	NCT00254592		PCD	2013Sep04	No	Yes	RR 100%	4	NCT00254592			Clinical activity	43	43																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Lapatinib + Trastuzumab		Terminated	NCT00251433		PCD	2010Jun10	Overexpression	Yes		1	23878115			Maximum tolerated dose/toxicity	53	53			31																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab		Not yet recruiting	NCT04383275		ECD	2025May15	Expression confirmed	No		4	NCT04383275			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	356	356																																									COSO28394862	2022Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab		Terminated	NCT01290718		PCD	2012Dec01	Expression confirmed	Yes	Slow accrual	4	NCT01290718			Overall Response Rate	4	4																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab		Not yet recruiting	NCT04922008	IRIS-C/D	ECD	2024Jun30	Expression confirmed	No		4	NCT04922008	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	356	356																																									COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab		Completed	NCT00107393		PCD	2008May01	Overexpression	No		4	NCT00107393			Overall survival	75	75																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Trastuzumab		Completed	NCT00331552		PCD	2011Feb01	Expression confirmed	Yes		4	NCT00331552			"Disease control rate, Clinical benefit rate"	28	28																					75									0	6	15									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride liposome + Trastuzumab		Completed	NCT00258960		PCD	2008Jul01	Overexpression	Yes		4	NCT00258960			Overall Response Rate	48	48			68.8				9.51		7.28-11.73							12			9.0-15.1					34.2			27.2-41.2														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Trastuzumab		Unknown	NCT02214004	HERAKLES	ECD	2019Mar01	Expression confirmed	No		4	NCT02214004			"Complete response, Pathological complete response"	132	132																																									COSO28394862	2021Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Trastuzumab		Completed	NCT00238290		PCD	2010Jan01	Overexpression	No		4	NCT00238290			Overall Response Rate	13	13																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Letrozole + Trastuzumab		Completed	NCT00134680		PCD	2005Jan01	Expression confirmed	Yes		1	16897431			Complete remission	31	31			26				20.6									5.8					52									1	7										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Trastuzumab + Vinorelbine		Completed	NCT00193089		PCD	2005Apr01	Expression confirmed	Yes		1	19299236	Untreated		Maximum tolerated dose/toxicity	60	60											12			9.1-16.3										40.8						16	25	13									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab + Vinorelbine		Completed	NCT00148681		PCD	2003May01	Overexpression	No		4	NCT00148681			Overall Response Rate	49	49																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Trastuzumab + Vinorelbine		Completed	NCT00148681		PCD	2003May01	Overexpression	No		4	NCT00148681			Overall Response Rate	49	49																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Filgrastim + Trastuzumab + Vinorelbine		Terminated	NCT00169104		PCD	2009Mar01	Overexpression	Yes		4	NCT00169104			Clinical activity	11	11																															1	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Docetaxel + Trastuzumab		Completed	NCT02748213		PCD	2006Mar01	Expression confirmed	Yes		4	NCT02748213	Untreated		Overall Response Rate	222	112	110	Docetaxel + Trastuzumab	70.5	72.7		0.717																																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim + Letrozole + Methotrexate + Paclitaxel + Tamoxifen + Trastuzumab + Vinorelbine		Completed	NCT00194779		PCD	2010Jun01	Expression confirmed	Yes	pCR 69%	3	NCT00194779			"Complete response, Pathological complete response"	42	42																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Gemcitabine + Trastuzumab		Completed	NCT00193076		PCD	2006May01	Overexpression	Yes		1	18952556	Previously-treated			27	27			66								7													26						2	16	6									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Gemcitabine + Trastuzumab		Completed	NCT00191451		PCD	2008Oct01	Expression confirmed	Yes		4	NCT00191451			Overall Response Rate	50	50							6.9		2.0-42.1							7.2			6.0-9.0											6	26	12									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00379015		PCD	2016Mar01	Overexpression	No		4	NCT00379015			"Complete response, Pathological complete response"	38	38																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Unknown	NCT00398489	HEDON			Expression confirmed	Yes	pCR 55.2%	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000967-24/results			"Complete response, Pathological complete response"	29	29																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00270894		PCD	2011Aug01	Expression confirmed	Yes	pCR 57.1%	4	NCT00270894			Maximum tolerated dose/toxicity	28	28																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Liposome-encapsulated doxorubicin citrate + Trastuzumab		Completed	NCT00712881		PCD	2015Sep17	Overexpression	Yes	pCR 41.3 v 54% p=0.154	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000709-12/results			"Complete response, Pathological complete response"	126	63	63	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Liposome-encapsulated doxorubicin citrate + Trastuzumab		Completed	NCT00129896		PCD	2008Dec01	Overexpression	No		4	NCT00129896			"Complete response, Pathological complete response"	73	73																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vatalanib		Terminated	NCT00216047		PCD	2006Aug01	Overexpression	Yes	"Slow accrual, Toxicity issues"	4	NCT00216047			Response rate	7	7																																									COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Oxaliplatin + Trastuzumab		Unknown	NCT01387295		ECD	2014Dec01	Expression confirmed	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014821-17/results			Response rate	38	38											12.8			6.9-18.6										24			17.2-30.8			2	13	21									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Oxaliplatin + Trastuzumab		Completed	NCT01387373		PCD	2017May01	Expression confirmed	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014863-37/results	Previously-treated		Overall Response Rate	14	14																																									COSO28394862	2022Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Oxaliplatin + Trastuzumab		Terminated	NCT00216073		PCD	2006Oct01	Overexpression	Yes	Slow accrual	4	NCT00216073			Overall Response Rate	11	11																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 cytotoxic T-cell helper peptide vaccine + Trastuzumab		"Active, not recruiting"	NCT00194714		PCD	2021Mar31	Overexpression	Yes	IR 90%	1	19720923			Immune response	21	21											17.7																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Paclitaxel		Completed	NCT01138046		PCD	2014Jan01	Overexpression	Yes		4	NCT01138046			Overall survival	12	12											13.9			7.6-27.9										35.6			-23.9			0	10	1									COSO28394862	2021Oct22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Paclitaxel		Completed	NCT00356811		PCD	2008Mar01	Overexpression	Yes		4	NCT00356811			Overall Response Rate	57	57			50.9		37.3-64.4											11.1			-9.2											0	29										COSO28394862	2021Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Paclitaxel		Completed	NCT00111787		PCD	2006Nov01	Overexpression	No		4	NCT00111787			"Complete response, Pathological complete response"	49	49																																									COSO28394862	2021Oct04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Gefitinib + Trastuzumab		Completed	NCT00086957		PCD	2015Aug01	Overexpression	Yes		4	NCT00086957			Maximum tolerated dose/toxicity	29	29											12.7			7.6-21.8																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Nab-paclitaxel + Trastuzumab		Recruiting	NCT03907800	NeoPATH	ECD	2022Oct01	No	No		4	NCT03907800	Untreated		"Complete response, Pathological complete response"	100	100																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Nab-paclitaxel + Trastuzumab		Completed	NCT00093145		PCD	2008Oct01	Overexpression	Yes		4	NCT00093145			Overall Response Rate	32	32			62.5				17.8									16.6					81.3																				COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Nab-paclitaxel + Trastuzumab		Completed	NCT00617942		PCD	2012Aug01	Expression confirmed	Yes	pCR 56.5%	4	NCT00617942			"Complete response, Pathological complete response"	23	23																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Nab-paclitaxel + Trastuzumab		Completed	NCT00617942		PCD	2012Aug01	Expression confirmed	Yes	pCR 32.4%	4	NCT00617942			"Complete response, Pathological complete response"	37	37																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Nab-paclitaxel + Trastuzumab		"Active, not recruiting"	NCT00618657		ECD	2021Jul01	Expression confirmed	No		4	NCT00618657			Progression free survival	132	132																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Autologous bone marrow transplantation + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim + Fluorouracil + Methotrexate + Radiotherapy + Tamoxifen		Completed	NCT00003953		PCD	2001Nov01	No	No		4	NCT00003953			Response rate	39	39																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab + Vinorelbine		Unknown	NCT04302441		ECD	2021Jun30	Expression confirmed	No		4	NCT04302441			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	550			Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab + Vinorelbine		Completed	NCT00093808		PCD	2008Dec01	Overexpression	Yes		4	NCT00093808			Overall Response Rate	45	45			67				13.2									11.3								28.5																	COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab + Vinorelbine		Terminated	NCT00130507		PCD	2009Jun01	Expression confirmed	Yes	Changed business priorities	4	NCT00130507			"Disease control rate, Clinical benefit rate"	14			Capecitabine + Vinorelbine																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Trastuzumab		"Active, not recruiting"	NCT00999804	HELEX	PCD	2014Nov01	Overexpression	Yes	"24w v 12w, pCR 24.7 v 11.6%"	4	NCT00999804			"Complete response, Pathological complete response"				Lapatinib + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Trastuzumab		"Active, not recruiting"	NCT00470704	Cohort 2 HR+	PCD	2013Nov30	Expression confirmed	Yes		1	26169615	Previously-treated		Overall Response Rate	26	26			23.1		9.0-43.6						5.4			3.6-7.6							42.3			26.1			23.8-41.4			0	6	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Trastuzumab		"Active, not recruiting"	NCT00470704	Cohort 1 HR+	PCD	2013Nov30	Expression confirmed	Yes		1	26169615	Previously-treated		Overall Response Rate	21	21			38.1		18.1-61.6						6.5			3.7-16.6							52.4			40			-33.3			2	6	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Trastuzumab		Unknown	NCT02238509		ECD	2017Oct01	Expression confirmed	No		4	NCT02238509			"Disease control rate, Clinical benefit rate"	154			Chemotherapy + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Trastuzumab		"Active, not recruiting"	NCT00470704	Cohort 2 HR-	PCD	2013Nov30	Expression confirmed	Yes		1	26169615	Previously-treated		Overall Response Rate	19	19			21.1		6.1-45.6						5.1			-3.7							36.8			36			-30.7			0	4	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Trastuzumab		"Active, not recruiting"	NCT00470704	Cohort 1 HR-	PCD	2013Nov30	Expression confirmed	Yes		1	26169615	Previously-treated		Overall Response Rate	19	19			63.2		38.4-83.7						8.8			-3.9							63.2									1	11	0									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Irinotecan + Trastuzumab		Completed	NCT00303992		PCD	2006Nov16	Overexpression	No		4	NCT00303992			Overall Response Rate	9	9																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ixabepilone + Trastuzumab		Completed	NCT00490646		PCD	2011Jun01	Expression confirmed	Yes		4	NCT00490646			Overall Response Rate	50	25	25	Docetaxel + Trastuzumab	60	52			11.5	16.5			11.3	13																													COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ixabepilone + Trastuzumab		Terminated	NCT00079326		PCD	2008Jul01	Expression confirmed	Yes	Slow accrual	4	NCT00079326			Overall Response Rate	39	39																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	HER2 peptide vaccine + Sargramostim		Completed	NCT01355393		PCD	2013Nov01	Expression confirmed	No		4	NCT01355393			Immune response	50	50																																									COSO28394862	2021Oct25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Trastuzumab		Completed	NCT00095706		PCD	2007Apr01	Overexpression	No		4	NCT00095706			Maximum tolerated dose/toxicity	50	50																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Ixabepilone + Trastuzumab		Completed	NCT00821886		PCD	2011Jul01	Overexpression	Yes	pCR 51.9%	4	NCT00821886			"Complete response, Pathological complete response"	52	52																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Ixabepilone + Trastuzumab		Completed	NCT00077376		PCD	2009Mar01	Overexpression	Yes		4	NCT00077376			Overall Response Rate	39	39																														3	13	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim + Paclitaxel + Radiotherapy + Tamoxifen		Completed	NCT00007904		PCD	2006Jun01	Overexpression	No		4	NCT00007904			Maximum tolerated dose/toxicity	16	16																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Doxorubicin hydrochloride liposome		Completed	NCT00004888		PCD	2008Apr01	Expression confirmed	Yes		4	NCT00004888			Maximum tolerated dose/toxicity	38	38																														1	17	11									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Doxorubicin hydrochloride liposome + Trastuzumab		Terminated	NCT00377780	MYOHERTAX	PCD	2015Aug01	Expression confirmed	Yes	Changed business priorities	4	NCT00377780			Maximum tolerated dose/toxicity	60	60																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Doxorubicin hydrochloride liposome + Trastuzumab		Unknown	NCT00250874				Overexpression	No		4	NCT00250874			Complete remission	45	45																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Doxorubicin hydrochloride liposome + Trastuzumab		Completed	NCT00004888		PCD	2008Apr01	Overexpression	Yes		4	NCT00004888			Maximum tolerated dose/toxicity	46	46																														4	17	11									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Fluorouracil + Methotrexate + Trastuzumab		Unknown	NCT00036868		PCD	2009Jun01	Overexpression	Yes		1	28324265			Response rate	90	71	19	Cyclophosphamide + Fluorouracil + Methotrexate	50	32			10.3	5.4			9.4	4.8																													COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Celecoxib + Trastuzumab		Completed	NCT00006381				Overexpression	No		4	NCT00006381					37																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Filgrastim + Trastuzumab + Vinorelbine		Completed	NCT00041067		PCD	2008Jan01	Expression confirmed	Yes	OS 1yr 93%	4	NCT00041067			Overall survival	76	76																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Doxorubicin hydrochloride liposome + Trastuzumab		Unknown	NCT03933319		ECD	2021Mar31	Expression confirmed	No		4	NCT03933319			Overall Response Rate	30	30																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Doxorubicin hydrochloride liposome + Trastuzumab		Terminated	NCT00903656		PCD	2012May01	Overexpression	Yes	Drug unavailable	4	NCT00903656			Clinical activity	24	24																																									COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Doxorubicin hydrochloride liposome + Trastuzumab		Completed	NCT00006825		PCD	2004Jul01	Overexpression	No		4	NCT00006825					40																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Trastuzumab		Unknown	NCT01428414		ECD	2014Aug01	Expression confirmed	No	"pCR 39.1% vs. 48.8%, p=0.365"	1	26084292			"Complete response, Pathological complete response"	100	50	50	Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Jan26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Trastuzumab		Unknown	NCT02934828		ECD	2017Dec01	Expression confirmed	Yes		2	10.1200/JCO.2019.37.15_suppl.e12118			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	86	43	43	Chemotherapy																															22.8	23.8							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Trastuzumab		Completed	NCT00003612		PCD	2005Dec01	Expressed/not	Yes		1	29530935	Untreated		Response rate	82	66	16												0.72		0.1											0.64	0.047														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Trastuzumab		Unknown	NCT01170143		ECD	2015Dec01	Expression confirmed	Yes	"QW vs Q3W, pCR 75.9 v 48.1,HR: 0.3, 95% CI 0.1?0.9; p = 0.03"	1	23635560	Untreated		"Complete response, Pathological complete response"	56	29	27	Carboplatin + Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Paclitaxel + Trastuzumab		Completed	NCT00768859	TRAIN	PCD	2011Aug01	Overexpression	Yes	pCR 43% 	1	28335887	Untreated		"Complete response, Pathological complete response"	108	108																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gemcitabine + Trastuzumab		Completed	NCT00191373				Overexpression	No		4	NCT00191373			Overall Response Rate	66	66																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gemcitabine + Trastuzumab		Completed	NCT00193063		PCD	2009May01	Overexpression	Yes		4	NCT00193063			Overall Response Rate	37	37			30								4			1.9-5.3																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Letrozole		Completed	NCT01275859		PCD	2014Apr01	Expression confirmed	Yes	pCR 0%	1	27491481	Untreated		"Complete response, Pathological complete response"	24	24			62.5																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	"CP-724,714"		Terminated	NCT00102895				Overexpression	Yes	"Serious adverse events, lack of efficacy"	4	NCT00102895			Clinical activity	25	25																																									COSO28394862	2021Oct01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Interleukin-2 + Trastuzumab		Completed	NCT00006228		PCD	2003Jul01	Overexpression	No		4	NCT00006228			Response rate	37	37																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Gefitinib + Trastuzumab		Completed	NCT00024154		PCD	2007Jul01	Overexpression	No		4	NCT00024154			Maximum tolerated dose/toxicity	132	132																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Trastuzumab		Unknown	NCT00842998	HERLAP	ECD	2011Dec01	Overexpression	Yes		1	24075779			Clinical activity	9	9											7.3			1.6-38.8										43			14.0-81.0														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Trastuzumab		Completed	NCT00444587		PCD	2011Aug01	Overexpression	Yes		4	NCT00444587			Time to progression	65	65																5.62			4.47-10.59																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	SB-AS15 + SB719125		Completed	NCT00140738		PCD	2008Sep29	Overexpression	Yes		1	26975189			Overall Response Rate	40	40			5																											1	1	10									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Terminated	NCT01329640	TraQ-Me 01	PCD	2011Sep01	Expression confirmed	Yes	Adverse events	2	10.1200/jco.2012.30.27_suppl.197			Progression free survival	9	9																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Completed	NCT00591851		PCD	2008Jun01	Overexpression	Yes	SAE 27.14%	4	NCT00591851			Maximum tolerated dose/toxicity	70	70																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Completed	NCT00550771		PCD	2010Aug23	Expression confirmed	Yes	SAE 11.86%	4	NCT00550771			Maximum tolerated dose/toxicity	59	59																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Completed	NCT00136539		PCD	2006Nov01	Overexpression	No		4	NCT00136539			Response rate	41	41																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Erlotinib + Trastuzumab		Completed	NCT00033514		PCD	2011Dec01	Overexpression	No		4	NCT00033514			Overall Response Rate	27	27																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT01423695		PCD	2009Dec01	Overexpression	No		4	NCT01423695				121	121																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT00003539		PCD	2003Feb01	Expression confirmed	Yes		1	11352950			Overall Response Rate	39	39			46																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT00003539		PCD	2003Feb01	Overexpression	Yes		1	11352950			Overall Response Rate	51	51			69																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT00542451		PCD	2014Apr21	Expression confirmed	Yes	DFS 3y 98.7% 95% CI 97.6-99.8	1	25564897			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	406	406																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT00019812				Overexpression	No		4	NCT00019812				55	55																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT00005635		PCD	2001Nov01	Overexpression	No		4	NCT00005635					80																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Trastuzumab		Completed	NCT02307227		PCD	2009Apr01	Expression confirmed	Yes	pCR 50%	1	25512030			"Complete response, Pathological complete response"	46	46																																									COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Trastuzumab		Unknown	NCT02510781		ECD	2016Dec01	Expression confirmed	Yes	"pCR 56.7 v 50.0 95% CI 43.8-69,6 p=0.457"	2	10.1158/1538-7445.SABCS20-PS13-14			"Complete response, Pathological complete response"	124	60	64	Docetaxel + Epirubicin hydrochloride + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Trastuzumab		Completed	NCT03140553	neoCARH	PCD	2019Nov11	Expression confirmed	Yes	"pCR 55.9 v 37.3%, p-=0.032"	1	33959195			"Complete response, Pathological complete response"	135	68	67	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab	95.5	89.4																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00068341		PCD	2013Nov01	Expression confirmed	Yes		4	NCT00068341			Overall Response Rate	29	29																																	75.9								COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Trastuzumab		Terminated	NCT00453635		PCD	2008Nov01	Expression confirmed	Yes	Slow accrual	4	NCT00453635	Untreated		Time to progression	88			Trastuzumab + Vinorelbine																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00232479		PCD	2008May01	Overexpression	Yes	pCR 43.2%	4	NCT00232479			"Complete response, Pathological complete response"	44	44																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00148668		PCD	2009Jan01	Expression confirmed	Yes	pCR 79.5 v 41.5	4	NCT00148668			"Complete response, Pathological complete response"	80	39	41	Trastuzumab + Vinorelbine																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Filgrastim + Paclitaxel + Trastuzumab + Vinorelbine		Terminated	NCT00041470		PCD	2008Aug01	Expression confirmed	Yes	Changed business priorities	4	NCT00041470			Response rate	38	38																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Trastuzumab		"Active, not recruiting"	NCT01340430		PCD	2015Dec01	Expression confirmed	No		4	NCT01340430			"Complete response, Pathological complete response"	43	43																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib + Vinorelbine		Completed	NCT01441596		PCD	2014Feb01	Overexpression	Yes	CNSN 12w 34.2 v 41.9%	4	NCT01441596	Previously-treated		No CNS progression	81	38	43	Physician's choice									2.84	4.25												8.61	12.02																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib + Vinorelbine		Completed	NCT01325428		PCD	2014Nov01	Overexpression	Yes		4	NCT01325428	Previously-treated		"Disease control rate, Clinical benefit rate"	10	10			10		0-45																20																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib + Vinorelbine		Terminated	NCT01531764		PCD	2013Sep01	Expression confirmed	Yes	Slow accrual	5	NCT01531764			Progression free survival	2	2																																									COSO28394862	2021Dec06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Sapitinib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Inetetamab + Pyrotinib		Not yet recruiting	NCT05621434		ECD	2024Dec10	Expression confirmed	No		4	NCT05621434	Untreated		Progression free survival	63	63																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Chemotherapy + Inetetamab + Pyrotinib		Recruiting	NCT04681911		ECD	2023Sep09	Yes	No		4	NCT04681911	Previously-treated		Overall Response Rate	71	71																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	TAC01-HER2		Recruiting	NCT04727151	TACTIC-2	ECD	2024Nov01	Expression confirmed	No		4	NCT04727151			Maximum tolerated dose/toxicity	70	70																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Not yet recruiting	NCT04419181		ECD	2025Jun01	Expression confirmed	No		4	NCT04419181			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	20	20																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Unknown	NCT04094896		ECD	2022Sep17	Expression confirmed	No		4	NCT04094896	Untreated		"Complete response, Pathological complete response"	200			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT01959490	Cohort 1T	PCD	2016Nov11	Expression confirmed	Yes	pCR 100%	4	NCT01959490			"Complete response, Pathological complete response"	6	6																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT01959490	Cohort 1P	PCD	2016Nov11	Expression confirmed	Yes	pCR 80%	4	NCT01959490			"Complete response, Pathological complete response"	5	5																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab + Tucatinib		"Active, not recruiting"	NCT03501979	TBCRC049	PCD	2021Jun22	Expression confirmed	Yes		3	https://www.onclive.com/view/safety-efficacy-of-tucatinib-trastuzumab-capecitabine-regimen-for-treatment-of-lm-in-her2-breast-cancer	Untreated		Overall survival	17	17																								11.9			-4.1														COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab + Tucatinib		Recruiting	NCT04721977	MK-7119-001	ECD	2024Jan26	Expression confirmed	No		4	NCT04721977	Previously-treated		Overall Response Rate	56	56																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Trastuzumab + Tucatinib		Recruiting	NCT04721977		ECD	2024Jan26	Expression confirmed	No		4	NCT04721977	Previously-treated		Overall Response Rate	56	56																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Disitamab vedotin		Not yet recruiting	NCT05134519		ECD	2024Sep30	Expression confirmed	No		4	NCT05134519	Untreated		"Complete response, Pathological complete response"	20	20																																									COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Disitamab vedotin		Recruiting	NCT05331326		ECD	2023Dec01	Expression confirmed	No		4	NCT05331326			Overall Response Rate	64	64																																									COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Disitamab vedotin		"Active, not recruiting"	NCT03501979		PCD	2021Jun22	Expression confirmed	No		4	NCT03500380			Overall survival	30	30																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Disitamab vedotin		"Active, not recruiting"	NCT03500380		ECD	2022Dec31	Expression confirmed	No		4	NCT03500380			Progression free survival	301			Capecitabine + Lapatinib																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Disitamab vedotin		"Active, not recruiting"	NCT03052634	C003 CANCER	PCD	2021Jun01	Expression confirmed	No		4	NCT03052634			"PFS, ORR"	112	112																																									COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Almonertinib + Pyrotinib		Recruiting	NCT04785729		ECD	2023Dec01	Expression confirmed	No		4	NCT04785729			Maximum tolerated dose/toxicity	36	36																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT00545688		PCD	2014Sep22	Expression confirmed	Yes	pCR 45.8	4	NCT00545688			"Complete response, Pathological complete response"	107	107																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab Deruxtecan		Recruiting	NCT04538742	DESTINY-Breast07	ECD	2025Apr30	Expression confirmed	No		4	NCT04538742			Maximum tolerated dose/toxicity	450	450																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		Completed	NCT04420598	DEBBRAH cohort 3	PCD	2021Sep30	Expression confirmed	Yes	ORR-IC 16w 44.4%	2	10.1093/neuonc/noac144			Overall Response Rate	9	9																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		Completed	NCT04420598	DEBBRAH cohort 2	PCD	2021Sep30	Expression confirmed	Yes	ORR-IC 16w 50%	2	10.1093/neuonc/noac144			Overall Response Rate	4	4																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		Completed	NCT04420598	DEBBRAH cohort 1	PCD	2021Sep30	Expression confirmed	Yes	PFS 16w 87.5%	2	10.1093/neuonc/noac144			Overall Response Rate	8	8																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		Recruiting	NCT04538742	DESTINY-Breast07	ECD	2025Apr30	Expression confirmed	No		4	NCT04538742			Maximum tolerated dose/toxicity	450	450																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04752059	TUXEDO-1	ECD	2022Jul28	Expression confirmed	Yes	Intracranial RR 73.3%	3	https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/trastuzumab-deruxtecan-t-dxd-in-her2-positive-breast-cancer-patients-pts-with-active-brain-metastases-primary-outcome-analysis-from-the-tuxedo			Response rate	14	14																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04132960	DAISY Cohort 2	PCD	2021Oct29	Overexpression	Yes		2	10.1158/1538-7445.SABCS21-PD8-02			Clinical activity	74	74							7.6		-5.4		6.7			-8.4																											COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04132960	DAISY Cohort 1	PCD	2021Oct29	Expression confirmed	Yes		2	10.1158/1538-7445.SABCS21-PD8-02			Clinical activity	72	72							9.9		6.2-9.7		11.1			6.7-8.7																											COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine + Tucatinib		Recruiting	NCT05323955		ECD	2024Apr01	Expression confirmed	No		4	NCT05323955			Progression free survival	48	48																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Atezolizumab + Trastuzumab-emtansine		Completed	NCT02924883	KATE2	PCD	2017Dec11	Expression confirmed	Yes		4	NCT02924883	Previously-treated		Progression free survival	202	133	69	Placebo + Trastuzumab-emtansine									8.2	6.8	0.82	0.55-1.23	0.3332																										COSO28394862	2022Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel		Unknown	NCT03273595		ECD	2019Jul01	Expression confirmed	No		4	NCT03273595			"Complete response, Pathological complete response"	100			Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Trastuzumab-emtansine		Recruiting	NCT04893109	ATEMPT 2.0	ECD	2025May01	Expression confirmed	No		4	NCT04893109	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	500			Paclitaxel + Trastuzumab																																							COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab + Trastuzumab-emtansine		Completed	NCT01835236		PCD	2018Jan11	Expression confirmed	No		4	NCT01835236	Previously-treated			208			Pertuzumab + Trastuzumab																																							COSO28394862	2021Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Atezolizumab + Pertuzumab + Trastuzumab		Recruiting	NCT05180006	BIS-Program cohort 2	ECD	2024Feb01	Expression confirmed	No		4	NCT05180006			Immune response	210																																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Atezolizumab + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03417544		ECD	2023Jul01	Overexpression	No		4	NCT03417544			Overall Response Rate	33	33																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Completed	NCT02536339	PATRICIA	PCD	2019May01	Expression confirmed	Yes		4	NCT02536339	Previously-treated		Overall Response Rate	40	40			10.8		3.03-25.42		4.6														67.6																				COSO28394862	2021Dec14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Recruiting	NCT04993014	HER2Cell Cohort 1	ECD	2024Apr30	Expression confirmed	No		4	NCT04993014			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	80			Trastuzumab																																							COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Recruiting	NCT04197687		ECD	2025Jan15	Expression confirmed	No		4	NCT04197687			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	480	480																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Completed	NCT00301899				Overexpression	Yes		1	20124182	Previously-treated		Clinical activity	66	66			24.2								5.5										50									5	11	17									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Completed	NCT00545688		PCD	2014Sep22	Expression confirmed	Yes	pCR 16.8	4	NCT00545688			"Complete response, Pathological complete response"	107	107																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Completed	NCT01674062		PCD	2008Feb01	Expression confirmed	Yes		4	NCT01674062			Overall Response Rate	66	66			24.2																		50																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pertuzumab + Trastuzumab		Not yet recruiting	NCT05332561	COGNITION-GUIDE Arm 6	ECD	2029Apr01	Yes	No		4	NCT05332561			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	240	240																																									COSO28394862	2022Apr25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib		Unknown	NCT03412383		ECD	2019Jan25	Yes	Yes		1	33145402			Progression free survival	10	10			40								4.9			3.8-6.0							60									1	3	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Pyrotinib		Not yet recruiting	NCT04255056		ECD	2021Feb01	Overexpression	No		4	NCT04255056	Previously-treated		"Complete response, Pathological complete response"	27	27																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Panobinostat		Terminated	NCT00777335		PCD	2010Mar01	Expression confirmed	Yes	Slow accrual	4	NCT00777335			Overall Response Rate	4	4																																									COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		Unknown	NCT01745965		PCD	2015Feb01	Expression confirmed	Yes	"pCR 41 v 15.1, p<0.001"	1	28682681			"Complete response, Pathological complete response"	248	119	129	Endocrine therapy + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		"Active, not recruiting"	NCT03587740	ATOP TRIAL	ECD	2026Aug30	Expression confirmed	No		4	NCT03587740		Geriatric	"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	82	82																																									COSO28394862	2022Jan24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		Completed	NCT00943670		PCD	2010Dec01	Expression confirmed	Yes		4	NCT00943670			Maximum tolerated dose/toxicity	51	51											4.3			4.0-6.7							39.2																				COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		Completed	NCT00679341		PCD	2010Nov01	Expression confirmed	Yes		4	NCT00679341	Untreated		Progression free survival	137	67	70	Docetaxel + Trastuzumab	64.2	58							14.2	9.2									74.6	81.2																			COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		Completed	NCT00679211		PCD	2009Sep01	Expression confirmed	Yes		4	NCT00679211	Previously-treated		Overall Response Rate	110	110			32.7								6.9			4.2-9.5							48.2																				COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		Completed	NCT00509769		PCD	2009Jan01	Expression confirmed	Yes		4	NCT00509769			Overall Response Rate	108	108			26.9		19.2-35.8						4.6			3.9-8.6																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab-emtansine		"Active, not recruiting"	NCT01853748	ATEMPT	PCD	2019Aug26	Expression confirmed	Yes	"DFS 3y 97.8, Primary outcome met"	1	34077270			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	497	383	114	Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Palbociclib		Terminated	NCT02774681		PCD	2019Feb13	Expression confirmed	Yes	Slow accrual	4	NCT02774681			Response rate	12	12																																									COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Tanespimycin		Terminated	NCT00096109		PCD	2012May01	No	Yes		4	NCT00096109			"PFS, ORR"	11	11			0								2			1.0-11.0																											COSO28394862	2021Sep30	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT01827163		PCD	2019Jan01	Expression confirmed	Yes	TR 80%	4	NCT01827163			"Treatment rate, Treatment completion, Compliance, Adherence to protocol"	20	20																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT01688609		PCD	2013Dec01	Overexpression	Yes	pCR 44.4%	4	NCT01688609			"Complete response, Pathological complete response"	18	18																																									COSO28394862	2022Feb28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Ganetespib		Completed	NCT01677455		PCD	2015Apr01	Expression confirmed	Yes		2	10.1158/0008-5472.SABCS13-P2-16-23			Overall Response Rate	6	6																															1	2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Niraparib + Trastuzumab		Recruiting	NCT03368729		ECD	2022Nov01	Expression confirmed	No		4	NCT03368729			Overall Response Rate	40	40																																									COSO28394862	2022Jan05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Dasatinib		Completed	NCT00371345		PCD	2009Mar01	Overexpression	Yes		4	NCT00371345			Overall Response Rate	9	9			11.1																		11.1																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinorelbine		Recruiting	NCT03414658		ECD	2023Jul01	Expression confirmed	No		4	NCT03414658	Previously-treated		Progression free survival	100	100																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinorelbine		Not yet recruiting	NCT04922008	IRIS-C/D	ECD	2024Jun30	Expression confirmed	No		4	NCT04922008	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	356	356																																									COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinorelbine		Completed	NCT00401427		PCD	2006Jun01	Overexpression	No		4	NCT00401427			Response rate	50	50																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinorelbine		Completed	NCT01242449	OVINTRA	PCD	2012Oct01	Expression confirmed	No		4	NCT01242449			Overall Response Rate	10	10																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab + Vinorelbine		Completed	NCT00433095				Overexpression	No		4	NCT00433095	Untreated		Response rate				Trastuzumab																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Everolimus + Trastuzumab + Vinorelbine		Completed	NCT01305941		PCD	2016Aug01	Expression confirmed	Yes		4	NCT01305941			Overall Response Rate	26	26																														0	1	17									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Everolimus + Paclitaxel + Trastuzumab		Completed	NCT00426556		PCD	2014Mar01	Overexpression	Yes		4	NCT00426556			Overall Response Rate	55	55			21.8								5.52			4.99-7.69										18.07			12.85-24.11														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab		Completed	NCT01373710	HIT	PCD	2018Apr01	Overexpression	Yes		1	29635147			Progression free survival	14	14																								7.3							3	7									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab		Completed	NCT01325207		PCD	2016Jun20	Expression confirmed	Yes		4	NCT01325207			Response rate	26	26																														0	5	13									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab		Completed	NCT00826267		PCD	2011Aug01	Expression confirmed	Yes		4	NCT00826267	Untreated		Overall Response Rate	11	11			36.4		10.9-69.2																100																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab		Completed	NCT00796978		PCD	2018Jan12	Expression confirmed	Yes	"SAE 14.3%, DFS 5yr 86.4%"	4	NCT00796978		Geriatric	Maximum tolerated dose/toxicity	55	55																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab		Terminated	NCT00427427				Overexpression	Yes	Slow accrual	4	NCT00427427			Maximum tolerated dose/toxicity	75	75																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Trastuzumab		Terminated	NCT00133796		PCD	2005Sep01	Overexpression	No		4	NCT00133796			Clinical activity	40	40																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Fulvestrant		Completed	NCT00272740				No	No		4	NCT00272740			"Disease control rate, Clinical benefit rate"	93	93																																									COSO28394862	2021Oct08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Buparlisib + Lapatinib		Suspended	NCT01589861	PIKHER2	ECD	2018Jan01	No	Yes		1	28950146	Previously-treated		Overall Response Rate	24	24																														1		18									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Pertuzumab + Trastuzumab		Recruiting	NCT04569747		ECD	2026Sep01	Expression confirmed	No		4	NCT04569747			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	375	375																																									COSO28394862	2022Jan14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Endocrine therapy + Pertuzumab + Trastuzumab		Recruiting	NCT04733118	PHERGAIN-2	ECD	2025Sep01	Expression confirmed	No		4	NCT04733118	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	393	393																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	MK2206		Terminated	NCT01319539		PCD	2013Jul01	No	Yes	Toxicity issues	4	NCT01319539			Marker phosphorylation	12	12																																									COSO28394862	2022Feb18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Copanlisib + Trastuzumab		Completed	NCT02705859	Panther	PCD	2021May01	Expression confirmed	Yes	PIK3CA mutation 50% patients	2	10.1200/JCO.2018.36.15_suppl.1036	Previously-treated		"CR, ORR"	12	12																																9									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Paclitaxel + Pilaralisib + Trastuzumab		Completed	NCT01042925		PCD	2012Dec01	Expression confirmed	Yes		1	25537644	Previously-treated		Unknown	20	20																															4										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Trastuzumab		Unknown	NCT03367676		ECD	2021Jan01	Expression confirmed	No		4	NCT03367676			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	112	112																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Trastuzumab		Recruiting	NCT03879577	ARETTA	ECD	2022Sep10	Expression confirmed	No		4	NCT03879577			"Complete response, Pathological complete response"	60	60																																									COSO28394862	2022Sep21	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Trastuzumab		Completed	NCT00006104		PCD	2003Jul01	Overexpression	No		4	NCT00006104				46	46																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Docetaxel + Trastuzumab		Completed	NCT00545688		PCD	2014Sep22	Expression confirmed	Yes	pCR 29.0	4	NCT00545688			"Complete response, Pathological complete response"	107	107																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine		Not yet recruiting	NCT03684863		ECD	2023Dec01	Expression confirmed	No		4	NCT03684863	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	200			Observation																																							COSO28394862	2022Jan10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Radiotherapy		"Active, not recruiting"	NCT05301881	COSMO	ECD	2035Apr01	No	No		4	NCT05301881	Previously-treated		Progression free survival	118	118																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Radiotherapy		Completed	NCT02898727	Local HER-O	PCD	2021Jul22	Expression confirmed	No		4	NCT02898727			Clinical activity	25	25																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Varlitinib		Completed	NCT02338245		PCD	2016May19	Expression confirmed	Yes	"TV -31 v -19.4%, p=0.132"	3	https://oncologypro.esmo.org/meeting-resources/esmo-asia-2017-congress/Multicenter-Phase-2-trial-of-varlitinib-versus-lapatinib-in-combination-with-capecitabine-in-patients-with-HER2-metastatic-breast-cancer-MBC-who-failed-prior-trastuzumab-therapy.-102P	Previously-treated		Tumour volume	50	24	26	Capecitabine + Lapatinib	40.9	45.5		1																																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib		Completed	NCT00967031	LANDSCAPE	PCD	2012Feb01	Expression confirmed	Yes	Primary outcome met	1	23122784	Untreated		Overall Response Rate	44	44			65.9																											0	29										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib		Terminated	NCT00496366		PCD	2009Dec31	Overexpression	No		4	NCT00496366			Response rate	11	11																																									COSO28394862	2021Oct08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib		Completed	NCT01050322	GLICO-0801 arm A	PCD	2010Dec01	Expression confirmed	Yes	No unexpected toxicities	2	10.1200/jco.2012.30.15_suppl.e11087	Previously-treated		"Disease control rate, Clinical benefit rate"	29	29																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib		Completed	NCT01262469	GERICO09	PCD	2011Dec01	Overexpression	No		4	NCT01262469	Previously-treated	Geriatric	Clinical activity	4	4																																									COSO28394862	2021Oct22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib		Completed	NCT00721630		PCD	2016Jul01	Overexpression	Yes		4	NCT00721630	Previously-treated		Overall Response Rate	23	23																															5	17									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Lapatinib		Completed	NCT00477464		PCD	2010Dec01	Overexpression	Yes		4	NCT00477464			"Disease control rate, Clinical benefit rate"	51	51			24				9.9		6.2-15.8		8.3			6.3-11.1		8.3			6.2-11.1		59			18.1			11.9-23.8														COSO28394862	2021Oct15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		Recruiting	NCT04355858	MULAN	ECD	2023May01	Yes	No		4	NCT04355858			Overall Response Rate	319	319																																									COSO28394862	2022Jul04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		"Active, not recruiting"	NCT03691051	Cohort B	PCD	2021Apr16	Expression confirmed	Yes		2	10.1200/JCO.2021.39.15_suppl.1037	Previously-treated		Overall Response Rate	19	19			42.1		20.3-66.5						5.6			3.4-10.7																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		"Active, not recruiting"	NCT03691051	Cohort A	PCD	2021Apr16	Expression confirmed	Yes		2	10.1200/JCO.2021.39.15_suppl.1037	Previously-treated		Overall Response Rate	59	59			74.6		61.6-85.0						12.1			9.0-14.7																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		Not yet recruiting	NCT04246502		ECD	2022Dec01	Expression confirmed	No		4	NCT04246502	untreated		Progression free survival	200			Capecitabine + Pertuzumab + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		Unknown	NCT02422199		PCD	2016Oct01	Expression confirmed	Yes		1	31430226	Previously-treated		Overall Response Rate	128	65	63	Capecitabine + Lapatinib	78.5	57.1		0.01					18.1	7	0.36	0.23-0.58	<0.001																										COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		Unknown	NCT03923166		ECD	2021Apr01	Overexpression	Yes in vitro		4	NCT03923166			Overall Response Rate	35	35																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		Recruiting	NCT04001621		ECD	2022May31	Expression confirmed	No		4	NCT04001621			Progression free survival	100	100																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Capecitabine + Pyrotinib		Recruiting	NCT03805399	FUTURE group A	ECD	2022Dec01	Yes	Yes		1	32719455			Overall Response Rate	2	2			100																																						COSO28394862	2022Dec01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Bevacizumab + Erlotinib		Completed	NCT00054132		PCD	2015Apr01	No	Yes		4	NCT00054132	Previously-treated		Overall Response Rate	37	37																															1	17									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Poziotinib		Completed	NCT02659514	Cohort 1	PCD	2020Mar11	Expression confirmed	Yes		4	NCT02659514	Previously-treated		Overall Response Rate	30	30			30		14.7-49.4		5.7		-1.8		4.1			1.5-5.6		4.1			1.5-5.6		60																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Poziotinib		Completed	NCT02544997		PCD	2020Feb01	Yes	No		4	NCT02544997	Previously-treated		Progression free survival	5	5																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Poziotinib		Completed	NCT02418689		PCD	2017Jun01	Overexpression	Yes		1	29978467	Previously-treated		Progression free survival	102	102			25.5								4.04			2.94-4.40																											COSO28394862	2022Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Poziotinib		Terminated	NCT04172597	Cohort 1	PCD	2022Mar29	Yes	No		4	NCT04172597			Overall Response Rate	1	1																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Poziotinib		Completed	NCT02659514	Cohort 2	PCD	2020Mar11	Expression confirmed	Yes		4	NCT02659514	Previously-treated		Overall Response Rate	27	27			30		13.8-50.2		13		-2.2		4.9			1.8-7.4		4.9			1.8-7.4		78																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib		"Active, not recruiting"	NCT01494662	Cohort 1	ECD	2022Dec01	Expression confirmed	No		1	31558424			Overall Response Rate	5	5																																									COSO28394862	2022Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib		"Active, not recruiting"	NCT02673398		PCD	2020Mar12	Overexpression	Yes		2	10.1200/JCO.2020.38.15_suppl.e13018	Previously-treated	Geriatric	Maximum tolerated dose/toxicity	25	25											2.6			2.56-5.26										17.4			-10.3				1	11									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib		Completed	NCT01670877		PCD	2021Feb11	Yes	Yes	Priary outcome met	2	10.1200/JCO.2016.34.15_suppl.516	Previously-treated		"Disease control rate, Clinical benefit rate"	16	16											5			8-Feb							36									1	1	3									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib		Completed	NCT00300781		PCD	2008Apr01	Overexpression	Yes	PFS 16w 77.8%	4	NCT00300781	Untreated		Progression free survival	70	70			52.9		40.6-64.9		13.9														62.9																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib		Completed	NCT00300781		PCD	2008Apr01	Overexpression	Yes	PFS 16w 58.2%	4	NCT00300781	Previously-treated		Progression free survival	66	66			24.2		14.5-36.4		9.3														31.8																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Neratinib		Completed	NCT00777101		PCD	2011Mar01	Expression confirmed	Yes		4	NCT00777101			Progression free survival	233	117	116	Capecitabine + Lapatinib	29.1	40.5			12.48	7.98			4.53	6.83	1.19	0.89-1.60	0.23						44.4	63.8		19.74	23.62																COSO28394862	2021Oct18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00051103		PCD	2005Jun01	Overexpression	Yes		1	19179558	Previously-treated			78	78			5.1													3.53					9			18.23																	COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00089999		PCD	2008Mar01	Expression confirmed	Yes		4	NCT00089999			Overall Response Rate	69	69							6.7		3.6-8.3		5.6			4.6-8.3		3.9			3.0-4.7		33.3									0	18										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00826267		PCD	2011Aug01	Expression confirmed	Yes		4	NCT00826267	Untreated		Overall Response Rate	8	8			75		34.9-96.8																100																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Terminated	NCT00820924		PCD	2011Jul01	Expression confirmed	Yes		1	22476856			Clinical activity	7	7																																1									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00555152		PCD	2014Aug28	Expression confirmed	No		4	NCT00555152			Change in Ki-67 expression	22	22																																									COSO28394862	2021Oct14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00320411		PCD	2009Apr01	Overexpression	Yes		4	NCT00320411			Overall Response Rate	58	58																1.94			1.71-5.51		17.2									1	8	18									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00105950	EGF103009	PCD	2007Sep01	Overexpression	Yes		1	19394894			Overall Response Rate	126	126			39				4.8		2.9-7.4		3.37			2.8-3.7																0	49										COSO28394862	2021Oct05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00263588		PCD	2007Sep25	Overexpression	Yes		4	NCT00263588			Overall Response Rate	143	143			6																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00206427		PCD	2011Jun01	Overexpression	Yes		4	NCT00206427			Clinical activity	47	47																														3	30	11									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00098605		PCD	2006Sep01	Overexpression	No		4	NCT00098605			Overall Response Rate	37	37																																									COSO28394862	2021Sep29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Lapatinib		Completed	NCT00062686		PCD	2005Feb01	Overexpression	No		4	NCT00062686			Response rate	200	200																																									COSO28394862	2021Sep28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib		Completed	NCT01441596		PCD	2014Feb01	Overexpression	Yes	CNSN 12w 30.0 v 41.9%	4	NCT01441596	Previously-treated		No CNS progression	83	40	43	Physician's choice									2.75	4.25												13.32	12.02																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib		Completed	NCT01325428		PCD	2014Nov01	Overexpression	Yes		4	NCT01325428			"Disease control rate, Clinical benefit rate"	26	26			31		14-52																35																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib		Completed	NCT01271725	LUX-Breast 2	PCD	2017Mar13	Overexpression	Yes		8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results	Previously-treated			74	74			18		28-Oct		5.54		2.80-8.32		2.83			2.37-4.28																											COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 2	Afatinib		Completed	NCT00826267		PCD	2011Aug01	Expression confirmed	Yes		4	NCT00826267	Untreated		Overall Response Rate	10	10			80		44.4-97.5																100																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib		Completed	NCT00553358	Neo ALTTO	PCD	2010May27	Overexpression	Yes	"pCR 24.7 v 29.5, p=0.34"	4	NCT00553358	Untreated		"Complete response, Pathological complete response"	303	154	149	Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Giredestrant + Hyaluronidase + LHRH agonist + Pertuzumab + Trastuzumab		Recruiting	NCT05296798		ECD	2026Aug31	Expression confirmed	No		4	NCT05296798			Progression free survival	812			Docetaxel + Hyaluronidase + LHRH agonist + Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	GLSI-100		Recruiting	NCT05232916	FLAMINGO-01	ECD	2026Dec01	Expression confirmed	No		4	NCT05232916			Progression free survival	598			Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride liposome + Pertuzumab + Trastuzumab		Recruiting	NCT05159193		ECD	2024Oct30	Expression confirmed	No		4	NCT05159193			"Complete response, Pathological complete response"	372			Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Trastuzumab + Tucatinib		Recruiting	NCT05132582	HER2CLIMB-05	ECD	2024Oct31	Expression confirmed	No		4	NCT05132582	Previously-treated		Progression free survival	650			Pertuzumab + Placebo + Trastuzumab																																							COSO28394862	2022Feb14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Aromatase inhibitors + Hemay022		Recruiting	NCT05122494	RC48-C018	ECD	2024Feb01	Overexpression	No		4	NCT05122494			Progression free survival	339			Capecitabine + Lapatinib																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04973319		ECD	2027Aug01	Expression confirmed	No		4	NCT04973319	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	450			Pertuzumab + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Abemaciclib + Endocrine therapy		"Active, not recruiting"	NCT04752332		ECD	2024Feb09	Expression confirmed	No		4	NCT04752332	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2450			Endocrine therapy + Placebo																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Pyrotinib + Trastuzumab		Recruiting	NCT04717531		ECD	2023Jun01	Expression confirmed	No		4	NCT04717531			"Complete response, Pathological complete response"	60			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Inetetamab + Sirolimus		Not yet recruiting	NCT04736589		ECD	2024Feb02	Expression confirmed	No		4	NCT04736589	Previously-treated		Progression free survival	270			Chemotherapy + Pyrotinib																																							COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Atezolizumab + Trastuzumab + Trastuzumab-emtansine		Recruiting	NCT04873362		ECD	2025Dec18	Expression confirmed	No		4	NCT04873362	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1700			Placebo + Trastuzumab + Trastuzumab-emtansine																																							COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	ARX788 + Pyrotinib		Recruiting	NCT05426486		ECD	2025Dec30	Expression confirmed	No		4	NCT05426486			"Complete response, Pathological complete response"	150			Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Placebo + Trastuzumab deruxtecan		Recruiting	NCT04784715	DESTINY-Breast09	ECD	2024Dec30	Expression confirmed	No		4	NCT04784715	Untreated		Progression free survival	1134			Pertuzumab + Taxane + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + QL1209 + Trastuzumab		Not yet recruiting	NCT04629846		ECD	2022Oct01	Expression confirmed	No		4	NCT04629846			"Complete response, Pathological complete response"	544			Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04290793		ECD	2022Mar01	Expression confirmed	Yes	pCR 75 v37.5%	2	10.1200/JCO.2022.40.16_suppl.e12604			"Complete response, Pathological complete response"	20	12	8	Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Trastuzumab	100	87.5																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Trastuzumab + Vinorelbine		Not yet recruiting	NCT04665986		ECD	2022Feb28	Expression confirmed	No		4	NCT04665986			"Complete response, Pathological complete response"	50	50		Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + TQ-B211		Unknown	NCT04385563		ECD	2021Feb01	Yes	No		4	NCT04385563	Untreated		Overall Response Rate	338			Docetaxel + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Pyrotinib + Trastuzumab		Recruiting	NCT05346861		ECD	2023Oct31	Expression confirmed	No		4	NCT05346861	Previously-treated		Progression free survival	240			Chemotherapy + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Fulvestrant + Pyrotinib		Recruiting	NCT04646759		ECD	2028Dec14	Expression confirmed	No		4	NCT04646759			Progression free survival	516			Capecitabine + Pyrotinib																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pyrotinib + Trastuzumab		Recruiting	NCT04254263		ECD	2023Aug01	Expression confirmed	No		4	NCT04254263			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	316			Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	BAT8001		Unknown	NCT04185649		ECD	2020Jul31	Expression confirmed	No		4	NCT04185649			Progression free survival	410			Capecitabine + Lapatinib																																							COSO28394862	2022Jan11	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab		Recruiting	NCT05474690		ECD	2024Sep30	Expression confirmed	No		4	NCT05474690			"Complete response, Pathological complete response"	456			Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cisplatin + Trastuzumab + Vinorelbine		Unknown	NCT03423849		ECD	2020Feb08	Expression confirmed	No		4	NCT03423849			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	200			Capecitabine + Cisplatin + Trastuzumab + Vinorelbine																																							COSO28394862	2022Jan10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Gemcitabine + Trastuzumab + Vinorelbine		Unknown	NCT03423849		ECD	2020Feb08	Expression confirmed	No		4	NCT03423849			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	200			Capecitabine + Gemcitabine + Trastuzumab + Vinorelbine																																							COSO28394862	2022Jan10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Atezolizumab + Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03595592		ECD	2026Dec15	Expression confirmed	No		4	NCT03595592			Event free survival	650	650																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03595592		ECD	2026Dec15	Expression confirmed	No		4	NCT03595592			Event free survival	650	650																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel		Unknown	NCT03349177		ECD	2019Nov27	No	No		4	NCT03349177	Untreated		"Complete response, Pathological complete response"	200	200																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Atezolizumab + Docetaxel or Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03199885		ECD	2023Jan31	Expression confirmed	No		4	NCT03199885			Progression free survival	600			Docetaxel or Paclitaxel + Pertuzumab + Placebo + Trastuzumab																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Endocrine therapy + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03161353	PHERGain Cohort A	ECD	2022Nov01	Expression confirmed	Yes	"pCR 57.7%, 95%CI 47.4-69.4"	2	10.1200/JCO.2020.38.15_suppl.503			"Complete response, Pathological complete response"	71	71																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Lapatinib + Trastuzumab-emtansine		"Active, not recruiting"	NCT03084939		PCD	2018Nov23	Expression confirmed	No		4	NCT03084939			Progression free survival	351	351																																									COSO28394862	2022Jan06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Epirubicin hydrochloride + Lapatinib + Paclitaxel		Unknown	NCT03085368		ECD	2018May01	Expression confirmed	No		4	NCT03085368			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	482			Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Jan05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel or Paclitaxel + Trastuzumab-dkst		Completed	NCT02472964	HERiTAge	PCD	2016Mar01	Expression confirmed	Yes		4	NCT02472964			Overall Response Rate	458	230	228	Docetaxel or Paclitaxel + Trastuzumab	69.6	64																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab duocarmazine		"Active, not recruiting"	NCT03262935	TULIP	PCD	2021Jul01	Expression confirmed	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-congress/primary-outcome-of-the-phase-iii-syd985.002-tulip-trial-comparing-vic-trastuzumab-duocarmazine-to-physician-s-choice-treatment-in-patients-with-p			Progression free survival	437	291	146	Physician's choice									7	4.9	0.64	0.49-0.84	0.002											0.83		0.153													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Ferric carboxymaltose + Liposome-encapsulated doxorubicin citrate + Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT02125344	GeparOcto-GBG 84	PCD	2016Nov01	Expression confirmed	Yes	"pCR 58.4 v 62.0, p=0.545"	1	30528802	Untreated		"Complete response, Pathological complete response"	230	111	119	Cyclophosphamide + Epirubicin hydrochloride + Ferric carboxymaltose + Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Pertuzumab + Trastuzumab		Unknown	NCT02514681	PRECIOUS	PCD	2018Dec31	Expression confirmed	Yes		2	10.1158/1538-7445.SABCS20-PD3-11			Progression free survival	217	108	109	Chemotherapy + Trastuzumab	18.9	19.6							5.3	4.2	0.755																												COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	CT-P6		Completed	NCT02162667		PCD	2016May26	Expression confirmed	Yes	pCR 46.77 v 50.39%	4	NCT02162667			"Complete response, Pathological complete response"	504	248	256	Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	MM-302 + Trastuzumab		Terminated	NCT02213744	HERMIONE	PCD	2016Dec01	Expression confirmed	Yes	No benefit of treatment	4	NCT02213744			Progression free survival	113			Chemotherapy + Trastuzumab																																							COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Doxorubicin hydrochloride + Fluorouracil + Methotrexate + Paclitaxel + Trastuzumab		Completed	NCT01998906		PCD	2012Jul01	Expression confirmed	Yes	mEFS NA v 43.6% HR 0.65 95%CI 0.44-0.96 p=0.0275	4	NCT01998906	Untreated		Event free survival	229	115	116	Cyclophosphamide + Doxorubicin hydrochloride + Fluorouracil + Methotrexate + Paclitaxel																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Anthracycline + Docetaxel or Paclitaxel + Pertuzumab + Trastuzumab		Completed	NCT01966471		PCD	2019Nov27	Expression confirmed	Yes		4	NCT01966471	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1658	826	832	Anthracycline + Pertuzumab + Trastuzumab-emtansine																															94.1	92.75	0.97	0.71-1.32	0.827				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Eribulin + Pertuzumab + Trastuzumab		Terminated	NCT02000596	1303GCC	PCD	2015Nov01	Overexpression	No		4	NCT02000596			Overall Response Rate	2	2																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Anastrozole + Fulvestrant + Pertuzumab + Trastuzumab		Terminated	NCT02000596	1303GCC	PCD	2015Nov01	Overexpression	No		4	NCT02000596			Overall Response Rate	2	2																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Aromatase inhibitors + Carboplatin + Docetaxel + Goserelin + Pertuzumab + Radiotherapy + Trastuzumab		"Active, not recruiting"	NCT02003209	Premenopausal	PCD	2016Oct31	Expression confirmed	No		4	NCT02003209			"Complete response, Pathological complete response"	315	315		Carboplatin + Docetaxel + Pertuzumab + Radiotherapy + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Aromatase inhibitors + Carboplatin + Docetaxel + Pertuzumab + Radiotherapy + Trastuzumab		"Active, not recruiting"	NCT02003209	Postmenopausal	PCD	2016Oct31	Expression confirmed	No		4	NCT02003209			"Complete response, Pathological complete response"	315	315		Carboplatin + Docetaxel + Pertuzumab + Radiotherapy + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Endocrine therapy + Palbociclib		"Active, not recruiting"	NCT01864746	PENELOPE-B 	PCD	2020Oct01	Expression confirmed	Yes		2	10.1200/JCO.20.03639	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1250	631	619	Endocrine therapy + Placebo																															81.2	77.7	0.93	0.74-1.17	0.525				COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Eribulin + Pertuzumab + Trastuzumab		Recruiting	NCT03264547	EMERALD	ECD	2022Apr30	Expression confirmed	No		4	NCT03264547	Previously-treated		Progression free survival	480			Docetaxel or Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Jan07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03595592		ECD	2026Dec15	Expression confirmed	No		4	NCT03595592			Event free survival	650	650																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT01996267	TRAIN-2	PCD	2018Dec01	Overexpression	Yes	"pCR 67 v 68%, p=0.95"	1	30413379			"Complete response, Pathological complete response"	418	212	206	Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Epirubicin hydrochloride + Nab-paclitaxel		Completed	NCT01690702	GAIN-2	PCD	2018Sep30	No	Yes		2	10.1200/JCO.2020.38.15_suppl.516			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2887	1429	1428																																		1.01	0.83-1.23	0.91				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Chemotherapy		Recruiting	NCT03561740	SMART	ECD	2023Jun15	Expression confirmed	No		4	NCT03561740			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	794			Chemotherapy																																							COSO28394862	2022Jan10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Chemotherapy		Unknown	NCT01662128		ECD	2014Jun01	No	No		4	NCT01662128			Maximum tolerated dose/toxicity	600	600																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Nab-paclitaxel + Pertuzumab + Trastuzumab		Recruiting	NCT05429684	Experimental B	ECD	2024Feb28	Expression confirmed	No		4	NCT05429684	Previously-treated		Overall Response Rate	120	120																																									COSO28394862	2022Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Nab-paclitaxel + Pertuzumab + Trastuzumab		Recruiting	NCT04547907		ECD	2022Dec31	Expression confirmed	No		4	NCT04547907			"Complete response, Pathological complete response"	558			Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Taxane + Trastuzumab		Completed	NCT02019277	SAPPHIRE	PCD	2016Nov04	Expression confirmed	Yes	SAE 54%	4	NCT02019277			Maximum tolerated dose/toxicity	50	50			73.3		58.1-85.4						17.02			12.48-31.18																											COSO28394862	2021Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Taxane + Trastuzumab		Completed	NCT01572038	PERUSE	PCD	2019Sep20	Expression confirmed	Yes	SAE 37.3%	4	NCT01572038	Untreated		Maximum tolerated dose/toxicity	1436	1436			79.5		77.1-81.2						20.67			18.9-23.1																											COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT01358877	APHINITY	PCD	2016Dec19	Expression confirmed	Yes		4	NCT01358877	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	4804	2400	2404	Carboplatin + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Placebo + Trastuzumab																															92.9	91.3	0.81	0.66-1.0	0.0446				COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Paclitaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT01779206	ADAPT	PCD	2019Sep01	Yes	Yes	"pCR 3m 90 v 34%, DFS 5y 98.5 v 82 HR 0.14 95% CI 0.03-0.64"	2	10.1200/JCO.2021.39.15_suppl.503			"Complete response, Pathological complete response"	134	92	42	Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Lapatinib + Liposome-encapsulated doxorubicin citrate + Paclitaxel + Trastuzumab		Completed	NCT01426880	GeparSixto	PCD	2013May01	Expression confirmed	Yes	"pCR 32.8 v 36.8, p=0.581"	1	24794243			"Complete response, Pathological complete response"	273	137	136	Lapatinib + Liposome-encapsulated doxorubicin citrate + Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Inetetamab + Vinorelbine		Completed	NCT01291667	HOPES			Expression confirmed	No		4	NCT01291667			Progression free survival	330																																										COSO28394862	2021Nov29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab deruxtecan		Recruiting	NCT05113251	DESTINY-Breast11	ECD	2024Feb05	Yes	No		4	NCT05113251	Untreated		"Complete response, Pathological complete response"	624			Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Metformin		Completed	NCT01101438		PCD	2021Sep21	Expression confirmed	Yes		2	10.1158/1538-7445.SABCS21-GS1-08	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	620			Placebo																								0.53	0.30-0.98	0.04							0.64	0.43-0.95	0.026				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Placebo + Trastuzumab-emtansine		Completed	NCT01120184		PCD	2014Sep30	Expression confirmed	Yes		4	NCT01120184	Untreated		Progression free survival	730	367	363		64.6	67.5			20.7	21.2			14.1	15.2	0.91	0.73-1.13	0.31																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Aromatase inhibitors + Lapatinib		Completed	NCT01160211		PCD	2016Mar11	Overexpression	Yes	"PFS 5yr 36.7 v 35.9, HR 0.85, 95% CI 0.62-1.17, p=0.32"	4	NCT01160211	Previously-treated		Progression free survival	235	118	117	Aromatase inhibitors + Trastuzumab	18.6	13.7		0.283	11.1	8.4													33.9	29.9																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Aromatase inhibitors + Lapatinib + Trastuzumab		Completed	NCT01160211		PCD	2016Mar11	Overexpression	Yes	"PFS 5yr 48.3 v 35.9, HR 0.62, 95% CI 0.45-0.88, p=0.063"	4	NCT01160211	Previously-treated		Progression free survival	237	120	117	Aromatase inhibitors + Trastuzumab	31.7	13.7		0.0017	14	8.4													40	29.9																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Pertuzumab + Trastuzumab		Completed	NCT02586025		PCD	2017Oct23	Expression confirmed	Yes	"pCR 39.3 v 21.8, p=0.0014"	4	NCT02586025	Untreated		"Complete response, Pathological complete response"	329	219	110	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab	88.6	78.2		0.0125																																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Pertuzumab + Trastuzumab		Not yet recruiting	NCT04337658	FAVOR	ECD	2024Apr30	Expression confirmed	No		4	NCT04337658			Progression free survival	493	493																																									COSO28394862	2022Jan14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Pertuzumab + Trastuzumab		Completed	NCT01026142	PHEREXA	PCD	2015May29	Expression confirmed	Yes		4	NCT01026142	Previously-treated		Progression free survival	452	228	224	Capecitabine + Trastuzumab	40.5	32.9			11.9	6.92			11.1	9	0.82	0.65-1.02	0.073	11.68	9				63.6	54		37.2	28.1																COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Nelipepimut-S + Sargramostim		Completed	NCT01479244	PRESENT	PCD	2016Sep21	Expression confirmed	Yes		1	31036542	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	758	376	382	Sargramostim																															16.7	16.76	1.564	0.960-2.549	0.07				COSO28394862	2021Nov29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Trastuzumab-emtansine		Completed	NCT02131064	KRISTINE	PCD	2015Dec31	Expression confirmed	Yes	pCR 44.4 v 56.1%	4	NCT02131064	Untreated		"Complete response, Pathological complete response"	444	223	221	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2021Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride		Unknown	NCT03349177		ECD	2019Nov27	No	No		4	NCT03349177	Untreated		"Complete response, Pathological complete response"	200	200																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride		Unknown	NCT00798070	PANTHER	PCD	2016Apr01	Expression confirmed	Yes	"EFS 86.7 v 82.1%, HR 0.79, 95% CI 0.63-0.99, p=0.04, Primary outcome not met"	1	27825007			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2000	1001	999	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Lapatinib + Trastuzumab		Completed	NCT00769470	TRIO-US B07	PCD	2013Nov01	Overexpression	Yes	"pCR 49 v 28%, p=0.09"	1	33203854			"Complete response, Pathological complete response"		58	36	Carboplatin + Docetaxel + Lapatinib																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Radiotherapy + Trastuzumab		"Active, not recruiting"	NCT00769379		PCD	2019Dec31	Expression confirmed	Yes	Primary outcome not met	2	10.1200/JCO.2020.38.15_suppl.508			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1965	977	988	Radiotherapy																								0.85	0.48-1.51	0.59					86.4	84.3	0.84	0.66-1.05	0.13				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Gemcitabine		Completed	NCT00670878		PCD	2011Oct01	Overexpression	No		4	NCT00670878			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	799			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab		Terminated	NCT00625898	BETH	PCD	2013Jun01	Expression confirmed	Yes	No benefit of treatment	3	https://ascopost.com/issues/march-15-2014/adding-bevacizumab-to-adjuvant-chemotherapytrastuzumab-fails-to-improve-survival-in-her2-positive-breast-cancer/			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	278			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab																															91	89							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Lapatinib + Paclitaxel		Completed	NCT00667251		PCD	2012Aug01	Overexpression	Yes		4	NCT00667251			Progression free survival	537	270	267		56	58							9.13	13.63									75.6	77.7		20.8	21.8																COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Lapatinib		Unknown	NCT03085368		ECD	2018May01	Expression confirmed	No		4	NCT03085368			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	482			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab		Completed	NCT00593697		PCD	2014Nov01	Expression confirmed	Yes	Trastuzumab duration 9 vs 51 wks	1	29852043			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2174	1085	1089	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab																															88	90.5	1.39	1.12-1.72					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Taxane + Trastuzumab		Completed	NCT01120184		PCD	2014Sep30	Expression confirmed	Yes		4	NCT01120184	Untreated		Progression free survival	728	365	363		69.3	67.5			12.5	21.2	0.45-0.85		13.7	15.2	0.87	0.69-1.08	0.141																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Taxane + Trastuzumab		Completed	NCT01120184		PCD	2014Sep30	Expression confirmed	Yes		4	NCT01120184	Untreated		Progression free survival	732	365	367		69.3	64.6			12.5	20.7	0.43-0.84		13.7	14.1	0.91	0.73-1.13	0.313																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Nab-paclitaxel + Trastuzumab		Completed	NCT01583426		PCD	2018Dec01	Expression confirmed	Yes	pCR 62 v 54% p=0.13	1	26869049			"Complete response, Pathological complete response"	396	199	197	Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Bevacizumab + Carboplatin + Paclitaxel + Trastuzumab		Terminated	NCT00520975		PCD	2015Oct01	Overexpression	Yes	Slow accrual	4	NCT00520975	Untreated			96			Carboplatin + Paclitaxel + Placebo + Trastuzumab																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Lapatinib + Paclitaxel		Unknown	NCT00486668		PCD	2012Jun01	Expression confirmed	Yes	"pCR 48.0 v 46.7%, p=0.96"	1	24095300			"Complete response, Pathological complete response"	105	48	57	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Doxorubicin hydrochloride + Lapatinib + Paclitaxel + Trastuzumab		Unknown	NCT00486668		PCD	2012Jun01	Expression confirmed	Yes	"pCR 55.6 v 46.7, p=0.23"	1	24095300			"Complete response, Pathological complete response"	117	60	57	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Trastuzumab		Completed	NCT03705429		PCD	2022May11	Expression confirmed	No		4	NCT03705429				51	51		Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00464646		PCD	2009Dec01	Expression confirmed	Yes	pCR 46.6%	4	NCT00464646			"Complete response, Pathological complete response"	73	73																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00288002				Expression confirmed	Yes	pCR 31.3	1	20308670			"Complete response, Pathological complete response"	144	144																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Bevacizumab + Carboplatin + Docetaxel + Trastuzumab		Terminated	NCT00625898	BETH	PCD	2013Jun01	Expression confirmed	Yes	No benefit of treatment	3	https://ascopost.com/issues/march-15-2014/adding-bevacizumab-to-adjuvant-chemotherapytrastuzumab-fails-to-improve-survival-in-her2-positive-breast-cancer/			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3231			Carboplatin + Docetaxel + Trastuzumab																															92	92							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Liposome-encapsulated doxorubicin citrate + Paclitaxel + Trastuzumab		Unknown	NCT00294996				Expression confirmed	Yes		1	24401928			Progression free survival	364	181	183	Paclitaxel + Trastuzumab									16.1	14.5	0.84	0.65-1.08	0.174									33.6	29	0.74	0.61-1.03	0.083													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Fulvestrant + Lapatinib		Completed	NCT00390455		PCD	2014Jul01	Expression confirmed	Yes		4	NCT00390455			Progression free survival	64	24	30	Fulvestrant + Placebo									5.9	3.3																													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00309556		PCD	2009Nov01	Expression confirmed	Yes	pCR 38.6 v 26.5% p=0.212	1	24347519			"Complete response, Pathological complete response"	93	44	49																																								COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Bevacizumab + Docetaxel + Trastuzumab		Completed	NCT00391092		PCD	2014Aug01	Expression confirmed	Yes		4	NCT00391092			Progression free survival	424	216	208	Docetaxel + Trastuzumab									16.5	13.7	0.82	0.65-1.02	0.078									38.5	38.3	1.01	0.74-1.38	0.95													COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride		Completed	NCT00121992		PCD	2010Dec02	Expression confirmed	Yes	DFS 77.3 v 75%	4	NCT00121992			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	46	22	24	Cyclophosphamide + Doxorubicin hydrochloride + Fluorouracil																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Trastuzumab		Completed	NCT00148876		PCD	2011Jan01	Overexpression	No		4	NCT00148876			Time to progression	482	78	78	Capecitabine	48.1	27		0.0115										8.2	5.6	0.69	0.48-0.97	0.0338				25.5	20.4			0.257													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00567554	GeparQuinto	PCD	2011Aug01	Expression confirmed	Yes	"pCR 30.3 v 22.7, 95%CI 0.47-0.97, p=0.04"	1	22257523			"Complete response, Pathological complete response"	615	307	308	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Lapatinib																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Trastuzumab		Completed	NCT00288002				Expression confirmed	Yes	pCR 32.9	1	20308670			"Complete response, Pathological complete response"	146	146																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil		Unknown	NCT03349177		ECD	2019Nov27	No	No		4	NCT03349177	Untreated		"Complete response, Pathological complete response"	200	200																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil		Completed	NCT00087178		PCD	2014Mar01	Overexpression	Yes	Primary outcome not met	1	35230585			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2722			Cyclophosphamide + Doxorubicin hydrochloride																								1.06	0.84-1.35	0.61							1.09	0.92-1.29	0.31				COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Paclitaxel		Completed	NCT00075270		PCD	2006Oct01	Overexpression	Yes	"mEFS 8.1 v 5.0m,HR=0.49,95%CI 0.3-0.8,p=0.008 "	1	19620495			Time to progression	86	49	37	Paclitaxel																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Paclitaxel		Completed	NCT00281658		PCD	2010Jun18	Expression confirmed	Yes		4	NCT00281658			Overall survival	444	222	222	Paclitaxel + Placebo	69.3	49.5			9.3	5.8			9.7	6.5	0.52	0.42-0.64							74.8	55.9		27.8	20.5	0.64	0.49-0.82	0.0005													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Trastuzumab		"Active, not recruiting"	NCT01104571	EPHOS-B	PCD	2017Aug30	Expression confirmed	Yes	pCR 10.6 v 0%	3	https://www.ejcancer.com/article/S0959-8049(16)31960-8/pdf	Untreated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	117	66	51	Observation																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Trastuzumab		Completed	NCT00320385		PCD	2007Jun01	Expression confirmed	Yes		4	NCT00320385			Progression free survival	291	146	145	Lapatinib									2.77	1.87	0.73	0.57-0.93	0.008									11.9	9	0.75	0.53-1.07	0.11													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Trastuzumab		Terminated	NCT00968968		PCD	2014Feb21	Overexpression	Yes	Slow accrual	4	NCT00968968			Progression free survival	37	20	17	Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Trastuzumab		Completed	NCT00553358	Neo ALTTO	PCD	2010May27	Overexpression	Yes	"pCR 51.3 v 29.5, p=0.0001"	4	NCT00553358	Untreated		"Complete response, Pathological complete response"	301	152	149	Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Radiotherapy + Trastuzumab		Terminated	NCT00016276		PCD	2005Mar01	Expression confirmed	Yes		4	NCT00016276			"Complete response, Pathological complete response"	396			Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Radiotherapy																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Dexrazoxane + Doxorubicin hydrochloride + Paclitaxel + Radiotherapy + Trastuzumab		Terminated	NCT00016276		PCD	2005Mar01	Expression confirmed	Yes		4	NCT00016276			"Complete response, Pathological complete response"	396			Cyclophosphamide + Dexrazoxane + Doxorubicin hydrochloride + Paclitaxel + Radiotherapy																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Trastuzumab		Completed	NCT00054587		PCD	2009Jun01	Expression confirmed	Yes	"DFS 10yr 68 vs 60%, HR 0.77, 95% CI 0.57-1.03, p=0.079 "	1	31634648			Progression free survival	528	260	268																																								COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Gemcitabine + Trastuzumab		Terminated	NCT00440622		PCD	2008Nov01	Overexpression	Yes	Slow accrual	4	NCT00440622			Time to progression	90			Capecitabine + Trastuzumab																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Letrozole		Completed	NCT00073528		PCD	2008Jun03	Expression confirmed	Yes		4	NCT00073528			Progression free survival	167	89	88	Letrozole + Placebo									8.17	3	0.71	0.53-0.96	0.019																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Anastrozole + Trastuzumab		Completed	NCT00022672	TAnDEM	PCD	2009Oct01	Overexpression	Yes		1	19786670			Progression free survival	207	103	104	Anastrozole									4.8	2.4	0.63	0.47-0.84	0.0016																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Trastuzumab		"Active, not recruiting"	NCT01275677		PCD	2017Jul31	Expression confirmed	Yes		1	31821109			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3200	1598	1602	Chemotherapy																															89.8	89.2							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Trastuzumab		Completed	NCT01104935	RESPECT	PCD	2017Oct31	Overexpression	Yes	Primary outcome not met	1	32936713		Geriatric	"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	266	131	135	Agatolimod + Trastuzumab																															93.8	89.5			p=0.51				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Trastuzumab		"Active, not recruiting"	NCT00004935		PCD	2014Nov06	Overexpression	Yes		1	27998961			Time to progression	173	86	87	Chemotherapy + Trastuzumab														12.2	10.3	0.7	0.5-1.1	0.1				35.6	36.3	0.9		0.55													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Chemotherapy + Trastuzumab		Completed	NCT00448279	THOR	PCD	2010Sep01	Overexpression	Yes	PFS 58.6 v 58.6%%	4	NCT00448279	Previously-treated		Progression free survival	58	29	29	Chemotherapy	31	27.6							9.7	9.4												26.7	19.1																COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Unknown	NCT00629278	Short-HER	ECD	2010Dec01	Expression confirmed	Yes		1	30219886			"DFS, OS"	1254	627	626	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Trastuzumab																															88	85	1.13	0.89-1.42					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Trastuzumab		Completed	NCT00005970		PCD	2005Apr25	Overexpression	Yes		1	16236738			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	394	133	261	Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel																															87.1	75.4	0.48	0.39-0.59	<0.0001				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Paclitaxel + Trastuzumab		Not yet recruiting	NCT05388500	PHARE-C	ECD	2030Dec15	Expression confirmed	No		4	NCT05388500			Time to progression	800			Trastuzumab																																							COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Paclitaxel + Trastuzumab		Recruiting	NCT05189067		ECD	2025Jan31	Expression confirmed	No		4	NCT05189067			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	190			Docetaxel + Trastuzumab																																							COSO28394862	2022Feb14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Paclitaxel + Trastuzumab		Completed	NCT00003440		PCD	2004Jul01	No	No		4	NCT00003440			Response rate	580																																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00047255		PCD	2006Jan01	Overexpression	Yes		1	21115860			Time to progression	263			Docetaxel + Trastuzumab	72	72												11.1	10.4	0.914	0.694-1.203	0.57				37.1	37.4			0.99													COSO28394862	2022Aug22	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Trastuzumab		Completed	NCT00769470	TRIO-US B07	PCD	2013Nov01	Overexpression	Yes	"pCR 28 v 47%, p=0.14"	1	33203854			"Complete response, Pathological complete response"	70	36	34	Carboplatin + Docetaxel + Lapatinib																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Trastuzumab		Completed	NCT00038402		PCD	2004Nov01	Expression confirmed	No		4	NCT00038402			Complete remission	74	74																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03161353	PHERGain Cohort B PET non-responders	ECD	2022Nov01	Expression confirmed	Yes	"pCR 25.9%, 95% CI 15.3-39.0"	2	10.1200/JCO.2020.38.15_suppl.503			"Complete response, Pathological complete response"	58	58																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Not yet recruiting	NCT04858529	neoCARHP	ECD	2024Apr30	Expression confirmed	No		4	NCT04858529			"Complete response, Pathological complete response"	300			Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab		Not yet recruiting	NCT04858529	neoCARHP	ECD	2024Apr30	Expression confirmed	No		4	NCT04858529			"Complete response, Pathological complete response"	300			Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Disitamab vedotin		Recruiting	NCT04400695		ECD	2022Dec31	Expression confirmed	No		4	NCT04400695			Progression free survival	366			Physician's choice																																							COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT02896855	PUFFIN	PCD	2018Jun27	Expression confirmed	Yes		4	5348			Progression free survival	243	122	121	Docetaxel + Placebo + Trastuzumab									16.5	12.5	0.6	0.45-0.81	0.0008																										COSO28394862	2022Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT02402712	MetaPHER	PCD	2019Feb22	Expression confirmed	Yes		4	NCT02402712			Maximum tolerated dose/toxicity	276	276			75.6								18.7																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT02625441	BOLD-1	PCD	2021Dec31	Expression confirmed	No		4	NCT02625441			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1366			Docetaxel + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT00567190	CLEOPATRA	PCD	2011May13	Expression confirmed	Yes		4	NCT00567190	Untreated		Progression free survival	808	402	406	Docetaxel + Placebo + Trastuzumab					20.22	12.49	0.51-0.85		18.5	12.4	0.62	0.51-0.75	<0.0001									57.1	40.8	0.69	0.58-0.82	<0.0001													COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Trastuzumab Deruxtecan		Recruiting	NCT04784715	DESTINY-Breast09	ECD	2024Dec30	Expression confirmed	No		4	NCT04784715			Progression free survival	1134			Pertuzumab + Taxane + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Trastuzumab Deruxtecan		Recruiting	NCT04784715		ECD	2024Dec30	Expression confirmed	No		4	NCT04784715	Untreated		Progression free survival	1134			Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab Deruxtecan		Recruiting	NCT04622319	DESTINY-Breast05	ECD	2025Dec31	Expression confirmed	No		4	NCT04622319	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1600			Trastuzumab-emtansine																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT03523585	DESTINY-Breast02	PCD	2022Jun30	Expression confirmed	Yes	Primary outcome met	6	https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improved-pfs-in-mbc-in-destiny-breast02.html			Progression free survival	600			Capecitabine + Lapatinib																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT03523585	DESTINY-Breast02	PCD	2022Jun30	Expression confirmed	Yes	Primary outcome met	6	https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improved-pfs-in-mbc-in-destiny-breast02.html			Progression free survival	600			Capecitabine + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab Deruxtecan		Recruiting	NCT04739761	DESTINY-Breast12	ECD	2024Jan19	Expression confirmed	No		4	NCT04739761	Previously-treated		"PFS, ORR"	500	500																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab Deruxtecan		Recruiting	NCT05113251	DESTINY-Breast11	ECD	2024Feb05	Yes	No		4	NCT05113251	Untreated		"Complete response, Pathological complete response"	624			Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab Deruxtecan		Recruiting	NCT04784715		ECD	2024Dec30	Expression confirmed	No		4	NCT04784715	Untreated		Progression free survival	1134			Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine + Tucatinib		Recruiting	NCT04457596	CompassHER2	ECD	2028Jan01	Expression confirmed	No		4	NCT04457596	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1031			Placebo + Trastuzumab-emtansine																																							COSO28394862	2022Jan17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine + Tucatinib		Recruiting	NCT03975647	HER2CLIMB-02	ECD	2024Apr30	Expression confirmed	No		4	NCT03975647			Progression free survival	565			Placebo + Trastuzumab-emtansine																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pertuzumab + Trastuzumab		Terminated	NCT02000596	1303GCC	PCD	2015Nov01	Overexpression	No		4	NCT02000596			Overall Response Rate	2	2																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Atezolizumab + Cyclophosphamide + Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride		"Active, not recruiting"	NCT03726879	IMpassion050 PD-L1-	PCD	2021Feb05	Expression confirmed	Yes	pCR 60.7 v 53.8%	2	10.1016/j.annonc.2021.05.800			"Complete response, Pathological complete response"	236	117	119	Cyclophosphamide + Paclitaxel + Pertuzumab + Placebo + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Pyrotinib		"Active, not recruiting"	NCT03980054		ECD	2022Jul31	Expression confirmed	No		4	NCT03980054	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1192			Placebo																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine		Terminated	NCT02144012		PCD	2016Jan01	Expression confirmed	Yes	SAE 23.5 v 33.3%	4	NCT02144012	Untreated		Progression free survival	49	49		Docetaxel + Trastuzumab									10.3	8.2																													COSO28394862	2021Dec13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine		Completed	NCT01419197	TH3RESA	PCD	2013Feb01	Expression confirmed	Yes		4	NCT01419197			Progression free survival	602	404	198	Physician's choice									6.2	3.3	0.528	0.422-0.661	<0.0001																										COSO28394862	2021Nov26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine		"Active, not recruiting"	NCT02568839	PREDIX HER2	PCD	2019Feb01	Expression confirmed	Yes	"pCR 43.9 v 45.5%, p=0.82"	1	34383001				197	98	99	Docetaxel + Pertuzumab + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine		Completed	NCT01702571	Cohort 2	PCD	2020Jul31	Expression confirmed	Yes	AEPI 51.4%	4	NCT01702571	Previously-treated		Maximum tolerated dose/toxicity	181	181			29.6				14.2		11.1-24.4		5.7			5.5-7.0							39.6			29.5			-21.1														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab-emtansine		Completed	NCT01702571	Cohort 1	PCD	2020Jul31	Expression confirmed	Yes	AEPI 23.1%	4	NCT01702571	Previously-treated		Maximum tolerated dose/toxicity	2002	2002			29.3				13.8		12.2-15.0		6.8			5.8-7.6							47.1			27.2			25.5-28.7														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Paclitaxel + Trastuzumab		"Active, not recruiting"	NCT00770809		PCD	2014Jan31	Expression confirmed	Yes	"pCR 56 v 46%, p=0.13"	4	NCT00770809			"Complete response, Pathological complete response"	233	116	117	Paclitaxel + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Paclitaxel + Trastuzumab		Terminated	NCT00272987		PCD	2009Jul31	Overexpression	Yes	Slow accrual	4	NCT00272987			Overall Response Rate	63	63																																									COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib + Paclitaxel + Trastuzumab		"Active, not recruiting"	NCT01526369		PCD	2015Nov01	Overexpression	Yes		4	NCT01526369	Untreated		Progression free survival	65	31	34	Paclitaxel + Trastuzumab									24	19.3	0.827		0.6									45.6	53.8	1.05		0.89													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab + Vinorelbine		Completed	NCT00103233				Expression confirmed	No		4	NCT00103233			Progression free survival	292	146	146	Vinorelbine																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Everolimus + Trastuzumab + Vinorelbine		Completed	NCT01007942	BOLERO-3	PCD	2015Jun01	Overexpression	Yes		4	NCT01007942			Progression free survival	569	284	285	Placebo + Trastuzumab + Vinorelbine	40.8	37.2							7	5.78	0.78	0.65-0.95	0.0067						59.2	53.3		23.46	24.08																COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Everolimus + Trastuzumab + Vinorelbine		Completed	NCT00426530		PCD	2010Jun01	Overexpression	Yes		1	21107682	Previously-treated		Maximum tolerated dose/toxicity	50	50			19.1								7.09										83																				COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Everolimus + Paclitaxel + Trastuzumab		Completed	NCT00876395	BOLERO-1	PCD	2014May30	Overexpression	Yes		4	NCT00876395	Untreated		Progression free survival	719	480	239	Paclitaxel + Placebo + Trastuzumab	67.1	69		0.73					14.95	14.49	0.89	0.73-1.08	0.117									48.56	49.97																COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab		Completed	NCT02040935	HOMERUS	PCD	2018Sep14	Expression confirmed	Yes	SAE 8%	3	https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h	Previously-treated		Maximum tolerated dose/toxicity	125	125																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab		Completed	NCT02721641		PCD	2015Feb01	Overexpression	Yes	SAE 15.94%	4	NCT02721641	Previously-treated		Maximum tolerated dose/toxicity	69	69																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Trastuzumab		Recruiting	NCT01785420		ECD	2025Apr01	Overexpression	No		4	NCT01785420			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1100			Placebo																																							COSO28394862	2021Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Fulvestrant + Pertuzumab + Trastuzumab		Not yet recruiting	NCT04337658	FAVOR	ECD	2024Apr30	Expression confirmed	No		4	NCT04337658			Progression free survival	493	493																																									COSO28394862	2022Jan14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Endocrine therapy + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03161353	PHERGain Cohort B PET responders	ECD	2022Nov01	Expression confirmed	Yes	"pCR 37.9%, 95%CI 31.6-44.5"	2	10.1200/JCO.2020.38.15_suppl.503			"Complete response, Pathological complete response"	227	227																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Trastuzumab		Unknown	NCT00430001	HERNATA			Expression confirmed	Yes		1	21149659			Time to progression	284	141	143	Trastuzumab + Vinorelbine	59.3	59.3												15.3	12.4	0.94	0.71-1.25	0.67				38.8	35.7	1.01	0.71-1.42	0.98													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Trastuzumab		Completed	NCT00146549		PCD	2007Aug01	Expression confirmed	Yes		1	17614302			Overall Response Rate	81	41	40	Trastuzumab + Vinorelbine	51	40		0.37										8.5	6			0.09																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Pyrotinib + Trastuzumab		"Active, not recruiting"	NCT03588091		PCD	2021Apr30	Expression confirmed	No		4	NCT03588091			"Complete response, Pathological complete response"	355			Docetaxel + Placebo + Trastuzumab																																							COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Docetaxel + Pyrotinib + Trastuzumab		"Active, not recruiting"	NCT03863223		ECD	2022Dec30	Expression confirmed	No		4	NCT03863223			Progression free survival	590			Docetaxel + Placebo + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Lapatinib		Completed	NCT00820222		PCD	2012Jun11	Expression confirmed	Yes	IDMC recommended closure	4	NCT00820222	Previously-treated		Maximum tolerated dose/toxicity	540	271	269	Capecitabine + Trastuzumab	27	31.6		0.27	6.2	8.4			6.6	8.05	1.3	1.04-1.64	0.021	8.2	6.7				41.3	43.9	0.61	22.7	27.3		0.95-1.90	0.095													COSO28394862	2021Oct20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Lapatinib		Terminated	NCT00508274	EGF109491	PCD	2015Dec02	Expression confirmed	Yes		1	21527065			"Disease control rate, Clinical benefit rate"	52	52							6.93				6.34			4.93-9.82							57.7									0	23	7									COSO28394862	2021Oct15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Pyrotinib		Recruiting	NCT05429684	Experimental C	ECD	2024Feb28	Yes	No		4	NCT05429684	Previously-treated		Overall Response Rate	120	120																																									COSO28394862	2022Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Pyrotinib		Unknown	NCT03080805	PHOEBE	PCD	2019Mar31	Expression confirmed	Yes		1	33581774	Previously-treated		Progression free survival	266	134	132	Capecitabine + Lapatinib	90	68			11.1	7			12.5	6.8	0.39	0.27-0.56	<0.0001	12.5	6.8	0.39	0.27-0.57		98	78																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Capecitabine + Pyrotinib		"Active, not recruiting"	NCT02973737		ECD	2023Jun01	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.1001	Previously-treated		Progression free survival	279	185	94	Capecitabine + Placebo	68.6	16							11.1	4.1	0.18	0.13-0.26	<0.001																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 3	Lapatinib		Completed	NCT00374322	TEACH	PCD	2011Sep01	Overexpression	Yes	DFS 84 vs 81.5% p=0.286	4	NCT00374322			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	3147	1571	1576	Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Trastuzumab		Recruiting	NCT04928261		ECD	2023Sep01	Expression confirmed	No		4	NCT04928261	Previously-treated		Response rate	50	50																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Inetetamab + Nab-paclitaxel + Toripalimab		Not yet recruiting	NCT05291910		ECD	2024Dec31	Expression confirmed	No		4	NCT05291910			Progression free survival	70	70																																									COSO28394862	2022May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Patuximab + Pyrotinib + Trastuzumab		Not yet recruiting	NCT04929548		ECD	2022Jan05	Expression confirmed	No		4	NCT04929548			"Complete response, Pathological complete response"	20	20																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Capecitabine + Pyrrolidine + Radiotherapy		Recruiting	NCT04767828		ECD	2022Jun01	Expression confirmed	No		4	NCT04767828			Time to progression	43	43																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Cyclophosphamide + Docetaxel or Paclitaxel + Doxorubicin hydrochloride + Trastuzumab		Completed	NCT02419742		PCD	2021Jun24	Overexpression	No		4	NCT02419742	Previously-treated		Maximum tolerated dose/toxicity	110	110																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Tamoxifen + Trastuzumab		Recruiting	NCT02062489		ECD	2025May01	No	No		4	NCT02062489			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	688			Placebo + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Docetaxel or Paclitaxel + Trastuzumab		Completed	NCT01301729		PCD	2014Jul01	Expression confirmed	Yes		4	NCT01301729	Previously-treated		Progression free survival	32	32			81.3		63.6-92.8						9.9			6.28-13.63																											COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Inetetamab + Vinorelbine		Recruiting	NCT05131841		ECD	2022Dec30	Expression confirmed	No		4	NCT05131841			Maximum tolerated dose/toxicity	60	60																																									COSO28394862	2022Feb14	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Letrozole + Trastuzumab		Terminated	NCT00171847	eLEcTRA	PCD	2008Oct01	Expression confirmed	Yes	Slow accrual	1	21862331	Untreated		Time to progression	57	26	31		27	13		0.3124	11.4	12.2								14.1	3.3				65	39																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Capecitabine + Docetaxel + Trastuzumab		Completed	NCT00127933	XeNA	PCD	2009Apr01	Expressed/not	Yes	pCR 50.0 v 15.8%	4	NCT00127933			"Complete response, Pathological complete response"	129	101	28		23.5																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Docetaxel + Pertuzumab + Trastuzumab		Completed	NCT02445586		PCD	2018Sep26	Expression confirmed	Yes		4	NCT02445586			Maximum tolerated dose/toxicity	52																																										COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Trastuzumab Deruxtecan		Recruiting	NCT04739761	DESTINY-B12	ECD	2024Jan19	Expression confirmed	No		4	NCT04739761	Previously-treated		"PFS, ORR"	500	500																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Phase 4	Trastuzumab-emtansine		Completed	NCT02658734		PCD	2019Dec14	Expression confirmed	Yes	SAE 40.0%	4	NCT02658734	Previously-treated		Maximum tolerated dose/toxicity	70	70																																									COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Trastuzumab-emtansine		Unknown	NCT04202328		ECD	2020Jul31	Expression confirmed	No		4	NCT04202328			Progression free survival	1000	1000																																									COSO28394862	2022Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Chemotherapy + Lapatinib + Trastuzumab		Completed	NCT04001634		PCD	2019May15	Expression confirmed	Yes		1	32195186			"ORR, PFS, OS"	277	277			42.6																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Pyrotinib + Vinorelbine		Completed	NCT04517305		PCD	2021May15	Expression confirmed	Yes		1	33996589			Progression free survival	97	97			34.3								7.8																														COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Pyrotinib + Vinorelbine		Completed	NCT04850625		PCD	2021Jun15	Expression confirmed	Yes		1	34422652			Progression free survival	224	92	132	Capecitabine + Lapatinib									5	8.3			<0.001																										COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Inetetamab		Not yet recruiting	NCT04963608		ECD	2021Dec01	Expression confirmed	No		4	NCT04963608				100	100																																									COSO28394862	2022Jan18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Lapatinib + Trastuzumab		Completed	NCT02056080	TRASTYVERE	PCD	2014Jan01	Expression confirmed	Yes		1	31203575	Previously-treated		"Disease control rate, Clinical benefit rate"	111	111			21.7								3.9										34.8			21.6																	COSO28394862	2021Dec10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Chemotherapy + Trastuzumab		Unknown					Expression confirmed	Yes	Reduction in recurrence HR 0.66 95% CI 0.62-0.71 p<0?0001	1	34339645			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	13864	1966	2569	Chemotherapy																																							COSO28394862	2022Feb18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Disitamab vedotin		Unknown					Expression confirmed	Yes		2	10.1200/JCO.2021.39.15_suppl.1022			Not defined	70	70			42.9								6.6																														COSO28394862	2022Oct06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Disitamab vedotin		Unknown					Overexpression	Yes		2	10.1200/JCO.2021.39.15_suppl.1022				118	70	48		42.9	36.9							6.6	5.7																													COSO28394862	2022Oct12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Retrospective/Meta-analysis	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT05594082		ECD	2024Jul01	Expression confirmed	No		4	NCT05594082			Progression free survival	150	150																																									COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Radiotherapy		Unknown	NCT03101683		ECD	2019Apr30	Overexpression	No		4	NCT03101683			Unknown	28	28																																									COSO28394862	2022Jan07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride liposome + Pertuzumab + Trastuzumab		Recruiting	NCT05656079		ECD	2024Sep01	Expression confirmed	No		4	NCT05656079			Maximum tolerated dose/toxicity	204			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab																																							COSO28394862	2023Jan12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Chemotherapy + Empegfilgrastim		Recruiting	NCT04905329		ECD	2022Dec31	No	No		4	NCT04905329			"Complete response, Pathological complete response"	285	285																																									COSO28394862	2022Jan19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Chemotherapy + Stereotactic radiotherapy		Recruiting	NCT03978663	TRIO	ECD	2023Nov01	No	No		4	NCT03978663			"Complete response, Pathological complete response"	40	40																																									COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Pyrotinib + Trastuzumab + Vinorelbine		Unknown	NCT03947242		ECD	2020Jun01	Expression confirmed	No		4	NCT03947242	Previously-treated		Overall Response Rate	48	48																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Carboplatin + Docetaxel + Pyrotinib + Trastuzumab		Unknown	NCT03756064		ECD	2020Jul31	Expression confirmed	No	"pCR 71.4 v 36.7%, p<0.5"	2	10.1200/JCO.2021.39.15_suppl.574			"Complete response, Pathological complete response"	51	21	30	Carboplatin + Docetaxel + Placebo + Trastuzumab	100	83.3																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	2	Unknown	Radiotherapy + Tremelimumab		Completed	NCT02563925		PCD	2021Jul14	Expression confirmed	No		4	NCT02563925			"Disease control rate, Clinical benefit rate"	28	28																																									COSO28394862	2021Dec15	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and (PIK3CA_Exon9 or PIK3CA_Exon20) 				breast / carcinoma / NS	3	Phase 2	Buparlisib + Lapatinib		Suspended	NCT01589861	PIKHER2	ECD	2018Jan01	Yes	Yes		1	28950146	Previously-treated		Overall Response Rate	4	4																																2									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and ERBB3_unspecified				breast / carcinoma / NS	3	Phase 1	Lumretuzumab + Paclitaxel + Pertuzumab		Completed	NCT01918254	Cohort 2	PCD	2016Oct07	Expression confirmed	Yes	Primary outcome not met	1	29349598	Untreated		Maximum tolerated dose/toxicity	20	20			30								4.2										75																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and ERBB3_unspecified				breast / carcinoma / NS	3	Phase 1	Lumretuzumab + Paclitaxel + Pertuzumab		Completed	NCT01918254	Cohort 3	PCD	2016Oct07	Expression confirmed	Yes	Primary outcome not met	1	29349598	Untreated		Maximum tolerated dose/toxicity	13	13			55.5								8.2										76.9																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and ESR1_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and GATA3_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and NRG1_unspecified				breast / carcinoma / NS	3	Phase 1	MM-111		Completed	NCT00911898		PCD	2012Mar01	Overexpression	Yes	SAE 15.0%	4	NCT00911898	Previously-treated		Maximum tolerated dose/toxicity	20	20																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 1	Alpelisib + Elgemtumab + Trastuzumab		Completed	NCT02167854		PCD	2021Jul07	No	Yes		1	33947692	Previously-treated		Maximum tolerated dose/toxicity	17	17																															1	14									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 1	Fulvestrant + MEN1611 + Trastuzumab		"Active, not recruiting"	NCT03767335	B-PRECISE-01	ECD	2022Jul31	Yes	No		4	NCT03767335			Maximum tolerated dose/toxicity	62	62																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 1	MEN1611 + Trastuzumab		"Active, not recruiting"	NCT03767335	B-PRECISE-01	ECD	2022Jul31	Yes	No		4	NCT03767335			Maximum tolerated dose/toxicity	62	62																																									COSO28394862	2022Jun20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 2	Buparlisib + Paclitaxel + Trastuzumab		Completed	NCT01816594	NeoPHOEBE	PCD	2015Feb18	Yes	Yes	Serious adverse events	1	28923573	Untreated		"Complete response, Pathological complete response"	50	50																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 2	Endocrine therapy + Hyaluronidase + Inavolisib + Pertuzumab + Trastuzumab		Not yet recruiting	NCT05306041		ECD	2026Mar01	Expression confirmed	No		4	NCT05306041			"Complete response, Pathological complete response"	170			Endocrine therapy + Hyaluronidase + Pertuzumab + Trastuzumab																																							COSO28394862	2022May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 2	Alpelisib + Tucatinib		Recruiting	NCT05230810		ECD	2023Jun30	Expression confirmed	No		4	NCT05230810	Previously-treated		Progression free survival	40	40																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 2	Gedatolisib + Trastuzumab		Recruiting	NCT03698383		ECD	2021Oct01	Expression confirmed	No		2	10.1158/1538-7445.SABCS20-PS11-39			Overall Response Rate	15	15																																									COSO28394862	2022Sep20	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 2	Copanlisib + Pertuzumab + Trastuzumab		Recruiting	NCT04108858		ECD	2023Jun30	Yes	No		4	NCT04108858			Progression free survival	12	12		Pertuzumab + Trastuzumab																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 3	Endocrine therapy + Palbociclib + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT02947685	PATINA	ECD	2023May31	No	No		4	NCT02947685			Progression free survival	496			Fulvestrant + Pertuzumab + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 3	Alpelisib + Fulvestrant + Trastuzumab		Recruiting	NCT05063786	ALPHABET	ECD	2026Jul01	Yes	No		4	NCT05063786	Previously-treated		Progression free survival	300			Capecitabine + Eribulin + Trastuzumab + Vinorelbine																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 3	Alpelisib + Trastuzumab		Recruiting	NCT05063786	ALPHABET	ECD	2026Jul01	Yes	No		4	NCT05063786	Previously-treated		Progression free survival	300			Capecitabine + Eribulin + Trastuzumab + Vinorelbine																																							COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 3	Alpelisib + Pertuzumab + Trastuzumab		Recruiting	NCT04208178		ECD	2025Jun16	Yes	No		4	NCT04208178			Progression free survival	511			Pertuzumab + Placebo + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PIK3CA_unspecified				breast / carcinoma / NS	3	Phase 3	Endocrine therapy + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT02947685	PATINA	ECD	2023May31	No	No		4	NCT02947685			Progression free survival	496			Anastrozole + Exemstane + Letrozole + Pertuzumab + Trastuzumab																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PTEN_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Everolimus + Trastuzumab		Completed	NCT00317720		PCD	2013Feb01	No	Yes	PTEN loss decreased OS	1	21730275			"Disease control rate, Clinical benefit rate"	47	47											4.1										34										7	9									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Copanlisib + Pertuzumab + Trastuzumab		Recruiting	NCT04108858		ECD	2023Jun30	Yes	No		4	NCT04108858			Progression free survival	12	12		Pertuzumab + Trastuzumab																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and TBX3_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and TOP2A_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Trastuzumab		Completed	NCT00493649		PCD	2013Apr01	Expression confirmed	Yes	DFS 24m 97.8%	4	NCT00493649			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	190	190																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and TOP2A_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Fluorouracil + Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT02339532		PCD	2019Oct07	Expression confirmed	No		4	NCT02339532			"Complete response, Pathological complete response"	86	86																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and TP53_unspecified				breast / carcinoma / NS	3	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561	IPATHER	ECD	2023Feb12	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and TP53_unspecified 				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Goserelin + Pertuzumab + Radiotherapy + Tamoxifen + Trastuzumab		"Active, not recruiting"	NCT02624973	PETREMAC ExpF Premenopausal	PCD	2020Jun01	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and TP53_unspecified 				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Letrozole + Pertuzumab + Radiotherapy + Trastuzumab		"Active, not recruiting"	NCT02624973	PETREMAC ExpF Postmenopausal	PCD	2020Jun01	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB2	ERBB2_unspecified and WT1_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + GSK2302024A + Paclitaxel + Trastuzumab		Terminated	NCT01220128	INDUCT Cohort C	PCD	2014Nov14	Expression confirmed	Yes	SAE 45.5 v 25.0%	4	NCT01220128			Maximum tolerated dose/toxicity	15	11	4	Carboplatin + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + Paclitaxel + Placebo + Trastuzumab																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB3	ERBB3_unspecified				breast / carcinoma / NS	3	Phase 1	Patritumab deruxtecan		Recruiting	NCT04610528	TOT-HER3	PCD	2022Jan30	Expression confirmed	Yes	"CS increase p=0.028, efficacy not correlated with expression level"	2	10.1158/1538-7445.SABCS21-PD13-04			CelTIL score	30	30																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB3	ERBB3_unspecified				breast / carcinoma / NS	3	Phase 2	Patritumab deruxtecan		"Active, not recruiting"	NCT02980341		PCD	2021Aug16	Expression confirmed	Yes		4	NCT02980341			Clinical activity	33	33			30																		45																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB3	ERBB3_unspecified				breast / carcinoma / NS	3	Phase 2	Patritumab deruxtecan		Recruiting	NCT04965766	ICARUS-BREAST	ECD	2023Jun11	Overexpression	No		4	NCT04965766	Previously-treated		Overall Response Rate	100	100																																									COSO28394862	2022Apr06	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB3	ERBB3_unspecified				breast / carcinoma / NS	3	Phase 2	Patritumab deruxtecan		"Active, not recruiting"	NCT02980341		PCD	2021Aug16	Expression confirmed	Yes		4	NCT02980341			Clinical activity	31	31			10																		16																				COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB4	ERBB4_unspecified				breast / carcinoma / NS	3	Phase 2	Chemotherapy + Inetetamab + Pyrotinib		Recruiting	NCT04681911		ECD	2023Sep09	Yes	No		4	NCT04681911	Previously-treated		Overall Response Rate	71	71																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB4	ERBB4_unspecified and CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab		Suspended	NCT03125928		ECD	2022Dec01	Overexpression	No		4	NCT03125928			Response rate	50	50																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ERBB4	ERBB4_unspecified and CD274_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib		Recruiting	NCT04872985		ECD	2023Dec31	No	No		4	NCT04872985			"Complete response, Pathological complete response"	140			Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Placebo																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ESR1	ESR1_unspecified				breast / carcinoma / NS	3	Phase 1	Erdafitinib + Fulvestrant + Palbociclib		"Active, not recruiting"	NCT03238196		ECD	2022Dec31	No	No		4	NCT03238196			Maximum tolerated dose/toxicity	35	35																																									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FANCL	FANCL_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 1	Infigratinib + Iohexol + Iopamidol + Tamoxifen		Terminated	NCT04504331		PCD	2021Oct22	Yes	No		4	NCT04504331			Maximum tolerated dose/toxicity	4	4																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Expression confirmed	Yes		2	10.1158/1538-7445.AM2021-CT173	Previously-treated		"Disease control rate, Clinical benefit rate"	27	27			7		24-Jan																29									0	2	5									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Futibatinib		Recruiting	NCT04024436		ECD	2022Dec31	Yes	No		4	NCT04024436			Overall Response Rate	168	168																																									COSO28394862	2021Nov01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Letrozole + Nintedanib		Completed	NCT02619162		PCD	2017Nov01	No	Yes	Primary outcome met	1	31126332	Previously-treated		Unknown	19	19																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547 + Fulvestrant		Completed	NCT01202591	GLOW	PCD	2014Sep01	Expression confirmed	Yes	Slow accrual	2	NCT01202591	Previously-treated		Maximum tolerated dose/toxicity	9	5	4	Fulvestrant																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547 + Letrozole		Completed	NCT01791985	RADICAL	PCD	2016Nov01	No	Yes		2	10.1200/JCO.2017.35.15_suppl.1059	Previously-treated		Maximum tolerated dose/toxicity	56	56											3.1			2.4-5.4							25										2	11									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547 + Anastrozole		Completed	NCT01791985	RADICAL	PCD	2016Nov01	No	Yes		2	10.1200/JCO.2017.35.15_suppl.1059	Previously-treated		Maximum tolerated dose/toxicity	56	56											3.1			2.4-5.4							25										2	11									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Nintedanib + Pembrolizumab		Terminated	NCT02389764		PCD	2018Jun08	No	Yes	Slow accrual	4	NCT02389764			Unknown	10	10																																									COSO28394862	2022Jul29	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547		Completed	NCT01202591	GLOW	PCD	2014Sep01	Expression confirmed	Yes	Slow accrual	2	NCT01202591	Previously-treated		Maximum tolerated dose/toxicity	127																																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547		Unknown	NCT01795768		ECD	2014Sep01	Expression confirmed	Yes		2	10.1200/jco.2015.33.15_suppl.2508	Previously-treated		Tumour volume	8	8			12.5																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified				breast / carcinoma / NS	3	Phase 2	Pemigatinib		Recruiting	NCT05560334		ECD	2024Sep08	Yes	No		4	NCT05560334	Previously-treated		Overall Response Rate	20	20																																									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified or FGFR4_unspecified				breast / carcinoma / NS	3	Phase 1	Erdafitinib + Fulvestrant + Palbociclib		"Active, not recruiting"	NCT03238196		ECD	2022Dec31	Overexpression	Yes		2	10.1158/1538-7445.SABCS20-PD1-03			Maximum tolerated dose/toxicity	18	18											3																					8									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR1	FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified or FGFR4_unspecified				breast / carcinoma / NS	3	Phase 2	Anlotinib + Fulvestrant		Recruiting	NCT04936295		ECD	2023Jun01	Yes	No		4	NCT04936295			"Disease control rate, Clinical benefit rate"	61	61																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR2	FGFR2_unspecified				breast / carcinoma / NS	3	Case study	Dovitinib		Unknown					Expression confirmed	Yes		1	23658459			Unknown	2	2																															2										COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR2	FGFR2_unspecified				breast / carcinoma / NS	3	Phase 1	Infigratinib + Iohexol + Iopamidol + Tamoxifen		Terminated	NCT04504331		PCD	2021Oct22	Yes	No		4	NCT04504331			Maximum tolerated dose/toxicity	4	4																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR2	FGFR2_unspecified				breast / carcinoma / NS	3	Phase 2	Futibatinib		Recruiting	NCT04024436		ECD	2022Dec31	Yes	No		4	NCT04024436			Overall Response Rate	168	168																																									COSO28394862	2021Nov01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR3	FGFR3_unspecified				breast / carcinoma / NS	3	Case study	Dovitinib		Unknown					Expression confirmed	Yes		1	23658459			Unknown	2	2																																2									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR3	FGFR3_unspecified				breast / carcinoma / NS	3	Phase 1	Infigratinib + Iohexol + Iopamidol + Tamoxifen		Terminated	NCT04504331		PCD	2021Oct22	Yes	No		4	NCT04504331			Maximum tolerated dose/toxicity	4	4																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
FGFR3	FGFR3_unspecified				breast / carcinoma / NS	3	Phase 2	Futibatinib		Recruiting	NCT04024436		ECD	2022Dec31	Yes	No		4	NCT04024436			Overall Response Rate	168	168																																									COSO28394862	2021Nov01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
KRAS	KRAS_unspecified				breast / carcinoma / NS	3	Phase 1	CYH33 + Fulvestrant		Not yet recruiting	NCT04856371		ECD	2022Mar01	No	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
KRAS	KRAS_unspecified				breast / carcinoma / NS	3	Phase 1	CYH33 + Letrozole + Palbociclib		Not yet recruiting	NCT04856371		ECD	2022Mar01	No	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
KRAS	KRAS_unspecified				breast / carcinoma / NS	3	Phase 1	CYH33 + Fulvestrant + Palbociclib		Not yet recruiting	NCT04856371		ECD	2022Mar01	No	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
KRAS	KRAS_unspecified				breast / carcinoma / NS	3	Phase 2	Paclitaxel + Pelareorep		Completed	NCT01656538	IND213	PCD	2016Nov18	No	Yes		5	https://immuno-oncologynews.com/reolysin/			Progression free survival	81	81																								17.4	10.4	0.65	0.46-0.91	0.1													COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
MAP2K1	MAP2K1_unspecified				breast / carcinoma / NS	3	Phase 2	Selumetinib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
MTOR	MTOR_unspecified				breast / carcinoma / NS	3	Phase 2	Vistusertib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
NF1	NF1_unspecified				breast / carcinoma / NS	3	Phase 1	TAS0612		Recruiting	NCT04586270	Cohort A	ECD	2023Oct01	Yes	No		4	NCT04586270			Overall Response Rate	242	242																																									COSO28394862	2022Jan25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
NF1	NF1_unspecified				breast / carcinoma / NS	3	Phase 2	Fulvestrant + Mirdametinib		Recruiting	NCT05054374		ECD	2024Sep14	Yes	No		4	NCT05054374			Maximum tolerated dose/toxicity	150	150																																									COSO28394862	2021Nov19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
NF1	NF1_unspecified				breast / carcinoma / NS	3	Phase 2	Binimetinib + Fulvestrant		Not yet recruiting	NCT05554354		ECD	2026Nov01	Yes	No		4	NCT05554354			Progression free survival	95	95																																									COSO28394862	2022Oct03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
NF1	NF1_unspecified				breast / carcinoma / NS	3	Phase 2	Famitinib + SHR7390		Recruiting	NCT04355858	MULAN	ECD	2023May01	Yes	No		4	NCT04355858			Overall Response Rate	319	319																																									COSO28394862	2022Jul04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Niraparib		Not yet recruiting	NCT05232006		ECD	2024Sep01	Yes	No		4	NCT05232006			Overall Response Rate	12	12																																									COSO28394862	2022Nov07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Not yet recruiting	NCT04756765		ECD	2024Mar01	Yes	No		4	NCT04756765			Overall Response Rate	30	30																																									COSO28394862	2022Nov07	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PDGFRB	PDGFRB_unspecified				breast / carcinoma / NS	3	Phase 2	Famitinb		Recruiting	NCT04355858	MULAN	ECD	2023May01	Yes	No		4	NCT04355858			Overall Response Rate	319	319																																									COSO28394862	2022Jul04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_Exon9 or PIK3CA_Exon20				breast / carcinoma / NS	3	Phase 2	Alpelisib + Fulvestrant		Terminated	NCT03386162	SAFIR PI3K	PCD	2022Nov18	No	Yes	Slow accrual	1	36071165	Previously-treated		Progression free survival	31			Chemotherapy																																							COSO28394862	2022Dec09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_H1047R	55873195		p.H1047R	breast / carcinoma / NS	3	Phase 1	Palbociclib + Taselisib		Unknown	NCT02389842	PIPA	PCD	2018Oct31	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3087	Previously-treated		Maximum tolerated dose/toxicity	1	1																															1										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Approved FDA	Alpelisib + Fulvestrant	Required	"Active, not recruiting"	NCT02437318	SOLAR-1	PCD	2018Jun12	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212526s007lbl.pdf	Previously-treated		Progression free survival	341	169	172	Fulvestrant + Placebo	35.7	16.2							11	5.7	0.65	0.50-0.85	0.0013																										COSO28394862	2023Jan23	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Buparlisib + Fulvestrant		Completed	NCT01339442		PCD	2016Dec21	No	Yes	Response not correlated with PIK3CA mutation status	1	26563128	Untreated	Postmenopausal	Maximum tolerated dose/toxicity	29	29																													58.6												COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Fulvestrant + RLY2608		Recruiting	NCT05216432		ECD	2025Jan31	Yes	No		4	NCT05216432			Maximum tolerated dose/toxicity	190	190																																									COSO28394862	2022Jan31	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Inavolisib + Letrozole + Palbociclib		Recruiting	NCT03006172		ECD	2022Nov30	Yes	Yes		2	10.1158/1538-7445.SABCS19-P1-19-46			Maximum tolerated dose/toxicity	31	31			42																		76										12	13									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	CYH33 + Letrozole + Palbociclib		Not yet recruiting	NCT04856371		ECD	2022Mar01	Yes	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	CYH33 + Fulvestrant + Palbociclib		Not yet recruiting	NCT04856371		ECD	2022Mar01	Yes	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	CYH33 + Fulvestrant		Not yet recruiting	NCT04856371		ECD	2022Mar01	Yes	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2022Jan24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Paclitaxel + Sapanisertib		Completed	NCT02412722		PCD	2018May31	Yes	Yes		1	29464110			Absorption rate	15	15			20																		53.3									1	2										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Palbociclib + Pictilisib		Unknown	NCT02389842	PIPA	PCD	2018Oct31	Yes	No		4	NCT02389842	Previously-treated		Maximum tolerated dose/toxicity	93	93																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Alpelisib + Trastuzumab-emtansine		Completed	NCT02038010		PCD	2015Apr15	No	Yes	Primary outcome met	4	NCT02038010	Previously-treated		Maximum tolerated dose/toxicity	6	6											10.6																														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Anastrozole + Fulvestrant + MK2206		Completed	NCT01344031		PCD	2011Jul01	No	Yes		1	26783290	Previously-treated	Postmenopausal	Maximum tolerated dose/toxicity	26	26																5.8					42										2										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Alpelisib + Enzalutamide		Recruiting	NCT03207529		ECD	2020Dec31	No	No		4	NCT03207529	Previously-treated		Maximum tolerated dose/toxicity	28	28																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Capivasertib		"Active, not recruiting"	NCT01226316		PCD	2019Apr26	Yes	Yes		1	29066505			Maximum tolerated dose/toxicity	26	26																															12										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Palbociclib + Taselisib		Unknown	NCT02389842	PIPA	PCD	2018Oct31	Yes	No		4	NCT02389842	Previously-treated		Maximum tolerated dose/toxicity	93	93																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Buparlisib + Letrozole		Completed	NCT01248494	VICC BRE 1055	PCD	2012Dec01	No	Yes	Response not correlated with PIK3CA mutation status	1	24663045	Untreated	Postmenopausal	Unknown	51	51																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Dactolisib + Letrozole		Completed	NCT01248494	VICC BRE 1055	PCD	2012Dec01	No	No		1	24663045	Untreated	Postmenopausal	Maximum tolerated dose/toxicity	72	72																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Buparlisib + Letrozole		Completed	NCT01923168		PCD	2017Jul07	No	Yes	Serious adverse events 27%	4	NCT01923168	Untreated	Postmenopausal	"CR, ORR"	81	81																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Nab-paclitaxel + Tilarginine acetate		Not yet recruiting	NCT05660083		ECD	2026Dec01	No	No		4	NCT05660083			Overall Response Rate	36	36																																									COSO28394862	2023Jan09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Elacestrant		Not yet recruiting	NCT05563220	ELEVATE Arm A	ECD	2024Dec31	Yes	No		4	NCT05563220			Maximum tolerated dose/toxicity	322	322																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Evexomostat		Recruiting	NCT05455619	Amelia-1	ECD	2026Mar01	Yes	No		4	NCT05455619			Maximum tolerated dose/toxicity	52	52																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant + Metformin		"Active, not recruiting"	NCT04300790	METALLICA	ECD	2023Dec31	Yes	No		4	NCT04300790	Previously-treated			68	68																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Dapagliflozin + Fulvestrant		Recruiting	NCT05025735		ECD	2022Dec01	Yes	No		4	NCT05025735			Hyperglycemia	25	25																																									COSO28394862	2021Nov17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Chemotherapy + Inetetamab + Pyrotinib		Recruiting	NCT04681911		ECD	2023Sep09	Yes	No		4	NCT04681911	Previously-treated		Overall Response Rate	71	71																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Ipatasertib + Palbociclib		Not yet recruiting	NCT04920708		ECD	2023Aug01	No	No		4	NCT04920708			Progression free survival	324			Fulvestrant + Palbociclib																																							COSO28394862	2021Aug24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel		Unknown	NCT03273595		ECD	2019Jul01	Expression confirmed	No		4	NCT03273595			"Complete response, Pathological complete response"	100			Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + TQB3525		Unknown	NCT04355520		ECD	2021Jun01	Yes	No		4	NCT04355520			Maximum tolerated dose/toxicity	42	42																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Nab-paclitaxel		Completed	NCT02379247		PCD	2017Sep21	Comparison with wt	Yes		1	33602685			Overall Response Rate	42	17	25										11.9	7.5	0.44	0.21-0.93	0.027						100	68	0.013	26.7	14.9	0.59	0.27-1.29	0.19													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Nab-paclitaxel		"Active, not recruiting"	NCT04216472		ECD	2022Dec31	Yes	No		4	NCT04216472			"Complete response, Pathological complete response"	8	8																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Eribulin		Suspended	NCT04345913		ECD	2022Dec31	No	No		4	NCT04345913			Progression free survival	18	18																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Atezolizumab + Capecitabine + Ipatasertib		"Active, not recruiting"	NCT03853707		ECD	2023Jun21	No	No		4	NCT03853707			Progression free survival	28	28																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Ipatasertib		"Active, not recruiting"	NCT03853707		ECD	2023Jun21	No	No		4	NCT03853707			Progression free survival	28	28																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT03853707		ECD	2023Jun21	No	No		4	NCT03853707			Progression free survival	28	28																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Everolimus + Nab-paclitaxel		Recruiting	NCT03805399	FUTURE group G	ECD	2022Dec01	Yes	Yes		1	32719455			Overall Response Rate	2	2			50																																						COSO28394862	2022Dec01	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Abemaciclib + Copanlisib + Fulvestrant		Recruiting	NCT03939897		ECD	2023Nov01	No	No		4	NCT03939897			Progression free survival	204			Abemaciclib + Fulvestrant																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Abemaciclib + Copanlisib + Fulvestrant		Recruiting	NCT03939897		ECD	2023Nov01	Yes	No		4	NCT03939897			Progression free survival	204			Abemaciclib + Fulvestrant																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Canagliflozin + Serabelisib		Unknown	NCT04073680		ECD	2021Jul15	Yes	No		4	NCT04073680			Response rate	60	60																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Letrozole		Terminated	NCT03128619	Arm A	PCD	2022Mar31	No	No		4	NCT03128619	Untreated	Postmenopausal	Change in Ki-67 expression	10			Letrozole + Palbociclib																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Fulvestrant		Withdrawn	NCT03803761		PCD	2022Feb19	Yes	Yes	Slow accrual	4	NCT03803761	Previously-treated	Postmenopausal	Maximum tolerated dose/toxicity	0	0																																									COSO28394862	2022May05	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Letrozole + Palbociclib		Terminated	NCT03128619	Arm B	PCD	2022Mar31	No	No		4	NCT03128619	Untreated	Postmenopausal	Change in Ki-67 expression	10			Copanlisib + Letrozole																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Atezolizumab + Carboplatin		"Active, not recruiting"	NCT03206203		ECD	2022Nov30	No	No		4	NCT03206203			Progression free survival	106																																										COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Capivasertib + Fulvestrant		"Active, not recruiting"	NCT01992952	FAKTION	PCD	2019Mar01	No	Yes		2	10.1200/JCO.2019.37.15_suppl.1005	Previously-treated	Postmenopausal	Progression free survival	140	69	71	Fulvestrant + Placebo									10.3	4.8	0.57	0.39-0.84	0.0017									26	20	0.59	0.34-1.05	0.071													COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Gemcitabine + Panitumumab		Completed	NCT00894504		PCD	2014Sep01	No	Yes	"No benefit of treatment, Response not correlated with mutation status"	1	27340049			Progression free survival	71	71			42								4.4													11.6						1	29										COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Letrozole + Taselisib		Completed	NCT02273973	LORELEI	PCD	2017Mar13	No	Yes	Response not correlated with PIK3CA mutation status	2	10.1093/annonc/mdx440.001		Postmenopausal	Overall Response Rate	334			Letrozole + Placebo	50	39.3		0.049																																			COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Apitolisib + Fulvestrant		Completed	NCT01437566		PCD	2016Apr01	No	Yes	Serious adverse events	1	27155741	Previously-treated	Postmenopausal	Progression free survival	30			Fulvestrant																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Anastrozole + Goserelin + MK2206		Terminated	NCT01776008		PCD	2015May01	Yes	Yes	Primary outcome not met	4	NCT01776008			"Complete response, Pathological complete response"	16	16																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Anastrozole + MK2206		Terminated	NCT01776008		PCD	2015May01	Yes	Yes	Primary outcome not met	4	NCT01776008		Postmenopausal	"Complete response, Pathological complete response"	16	16																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	MK2206		Terminated	NCT01319539		PCD	2013Jul01	No	Yes	Toxicity issues	4	NCT01319539			Marker phosphorylation	12	12																																									COSO28394862	2022Feb18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Anastrozole + Palbociclib		"Active, not recruiting"	NCT01723774	Arm 2	PCD	2021Apr13	Yes	Yes	CCA 15d 100%	4	NCT01723774			Cell cycle arrest	16	16			76.9																																						COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Inavolisib		Not yet recruiting	NCT05332561	COGNITION-GUIDE Arm 2	ECD	2029Apr01	Yes	No		4	NCT05332561			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	240	240																																									COSO28394862	2022Apr25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Capivasertib + Paclitaxel		Completed	NCT01625286	BEECH	PCD	2017Jan28	Yes	Yes	No benefit of treatment	4	NCT01625286			Progression free survival	110	54	56	Placebo									10.9	8.4	0.8	0.6-1.06	0.308																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Capivasertib + Paclitaxel		Unknown	NCT02423603	PAKT	ECD	2020Jun01	No	Yes		2	10.1200/JCO.2018.36.15_suppl.1007			Progression free survival	140	70	70	Paclitaxel + Placebo									5.9	4.2	0.75	0.52-1.08	0.06									19.1	12.6	0.64	0.4-1.01	0.02													COSO28394862	2022Sep12	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Ipatasertib + Paclitaxel		Completed	NCT02162719	LOTUS	PCD	2016Jun07	Yes	Yes		1	28800861	Untreated		Unknown	32	26	16		50	44			11.2	6.1			9	4.9	0.44	0.20-0.99	0.041						54	44																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Cisplatin + Pictilisib		Terminated	NCT01918306		PCD	2014Dec01	No	Yes	Serious adverse events	4	NCT01918306			"MTD, ORR, Toxicity"	11	11																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Pictilisib		Completed	NCT01437566	Part 2	PCD	2016Apr01	Yes	Yes	No benefit of treatment	1	27155741	Previously-treated	Postmenopausal		61	41	20	Fulvestrant + Placebo	7.3	5		0.73					5.4	10	1.07	0.53-2.18	0.84																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Pictilisib		Completed	NCT01437566	Part 1 	PCD	2016Apr01	Yes	Yes	No benefit of treatment	1	27155741	Previously-treated	Postmenopausal		70	38	32	Fulvestrant + Placebo									6.5	5.1	0.73	0.42-1.28	0.27																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Letrozole		"Active, not recruiting"	NCT03056755	BYLieve	PCD	2021Jun14	No	No		4	NCT03056755	Previously-treated		Progression free survival	382	382																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Letrozole		Completed	NCT01923168		PCD	2017Jul07	Yes	Yes	Primary outcome not met	2	10.1158/1078-0432.CCR-18-3160	Untreated	Postmenopausal	"CR, ORR"	257	131	126	Letrozole + Placebo	43	45																																					COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Ganitumumab		Terminated	NCT01708161	Arm 1	PCD	2014Dec26	Yes	Yes	No benefit of treatment	2	10.1016/S0959-8049(16)30205-2			Overall Response Rate	47	47																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT05392608	SEQUEL-Breast	ECD	2024Dec01	Yes	No		4	NCT05392608	Previously-treated		Progression free survival	130	130																																									COSO28394862	2022Oct03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Terminated	NCT04862143	TELEPIK	PCD	2022Sep19	Yes	No		4	NCT04862143			Quality of life	2	2																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT04762979		ECD	2024Jan01	Yes	No		4	NCT04762979	Previously-treated		Progression free survival	44	44																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT04524000		ECD	2023Jun30	Yes	No		4	NCT04524000			Overall Response Rate	50	50																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT04544189		ECD	2023Mar30	Yes	No		4	NCT04544189			Progression free survival	135			Alpelisib + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		"Active, not recruiting"	NCT03056755	BYLieve	PCD	2021Jun14	No	Yes	PFS 6m 50.4%	1	33794206	Previously-treated		Progression free survival	121	121			17									7.3		6.0-8.3										17.3			25-Nov														COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Paclitaxel + Pilaralisib + Trastuzumab		Completed	NCT01042925		PCD	2012Dec01	No	Yes	Response not correlated with PIK3CA mutation status	1	25537644	Previously-treated		Unknown	20	20																															4										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Pilaralisib + Trastuzumab		Completed	NCT01042925		PCD	2012Dec01	No	Yes	Response not correlated with PIK3CA mutation status	1	25537644	Previously-treated		Unknown	21	21																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Paclitaxel + Pictilisib		Completed	NCT01740336	PEGGY	PCD	2015Oct20	Yes	Yes	No benefit of treatment	1	27573562	Previously-treated		Unknown	183			Paclitaxel																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Buparlisib + Fulvestrant		Terminated	NCT01633060	BELLE-3	PCD	2016May23	No	Yes	Serious adverse events	1	29223745	Previously-treated		Progression free survival	432	289	143	Fulvestrant + Placebo									3.9	1.8	0.67	0.53-0.84	0.0003																										COSO28394862	2022Aug16	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Inavolisib		Not yet recruiting	NCT05646862		ECD	2028May31	Yes	No		4	NCT05646862	Previously-treated		Progression free survival	400	400																																									COSO28394862	2023Jan09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Ribociclib		Not yet recruiting	NCT05625087	SAFIR 03 ARRIBA	ECD	2028Jul01	Yes	No		4	NCT05625087			Progression free survival	162	162																																									COSO28394862	2023Jan09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Inavolisib + Palbociclib		Recruiting	NCT04191499		ECD	2025Sep19	Yes	No		4	NCT04191499			Progression free survival	400			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022Jan13	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Capivasertib + Fulvestrant + Palbociclib		Recruiting	NCT04862663	CAPItello-292	ECD	2025Oct07	Yes	No		4	NCT04862663			Progression free survival	700			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Ipatasertib + Paclitaxel + Placebo		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Atezolizumab + Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Capivasertib + Fulvestrant		Recruiting	NCT04305496	CAPItello-291	PCD	2022Aug15	No	No		4	NCT04305496			Progression free survival	834			Fulvestrant + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Ipatasertib		Recruiting	NCT04650581	FINER	ECD	2024Jun30	No	No		4	NCT04650581			Progression free survival	250			Fulvestrant + Placebo																																							COSO28394862	2021Nov02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Ipatasertib + Palbociclib		"Active, not recruiting"	NCT04060862		ECD	2023Apr30	No	No		4	NCT04060862			Progression free survival	20			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Alpelisib + Nab-paclitaxel		Recruiting	NCT04251533	EPIK-B3	ECD	2026Apr10	Yes	No		4	NCT04251533			"PFS, ORR"	566	566		Nab-paclitaxel + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Trastuzumab		Completed	NCT00829166	EMILIA	PCD	2012Jul01	Yes	Yes		1	26920887	Previously-treated		"OS, PFS"	79	40	39	Capecitabine + Lapatinib									10.9	4.3	0.45	0.25-0.82																											COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Paclitaxel + Placebo		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Taselisib		Terminated	NCT02340221	SANDPIPER	PCD	2021Jun29	No	Yes		2	10.1200/JCO.2018.36.18_suppl.LBA1006	Previously-treated	Postmenopausal	Progression free survival	516	340	176	Fulvestrant + Placebo	28	11.9		0.0002	8.7	7.2			7.4	5.4	0.7		0.0037						51.5	37.3																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Alpelisib + Fulvestrant		Not yet recruiting	NCT05625087	SAFIR 03 ARRIBA	ECD	2028Jul01	Yes	No		4	NCT05625087			Progression free survival	162	162																																									COSO28394862	2023Jan09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Alpelisib + Fulvestrant		Recruiting	NCT05038735	EPIK-B5	ECD	2026Aug31	Yes	No		4	NCT05038735	Previously-treated		Progression free survival	234			Fulvestrant + Placebo																																							COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Buparlisib + Paclitaxel		Completed	NCT01572727	BELLE-4	PCD	2015Jun01	Yes	Yes	No benefit of treatment	1	27803006	Untreated	Postmenopausal	"CR, ORR"	416	207	209	Paclitaxel																																							COSO28394862	2021Nov17	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 4	Alpelisib + Fulvestrant		Recruiting	NCT05631795	ALPINIST	ECD	2024Nov15	Yes	No		4	NCT05631795			Maximum tolerated dose/toxicity	100	100																																									COSO28394862	2023Jan09	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Retrospective/Meta-analysis	Trastuzumab		Unknown					Comparison with wt	Yes	pCR 24.3 vs 33.8 p=0.27	1	25199759			Clinical activity	173	37	136																																								COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified or PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Buparlisib + Fulvestrant		Completed	NCT01610284	BELLE-2	PCD	2015Apr29	Expression confirmed	Yes		1	28576675	Previously-treated		Progression free survival	1149	576	571	Fulvestrant + Placebo									6.9	5	0.78	0.67-0.89	0.00021																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified or PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Buparlisib + Fulvestrant		Completed	NCT01610284	BELLE-2	PCD	2015Apr29	Expression confirmed	Yes		1	28576675	Previously-treated		Progression free survival	372	188	184	Fulvestrant + Placebo									6.8	4	0.76	0.60-0.97	0.014																										COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PIK3CA	PIK3CA_unspecified or PTEN_unspecified or TP53_unspecified				breast / carcinoma / NS	3	Phase 3	Everolimus + Nab-paclitaxel + Trastuzumab + Trastuzumab-emtansine		Recruiting	NCT05429684	Experimental D	ECD	2024Feb28	Yes	No		4	NCT05429684	Previously-treated		Overall Response Rate	120	120																																									COSO28394862	2022Sep27	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PPP2R2A	PPP2R2A_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 1	CYH33 + Fulvestrant		Not yet recruiting	NCT04856371		ECD	2022Mar01	No	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 1	CYH33 + Letrozole + Palbociclib		Not yet recruiting	NCT04856371		ECD	2022Mar01	No	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 1	CYH33 + Fulvestrant + Palbociclib		Not yet recruiting	NCT04856371		ECD	2022Mar01	No	No		4	NCT04856371			Maximum tolerated dose/toxicity	228	228																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Ipatasertib + Paclitaxel		Completed	NCT02162719	LOTUS	PCD	2016Jun07	Yes	Yes		1	28800861	Untreated		Unknown	32	26	16		50	44			11.2	6.1			9	4.9	0.44	0.20-0.99	0.041						54	44																			COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Fulvestrant + Ipatasertib + Palbociclib		Not yet recruiting	NCT04920708		ECD	2023Aug01	No	No		4	NCT04920708			Progression free survival	324			Fulvestrant + Palbociclib																																							COSO28394862	2021Aug24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel		Unknown	NCT03273595		ECD	2019Jul01	Yes	No		4	NCT03273595			"Complete response, Pathological complete response"	100			Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																							COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Alpelisib + Nab-paclitaxel		"Active, not recruiting"	NCT04216472		ECD	2022Dec31	Yes	No		4	NCT04216472			"Complete response, Pathological complete response"	8	8																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Copanlisib + Eribulin		Suspended	NCT04345913		ECD	2022Dec31	No	No		4	NCT04345913			Progression free survival	18	18																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Abemaciclib + Copanlisib + Fulvestrant		Recruiting	NCT03939897		ECD	2023Nov01	Yes	No		4	NCT03939897			Progression free survival	204			Abemaciclib + Fulvestrant																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Paclitaxel + Placebo		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Capivasertib + Fulvestrant + Palbociclib		Recruiting	NCT04862663	CAPItello-292	ECD	2025Oct07	Yes	No		4	NCT04862663			Progression free survival	700			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Ipatasertib + Paclitaxel + Placebo		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Atezolizumab + Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			Progression free survival	242	242																																									COSO28394862	2022Aug04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Capivasertib + Fulvestrant		Recruiting	NCT04305496	CAPItello-291	PCD	2022Aug15	No	No		4	NCT04305496			Progression free survival	834			Fulvestrant + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Fulvestrant + Ipatasertib		Recruiting	NCT04650581	FINER	ECD	2024Jun30	No	No		4	NCT04650581			Progression free survival	250			Fulvestrant + Placebo																																							COSO28394862	2021Nov02	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Fulvestrant + Ipatasertib + Palbociclib		"Active, not recruiting"	NCT04060862		ECD	2023Apr30	No	No		4	NCT04060862			Progression free survival	20			Fulvestrant + Palbociclib + Placebo																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Alpelisib + Nab-paclitaxel		Recruiting	NCT04251533	EPIK-B3	ECD	2026Apr10	Yes	No		4	NCT04251533			"PFS, ORR"	566	566		Nab-paclitaxel + Placebo																																							COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Everolimus + Trastuzumab + Vinorelbine		Completed					Yes	Yes		1	27091708			Unknown	49			Trastuzumab + Vinorelbine											0.54	0.31-0.96	0.04																										COSO28394862	2021Dec08	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Retrospective/Meta-analysis	Trastuzumab		Unknown		BCIRG-005/6			Expression confirmed	Yes	Response not correlated with expression status	1	25649019			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2364																																										COSO28394862	2022Nov18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RAD51B	RAD51B_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RAD51C	RAD51C_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RAD51C	RAD51C_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RAD51D	RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RAD51D	RAD51D_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RAD54L	RAD54L_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT04892693		ECD	2023May10	Yes	No		4	NCT04892693			Response rate	70	70																																									COSO28394862	2021Aug26	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RB1	RB1_unspecified				breast / carcinoma / NS	3	Phase 1	Erdafitinib + Fulvestrant + Palbociclib		"Active, not recruiting"	NCT03238196		ECD	2022Dec31	No	No		4	NCT03238196			Maximum tolerated dose/toxicity	35	35																																									COSO28394862	2023Jan04	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RET	RET_unspecified				breast / carcinoma / NS	3	Phase 2	Vandetanib		Terminated	NCT01934335		PCD	2018Dec21	No	Yes	Drug unavailable	4	NCT01934335			Change in Ki-67 expression	10	6	4																																								COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RET	RET_unspecified				breast / carcinoma / NS	3	Phase 2	Fulvestrant + Vandetanib		Unknown	NCT02530411	FURVA	ECD	2018Dec01	No	No		4	NCT02530411			Progression free survival	160	160																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
RET	RET_unspecified				breast / carcinoma / NS	3	Phase 2	Lenvatinib		Unknown	NCT03168074		ECD	2021Mar28	No	No		4	NCT03168074			Clinical activity	30	30																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
ROS1	ROS1_unspecified				breast / carcinoma / NS	3	Phase 2	Crizotinib + Fulvestrant		Recruiting	NCT03620643	ROLo	ECD	2023May01	Yes	No		4	NCT03620643			Overall Response Rate	58	58																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TACSTD2	TACSTD2_unspecified				breast / carcinoma / NS	3	Phase 2	Sacituzumab govitecan		Not yet recruiting	NCT05332561	COGNITION-GUIDE Arm 5	ECD	2029Apr01	Overexpression	No		4	NCT05332561			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	240	240																																									COSO28394862	2022Apr25	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Out of trials human study	Tamoxifen		Unknown					Comparison with wt	Yes		1	10786679			Unknown					31	66							3	9.6																													COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 1	Ad5CMV-p53 gene + Chemotherapy		Completed	NCT00004038		PCD	2001May01	No	No		4	NCT00004038			Clinical activity	20	20																																									COSO28394862	2021May18	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 1	ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride		Recruiting	NCT05622058		ECD	2023Sep01	Yes	No		4	NCT05622058			Overall Response Rate	26	26																																									COSO28394862	2023Jan10	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Atezolizumab + Cobimetinib		Terminated	NCT03566485	BRE 17107	PCD	2020Dec10	Yes	No		4	NCT03566485			Overall Response Rate	12	12																																									COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Chemotherapy + Inetetamab + Pyrotinib		Recruiting	NCT04681911		ECD	2023Sep09	Yes	No		4	NCT04681911	Previously-treated		Overall Response Rate	71	71																																									COSO28394862	2022May19	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Ad5CMV-p53 gene + Docetaxel + doxorubicin hydrochloride		Completed	NCT00044993				No	No		4	NCT00044993			Not defined																																											COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Goserelin + Radiotherapy + Tamoxifen		"Active, not recruiting"	NCT02624973	PETREMAC ExpB Premenopausal	PCD	2020Jun01	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Letrozole + Radiotherapy		"Active, not recruiting"	NCT02624973	PETREMAC ExpB Postmenopausal	PCD	2020Jun01	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide		Recruiting	NCT02645149	MatchMel	ECD	2027Jul01	Yes	No		4	NCT02645149			Unknown	1000	1000																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide		Recruiting	NCT02965950	The p53 Breast Cancer Trial 	ECD	2023May01	Yes	No		4	NCT02965950			Overall Response Rate	190	190																																									COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	2023Jun25	Yes	No		4	NCT04335669			"Complete response, Pathological complete response"	820	820																																									COSO28394862	2022Jan28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
VEGFA	VEGFA_unspecified				breast / carcinoma / NS	3	Phase 2	Vandetanib		"Active, not recruiting"	NCT02299999	SAFIR02_Breast	ECD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							COSO28394862	2022May03	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
WT1	WT1_unspecified				breast / carcinoma / NS	3	Phase 2	"Carboplatin + Cyclophosphamide + Paclitaxel + WT1, Cyclin B1, CEF antigen-loaded autologous DC vaccine + doxorubicin hydrochloride"		Completed	NCT02018458		PCD	2019Sep18	Expression confirmed	Yes	CR 40%	4	NCT02018458			Maximum tolerated dose/toxicity	10	10																														4			15.6								COSO28394862	2022Oct24	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
WT1	WT1_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + GSK2302024A + Paclitaxel		Terminated	NCT01220128	INDUCT Cohort D	PCD	2014Nov14	Expression confirmed	Yes	SAE 0%	4	NCT01220128			Maximum tolerated dose/toxicity	8	8																																									COSO28394862	2022Nov28	COSO28394862	breast	NS	NS	NS	carcinoma	NS	NS	NS	breast
AKT1	AKT1_unspecified or ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_undefined or FANCD2_undefined or FANCE_undefined or FANCF_undefined or FANCG_undefined or FANCL_undefined or MRE11_unspecified or NBN_unspecified or PALB2_unspecified or PIK3CA_unspecified or PTEN_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Capecitabine		Recruiting	NCT04768426		ECD	2026Feb01	Yes	No		4	NCT04768426	Previously-treated		Clinical activity	25	25																																									COSO283911696	2021May18	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AKT1	AKT1_unspecified or PIK3CA_unspecified or PTEN_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT05498896	BARBICAN	PCD	2021Jan29	No	No		4	NCT05498896	Untreated		"Complete response, Pathological complete response"	146			Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel																																							COSO283911696	2022Oct24	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	2024Jan01	Expression confirmed	No		4	NCT04360941			Overall Response Rate	45	45																																									COSO283911696	2022Dec09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Enzalutamide		Unknown	NCT02676986	ARB	ECD	2020Mar01	Expression confirmed	Yes	"Ki67 -8%, Primary outcome not met"	2	10.1016/j.annonc.2021.08.490			Change in Ki-67 expression	27	27																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Carboplatin + Cyclophosphamide + Epirubicin + Nab-paclitaxel		Not yet recruiting	NCT05582499	FASCINATE-N TN3-2	ECD	2024Sep01	Expression confirmed	No		4	NCT05582499			"Complete response, Pathological complete response"	716			Chemotherapy + Nab-paclitaxel + Pertuzumab + Trastuzumab																																							COSO283911696	2023Jan13	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Carboplatin + Cyclophosphamide + Epirubicin + Nab-paclitaxel + Pyrotinib		Not yet recruiting	NCT05582499	FASCINATE-N TN3-1	ECD	2024Sep01	Expression confirmed	No		4	NCT05582499			"Complete response, Pathological complete response"	716			Chemotherapy + Nab-paclitaxel + Pertuzumab + Trastuzumab																																							COSO283911696	2023Jan13	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Dexamethasone + Docetaxel + Seviteronel		Not yet recruiting	NCT04947189	4CAST	ECD	2023Jul01	No	No		4	NCT04947189			Maximum tolerated dose/toxicity	65	65																																									COSO283911696	2022Jul08	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Bicalutamide + Ribociclib		Recruiting	NCT03090165	BRE15-024	ECD	2023Dec01	Expression confirmed	No		4	NCT03090165			"Disease control rate, Clinical benefit rate"	37	37																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Enobosarm + Pembrolizumab		"Active, not recruiting"	NCT02971761		PCD	2020Oct28	Expression confirmed	Yes		1	33141975			Overall Response Rate	16	16			13								2.6			1.9-3.1							25			25.5			-10.4														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Enobosarm		Terminated	NCT02368691		PCD	2017Sep22	Expression confirmed	Yes	Lack of efficacy	4	NCT02368691	Previously-treated		"Disease control rate, Clinical benefit rate"	32	32																																									COSO283911696	2022Jul07	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Seviteronel		Completed	NCT02130700	"Cohort 1,2"	PCD	2017Sep01	Expression confirmed	No		4	NCT02130700			"PFS, ORR"	17	17																																									COSO283911696	2022Jul07	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Transdermal 4-hydroxytestosterone		"Active, not recruiting"	NCT02067741		PCD	2018Aug02	Expression confirmed	Yes	"Primary outcome not met, Slow accrual, DCR 24w 0%"	2	10.1093/annonc/mdz100.014			"Disease control rate, Clinical benefit rate"	8	8											2.5			0.7-2.9										10.8			3.3-10.9														COSO283911696	2022Nov18	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Bicalutamide		Unknown	NCT02353988		ECD	2017Jan01	Expression confirmed	No		4	NCT02353988			"PFS, DCR"	60			Physician's choice																																							COSO283911696	2022Jul07	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Bicalutamide		Terminated	NCT02348281		PCD	2015Dec01	Expression confirmed	Yes	Slow accrual	4	NCT02348281			"Disease control rate, Clinical benefit rate"	1	1																																									COSO283911696	2022Jul07	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Enzalutamide		"Active, not recruiting"	NCT02750358		ECD	2023May01	Expression confirmed	No		4	NCT02750358			Maximum tolerated dose/toxicity	50	50																																									COSO283911696	2022Jul07	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 3	Bicalutamide		Terminated	NCT03055312	SYSUCC-007	PCD	2020Nov15	Expression confirmed	No		4	NCT03055312			"Disease control rate, Clinical benefit rate"	36	36		Physician's choice																																							COSO283911696	2022Jul08	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 1	Buparlisib + Olaparib		Completed	NCT01623349		PCD	2019May01	No	Yes	Clinical benefit	2	10.1200/jco.2014.32.15_suppl.2510	Previously-treated		Maximum tolerated dose/toxicity	9	9																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 1	Alpelisib + Olaparib		Completed	NCT01623349		PCD	2019May01	No	Yes		1	35149538	Previously-treated		Maximum tolerated dose/toxicity	17	17			18				7.4														59																				COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
BRCA1	BRCA1_unspecified or BRCA2_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Carboplatin + Olaparib + Paclitaxel + Pembrolizumab		Not yet recruiting	NCT05485766		ECD	2025Sep30	Yes	No		4	NCT05485766			"Complete response, Pathological complete response"	23	23																																									COSO283911696	2022Sep26	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CCR5	CCR5_unspecified and CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Carboplatin + Leronlimab		"Active, not recruiting"	NCT03838367		ECD	2022Jul15	Expression confirmed	No		4	NCT03838367			Progression free survival	48	48																																									COSO283911696	2022Aug04	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Approved FDA	Chemotherapy + Pembrolizumab	Not required	"Active, not recruiting"	NCT03036488	KEYNOTE-522 	ECD	2025Sep30	No	Yes	"pCR 63.0 v 55.6%, EFS 84 v 76 HR 0.63 95% CI 0.48-0.82 p=0.00031"	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf			"CR, EFS"	1174	784	390	Chemotherapy																																							COSO283911696	2022Dec01	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Approved FDA	Chemotherapy + Pembrolizumab	Required	"Active, not recruiting"	NCT02819518	KEYNOTE-355 PD-L1 CPS >=10%	PCD	2021Jun15	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf			"OS, PFS"	323	220	103	Chemotherapy + Placebo	53	41			12.8	7.3			9.7	5.6	0.65	0.49-0.86	0.0012									23	16.1	0.73	0.55-0.95	0.0093													COSO283911696	2022Dec01	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT01848834	KEYNOTE-012 Cohort A	PCD	2016Apr26	Expression confirmed	Yes		4	NCT01848834			Overall Response Rate	32	32			15.6		5.3-32.8																																				COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Camrelizumab + Carboplatin + Docetaxel		Recruiting	NCT05475678		ECD	2024Dec31	No	No		4	NCT05475678			"Complete response, Pathological complete response"	369			Carboplatin + Docetaxel																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Atezolizumab + Paclitaxel		Withdrawn	NCT05093387		PCD	2022Nov10	No	No		4	NCT05093387			"Disease control rate, Clinical benefit rate"	0	0																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Toripalimab		Completed	NCT02838823	PD-L1 >= 1%	PCD	2018Dec01	Expression confirmed	Yes		1	31700871	Previously-treated		Maximum tolerated dose/toxicity	9	9			11.1																		22.2																				COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Toripalimab		Completed	NCT02838823		PCD	2018Dec01	No	Yes		1	31700871	Previously-treated		Maximum tolerated dose/toxicity	20	20			5																		35										1	6									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel		Completed	NCT03800836		PCD	2022Mar15	No	No		4	NCT03800836			Overall Response Rate	140	140																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Atezolizumab + Ipatasertib + Nab-paclitaxel		Completed	NCT03800836	Arm B	PCD	2022Mar15	No	Yes		2	10.1158/1538-7445.SABCS20-PS12-28			Overall Response Rate	20	20			65		41-85		7.3		3.9-7.4																																COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Pembrolizumab + Ruxolitinib		Recruiting	NCT03012230		ECD	2023Apr01	No	No		4	NCT03012230			Maximum tolerated dose/toxicity	18	18																																									COSO283911696	2022Jul29	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Atezolizumab + Ipatasertib + Paclitaxel		Completed	NCT03800836	Arm A	PCD	2022Mar15	No	Yes		2	10.1158/1538-7445.SABCS20-PS12-28			Overall Response Rate	70	70			51		39-64		7.4		5.6-12.9																																COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Atezolizumab + Ipatasertib		Completed	NCT03800836		PCD	2022Mar15	No	No		4	NCT03800836			Overall Response Rate	140	140																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	2024Jan01	Expression confirmed	No		4	NCT04360941			Overall Response Rate	45	45																																									COSO283911696	2022Dec09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT02555657	KEYNOTE-119 PD-L1 CPS ?1%	PCD	2019Apr11	Expression confirmed	Yes		4	NCT02555657			Overall survival	405	203	202	Chemotherapy	12.3	9.4		0.1752																		10.7	10.2	0.86	0.69-1.06	0.0728													COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT02555657	KEYNOTE-119 PD-L1 CPS ?10%	PCD	2019Apr11	Expression confirmed	Yes		4	NCT02555657			Overall survival	194	96	98	Chemotherapy	17.7	9.2		0.0457																		12.7	11.6	0.78	0.57-1.06	0.0574													COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 1	Pembrolizumab		Completed	NCT02555657	KEYNOTE-119	PCD	2019Apr11	Expression confirmed	Yes		4	NCT02555657			Overall survival	622	312	310	Chemotherapy	9.6	10.6		0.6629																		9.9	10.8	0.97	0.82-1.15	0.3802													COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Pembrolizumab		Completed	NCT02447003	KEYNOTE-086 cohort B	PCD	2019Feb18	Expression confirmed	Yes		4	NCT02447003	Untreated		Overall Response Rate	84	84			21.4		13.9-31.4		10.4		-4.2		2.1			2.0-2.2							23.9			18			12.9-23.0														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Radiotherapy + Talazoparib		Recruiting	NCT04690855	TARA	ECD	2023Jul01	Expression confirmed	No		4	NCT04690855			Overall Response Rate	23	23																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Carboplatin + Gemcitabine + Pembrolizumab		Recruiting	NCT02755272		ECD	2023Oct01	No	No		4	NCT02755272			Overall Response Rate	87			Carboplatin + Gemcitabine																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Carboplatin + Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel		"Active, not recruiting"	NCT04770272	neoMono	ECD	2023Aug01	No	No		4	NCT04770272			"Complete response, Pathological complete response"	416	416																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Apatinib + Carboplatin + Nab-paclitaxel + Sintilimab		Recruiting	NCT04722718		ECD	2022Dec31	No	No		4	NCT04722718			"Complete response, Pathological complete response"	34	34																																									COSO283911696	2022Sep27	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Pelareorep + Retifanlimab		Recruiting	NCT04445844		ECD	2022Dec30	No	No		4	NCT04445844			Overall Response Rate	25	25																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride liposome		"Active, not recruiting"	NCT03164993		ECD	2023Dec31	No	No		4	NCT03164993			Progression free survival	75	75																																									COSO283911696	2022Oct24	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Carboplatin + Pembrolizumab		Recruiting	NCT03095352		ECD	2023Sep30	No	No		4	NCT03095352	Previously-treated		"PFS, DCR"	84			Carboplatin + Pembrolizumab																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Pacmilimab + Praluzatamab Ravtansine		"Active, not recruiting"	NCT04596150	CTMX-2009-002 Arm C	ECD	2023Sep30	No	No		4	NCT04596150			Overall Response Rate	125	125																																									COSO283911696	2022Nov29	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Eribulin + Pembrolizumab		Completed	NCT02513472	ENHANCE-1 PD-L1+	PCD	2019Jul31	No	Yes		4	NCT02513472	Previously-treated		Overall Response Rate	45	45			24.4		12.9-39.5		8.2		5.1-25.1		4.1			2.1-4.8							28.9			14			11.0-19.4														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Eribulin + Pembrolizumab		Completed	NCT02513472	ENHANCE-1 PD-L1+	PCD	2019Jul31	No	Yes		4	NCT02513472	Untreated		Overall Response Rate	29	29			34.5		17.9-54.3		8.3		-3.2		6.1			4.1-10.2							48.3			21			8.3-29.0														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Eribulin + Pembrolizumab		Completed	NCT02513472	ENHANCE-1	PCD	2019Jul31	No	Yes		4	NCT02513472	Previously-treated		Overall Response Rate	101	101			21.8		14.2-31.1		8.6		6.2-25.1		4.1			2.3-4.4							29.7			15.5			12.5-18.7														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Eribulin + Pembrolizumab		Completed	NCT02513472	ENHANCE-1	PCD	2019Jul31	No	Yes		4	NCT02513472	Untreated		Overall Response Rate	66	66			25.8		15.8-38.0		9		6.2-22.2		4.2			3.5-5.5							36.4			17.4			13.2-21.0														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Chemotherapy + PVX-410 + Pembrolizumab		Not yet recruiting	NCT04634747		ECD	2023Apr01	Expression confirmed	No		4	NCT04634747			Progression free survival	53	53																																									COSO283911696	2022Jul29	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Durvalumab + Paclitaxel		Completed	NCT02628132		PCD	2019Dec31	Expression confirmed	Yes	Expression not correlated with efficacy	1	34580336			Maximum tolerated dose/toxicity	14	14			36								5										64			20.7																	COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Nab-paclitaxel + Pembrolizumab + Radiotherapy		Recruiting	NCT05233696		ECD	2025Apr19	Expression confirmed	No		4	NCT05233696			Progression free survival	29	29																																									COSO283911696	2022Jul29	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab + Trilaciclib		"Active, not recruiting"	NCT05112536		PCD	2022Oct31	No	No		4	NCT05112536			Immune response	24	24																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Carboplatin + Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab		"Active, not recruiting"	NCT02957968		ECD	2025Feb28	No	No		4	NCT02957968			Immune cell infiltration	47	47																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Carboplatin + Durvalumab + Oleclumab + Paclitaxel		"Active, not recruiting"	NCT03616886	SYNERGY	ECD	2023Jul01	No	No		4	NCT03616886	Untreated		"Disease control rate, Clinical benefit rate"	129			Carboplatin + Durvalumab + Paclitaxel																																							COSO283911696	2022Jun06	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Sacituzumab govitecan		"Active, not recruiting"	NCT03424005	Morpheus-TNBC	ECD	2024May03	Expression confirmed	No		4	NCT03424005	Untreated		Overall Response Rate	280			Atezolizumab + Nab-paclitaxel																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Nab-paclitaxel + Tocilizumab		"Active, not recruiting"	NCT03424005	Morpheus-TNBC	ECD	2024May03	Expression confirmed	No		4	NCT03424005	Untreated		Overall Response Rate	280			Atezolizumab + Nab-paclitaxel																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	PGG beta-glucan + Pembrolizumab		Completed	NCT02981303	IMPRIME 1	PCD	2020Dec31	No	Yes		2	10.1200/JCO.2019.37.15_suppl.2550	Previously-treated		Overall Response Rate	44	44			13.6																					13.7							6	18									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Nab-paclitaxel + SG001		Recruiting	NCT05068141		ECD	2022Oct01	No	No		4	NCT05068141			Overall Response Rate	79	79																																									COSO283911696	2022Jun01	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine		Recruiting	NCT04739670	BELLA	ECD	2025Sep01	Expression confirmed	No		4	NCT04739670			Progression free survival	31	31																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Anlotinib + Anthracycline + Nab-paclitaxel + Tislelizumab		Recruiting	NCT04914390	NeoATCT	ECD	2022Jul31	Expression confirmed	No		4	NCT04914390			"Complete response, Pathological complete response"	32	32																																									COSO283911696	2022May31	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Eribulin + Tislelizumab		Not yet recruiting	NCT04913571	TEMPLATE subgroup B	ECD	2022Jun01	Expression confirmed	No		4	NCT04913571	Previously-treated		Overall Response Rate	265	265																																									COSO283911696	2022May31	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Cisplatin + Nab-paclitaxel + Olaparib + Pembrolizumab		Not yet recruiting	NCT05174832		ECD	2023Dec01	Expression confirmed	No		4	NCT05174832	Previously-treated		Progression free survival	136			Cisplatin + Nab-paclitaxel + Pembrolizumab																																							COSO283911696	2022Jul29	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Anti-HER2/HER3 Dendritic Cell Vaccine + Celecoxib + Interferon alpha-2B + Pembrolizumab + Rintatolimod		Recruiting	NCT04348747		ECD	2024Apr15	No	No		4	NCT04348747			Intracranial Response Rate	23	23																																									COSO283911696	2022Jul29	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Atezolizumab + Carboplatin + Nab-paclitaxel		Recruiting	NCT05266937		ECD	2022Jul03	Expression confirmed	No		4	NCT05266937			Overall survival	104	104																																									COSO283911696	2022Oct10	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Durvalumab		"Active, not recruiting"	NCT02299999	SAFIR02_Breast PD-L1-	ECD	2022Dec01	Expression confirmed	Yes		1	33462450			Progression free survival	29	17	12	Chemotherapy																						19.5	14	0.49	0.18-1.34	0.1567													COSO283911696	2022Sep09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Durvalumab		"Active, not recruiting"	NCT02299999	SAFIR02_Breast PD-L1+	ECD	2022Dec01	Expression confirmed	Yes		1	33462450			Progression free survival	32	18	14	Chemotherapy																						27.3	12.1	0.37	0.12-1.13	0.0678													COSO283911696	2022Sep09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Durvalumab		Completed	NCT02685059	GeparNuevo	PCD	2018Mar01	Expression confirmed	Yes	"pCR 53.4 v 44.2% p=0.287, Efficacy correlated with expression status p=0.0045"	1	31095287			"Complete response, Pathological complete response"	174	88	86	Cyclophosphamide + Epirubicin + Nab-paclitaxel + Placebo																																							COSO283911696	2022Nov04	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Durvalumab + Olaparib		Recruiting	NCT02484404		ECD	2023Jan30	No	No		4	NCT02484404			Overall Response Rate	384	384																																									COSO283911696	2022Oct12	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 2	Pembrolizumab		Completed	NCT02447003	KEYNOTE-086 cohort A PD-L1+	PCD	2019Feb18	Expression confirmed	Yes		4	NCT02447003	Previously-treated		Overall Response Rate	105	105			5.7		2.4-12.2				-6.3		2			1.9-2.1							9.5			8.8			7.1-11.2														COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Ipatasertib + Paclitaxel		"Active, not recruiting"	NCT04177108		ECD	2022Dec30	No	No		4	NCT04177108			"OS, PFS"	242			Paclitaxel + Placebo																																							COSO283911696	2022Oct12	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Pembrolizumab + Sacituzumab govitecan		Recruiting	NCT05382286	ASCENT-04	ECD	2027Feb01	Expression confirmed	No		4	NCT05382286			Progression free survival	440			Chemotherapy + Pembrolizumab																																							COSO283911696	2022Oct11	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel		Completed	NCT03197935	IMpassion031 PD-L1+	PCD	2020Apr03	Expression confirmed	Yes	pCR 68.83 v 49.33% p=0.0206	4	NCT03197935			"Complete response, Pathological complete response"	153	77	75	Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel + Placebo																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel		Completed	NCT03197935	IMpassion031	PCD	2020Apr03	No	Yes	pCR 57.58 v 41.07% p=0.0044	4	NCT03197935			"Complete response, Pathological complete response"	333	165	168	Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel + Placebo																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Carboplatin + Gemcitabine + Trilaciclib		"Active, not recruiting"	NCT04799249	PRESERVE 2 cohort 2	ECD	2024Jun30	Expression confirmed	No		4	NCT04799249			Overall survival	194			Carboplatin + Gemcitabine + Placebo																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Capecitabine + Carboplatin + Gemcitabine		Recruiting	NCT03371017	IMpassion132	ECD	2023Apr30	No	No		4	NCT03371017			Overall survival	572			Capecitabine + Carboplatin + Gemcitabine + Placebo																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Nab-paclitaxel + Toripalimab		Recruiting	NCT04085276	TORCHLIGHT	ECD	2022Dec30	No	No		4	NCT04085276			Progression free survival	561			Nab-paclitaxel + Placebo																																							COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Camrelizumab + Nab-paclitaxel		Recruiting	NCT04335006		ECD	2024Jan01	No	No		4	NCT04335006	Untreated		Progression free survival	780			Nab-paclitaxel																																							COSO283911696	2022Jun06	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Apatinib + Camrelizumab + Nab-paclitaxel		Recruiting	NCT04335006		ECD	2024Jan01	No	No		4	NCT04335006	Untreated		Progression free survival	780			Nab-paclitaxel																																							COSO283911696	2022Jun06	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Nab-paclitaxel		"Active, not recruiting"	NCT04148911	EL1SSAR	ECD	2024Dec15	Expression confirmed	No		4	NCT04148911			Maximum tolerated dose/toxicity	184	184																																									COSO283911696	2022Oct14	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Nab-paclitaxel		Completed	NCT02425891	IMpassion130 PD-L1 IC1/2/3	PCD	2020Apr14	Expression confirmed	Yes		4	NCT02425891			"OS, PFS"	269	185	184	Nab-paclitaxel + Placebo	58.9	42.6		0.0016	8.48	5.49	0.43-0.86	0.0047	7.46	4.96	0.62	0.49-0.78	<0.0001									25.43	17.91	0.67	0.53-0.86	0.0016													COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Nab-paclitaxel		Completed	NCT02425891	IMpassion130	PCD	2020Apr14	No	Yes		4	NCT02425891			"OS, PFS"	902	451	451	Nab-paclitaxel + Placebo	56	45.9		0.0021	7.39	5.62	0.63-0.98	0.0285	7.16	5.49	0.8	0.69-0.92	0.0025									21.03	18.73	0.87	0.75-1.02	0.077													COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Atezolizumab + Chemotherapy		"Active, not recruiting"	NCT03281954		ECD	2023Dec31	No	No		4	NCT03281954			"CR, EFS"	1550			Chemotherapy + Placebo																																							COSO283911696	2022Aug04	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
CD274	CD274_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	2	Phase 3	Avelumab		"Active, not recruiting"	NCT02926196		ECD	2022Jun01	No	No		4	NCT02926196			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	474			Observation																																							COSO283911696	2022Dec09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
EGFR	EGFR_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Gefitinib		Unknown	NCT01732276		ECD	2015Apr01	Expression confirmed	No		4	NCT01732276			"Disease control rate, Clinical benefit rate"	50	50																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
NT5E	NT5E_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Carboplatin + Durvalumab + Oleclumab + Paclitaxel		"Active, not recruiting"	NCT03616886	SYNERGY	ECD	2023Jul01	No	No		4	NCT03616886	Untreated		"Disease control rate, Clinical benefit rate"	129			Carboplatin + Durvalumab + Paclitaxel																																							COSO283911696	2022Jun06	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
PIK3CA	PIK3CA_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	2024Jan01	No	No		4	NCT04360941			Overall Response Rate	45	45																																									COSO283911696	2022Dec09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
PTEN	PTEN_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	2024Jan01	No	No		4	NCT04360941			Overall Response Rate	45	45																																									COSO283911696	2022Dec09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
RB1	RB1_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	2024Jan01	No	No		4	NCT04360941			Overall Response Rate	45	45																																									COSO283911696	2022Dec09	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
TP53	TP53_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Cyclophosphamide + Olaparib + Radiotherapy		"Active, not recruiting"	NCT02624973	PETREMAC arm H	PCD	2020Jun01	Yes	Yes		1	33242536			Biomarker discovery	32	32			56.3		39.3-71.8																									1	17										COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
WT1	WT1_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		"Active, not recruiting"	NCT03761914		ECD	2022Nov30	Expression confirmed	No		4	NCT03761914			"Complete response, Pathological complete response"	90	90																																									COSO283911696	2022Nov28	COSO283911696	breast	NS	NS	NS	carcinoma	basal_(triple-negative)_carcinoma	NS	NS	breast
AR	AR_unspecified and ESR1_unspecified				breast / carcinoma / ER-positive carcinoma	3	Phase 2	Aromatase inhibitors + Bicalutamide		Unknown	NCT02910050	BETTER	ECD	2018Sep01	Expression confirmed	Yes		1	31434793			"Disease control rate, Clinical benefit rate"	18	18											2.7										16.7									0	0	3									COSO283919543	2022Nov28	COSO283919543	breast	NS	NS	NS	carcinoma	ER-positive_carcinoma	NS	NS	breast
ESR1	ESR1_unspecified				breast / carcinoma / ER-positive carcinoma	3	Phase 2	Enzalutamide + Exemstane		Unknown	NCT02676986	ARB	ECD	2020Mar01	Expression confirmed	Yes	"Ki67 -60 v -56%, Primary outcome not met"	2	10.1016/j.annonc.2021.08.490			Change in Ki-67 expression	194	130	64	Exemstane																																							COSO283919543	2022Nov28	COSO283919543	breast	NS	NS	NS	carcinoma	ER-positive_carcinoma	NS	NS	breast
ERBB2	ERBB2_unspecified				breast / carcinoma in situ / ductal carcinoma in situ	3	Phase 1	H2NVAC + Sargramostim		Recruiting	NCT04144023		ECD	2023Jun01	Expression confirmed	No		4	NCT04144023	Untreated		Maximum tolerated dose/toxicity	43	43																																									COSO28395294	2022Jan11	COSO28395294	breast	NS	NS	NS	carcinoma_in_situ	ductal_carcinoma_in_situ	NS	NS	breast
ALK	ALK_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																									COSO36286315	2022Nov28	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
ALK	ALK_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Ceritinib		Withdrawn	NCT02289144		PCD	2019Jan01	No	No	Development discontinued	4	NCT02289144			Time to progression	0	0																																									COSO36286315	2021May18	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600			p.V600X	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Vemurafenib		Completed	NCT01286753		PCD	2014Nov01	Yes	Yes		4	NCT01286753	Untreated		Best overall response	26	26			42.3																																						COSO36286315	2021May18	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600			p.V600X	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	HLX208		Recruiting	NCT05102292		ECD	2023May30	Yes	No		4	NCT05102292			Overall Response Rate	25	25																																									COSO36286315	2022Jan24	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600			p.V600X	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Vemurafenib		Completed	NCT01286753		PCD	2014Nov01	Yes	Yes		4	NCT01286753	Previously-treated		Best overall response	22	22			27.3																																						COSO36286315	2021May18	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Dabrafenib + Trametinib		Recruiting	NCT04739566	ANAPLAST-NEO	ECD	2024Jan22	Yes	No		4	NCT04739566			Overall Response Rate	18	18																																									COSO36286315	2022May03	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Cemiplimab + Dabrafenib + Trametinib		Recruiting	NCT04238624		ECD	2024Jun20	Yes	No		4	NCT04238624			Overall Response Rate	15	15																																									COSO36286315	2022Aug04	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Atezolizumab + Cobimetinib + Vemurafenib		Recruiting	NCT03181100		ECD	2023Jul27	Yes	No		4	NCT03181100			Overall survival	50																																										COSO36286315	2022May03	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	thyroid / carcinoma / anaplastic carcinoma	1	Approved FDA	Dabrafenib + Trametinib	Required	Completed	NCT02034110	BRF117019	PCD	2021Dec10	Yes	Yes		1	35026411			Overall Response Rate	36	36			56		38.1-72.1						6.7													14.5																	COSO36286315	2022Dec14	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	thyroid / carcinoma / anaplastic carcinoma	1	Phase 1	Dabrafenib + Intensity modulated radiation therapy + Trametinib		Recruiting	NCT03975231		ECD	2025Apr30	Yes	No		4	NCT03975231			Maximum tolerated dose/toxicity	6	6																																									COSO36286315	2022Nov09	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
TP53	TP53_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 1	BI 3011441		Completed	NCT04742556		PCD	2022Oct13	Yes	No		4	NCT04742556			Maximum tolerated dose/toxicity	15	15																																									COSO36286315	2022Nov28	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
TP53	TP53_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Cisplatin + Crolibulin		Completed	NCT01240590		PCD	2015Aug31	No	Yes		2	10.1200/jco.2013.31.15_suppl.6074			Progression free survival	8	8																														1		1									COSO36286315	2022Nov28	COSO36286315	thyroid	NS	NS	NS	carcinoma	anaplastic_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 1	Dabrafenib + Lapatinib		"Active, not recruiting"	NCT01947023		ECD	2023Jul01	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.6087			Maximum tolerated dose/toxicity	19	19			58								18																														COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 1	CDX-3379 + Vemurafenib		Completed	NCT02456701		PCD	2016Oct13	Yes	Yes	Primary outcome met	1	35045748			Response rate	6	6			33.33																												2										COSO36284862	2022Dec13	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 1	Dabrafenib + Pazopanib		Completed	NCT01713972		PCD	2016Jul30	Expression confirmed	Yes		2	10.1200/PO.17.00247			Maximum tolerated dose/toxicity	1	1																																1									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 2	Dabrafenib + Trametinib		Recruiting	NCT05182931	I-FIRST	ECD	2024Dec30	Yes	No		4	NCT05182931	Previously-treated		Progression free survival	80	80																																									COSO36284862	2022Aug04	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 2	Dabrafenib + Radioiodine + Trametinib		"Active, not recruiting"	NCT03244956	MERAIODE	ECD	2021Nov18	Yes	Yes		2	10.1210/jendso/bvab048.1789			Overall Response Rate	21	21			38		18-61																90																				COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Unknown	Dabrafenib + Trametinib		Recruiting	NCT05099068	PLANET	ECD	2025Sep15	Yes	No		4	NCT05099068			"PFS, ORR"	500	500																																									COSO36284862	2022Jan24	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E/M	56056643 + 56059110 + 56075762		p.V600E + p.V600M	thyroid / carcinoma / NS	3	Phase 2	Binimetinib + Encorafenib		Recruiting	NCT04061980		ECD	2023Jul30	Yes	No		4	NCT04061980			Overall Response Rate	40	40																																									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E/M	56056643 + 56059110 + 56075762		p.V600E + p.V600M	thyroid / carcinoma / NS	3	Phase 2	Binimetinib + Encorafenib + Nivolumab		Recruiting	NCT04061980		ECD	2023Jul30	Yes	No		4	NCT04061980			Overall Response Rate	40	40																																									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	2	Phase 2	Sorafenib + Temsirolimus		Completed	NCT01025453		PCD	2018Jan16	No	Yes		4	NCT01025453	Previously-treated		Overall Response Rate	31	31																															8	21									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	2	Phase 2	Sorafenib		Terminated	NCT00095693		PCD	2005Aug01	Yes	Yes	Serious adverse events	2	10.1200/jco.2013.31.15_suppl.e17009			Overall Response Rate	25	25																																									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	2	Phase 2	Everolimus + Sorafenib		"Active, not recruiting"	NCT01263951		PCD	2021Feb01	No	Yes		2	10.1200/jco.2015.33.15_suppl.6072			Progression free survival	13	13																															1	18									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	2	Phase 3	Sorafenib		Completed	NCT00984282 	DECISION	PCD	2012Aug31	Comparison with wt	Yes		1	24768112	Previously-treated		Progression free survival	77	34	43										20.5	9.4	0.46	0.24-0.9	0.02																										COSO36284862	2021Nov03	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
CD274	CD274_unspecified				thyroid / carcinoma / NS	3	Phase 2	Cabozantinib + Ipilimumab + Nivolumab		"Active, not recruiting"	NCT03914300		ECD	2023Jan15	No	No		4	NCT03914300	Previously-treated		Overall Response Rate	24	24																																									COSO36284862	2022Jun23	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
CD274	CD274_unspecified				thyroid / carcinoma / NS	3	Phase 2	Lenvatinib + Pembrolizumab		"Active, not recruiting"	NCT02973997		ECD	2022Oct08	No	No		4	NCT02973997			Response rate	60	60																																									COSO36284862	2022Aug01	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
CD274	CD274_unspecified				thyroid / carcinoma / NS	3	Retrospective/Meta-analysis	Lenvatinib + Pembrolizumab		Unknown					Expression confirmed	Yes	Efficacy correlated with expression status	2	10.1089/thy.2020.0322				6	6			66								16.5																			4		1									COSO36284862	2022Dec12	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
FGFR1	FGFR1_unspecified				thyroid / carcinoma / NS	3	Phase 2	Pazopanib		Completed	NCT01813136	PAZOTHYR	PCD	2019Jan01	No	Yes		2	10.1200/JCO.2020.38.15_suppl.6540			Time to progression	168	168											14.7			9.3-17.4							89.4																				COSO36284862	2021May18	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
KRAS	HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61				thyroid / carcinoma / NS	3	Phase 2	Radioiodine + Trametinib		"Active, not recruiting"	NCT02152995	Cohort A	PCD	2021Aug25	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.6089			"PFS, ORR"	14	14			57																		78																				COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
HRAS	HRAS_unspecified				thyroid / carcinoma / NS	3	Phase 2	Tipifarnib		Completed	NCT02383927		ECD	2020Nov30	Yes	No		4	NCT02383927	Previously-treated		Overall Response Rate	63	63																																									COSO36284862	2022Aug12	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
NRAS	NRAS_unspecified				thyroid / carcinoma / NS	3	Phase 2	Everolimus + Sorafenib		"Active, not recruiting"	NCT01263951		PCD	2021Feb01	No	Yes		2	10.1200/jco.2015.33.15_suppl.6072			Progression free survival	13	13																															1	18									COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
NRAS	NRAS_unspecified				thyroid / carcinoma / NS	3	Phase 2	Trametinib		Recruiting	NCT05182931	I-FIRST	ECD	2024Dec30	Yes	No		4	NCT05182931	Previously-treated		Progression free survival	80	80																																									COSO36284862	2022Aug04	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
NRAS	NRAS_unspecified				thyroid / carcinoma / NS	3	Phase 3	Radioiodine + Selumetinib		Terminated	NCT01843062	ASTRA	PCD	2018May18	No	Yes	Primary outcome not met	4	NCT01843062			Complete remission	233	155	78	Placebo + Radioiodine																																							COSO36284862	2022May03	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
NTRK1	NTRK1_fusions				thyroid / carcinoma / NS	3	Phase 1	Taletrectinib		Completed	NCT02279433		PCD	2019Mar01	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.2514	Previously-treated		Clinical activity	1	1																															1										COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				thyroid / carcinoma / NS	3	Phase 2	Larotrectinib		Recruiting	NCT02576431	NAVIGATE Arm 2	ECD	2023Aug15	Yes	No		4	NCT02576431			Best overall response	204	204																																									COSO36284862	2022Jul15	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_fusions				thyroid / carcinoma / NS	1	Approved FDA	Pralsetinib	Required	"Active, not recruiting"	NCT03037385	ARROW	ECD	2023Dec31	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf	Previously-treated		Overall Response Rate	9	9			89		52-100																																				COSO36284862	2023Jan19	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_fusions				thyroid / carcinoma / NS	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	2024Mar21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	Untreated		Overall Response Rate	8	8			100		63-100																																				COSO36284862	2023Jan23	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_fusions				thyroid / carcinoma / NS	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	2024Mar21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	Previously-treated		Overall Response Rate	19	19			79		54-94		18.4		-7.6																																COSO36284862	2023Jan23	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_fusions				thyroid / carcinoma / NS	1	Phase 2	Selpercatinib		"Active, not recruiting"	NCT04280081	LIBRETTO-321	PCD	2021Mar25	Yes	Yes		4	NCT04280081			Overall Response Rate	1	1			100																												1										COSO36284862	2022Nov28	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_fusions				thyroid / carcinoma / NS	1	Phase 2	Radioiodine + Selpercatinib		Not yet recruiting	NCT05668962		ECD	2024Mar01	Yes	No		4	NCT05668962			Overall Response Rate	30	30																																									COSO36284862	2023Jan09	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / NS	3	Phase 1	Alectinib		Terminated	NCT03131206		PCD	2018Nov08	Yes	Yes	"Slow accrual, Lack of efficacy"	4	NCT03131206			Overall Response Rate	5	5																																									COSO36284862	2021Oct29	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / NS	3	Phase 2	Selpercatinib		Recruiting	NCT04759911		ECD	2024Sep10	Yes	No		4	NCT04759911			Overall Response Rate	30	30																																									COSO36284862	2022May03	COSO36284862	thyroid	NS	NS	NS	carcinoma	NS	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / papillary carcinoma	3	Phase 1	Agerafenib		Completed	NCT01877811		PCD	2018Dec01	No	Yes		2	10.1200/JCO.2016.34.15_suppl.2574			Maximum tolerated dose/toxicity	1	1																															1										COSO36286294	2022Nov28	COSO36286294	thyroid	NS	NS	NS	carcinoma	papillary_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / papillary carcinoma	3	Phase 1	XL281		Unknown					Yes	Yes		2	10.1200/jco.2009.27.15s.3513			Unknown	2	2																																2									COSO36286294	2021May18	COSO36286294	thyroid	NS	NS	NS	carcinoma	papillary_carcinoma	NS	NS	thyroid
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / papillary carcinoma	3	Phase 2	Vemurafenib		"Active, not recruiting"	NCT01709292		ECD	2022Sep30	Yes	No		4	NCT01709292			Marker phosphorylation	24	24																																									COSO36286294	2022May03	COSO36286294	thyroid	NS	NS	NS	carcinoma	papillary_carcinoma	NS	NS	thyroid
RET	KIF5B-RET_fusion COSF1231				thyroid / carcinoma / medullary carcinoma	4	Case study	Selpercatinib		Unknown					Yes	Yes		1	29912274			Unknown	1	1																															1										COSO36286327	2021May18	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET V804M or RET_M918T	60685905 + 60710027		p.M918T + p.V804M	thyroid / carcinoma / medullary carcinoma	4	Case study	Selpercatinib		Unknown					Yes	Yes		1	29912274	Previously-treated		Unknown	1	1																															1										COSO36286327	2021May18	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_C634R	60686093		p.C634R	thyroid / carcinoma / medullary carcinoma	3	Phase 2	Sorafenib		"Active, not recruiting"	NCT00390325		PCD	2017Jan30	Yes	Yes		1	20368568			Overall Response Rate	1	1																																1									COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_M918T	60685905		p.M918T	thyroid / carcinoma / medullary carcinoma	2	Phase 2	Sorafenib		"Active, not recruiting"	NCT00390325		PCD	2017Jan30	Yes	Yes		1	20368568			Overall Response Rate	9	9																															1	8									COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_M918T	60685905		p.M918T	thyroid / carcinoma / medullary carcinoma	2	Phase 2	Vandetanib		Completed	NCT00514046		PCD	2019Dec10	Yes	Yes		1	29187393		Pediatric	Overall Response Rate	16	16			59								80.4																				10	6									COSO36286327	2023Jan25	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_M918T	60685905		p.M918T	thyroid / carcinoma / medullary carcinoma	2	Phase 3	Cabozantinib		Completed	NCT00704730	EXAM	PCD	2011Oct01	Yes	Yes		1	27525386			Progression free survival	126	81	45										14.08	3.92	0.15	0.08-0.28	<0.0001																										COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Approved FDA	Pralsetinib	Required	"Active, not recruiting"	NCT03037385	ARROW	ECD	2023Dec31	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf	Previously-treated		Overall Response Rate	55	55			60		44-73				-15.1																																COSO36286327	2023Jan19	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	2024Mar21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	Untreated		Overall Response Rate	88	88			73		62-82		22																																		COSO36286327	2023Jan23	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	2024Mar21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	Previously-treated		Overall Response Rate	55	55			69		55-81				-19.1																																COSO36286327	2023Jan23	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Approved FDA	Pralsetinib	Required	"Active, not recruiting"	NCT03037385	ARROW	ECD	2023Dec31	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf			Overall Response Rate	29	29			66		46-82																																				COSO36286327	2023Jan19	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 1	DS-5010 		"Active, not recruiting"	NCT03780517		ECD	2023Apr30	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.3008			Maximum tolerated dose/toxicity	16	16			44																																						COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 2	Sunitinib		"Active, not recruiting"	NCT00381641		PCD	2016Dec31	No	Yes		4	NCT00381641			Overall Response Rate	25	25			28													19.3			7.7-34.6					65.4			27.0-69.5														COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 2	Selpercatinib		"Active, not recruiting"	NCT04280081	LIBRETTO-321	PCD	2021Mar25	Yes	Yes		4	NCT04280081			Overall Response Rate	26	26			57.7																											2	13										COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 2	Ponatinib		Withdrawn	NCT03838692		PCD	2021Jun14	No	No		4	NCT03838692			Overall Response Rate	0	0																																									COSO36286327	2022May03	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 2	Ponatinib		Terminated	NCT01838642		PCD	2015Dec01	Comparison with wt	Yes	Changed business priorities	4	NCT01838642			Overall Response Rate	3	3																																									COSO36286327	2021May18	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 3	Cabozantinib		Completed	NCT00704730	EXAM	PCD	2011Oct01	No	Yes		1	27525386			Progression free survival	169	107	62										13.85	4.62	0.23	0.14-0.38	<0.0001																										COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	1	Phase 3	Pralsetinib		Not yet recruiting	NCT04760288	AcceleRET-MTC	ECD	2027Oct06	Yes	No		4	NCT04760288	Previously-treated		Progression free survival	198			Cabozantinib																																							COSO36286327	2022Nov28	COSO36286327	thyroid	NS	NS	NS	carcinoma	medullary_carcinoma	NS	NS	thyroid
AKT1	AKT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MK2206		Completed	NCT01802320		PCD	2015Jun01	No	Yes		4	NCT01802320	Previously-treated		Overall Response Rate	18	18			0								1.87													6.8			5.83-7.77														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
AKT1	AKT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		"Active, not recruiting"	NCT01312857		ECD	2023Mar01	Comparison with wt	No		1	33938493			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	0	0	0	Dexamethasone + FOLFIRI + Floxuridine																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ALK	ALK_fusions				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Entrectinib		"Active, not recruiting"	NCT02568267	STARTRK-2	ECD	2024Dec31	Yes	No		4	NCT02568267	Previously-treated		Overall Response Rate	700	700																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ALK	ALK_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ALK	ALK_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ceritinib		Terminated	NCT02638909		PCD	2018Mar29	Yes	Yes	Slow accrual	4	NCT02638909			"Disease control rate, Clinical benefit rate"	0	0																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
APC	APC_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
APC	APC_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
APC	APC_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ATM	ATM_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	BAY1895344 + Pembrolizumab		"Active, not recruiting"	NCT04095273	cohort 2a	ECD	2023Mar16	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	56	56																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ATM	ATM_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Elimusertib + FOLFIRI		Recruiting	NCT04535401		ECD	2022Dec31	Expression confirmed	No		4	NCT04535401			Maximum tolerated dose/toxicity	90	90																																									COSO28864826	2021Nov02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ATM	ATM_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT04166604	LONGBOARD	ECD	2021Nov15	No	No		4	NCT04166604			Maximum tolerated dose/toxicity	250	250																																									COSO28864826	2022Oct11	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BCL2	BCL2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Oblimersen sodium		Completed	NCT00004870		PCD	2002Sep01	Expression confirmed	No		4	NCT00004870			Maximum tolerated dose/toxicity																																											COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600			p.V600X	large intestine / carcinoma / adenocarcinoma	3	Phase 1	ASN003		Terminated	NCT02961283		PCD	2019Feb01	Yes	No		4	NCT02961283			"Disease control rate, Clinical benefit rate"	24	24																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600			p.V600X	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Belvarafenib + Cetuximab		Recruiting	NCT03284502		ECD	2023Sep30	Yes	No		4	NCT03284502			Maximum tolerated dose/toxicity	140	140																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	BRAF_V600 or KRAS_unspecified or NRAS_unspecified or MAP2K1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Panitumumab + Trametinib		Recruiting	NCT03087071	Cohort 2	ECD	2023Jul01	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.3520	Previously-treated		Response rate	19	19			0								2.1										63			5.9																	COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Cetuximab + Encorafenib	Required	"Active, not recruiting"	NCT02928224	BEACON	PCD	2019Feb11	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf			Overall survival	441	220	221	Cetuximab + Irinotecan	20	2		0.0001	6.1				4.2	1.5	0.4		<0.0001									15.3						2	10										COSO28864826	2023Jan19	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Panitumumab + Vemurafenib		Completed	NCT01791309		PCD	2015Mar01	Yes	Yes		2	10.1200/jco.2015.33.3_suppl.611 			Overall Response Rate	16	16																															2	8									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Camrelizumab + Cetuximab + Vemurafenib		Recruiting	NCT05019534		ECD	2022Aug01	Yes	No		4	NCT05019534	Previously-treated		Maximum tolerated dose/toxicity	12	12																																									COSO28864826	2022Jun06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Cetuximab + Encorafenib + PF-07284892		Recruiting	NCT04800822	Cohort 6	ECD	2026Feb04	Yes	No		4	NCT04800822	Untreated		Overall Response Rate	211	211																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Cetuximab + Encorafenib + PF-07284892		Recruiting	NCT04800822	Cohort 4/5	ECD	2026Feb04	Yes	No		4	NCT04800822	Previously-treated		Overall Response Rate	211	211																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Cetuximab + Encorafenib		Unknown					Yes	Yes		1	28363909	Previously-treated		Unknown	26	26			19.2																											1	4	15									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Alpelisib + Cetuximab + Encorafenib		Unknown					Yes	Yes		1	28363909	Previously-treated		Unknown	28	28			17.9																												5	21									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cobimetinib + Vemurafenib		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Expression confirmed	Yes		3	https://www.tapur.org/sites/tapur.org/files/Cobimetinib_Vemurafenib-CRC-BRAF_V600E_01.18.20_FINAL.pdf	Previously-treated		"Disease control rate, Clinical benefit rate"	28	28			29		13-49						3.65			3.32-4.18							57			8.98			6.02-11.4														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + Encorafenib + Hydroxychloroquine		Recruiting	NCT05576896			2024Jul01	Yes	No		4	NCT05576896			Overall Response Rate	43	43																																									COSO28864826	2023Jan06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + Encorafenib + Nivolumab		Recruiting	NCT05308446		ECD	2024Aug31	Yes	No		4	NCT05308446			Progression free survival	84			Cetuximab + Encorafenib																																							COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + ERAS-007 + Encorafenib		Recruiting	NCT05039177	HERKULES-3	ECD	2024Aug01	Yes	No		4	NCT05039177			Maximum tolerated dose/toxicity	200	200																																									COSO28864826	2021Nov12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + Encorafenib + FOLFIRI		Recruiting	NCT05004350	NAUTICALCRC	ECD	2024Apr01	Yes	No		4	NCT05004350			Progression free survival	103	103																																									COSO28864826	2021Nov02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	HLX208		Recruiting	NCT05127759		ECD	2023Jul30	Yes	No		4	NCT05127759	Previously-treated		Overall Response Rate	25	25																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	HLX208		Recruiting	NCT04984369		ECD	2022Aug15	Yes	No		4	NCT04984369	Previously-treated		Overall Response Rate	50	50																																									COSO28864826	2021Nov02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + FOLFOXIRI 		"Active, not recruiting"	NCT04034459	FIRE-4.5	ECD	2022Nov01	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2021.39.15_suppl.3502			Overall Response Rate	108	73	35	Bevacizumab + FOLFOXIRI 	66.7	52		0.23					8.3	5.9			0.03																										COSO28864826	2022Dec05	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Binimetinib + Encorafenib + Nivolumab		"Active, not recruiting"	NCT04044430		ECD	2023Nov30	Yes	No		4	NCT04044430			Radiographic response rate	2	2																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + FOLFIRI + Vemurafenib		Recruiting	NCT03727763	IMPROVEMENT	ECD	2021Dec01	Yes	Yes		2	10.1016/j.annonc.2021.08.962			Overall Response Rate	16	16			81.3																		100									2	11	3									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	HL-085 + Vemurafenib		Not yet recruiting	NCT05233332		ECD	2024Jan20	Yes	No		4	NCT05233332			Overall Response Rate	186	186																																									COSO28864826	2022Nov01	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + XL281		Completed	NCT01086267		PCD	2011Aug01	Yes	No		4	NCT01086267			Maximum tolerated dose/toxicity	17	17		XL281																																							COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Fotemustine + Vemurafenib		Completed	NCT01983124		PCD	2014Apr01	Yes	Yes		1	29552321	Previously-treated		Progression free survival	31	31											3.9										61.3									1	4	14									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + Encorafenib + WNT974		Completed	NCT02278133		PCD	2016May31	Yes	No		4	NCT02278133			Maximum tolerated dose/toxicity	20	20																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Dabrafenib + Panitumumab + Trametinib		Completed	NCT01750918		PCD	2020Jun18	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.103			Progression free survival	35	35			26																											1	8	20									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Binimetinib + Cetuximab + Encorafenib		Not yet recruiting	NCT05510895	NeoBRAF	ECD	2024Jul31	Yes	No		4	NCT05510895			Tumour volume	48	48																																									COSO28864826	2022Sep26	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Dabrafenib + Spartalizumab + Trametinib		Recruiting	NCT03668431		ECD	2022Sep01	Yes	No		4	NCT03668431			Overall Response Rate	25	25																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Binimetinib + Cetuximab + Encorafenib		"Active, not recruiting"	NCT03693170	ANCHOR-CRC	PCD	2020Jun29	Yes	Yes		3	https://www.esmo.org/oncology-news/first-line-encorafenib-binimetinib-and-cetuximab-combination-provides-clinical-benefit-and-manageable-safety-in-braf-v600e-mutated-mcrc	Untreated		Overall Response Rate	92	92			47.8		37.3-58.5						5.8			4.6-6.4							88			17.2			-14.1														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Bevacizumab + Chemotherapy		Recruiting	NCT05540951		PCD	2022Aug30	Yes	No		4	NCT05540951			"ORR, PFS, OS"	78			Cetuximab + Irinotecan + Vemurafenib																																							COSO28864826	2022Sep26	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin calcium + Oxaliplatin		Recruiting	NCT04607421	BREAKWATER	ECD	2024Sep16	Yes	No		4	NCT04607421			Progression free survival	765																																										COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Cetuximab + Encorafenib		Recruiting	NCT04607421	BREAKWATER	ECD	2024Sep16	Yes	No		4	NCT04607421			Progression free survival	765																																										COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Binimetinib + Cetuximab + Encorafenib		Recruiting	NCT03803553		ECD	2022Feb01	Yes	No		4	NCT03803553			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	500																																										COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Unknown	Cetuximab + Encorafenib		Recruiting	NCT05099068	PLANET	ECD	2025Sep15	Yes	No		4	NCT05099068			"PFS, ORR"	500	500																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462		Recruiting	NCT04294160		ECD	2024Oct25	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	350	350																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + Spartalizumab		Recruiting	NCT04294160		ECD	2024Oct25	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	350	350																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + TNO155		Recruiting	NCT04294160		ECD	2024Oct25	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	350	350																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + Naporafenib		Recruiting	NCT04294160		ECD	2024Oct25	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	350	350																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + Trametinib		Recruiting	NCT04294160		ECD	2024Oct25	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	350	350																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Adavosertib + Irinotecan		Completed	NCT02906059		PCD	2020Mar12	Yes	No		4	NCT02906059			Maximum tolerated dose/toxicity	7	7																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Cetuximab + PF-07799933		Recruiting	NCT05355701		ECD	2026Mar17	Yes	No		4	NCT05355701			Maximum tolerated dose/toxicity	174	174																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	2022Sep01	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Belvarafenib		Completed	NCT03118817		PCD	2020Feb04	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3000			Overall Response Rate	7	7																															2										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Regorafenib		Terminated	NCT02175654		PCD	2016Feb01	Yes	Yes	Slow accrual	4	NCT02175654			Progression free survival	15	15																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Encorafenib + Pembrolizumab		Recruiting	NCT05217446	SEAMARK	ECD	2026Mar28	Yes	No		4	NCT05217446	Untreated		Progression free survival	104			Pembrolizumab																																							COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Regorafenib + Sintilimab		Not yet recruiting	NCT04745130		ECD	2022Jun30	Comparison with wt	No		4	NCT04745130	Previously-treated		Overall Response Rate	90	90																																									COSO28864826	2022Sep27	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ulixertinib		Recruiting	NCT04488003	Group 4	ECD	2023Aug01	Yes	No		4	NCT04557956			Overall Response Rate	528	528																																									COSO28864826	2022Jul04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Vinorelbine		Unknown	NCT03482362	EORTC1616	ECD	2019Dec01	Yes	No		4	NCT03482362			Progression free survival	82	82																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Autologous Dendritic Cells vaccine + Avelumab		Completed	NCT03152565	AVEVAC	PCD	2019Jun30	No	Yes		2	10.1016/annonc/annonc698			Progression free survival	19	19											3.1			2.1-5.3										12.2			3.2-23.2					4									COSO28864826	2022Dec09	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT03223779		ECD	2023Jan01	No	No		4	NCT03223779			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	56	56																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Folfirinox		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ascorbic acid		Unknown	NCT04035096		ECD	2021Dec31	Yes	No		4	NCT04035096			Radiographic response rate	40	40																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		"Active, not recruiting"	NCT01312857		ECD	2023Mar01	Comparison with wt	No		1	33938493			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2			Dexamethasone + FOLFIRI + Floxuridine																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Alpelisib + Cetuximab + Encorafenib		Completed	NCT01719380		PCD	2015Oct31	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.3544			Progression free survival	152	52	50	SAR260301 + Vemurafenib	27	22							5.4	4.2	0.69	0.43-1.11	0.064																										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Fluorouracil + Leucovorin calcium + Vemurafenib		Completed	NCT02291289	MODUL	PCD	2019May31	Yes	Yes		4	NCT02291289			Progression free survival	60	40	20	Bemarituzumab + Chemotherapy									9.99	11.6	0.95	0.50-1.82 	0.87																										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Completed	NCT03542877		PCD	2020Oct19	No	No		4	NCT03542877	Previously-treated		Progression free survival	44	44																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MK2206		Completed	NCT01802320		PCD	2015Jun01	No	Yes		4	NCT01802320	Previously-treated		Overall Response Rate	18	18			0								1.87													6.8			5.83-7.77														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFIRI		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	2022Oct01	Yes	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																							COSO28864826	2022Sep15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or HRAS_unspecified or KRAS_unspecified or NRAS_unspecified or MAP2K1_unspecified or MAP2K2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	HL-085 + Vemurafenib		Not yet recruiting	NCT05233332		ECD	2024Jan20	Yes	No		4	NCT05233332			Overall Response Rate	186	186																																									COSO28864826	2022Nov01	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Regorafenib		Recruiting	NCT05312398	CAPRI 2 GOIM	ECD	2025Aug15	Yes	No		4	NCT05312398			Response rate	200	200																																									COSO28864826	2022May19	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT05312398	CAPRI 2 GOIM	ECD	2025Aug15	Yes	No		4	NCT05312398			Response rate	200	200																																									COSO28864826	2022Oct11	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Palbociclib		Completed	NCT01037790	Arm 2	PCD	2019Oct01	Yes	Yes		4	NCT01037790			Response rate	18	18																															0	6									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + FOLFOX		Recruiting	NCT05312398	CAPRI 2 GOIM	ECD	2025Aug15	Yes	No		4	NCT05312398			Response rate	200	200																																									COSO28864826	2022May19	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRCA1	BRCA1_unspecified or BRCA2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT05201612	PEMBROLA	ECD	2024Sep01	Yes	No		4	NCT05201612	Previously-treated		Overall Response Rate	40	40																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRCA1	BRCA1_unspecified or BRCA2_unspecified or PALB2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib		Recruiting	NCT03337087		ECD	2023Aug24	Yes	No		4	NCT03337087			Overall Response Rate	18	18																																									COSO28864826	2022Dec02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
RET	CCDC6-RET_fusion COSF1271				large intestine / carcinoma / adenocarcinoma	3	Out of trials human study	Agerafenib		Unknown					Yes	Yes		1	29538669			Unknown	1	1																														1											COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Avelumab + Bevacizumab + CEA-targeted adenoviral vaccine + Capecitabine + FOLFOX		Terminated	NCT03050814	QUILT-2.004	PCD	2021Aug25	No	Yes	No benefit of treatment	2	10.1016/j.annonc.2020.04.043	Untreated		Progression free survival	20	10	10	Bevacizumab + Capecitabine + FOLFOX																																							COSO28864826	2022Dec09	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Capecitabine		Recruiting	NCT05609370	Arm C	ECD	2025Feb01	Expression confirmed	No		4	NCT05609370			Progression free survival	202	202																																									COSO28864826	2023Jan13	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Capecitabine + LBL-007		Recruiting	NCT05609370	Arm B	ECD	2025Feb01	Expression confirmed	No		4	NCT05609370			Progression free survival	202	202																																									COSO28864826	2023Jan13	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Capecitabine + LBL-007 + Tislelizumab		Recruiting	NCT05609370	Arm A	ECD	2025Feb01	Expression confirmed	No		4	NCT05609370			Progression free survival	202	202																																									COSO28864826	2023Jan13	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Fruquintinib or Regorafenib + Toripalimab		Recruiting	NCT04483219		ECD	2022Jul31	No	No		4	NCT04483219			Progression free survival	53	53																																									COSO28864826	2022Jul26	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Favezelimab + Pembrolizumab		"Active, not recruiting"	NCT05064059		ECD	2024Feb09	Expression confirmed	No		4	NCT05064059			Overall survival	432			Regorafenib + Trifluridine and tipiracil hydrochloride																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	MK-4280A		Recruiting	NCT05600309		ECD	2024Aug15	Expression confirmed	No		4	NCT05600309	Previously-treated		Overall survival	94			Regorafenib + Trifluridine and tipiracil hydrochloride																																							COSO28864826	2023Jan13	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Nivolumab-Relatlimab-rmbw		Recruiting	NCT05328908	RELATIVITY-123	ECD	2025Jan29	Expression confirmed	No		4	NCT05328908	Previously-treated		Overall survival	700			Regorafenib or Trifluridine-Tipiracil hydrochloride 																																							COSO28864826	2022Oct11	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified or MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Atezolizumab		Recruiting	NCT02997228	COMMIT	ECD	2024Nov30	Expression confirmed	No		4	NCT02997228			Progression free survival	231			Bevacizumab + FOLFOX-6																																							COSO28864826	2022Jul21	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified or MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Atezolizumab + Bevacizumab + mFOLFOX6		Recruiting	NCT02997228	COMMIT	ECD	2024Nov30	Expression confirmed	No		4	NCT02997228			Progression free survival	231			Bevacizumab + FOLFOX-6																																							COSO28864826	2022Jul21	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Cetuximab	Required	Completed	NCT00079066	CO.17	PCD	2006Nov03	Expression confirmed	Yes		4	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	Previously-treated		Overall survival	572	287	285	Best supportive care																						6.1	4.6	0.77	0.64-0.92	0.005													COSO28864826	2023Jan23	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	FOLFIRI + Ramucirumab	Not required	Completed	NCT01183780	RAISE	PCD	2016Jun20	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf			Progression free survival	1072	536	536	FOLFIRI + Placebo									5.7	4.5	0.79	0.70-0.90	<0.01									13.1	11.7	0.85	0.73-0.98	0.023													COSO28864826	2023Jan23	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Cetuximab + Irinotecan	wt KRAS	Completed		BOND			Expression confirmed	Yes		1	15269313			Unknown	329	218	111	Cetuximab	22.9	10.8		0.007	5.7	4.2													55.5	32.4	<0.001																		COSO28864826	2023Jan17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Cetuximab + FOLFIRI	wt KRAS	Completed	NCT00154102	CRYSTAL	PCD	2006Dec01	Expression confirmed	Yes	Efficacy not correlated with expression status PMID:23265711 	1	19339720	Untreated		Progression free survival	1198	599	599	FOLFIRI									8.9	8	0.85	0.72-0.99	0.048									19.9	18.6	0.93	0.81-1.07	0.31													COSO28864826	2023Jan17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Panitumumab	wt KRAS	Completed	NCT01412957	20100007	PCD	2014Jun01	No	Yes		1	27736842	Previously-treated		Overall survival	377	189	188	Best supportive care																						10	6.9	0.7	0.53-0.93	0.0135													COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Panitumumab	wt KRAS	Completed	NCT01001377	20080763	PCD	2013Feb05	No	Yes		1	24739896	Previously-treated		Overall survival	1010	506	504	Cetuximab																						10.4	10	0.97	0.84-1.11														COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Panitumumab	wt KRAS	Completed	NCT00113763	20020408	PCD	2008Oct01	Expression confirmed	Yes		1	17470858	Previously-treated		Progression free survival	463	231	232	Best supportive care	10	0		0.001					1.83	1.69																													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Pelitinib		Unknown					Yes	Yes		1	16364494			Unknown	15	15																														2											COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Nazartinib + TNO155		Recruiting	NCT03114319		ECD	2024Feb27	Yes	No		4	NCT03114319			Maximum tolerated dose/toxicity	255	255																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Gatipotuzumab + Tomuzotuximab		Completed	NCT03360734	GATTO	PCD	2020May04	Yes	Yes		2	10.1016/S0959-8049(20)31083-2			Maximum tolerated dose/toxicity	19	19							5.8																								4										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Regorafenib		"Active, not recruiting"	NCT03992456	PULSE	ECD	2022Dec31	No	No		4	NCT03992456			Overall survival	120	120																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	AFM24 + SNK01		Recruiting	NCT05099549		ECD	2025Nov01	Expression confirmed	No		4	NCT05099549			Overall Response Rate	121	121																																									COSO28864826	2021Nov16	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Trifluridine and tipiracil hydrochloride		"Active, not recruiting"	NCT03992456	PULSE	ECD	2022Dec31	No	No		4	NCT03992456			Overall survival	120	120																																									COSO28864826	2022Oct11	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Erlotinib + Pemetrexed		Completed	NCT03086538		PCD	2020Jan30	Expression confirmed	Yes	Primary outcome met	1	31820199			Overall Response Rate	29	29			10.3																		62.1										3	15									COSO28864826	2022Nov29	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	EGFR CAR-CD3-CD28-4-1BB-expressing autologous T-lymphocytes		Unknown	NCT03152435		ECD	2019Sep01	Expression confirmed	No		4	NCT03152435			Maximum tolerated dose/toxicity	20	20																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT00202787		PCD	2009Feb01	No	No		3	https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001700-12/results			Overall Response Rate	136	68	68	FOLFOX-4	47.1	54.4			6.7	9.6			8.05	10.09				8.77	9.45				95.6	88.2		19.52	26.38			0.02													COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Bevacizumab + Erlotinib + FOLFOX		Completed					No	Yes		1	28979818	Previously-treated		Unknown	132	66	65	Bevacizumab + FOLFOX									9.6	6.9	1.15	0.88-1.39	0.021																										COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	FOLFIRI + Imgatuzumab		Completed	NCT01326000		PCD	2013Dec01	Expression confirmed	Yes	No benefit of treatment	2	10.1200/jco.2015.33.3_suppl.669 	Previously-treated		Progression free survival				FOLFIRI																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Futuximab		Completed	NCT02083653		PCD	2016Oct24	No	Yes	Primary outcome not met	1	29423521	Previously-treated		Overall survival	254			Best supportive care																																							COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Futuximab		Terminated	NCT03549338		PCD	2019Mar01	No	Yes	Administrative reasons	4	NCT03549338	Previously-treated		Maximum tolerated dose/toxicity	2	2																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Panitumumab		"Active, not recruiting"	NCT03992456	PULSE	ECD	2022Dec31	No	No		4	NCT03992456			Overall survival	120	120																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Panitumumab		Recruiting	NCT03087071	Cohort 1	ECD	2023Jul01	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.3520	Previously-treated		Response rate	3	3			0																		67																				COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Duligotuzumab + FOLFIRI		Completed	NCT01652482		PCD	2014Nov01	No	Yes	No benefit of treatment	1	29506988	Previously-treated		Progression free survival																																											COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Pelitinib		Completed	NCT00072748		PCD	2004Oct01	No	Yes	Serious adverse events	1	24574860	Previously-treated		Not defined	63	63																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 3	Cetuximab + FOLFIRI		Not yet recruiting	NCT02942706	BLOC-1	ECD	2022Oct01	No	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																							COSO28864826	2021Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	1	Unknown	FOLFIRI + Regorafenib		Completed	NCT03698253		PCD	2018Jun01	Expression confirmed	Yes		1	30594039			Progression free survival	28	28											2.5										46.4			9.6																	COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EGFR	EGFR_unspecified or PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Folfirinox + Panitumumab		"Active, not recruiting"	NCT01328171	VOLFI	PCD	2017Jun01	No	Yes		1	31609637	Untreated		Overall Response Rate	96	63	33	Folfirinox	87.3	60.6		0.004																																			COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
EPCAM	EPCAM_unspecified or MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Aspirin + Atorvastin		Recruiting	NCT04379999		ECD	2022Sep01	Yes	No		4	NCT04379999			Change in Ki-67 expression	46	46																																									COSO28864826	2022Mar14	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Approved FDA	Capecitabine + Trastuzumab + Tucatinib		"Active, not recruiting"	NCT03043313	MOUNTAINEER	PCD	2022Mar28	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213973s004lbl.pdf			Overall Response Rate	84	84			52.2				10.4				8.1													18.7							12										COSO28864826	2023Jan23	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT02564900		PCD	2019Feb01	Expression confirmed	Yes		4	NCT02564900			Overall Response Rate	20	20			5		0.1-24.9		13.4				4			2.7-5.6							80			15.6			-4.8														COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Poziotinib		Terminated	NCT04172597	Cohort 2	PCD	2022Mar29	Yes	No		4	NCT04172597			Overall Response Rate	1	1																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Capecitabine + Celecoxib + Disitamab vedotin + Tislelizumab		Not yet recruiting	NCT05578287	DETECT	ECD	2024Dec15	Expression confirmed	No		4	NCT05578287	Previously-treated		Maximum tolerated dose/toxicity	29	29																																									COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Disitamab vedotin + Tislelizumab		Recruiting	NCT05493683		ECD	2025Jul01	Expression confirmed	No		4	NCT05493683			Overall Response Rate	29	29																																									COSO28864826	2022Oct06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Disitamab vedotin + Pyrotinib + Tislelizumab		Not yet recruiting	NCT05350917		ECD	2025Jun20	Expression confirmed	No		4	NCT05350917	Previously-treated		Overall Response Rate	20	20																																									COSO28864826	2022Oct06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Disitamab vedotin + Pembrolizumab		Not yet recruiting	NCT05333809		ECD	2024Jul01	Expression confirmed	No		4	NCT05333809	Previously-treated		Overall Response Rate	30	30																																									COSO28864826	2022Oct06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Loperamide + Neratinib		"Active, not recruiting"	NCT01953926	SUMMIT	ECD	2022Oct31	Yes	Yes		1	29420467			Overall Response Rate	12	12			0		0.0?26.5						1.8										8.3	0.2?38.5																			COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Camrelizumab + Chemotherapy + Trastuzumab		Not yet recruiting	NCT05193292		ECD	2024Jan01	Expression confirmed	No		4	NCT05193292			Overall Response Rate	77	77																																									COSO28864826	2022Jun06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pyrotinib + Trastuzumab		Recruiting	NCT04380012		ECD	2021Dec17	Expression confirmed	Yes	Promising efficacy	1	36382603			Overall Response Rate	18	18			22.2		6.4-47.6						3.4			1.8-4.3							61.1																				COSO28864826	2022Dec05	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pyrotinib + Trastuzumab		Recruiting	NCT04960943		ECD	2022Sep09	Expression confirmed	Yes	SAE 31.3%	1	35941028	Previously-treated		Overall Response Rate	16	16			50								7.53			5.19-9.87							75			16.8			8.72-24.87			0	8	4									COSO28864826	2022Dec02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Capecitabine + Pertuzumab + Trastuzumab		Completed	NCT02291289	MODUL Cohort 3	PCD	2019May31	Yes	Yes		4	NCT02291289			Progression free survival	5	3	2	Bemarituzumab + Chemotherapy									4.44	4.04																													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pertuzumab + Trastuzumab-emtansine		Unknown	NCT03225937	HERACLES	ECD	2018Dec01	Expression confirmed	No		4	NCT03225937			Overall Response Rate	54	54																																									COSO28864826	2022Jan06	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Lapatinib + Trastuzumab		Unknown	NCT03225937	HERACLES-A	ECD	2018Dec01	Expression confirmed	Yes		1	32919890			Overall Response Rate	32	32			28								4.7			3.7-6.1										10			7.9-15.8			1	8	13									COSO28864826	2022Sep16	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Irinotecan + Trastuzumab		Completed	NCT00003995		PCD	2006Mar01	Overexpression	No		4	NCT00003995				32	32																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Chemotherapy + Trastuzumab		Unknown	NCT03185988	Arm 4	ECD	2021Jul01	Expression confirmed	Yes	Expression correlated with efficacy	2	10.1200/JCO.2022.40.4_suppl.301	Previously-treated		Overall Response Rate	21	21			28.6								4.3			2.65-5.95							85.7										21	12									COSO28864826	2022Dec01	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Trastuzumab Deruxtecan		Completed	NCT03384940	DESTINY-CRC01 cohort C	PCD	2019Aug09	Expression confirmed	Yes		4	NCT03384940			Overall Response Rate	18	18			0								1.4			1.3-2.1							22.2			7.7			2.2-13.9														COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Trastuzumab Deruxtecan		Completed	NCT03384940	DESTINY-CRC01 cohort A	PCD	2019Aug09	Overexpression	Yes		4	NCT03384940			Overall Response Rate	53	53			47.2								6.9			4.1-8.7							83			15.5			8.8-20.8														COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04744831	DESTINY-CRC02	ECD	2023Feb01	Overexpression	No		4	NCT04744831	Previously-treated		Overall Response Rate	122	122																																									COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04744831	DESTINY-CRC02	ECD	2023Feb01	Expression confirmed	No		4	NCT04744831			Overall Response Rate	122	122																																									COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Trastuzumab Deruxtecan		"Active, not recruiting"	NCT04744831	DESTINY-CRC02	ECD	2023Feb01	Expression confirmed	No		4	NCT04744831			Overall Response Rate	122	122																																									COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pertuzumab + Trastuzumab		Unknown	UMIN000027887	TRIUMPH			Expression confirmed	Yes	Primary outcome met	1	34764486			Overall Response Rate	27	27			30																																						COSO28864826	2022Feb17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pertuzumab + Trastuzumab		"Active, not recruiting"	NCT03365882	S1613	ECD	2023Nov01	Overexpression	No		4	NCT03365882			"ORR, OS"	240	240		Cetuximab + Irinotecan																																							COSO28864826	2022Dec09	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pertuzumab + Trastuzumab		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Overexpression	Yes		3	https://www.tapur.org/sites/tapur.org/files/Pertuzumab_Trastuzumab-CRC-ERBB2_01.18.20_FINAL.pdf	Previously-treated		"Disease control rate, Clinical benefit rate"	28	28			25		Nov-45						3.97			2.56-6.32							50			25.1			-5.09														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pyrotinib		Recruiting	NCT04380012		ECD	2021Dec17	Expression confirmed	No		4	NCT04380012			Overall Response Rate	40	40																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Trastuzumab-emtansine		Unknown	NCT03418558	RESCUE	ECD	2019Jun01	Overexpression	No		4	NCT03418558	Previously-treated		Overall Response Rate	13	13																																									COSO28864826	2022Jan10	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Capecitabine + Pyrotinib		Not yet recruiting	NCT04227041		ECD	2021Jan10	Expression confirmed	No		4	NCT04227041			Progression free survival	34	34																																									COSO28864826	2022May19	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Trastuzumab + Tucatinib + mFOLFOX6		Recruiting	NCT05253651	MOUNTAINEER-03	ECD	2025Aug31	Expression confirmed	No		4	NCT05253651			Progression free survival	400			Bevacizumab + mFOLFOX6																																							COSO28864826	2022May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Capecitabine + IAH0968 + Oxaliplatin		Not yet recruiting	NCT05673512		ECD	2025Mar01	Expression confirmed	No		4	NCT05673512			Progression free survival	279			Capecitabine + Oxaliplatin + Placebo																																							COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 4	Disitamab vedotin + Fruquintinib		Not yet recruiting	NCT05661357		ECD	2024Jan31	Expression confirmed	No		4	NCT05661357	Previously-treated		Overall Response Rate	12	12																																									COSO28864826	2023Jan12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	2	Unknown	Pyrotinib + Trastuzumab		Unknown	NCT03843749		ECD	2019Jul01	Expression confirmed	No		4	NCT03843749			Overall Response Rate	30	30																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified and (BRAF_unspecified or KRAS_unspecified or NRAS_unspecified or PIK3CA_unspecified)				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trastuzumab + Trifluridine and tipiracil hydrochloride + Tucatinib		Not yet recruiting	NCT05356897		ECD	2024May30	Expression confirmed	No		4	NCT05356897			Progression free survival	30	30																																									COSO28864826	2022Oct11	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified and KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pyrotinib + Trastuzumab		Recruiting	NCT04960943		ECD	2022Sep09	Comparison with wt	Yes		1	35941028	Previously-treated		Overall Response Rate	16	2	14		0	57.1							1.63	7.53			0.02						0	85.7			4.13			0.001													COSO28864826	2022Dec02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB3	ERBB3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Patritumab deruxtecan		Terminated	NCT04479436		PCD	2022Feb03	Expression confirmed	Yes	No benefit of treatment	4	NCT04479436			Overall Response Rate	40	40																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dovitinib		Completed	NCT01676714		PCD	2016Jan01	No	Yes	"Serious adverse events, no benefit of treatment"	2	10.1200/jco.2016.34.4_suppl.616	Previously-treated		Overall Response Rate	9	9																																1									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pemigatinib		"Active, not recruiting"	NCT04096417		PCD	2022May13	Yes	No		4	NCT04096417			Overall Response Rate	24	24																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dovitinib		Terminated	NCT01888965		PCD	2014Aug01	No	Yes	Serious adverse events	4	NCT01888965			Biomarker discovery	9	9																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Best supportive care + Nintedanib		Completed	NCT02149108	LUME-Colon 1	PCD	2016May13	No	Yes	Primary outcome not met	1	30010751	Previously-treated		"OS, PFS"	765	384	381	Best supportive care + Placebo									1.5	1.4	0.58	0.49-0.69	<0.0001									6.4	6	1.01	0.86-1.19	0.87													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FGFR2	FGFR2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pemigatinib		"Active, not recruiting"	NCT04096417		PCD	2022May13	Yes	No		4	NCT04096417			Overall Response Rate	24	24																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FGFR3	FGFR3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pemigatinib		"Active, not recruiting"	NCT04096417		PCD	2022May13	Yes	No		4	NCT04096417			Overall Response Rate	24	24																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FLT3	FLT3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR	ECD	2024Dec31	Expression confirmed	Yes		2	10.1007/s11523-020-00752-8			Overall Response Rate	3581	3581			0								2.33																					2									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
FLT3	FLT3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Famitinb		Completed	NCT02390947	FACT	PCD	2019Feb01	No	No		4	NCT02390947			Overall survival	543	543																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
HRAS	HRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	2022Sep01	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	HRAS_unspecified or KRAS_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Binimetinib + FOLFIRI		Recruiting	NCT02613650		ECD	2023Apr30	Yes	No		4	NCT02613650			Maximum tolerated dose/toxicity	30	30																																									COSO28864826	2022Jul12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	HRAS_unspecified or KRAS_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Capecitabine + Oxaliplatin + Sintilimab		Recruiting	NCT05171660		ECD	2022Dec06	Yes	No		4	NCT05171660			Overall Response Rate	23	23																																									COSO28864826	2022Sep27	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	HRAS_unspecified or KRAS_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pembrolizumab + THOR-707		"Active, not recruiting"	NCT05104567	Pegathor Gastrointestinal 203 Cohort D1	ECD	2024Jan23	Yes	No		4	NCT05104567			Overall Response Rate	280	280																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Pembrolizumab + Sargramostim + Zotiraciclib		Terminated	NCT02933944		PCD	2019Feb01	No	Yes	Changed business priorities	4	NCT02933944			Maximum tolerated dose/toxicity	6	6																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Pembrolizumab + Zotiraciclib		Terminated	NCT02933944		PCD	2019Feb01	Yes	Yes	Changed business priorities	4	NCT02933944			Maximum tolerated dose/toxicity	6	6																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Zotiraciclib		Terminated	NCT02933944		PCD	2019Feb01	Yes	Yes	Changed business priorities	4	NCT02933944			Maximum tolerated dose/toxicity	6	6																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Cetuximab + Selumetinib		Completed	NCT01217450		PCD	2012Dec01	Yes	Yes		1	26666244	Previously-treated		Unknown	4	4																															1	3									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT00125034	OPUS	PCD	2007Mar01	Yes	Yes	PFS greater for control	1	19114683			Overall Response Rate	99	52	47										5.5	8.6	1.83	1.095-3.056	0.0192						85	85																			COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Completed	NCT00079066	CO.17	PCD	2006Nov03	Yes	Yes	No benefit of treatment	1	18946061			Overall survival	151	75	76	FOLFIRI + Imgatuzumab									1.8	1.8												4.5	4.6	0.98	0.7-1.37	0.89													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab + FOLFIRI		Completed	NCT00154102	CRYSTAL	PCD	2006Dec01	Comparison with wt	Yes	No benefit of treatment	1	21502544	Untreated		Progression free survival	531	214	316	FOLFIRI									7.4	9.9												16.2	23.5																COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 3	Panitumumab		Completed	NCT00113763	20020408	PCD	2008Oct01	Yes	Yes	No benefit of treatment	1	18316791			Progression free survival	184	84	100	Best supportive care									1.7	1.69	0.99	0.73-1.36																											COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12 or KRAS_G13 or KRAS_Q61				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Irinotecan + Simvastatin		Completed	NCT01281761		PCD	2012Sep01	Yes	Yes	No benefit of treatment	1	24468885	Previously-treated		Unknown	52	52			1.9								3.7										65.4			12.8																	COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Panitumumab + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	2024Aug26	Yes	Yes		5	https://www.amgen.com/newsroom/press-releases/2021/09/lumakras-sotorasib-combined-with-vectibix-panitumumab-showed-encouraging-efficacy-and-safety-in-patients-with-kras-g12cmutated-colorectal-cancer			Maximum tolerated dose/toxicity	26	26			27																		81																				COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Adagrasib		Recruiting	NCT03785249	KRYSTAL-1	ECD	2022Dec01	Yes	Yes		1	35167329			Maximum tolerated dose/toxicity	2	2			50				4.2																								1										COSO28864826	2023Jan19	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	large intestine / carcinoma / adenocarcinoma	3	Phase 3	Adagrasib + Cetuximab		Recruiting	NCT04793958	KRYSTAL-10	ECD	2023Sep30	Yes	No		4	NCT04793958			"OS, PFS"	420			mFOLFOX6																																							COSO28864826	2021Nov02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab + GFH925		Recruiting	NCT05497336		ECD	2023Aug30	Yes	No		4	NCT05497336			Overall Response Rate	80	80																																									COSO28864826	2022Oct03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	large intestine / carcinoma / adenocarcinoma	3	Phase 3	Panitumumab + Sotorasib		Recruiting	NCT05198934	CodeBreak 300	ECD	2023Apr03	Yes	No		4	NCT05198934			Progression free survival	153			Physician's choice																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092 + 105058461		p.G12C	large intestine / carcinoma / adenocarcinoma	3	Phase 3	GFH925		Recruiting	NCT05497336		ECD	2023Aug30	Yes	No		4	NCT05497336			Overall Response Rate	80	80																																									COSO28864826	2022Oct03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	large intestine / carcinoma / adenocarcinoma	3	Case study	MK-8353 + Pembrolizumab		Terminated	NCT01358331		PCD	2014May20	Yes	Yes		1	29467321			Unknown	1	1																															1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pembrolizumab + T-cell transfer 		Recruiting	NCT01174121		ECD	2023Dec29	Yes	Yes		1	27959684			Unknown	1	1																															1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Case study	Pembrolizumab + T-cell transfer 		Terminated	NCT02933944		PCD	2019Feb01	Yes	Yes	Changed business priorities	1	27959684			Unknown	1	1																															1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	Atezolizumab + Cobimetinib		Completed	NCT01988896		PCD	2019Nov04	Yes	Yes		1	30918950			Maximum tolerated dose/toxicity	57	57			9		29-Mar						2			1.8-2.6										9.5			6.0-17.6				5	12									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	BI 1701963 + Irinotecan		Terminated	NCT04627142		PCD	2022Jan18	Yes	No		4	NCT04627142	Previously-treated		Overall Response Rate	15	15																																									COSO28864826	2022Jun20	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	2022Sep01	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	ERAS-007		Completed	NCT03415126	ASN007-101 Group 3	PCD	2020Jun30	No	No		4	NCT03415126			Overall Response Rate	49	49																																									COSO28864826	2022Jul12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	Adavosertib + Irinotecan		Completed	NCT02906059		PCD	2020Mar12	Yes	No		4	NCT02906059			Maximum tolerated dose/toxicity	7	7																																									COSO28864826	2022May16	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	FOLFOX-6 + Selinexor		Terminated	NCT02384850	SENTINEL	PCD	2017Mar09	No	Yes	Primary outcome not met	1	32598257			Unknown	10	10																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	MK-8353 + Pembrolizumab		"Active, not recruiting"	NCT02972034		ECD	2022Dec02	No	No		4	NCT02972034			Maximum tolerated dose/toxicity	182	182																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	Selinexor		Unknown	NCT02137356		ECD	2017Jun01	No	No		4	NCT02137356			Maximum tolerated dose/toxicity	28	28																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 1	Bevacizumab + FOLFIRI + Pelareorep		Completed	NCT01274624	REO 022	PCD	2018Feb01	Yes	Yes		5	https://www.oncolyticsbiotech.com/press-releases/detail/434/oncolytics-biotech-announces-positive-clinical-trial	Untreated		Maximum tolerated dose/toxicity	6	6												15.1												24.8							3										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	FOLFOX + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	IMM-1-104		Recruiting	NCT05585320		ECD	2026Jun01	Yes	No		4	NCT05585320	Previously-treated		Overall Response Rate	156	156																																									COSO28864826	2023Jan05	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab + VS-6766		Recruiting	NCT05200442		ECD	2024Apr01	Yes	No		4	NCT05200442			Overall Response Rate	53	53																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Nivolumab + SX682		Recruiting	NCT04599140	STOPTRAFFIC-1	ECD	2024Jan31	Yes	No		4	NCT04599140			Maximum tolerated dose/toxicity	53	53																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Atezolizumab + Cobimetinib + Hydroxychloroquine		Recruiting	NCT04214418	MEKiAUTO	ECD	2023Sep01	Yes	No		4	NCT04214418			Maximum tolerated dose/toxicity	175	175																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Bevacizumab + FOLFIRI + Onvansertib		"Active, not recruiting"	NCT03829410		ECD	2023Dec01	Yes	Yes		5	https://cardiffoncology.investorroom.com/2021-09-08-Cardiff-Oncology-Announces-New-Data-from-Phase-1b-2-Trial-in-KRAS-mutated-Metastatic-Colorectal-Cancer-Showing-Robust-Objective-Response-Rate-and-Progression-Free-Survival			Overall Response Rate	32	32			38								9.4																				8										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Plocabulin		Completed	NCT03427268		PCD	2019Feb11	No	Yes	3m PFS 20.7% (95% CI 8.0-39.7) 	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000257-39/results#endPointsSection	Previously-treated		Progression free survival	29	29											2.6			1.3-2.8										9.8			4.6-999 					9									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Vinorelbine		Unknown	NCT03482362	EORTC1616	ECD	2019Dec01	Yes	No		4	NCT03482362			Progression free survival	82	82																																									COSO28864826	2021Jun22	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab + Folfirinox		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Irinotecan + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab + Sorafenib		Completed	NCT00326495		PCD	2014Nov05	No	Yes	No benefit of treatment	1	25861837			"Disease control rate, Clinical benefit rate"	51	51																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Bevacizumab + FOLFOX-6 + Pelareorep		Completed	NCT01622543	IND 210	PCD	2017Jan18	No	Yes		4	NCT01622543			Progression free survival	103	51	52	Bevacizumab + FOLFOX-6	52.9	34.6		0.06					7.33	9.13	1.59	1.00-2.53	0.046									19.3	20			0.36													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Pembrolizumab + T-cell transfer 		Recruiting	NCT01174121		ECD	2023Dec29	No	No		4	NCT01174121			Unknown	93																																										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	FOLFOX-6 + Sorafenib		Completed	NCT00865709	RESPECT	PCD	2011Jan01	No	Yes	"No benefit of treatment, no effect of KRAS or BRAF mutation status"	1	23532888			Progression free survival	198	97	101	Placebo									9.1	8.7	0.88		0.23									17.5	18.2																COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Irinotecan + Sorafenib		Completed	NCT01715441	NEXIRI 2-PRODIGE 27	PCD	2015Mar01	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.3545	Previously-treated		Progression free survival	104	57	57	Sorafenib									3.7	2.1												7	5.1																COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Irinotecan + Sorafenib		Completed	NCT01715441	NEXIRI 2-PRODIGE 27	PCD	2015Mar01	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.3545	Previously-treated		Progression free survival	103	57	56	Irinotecan									3.7	1.9												7	6.3																COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cabozantinib		Completed	NCT03542877		PCD	2020Oct19	No	No		4	NCT03542877	Previously-treated		Progression free survival	44	44																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab + FOLFIRI		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Cetuximab		Recruiting	NCT04189055	CETIDYL	ECD	2023Apr01	Yes	No		4	NCT04189055			Response rate	72	72		FOLFIRI																																							COSO28864826	2021Nov01	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	FOLFOX + Panitumumab		Completed	NCT00364013	PRIME	PCD	2009Aug01	Yes	Yes	PFS greater for control	4	NCT00364013	Untreated		Progression free survival	440	221	219		39.5	40.3		0.9822	7.5	8			7.3	8.8	1.29	1.04-1.62	0.0227	7.5	9							15.5	19.3			0.0678													COSO28864826	2023Jan23	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Bevacizumab + mFOLFOXIRI		Recruiting	NCT04781270		ECD	2024Mar30	Yes	No		4	NCT04781270			Resection rate	308			Bevacizumab + mFOLFOX6																																							COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Bevacizumab + FOLFIRI		Recruiting	NCT04776655		ECD	2023Apr29	Yes	No		4	NCT04776655			Progression free survival	280			Cetuximab + FOLFIRI																																							COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Atezolizumab + Cobimetinib		Completed	NCT02788279	IMblaze370	PCD	2018Mar09	No	Yes	Primary outcome not met	1	31003911	Previously-treated		Overall survival	273	183	90	Regorafenib																						8.87	8.51			0.987													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Bevacizumab		Completed	NCT00109070				No	Yes	Response not correlated with mutation status	1	19144677	Untreated		Unknown	230																																										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	2022Oct01	Yes	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																							COSO28864826	2021Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 4	Bevacizumab		Unknown					Yes	Yes	Response not correlated with mutation status	1	29085005			Unknown	141	141																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Unknown	Stereotactic Body Radiation Therapy		Recruiting	NCT04854213		ECD	2023Jun01	Yes	No		4	NCT04854213			Response rate	25	25																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	2	Unknown	FOLFIRI + Regorafenib		Completed	NCT03698253		PCD	2018Jun01	Comparison with wt	Yes		1	30594039	Previously-treated		Progression free survival	41	23	18																				47.8	72.2		6	14.4	0.4	0.18-0.86	0.014													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified and TP53_unspecified				large intestine / carcinoma / adenocarcinoma	2	Phase 2	Adavosertib		Unknown	EudraCT201200511112	FOCUS4-C			Yes	Yes		1	34538072			Progression free survival	69	44	25	Observation									3.61	1.87	0.35	0.18-0.68	0.0022									14	12.8	0.92	0.44-1.94	0.93													COSO28864826	2022Feb15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified or MET_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Binimetinib + Crizotinib		Completed	NCT02510001	MErCuRIC1	PCD	2018Dec03	No	Yes		4	NCT02510001			"Disease control rate, Clinical benefit rate"	30	30																																7									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Binimetinib + Palbociclib		"Active, not recruiting"	NCT03981614		PCD	2021Aug23	Yes	Yes		2	10.1200/JCO.2022.40.4_suppl.116			Progression free survival	82	41	41	Trifluridine and tipiracil hydrochloride									2.1	2.1	0.86	0.52-1.44										7.7	6.6	0.77	0.39-1.511														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	ERAS-007 + Palbociclib		Recruiting	NCT05039177	HERKULES-3	ECD	2024Aug01	Yes	No		4	NCT05039177			Maximum tolerated dose/toxicity	200	200																																									COSO28864826	2021Nov12	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified or NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + FOLFIRI + Onvansertib		Recruiting	NCT05593328		ECD	2024Nov01	Yes	No		4	NCT05593328	Previously-treated		Overall Response Rate	150			Bevacizumab + FOLFOX																																							COSO28864826	2023Jan05	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MAP2K1	MAP2K1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		"Active, not recruiting"	NCT01312857		ECD	2023Mar01	Comparison with wt	No		1	33938493			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	0	0	0	Dexamethasone + FOLFIRI + Floxuridine																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MAP2K1	MAP2K1_unspecified or MAP2K2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ulixertinib		Recruiting	NCT04488003	Group 6	ECD	2023Aug01	Yes	No		4	NCT04557956			Overall Response Rate	528	528																																									COSO28864826	2022Jul04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Cabozantinib		Completed	NCT02008383		PCD	2018May10	Expression confirmed	Yes		2	10.1200/JCO.2018.36.15_suppl.3555			Overall Response Rate	3	3			0																																						COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Cabozantinib + Panitumumab		Completed	NCT02008383		PCD	2018May10	Expression confirmed	Yes		2	10.1200/JCO.2018.36.15_suppl.3555			Overall Response Rate	4	4			25																												1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Crizotinib		"Active, not recruiting"	NCT02034981	AcSe	PCD	2019Jun01	Expression confirmed	Yes		2	10.1200/jco.2015.33.15_suppl.2595			Overall Response Rate	10	10																																2									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Tepotinib		Terminated	NCT04515394	PERSPECTIVE	PCD	2022Mar14	Expression confirmed	No		4	NCT04515394			Overall Response Rate	3	3																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	RC108		Not yet recruiting	NCT05628857		ECD	2024Oct15	Expression confirmed	No		4	NCT05628857			Overall Response Rate	240	240																																									COSO28864826	2023Jan10	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Savolitinib		"Active, not recruiting"	NCT03592641		ECD	2023Jan31	Expression confirmed	No		4	NCT03592641			Overall Response Rate	15	15																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Irinotecan + Tivantinib		Completed	NCT01075048		PCD	2012Oct12	Expression confirmed	Yes		1	26891420	Previously-treated		Progression free survival	44	24	20	Cetuximab + Irinotecan + Placebo	54	30							7.9	5.8	0.74	0.36-1.52	0.41									22.3	17.6	0.58	0.25-1.36	0.2													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Tivantinib		Completed	NCT01892527		PCD	2016May01	Expression confirmed	Yes		2	10.1093/annonc/mdx263.027	Previously-treated		Overall Response Rate	42	42											2.1			1.8-4.5										8.5			6.6-12.4			1	3	11									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Pembrolizumab	Required	"Active, not recruiting"	NCT02563002	KEYNOTE-1 7	PCD	2021Feb19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s127lbl.pdf			"OS, PFS"	307	153	154		44	33				10.6			16.5	8.2	0.6		0.0004																										COSO28864826	2023Jan17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Durvalumab + Tremelimumab		Completed	NCT03005002		PCD	2019Nov26	No	Yes	Lack of efficacy	1	31857446			Clinical activity	9	9																																									COSO28864826	2022Sep15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified 				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT05310643	NIPIRESCUE	ECD	2024Dec15	Expression confirmed	No		4	NCT05310643			Overall Response Rate	30	30																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified 				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pembrolizumab		Completed	NCT01876511	Cohort A	PCD	2019Aug01	Yes	Yes		1	28596308			Progression free survival	40	40			52		36-38																82									5	16	12									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified 				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Aspirin		Recruiting	NCT02813824	AAS-Lynch	ECD	2026Jun15	Yes	No		4	NCT02813824			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	852			Placebo																																							COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MSH2	MSH2_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Pembrolizumab	Required	"Active, not recruiting"	NCT02563002	KEYNOTE-1 7	PCD	2021Feb19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s127lbl.pdf			"OS, PFS"	307	153	154		44	33				10.6			16.5	8.2	0.6		0.0004																										COSO28864826	2023Jan17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MSH2	MSH2_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Durvalumab + Tremelimumab		Completed	NCT03005002		PCD	2019Nov26	No	Yes	Lack of efficacy	1	31857446			Clinical activity	9	9																																									COSO28864826	2022Sep15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MSH2	MSH2_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 2	Methotrexate		Terminated	NCT00952016	MESH	PCD	2014Sep01	Yes	Yes	Slow accrual	4	NCT00952016			Overall Response Rate	2	2																																									COSO28864826	2022Mar14	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MSH6	MSH6_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Pembrolizumab	Required	"Active, not recruiting"	NCT02563002	KEYNOTE-1 7	PCD	2021Feb19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s127lbl.pdf			"OS, PFS"	307	153	154		44	33				10.6			16.5	8.2	0.6		0.0004																										COSO28864826	2023Jan17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MSH6	MSH6_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Durvalumab + Tremelimumab		Completed	NCT03005002		PCD	2019Nov26	No	Yes	Lack of efficacy	1	31857446			Clinical activity	9	9																																									COSO28864826	2022Sep15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_Q61K	54736310 + 54742235 + 54754425 + 54762707 + 104538738		p.Q61K	large intestine / carcinoma / adenocarcinoma	4	Case study	Binimetinib + Palbociclib		Completed	NCT02065063		PCD	2016Jun23	Yes	Yes		2	10.1158/1535-7163.TARG-15-PR06			Maximum tolerated dose/toxicity	1	1																															1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_Q61K	54736310 + 54742235 + 54754425 + 54762707 + 104538738		p.Q61K	large intestine / carcinoma / adenocarcinoma	4	Case study	Bevacizumab + Valproic acid		Unknown					Yes	Yes		1	23400451			Unknown	1	1																															1										COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	NRAS_Q61K and TP53_V272M and TP53_R273C	52661812		p.V272M	large intestine / carcinoma / adenocarcinoma	4	Case study	Bevacizumab + Valproic acid		Unknown					Yes	Yes		1	23400451			Unknown	1	1																															1										COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Adavosertib + Irinotecan		Completed	NCT02906059		PCD	2020Mar12	Yes	No		4	NCT02906059			Maximum tolerated dose/toxicity	7	7																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	2022Sep01	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Nivolumab + SX682		Recruiting	NCT04599140	STOPTRAFFIC-1	ECD	2024Jan31	Yes	No		4	NCT04599140			Maximum tolerated dose/toxicity	53	53																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + PHY906		Completed	NCT00730158		PCD	2016Jun01	Yes	Yes		4	NCT00730158			Maximum tolerated dose/toxicity	26	14	12	Irinotecan	50	83.3							4.01	3.42																													COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Yttrium-90		Suspended	NCT04108481	iRE-C	ECD	2023Dec31	No	No		4	NCT04108481			Maximum tolerated dose/toxicity	18	18																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		"Active, not recruiting"	NCT01312857		ECD	2023Mar01	Comparison with wt	No		1	33938493			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	2	1	1	Dexamethasone + FOLFIRI + Floxuridine																																							COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Fluorouracil + Imalumab + Leucovorin calcium		Terminated	NCT02448810		PCD	2017Feb15	No	Yes	No benefit of treatment	4	NCT02448810			Progression free survival	115	115																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Completed	NCT03542877		PCD	2020Oct19	No	No		4	NCT03542877	Previously-treated		Progression free survival	44	44																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04189055	CETIDYL	ECD	2023Apr01	Yes	No		4	NCT04189055			Response rate	72	72		FOLFIRI																																							COSO28864826	2021Nov01	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	2022Oct01	Yes	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																							COSO28864826	2021Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Entrectinib		"Active, not recruiting"	NCT02568267	STARTRK-2	ECD	2024Dec31	Yes	No		4	NCT02568267	Previously-treated		Overall Response Rate	700	700																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
NTRK1	NTRK1_fusions or NTRK2_fusions or NTRK3_fusions				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Larotrectinib		Recruiting	NCT02576431	NAVIGATE Arm 4	ECD	2023Aug15	Yes	No		4	NCT02576431			Best overall response	204	204																																									COSO28864826	2022Jul15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_Exon20				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	2022Oct01	Yes	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																							COSO28864826	2022Sep15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Palbociclib + Taselisib		Unknown	NCT02389842	PIPA	PCD	2018Oct31	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3087	Previously-treated			2	2																																2									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Insulin Suppressing Diet + Serabelisib		Recruiting	NCT05300048	Cohort 2	ECD	2024Sep01	Yes	No		4	NCT05300048			Overall Response Rate	68	68																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	TVB2640		Recruiting	NCT02980029		ECD	2022Dec31	No	No		4	NCT02980029			Metabolic endpoints (malonyl carnitine and tripalmitin levels) 	48	48																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Alpelisib + Capecitabine		Not yet recruiting	NCT04753203		ECD	2024Feb28	Yes	No		4	NCT04753203	Previously-treated		Progression free survival	65	65																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MEN1611 + Trastuzumab		Recruiting	NCT04495621	C-PRECISE-01	ECD	2023Jul01	Yes	No		4	NCT04495621			Overall Response Rate	42	42																																									COSO28864826	2021Dec08	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dexamethasone + FOLFIRI + Floxuridine + Panitumumab		"Active, not recruiting"	NCT01312857		ECD	2023Mar01	Comparison with wt	Yes		1	33938493			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	75	11	64	Dexamethasone + FOLFIRI + Floxuridine																															45.5	49.9			0.185			15	COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Terminated	NCT03311750	A-REPEAT	PCD	2021Mar31	No	No		4	NCT03311750			Overall Response Rate	23	23																																									COSO28864826	2022May03	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Telaglenastat		"Active, not recruiting"	NCT02861300		ECD	2023Jan01	Yes	No		4	NCT02861300	Previously-treated		"Disease control rate, Clinical benefit rate"	53	53																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Completed	NCT03542877		PCD	2020Oct19	Yes	Yes	Promising activity	2	10.1200/JCO.2020.38.4_suppl.103	Previously-treated		Progression free survival	1	1																															1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MK2206		Completed	NCT01802320		PCD	2015Jun01	No	Yes		4	NCT01802320	Previously-treated		Overall Response Rate	18	18			0								1.87													6.8			5.83-7.77														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Aspirin		"Active, not recruiting"	NCT00565708	ASCOLT	ECD	2025Dec01	No	No		4	NCT00565708	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	1587			Placebo																																							COSO28864826	2021Oct27	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified and PTEN_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Insulin Suppressing Diet + Serabelisib		Recruiting	NCT05300048	Cohort 2	ECD	2024Sep01	Yes	No		4	NCT05300048			Overall Response Rate	68	68																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PMS2	PMS2_unspecified				large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Pembrolizumab	Required	"Active, not recruiting"	NCT02563002	KEYNOTE-1 7	PCD	2021Feb19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s127lbl.pdf			"OS, PFS"	307	153	154		44	33				10.6			16.5	8.2	0.6		0.0004																										COSO28864826	2023Jan17	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PMS2	PMS2_unspecified				large intestine / carcinoma / adenocarcinoma	1	Phase 1	Durvalumab + Tremelimumab		Completed	NCT03005002		PCD	2019Nov26	No	Yes	Lack of efficacy	1	31857446			Clinical activity	9	9																																									COSO28864826	2022Sep15	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PTEN	PTEN_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MK2206		Completed	NCT01802320		PCD	2015Jun01	No	Yes		4	NCT01802320	Previously-treated		Overall Response Rate	18	18			0								1.87													6.8			5.83-7.77														COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
RET	RET_unspecified				large intestine / carcinoma / adenocarcinoma	3	Out of trials human study	Agerafenib		Unknown					Comparison with wt	Yes		1	29538669			Unknown		24	291																							14	38	4.59	3.64-32.66	<0.001													COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ROS1	ROS1_fusions				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Entrectinib		"Active, not recruiting"	NCT02568267	STARTRK-2	ECD	2024Dec31	Yes	No		4	NCT02568267	Previously-treated		Overall Response Rate	700	700																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	2022Sep01	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																									COSO28864826	2022Aug04	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Folfirinox		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cyclophosphamide		Terminated	NCT03149679	The p53 colorectal cancer trial	PCD	2020Aug07	Yes	Yes	No benefit of treatment	4	NCT03149679			Overall Response Rate	12	12																																									COSO28864826	2022Oct24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFIRI		Completed	NCT01442935		PCD	2015Dec01	No	Yes	Primary outcome not met	2	10.1200/JCO.2018.36.15_suppl.3535			Resection rate	256	256																																									COSO28864826	2021Aug02	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04853043		ECD	2023Jul01	Yes	No		4	NCT04853043	Previously-treated		Progression free survival	21	21																																									COSO28864826	2022Jan24	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
WT1	WT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	"WT1, NY-ESO-1, PRAME and Survivin-specific allogenic CTLs"		Recruiting	NCT02494167	ADSPAM	ECD	2023Apr01	Expression confirmed	Yes		1	33270816			Maximum tolerated dose/toxicity	25	25																														1	1										COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
WT1	WT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		"Active, not recruiting"	NCT03761914		ECD	2022Nov30	Expression confirmed	No		4	NCT03761914			"Complete response, Pathological complete response"	90	90																																									COSO28864826	2022Nov28	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
WT1	WT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Hematopoietic Stem Cell Transplant + WT1-A10/AS01B immunotherapeutic GSK2130579A		Completed	NCT01819558	ALLO-WT1	PCD	2015Mar01	Expression confirmed	No		4	NCT01819558			Maximum tolerated dose/toxicity	2	2																																									COSO28864826	2021May18	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
XRCC3	XRCC3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT04166604	LONGBOARD	ECD	2021Nov15	No	No		4	NCT04166604			Maximum tolerated dose/toxicity	250	250																																									COSO28864826	2022Oct11	COSO28864826	large_intestine	NS	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
APC	APC_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	2015Mar01	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3										COSO28664826	2021May18	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
APC	APC_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Binimetinib + Encorafenib		Recruiting	NCT03839342	BEAVER	ECD	2023Dec01	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.e15038			Overall Response Rate	1	1																															1										COSO28664826	2022Nov28	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	2015Mar01	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3										COSO28664826	2021May18	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Radiotherapy + Trametinib		"Active, not recruiting"	NCT01740648		PCD	2021Sep29	No	Yes	pCR 25%	1	32253228			Maximum tolerated dose/toxicity	9	9																														3			88.9								COSO28664826	2022Nov28	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
BRAF	BRAF_unspecified or KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	2015Mar01	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3										COSO28664826	2021May18	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
CD274	CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab		Recruiting	NCT05009069		ECD	2023Jun30	No	No		4	NCT05009069			"Complete response, Pathological complete response"	76			Atezolizumab + Capecitabine or fluorouracil + Radiotherapy																																							COSO28664826	2022Jun27	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
ERBB2	ERBB2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Trastuzumab + Tucatinib		Recruiting	NCT05672524		ECD	2025Dec30	Overexpression	No		4	NCT05672524			"Complete response, Pathological complete response"	37	37																																									COSO28664826	2023Jan12	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified 				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Chemotherapy + Emepepimut-S + Radiotherapy		Completed	NCT01507103	SPRINT	PCD	2014Jun01	Expression confirmed	Yes	ICI 0.54 v 1.54	4	NCT01507103			Immune cell infiltration	63	33	30	Chemotherapy																																							COSO28664826	2022Nov28	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified 				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy		Completed	NCT01507103	SPRINT	PCD	2014Jun01	Expression confirmed	Yes	ICI 0.61 v 1.54	4	NCT01507103			Immune cell infiltration	57	27	30	Chemotherapy																																							COSO28664826	2022Nov28	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	2015Mar01	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3										COSO28664826	2021May18	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Alpelisib + Infigratinib		Completed	NCT01928459		PCD	2016Aug01	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.2500			Maximum tolerated dose/toxicity	1	1																															1										COSO28664826	2022Nov28	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Alpelisib		Completed	NCT01219699		PCD	2015Feb05	Yes	Yes		1	29401002			Maximum tolerated dose/toxicity	1	1																															1										COSO28664826	2022Nov28	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
PTEN	PTEN_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	2015Mar01	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3										COSO28664826	2021May18	COSO28664826	large_intestine	rectum	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
KRAS	KRAS_unspecified and CD274_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pembrolizumab		"Active, not recruiting"	NCT02919969		PCD	2021Dec01	No	No		4	NCT02919969			Overall Response Rate	32	32																																									COSO27734826	2022Aug01	COSO27734826	large_intestine	anus	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
MLH1	MLH1_unspecified				large intestine / adenoma / NS	3	Phase 2	Nivolumab		Unknown	NCT03631641		ECD	2020Dec31	No	No		4	NCT03631641			Response rate	3	3																																									COSO28584837	2022May03	COSO28584837	large_intestine	colon	NS	NS	adenoma	NS	NS	NS	large_intestine
MSH2	MSH2_unspecified				large intestine / adenoma / NS	3	Phase 2	Nivolumab		Unknown	NCT03631641		ECD	2020Dec31	No	No		4	NCT03631641			Response rate	3	3																																									COSO28584837	2022May03	COSO28584837	large_intestine	colon	NS	NS	adenoma	NS	NS	NS	large_intestine
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Alpelisib		Completed	NCT01219699		PCD	2015Feb05	Yes	Yes		1	29401002			Maximum tolerated dose/toxicity	1	1																															1										COSO28584826	2022Nov28	COSO28584826	large_intestine	colon	NS	NS	carcinoma	adenocarcinoma	NS	NS	large_intestine
AFP	AFP_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Approved FDA	Best supportive care + Ramucirumab	Required	Completed	NCT02435433	REACH-2	PCD	2018Mar15	Expression confirmed	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf			Overall survival	292	197	95	Best supportive care + Placebo	4.6	1.1							2.8	1.6	0.45	0.34-0.60	<0.0001									8.5	7.3	0.71	0.53-0.95	0.02													COSO29825606	2023Jan23	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
ALK	ALK_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Ascrinvacumab		Terminated	NCT01911273		PCD	2014Jul01	No	Yes	Development discontinued	3	NCT01911273	Previously-treated		Overall survival	3			Best supportive care																																							COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
BRCA1	BRCA1_unspecified or BRCA2_unspecified				liver / carcinoma / hepatocellular carcinoma	7	Phase 2	Temozolomide + Veliparib		Terminated	NCT01205828		PCD	2014Oct01	No	Yes	No benefit of treatment	4	NCT01205828			"Disease control rate, Clinical benefit rate"	16	16																																									COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Approved FDA	Pembrolizumab	Not required	"Active, not recruiting"	NCT02702414	KEYNOTE-224	PCD	2021Jan19	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf			Overall Response Rate	104	104			17		26-Nov																																				COSO29825606	2022Nov30	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Approved FDA	Atezolizumab + Bevacizumab	Not required	"Active, not recruiting"	NCT03434379	IMbrave150	PCD	2020Aug31	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf	Untreated		"OS, PFS"	501	336	165	Sorafenib	28	12		<0.0001		6.3			6.8	4.3	0.59	0.47-0.76	<0.0001										13.2	0.85	0.42-0.79	0.0006													COSO29825606	2023Jan23	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 1	Durvalumab + Tremelimumab		Recruiting	NCT04605731		ECD	2023Dec31	No	No		4	NCT04605731			Overall Response Rate	32	32																																									COSO29825606	2022Aug01	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Apatinib + Camrelizumab		Recruiting	NCT04701060		ECD	2022Feb04	No	No		4	NCT04701060			Overall Response Rate	30	30																																									COSO29825606	2022Aug04	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Bevacizumab + Toripalimab		"Active, not recruiting"	NCT04605796		PCD	2020Dec22	No	Yes	SAE 27.8%	2	10.1200/JCO.2022.40.4_suppl.435			Overall Response Rate	52	52			37.2								9.9			5.5-11.0							78.8									1	16										COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Camrelizumab + Lenvatinib		Recruiting	NCT04443309		ECD	2022Aug01	No	No		4	NCT04443309	Untreated		Overall Response Rate	53	53																																									COSO29825606	2022Aug04	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Durvalumab + TACE + Tremelimumab		Recruiting	NCT04522544		ECD	2024Mar31	No	No		4	NCT04522544			Overall Response Rate	84	84																																									COSO29825606	2022Jul22	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Durvalumab + Tremelimumab + Yttrium-90 SIRT		Recruiting	NCT04522544		ECD	2024Mar31	No	No		4	NCT04522544			Overall Response Rate	84	84																																									COSO29825606	2022Jul22	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Lenvatinib + MK-7684A		Recruiting	NCT05007106	KEYVIBE-005	ECD	2025Feb19	Expression confirmed	No		4	NCT05007106			"OS, PFS"	610	610																																									COSO29825606	2022Jun23	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Thermal ablation + Toripalimab		Recruiting	NCT05240404		ECD	2023Jul31	No	No		4	NCT05240404	Previously-treated		"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	116			Thermal ablation																																							COSO29825606	2022Jun15	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Lenvatinib + Nivolumab		"Active, not recruiting"	NCT03841201	IMMUNIB	ECD	2022Nov01	No	Yes	"SAE 30.6%, Primary outcome not met"	2	10.1200/JCO.2022.40.16_suppl.4107			Overall Response Rate	50	50			28								9					11.5								27.1						3	11	23									COSO29825606	2022Dec08	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Lenvatinib + Tislelizumab		Not yet recruiting	NCT04834986		ECD	2022Apr30	No	No		4	NCT04834986			Maximum tolerated dose/toxicity	30	30																																									COSO29825606	2022Jun07	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 3	Nivolumab		"Active, not recruiting"	NCT02576509		ECD	2019May30	No	Yes		4	NCT02576509			Overall survival	743	371	372	Sorafenib	15.4	7							3.68	3.75	0.93	0.79-1.10										16.39	14.69	0.85	0.71-1.02	0.0752													COSO29825606	2022Aug12	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 3	Lenvatinib + Toripalimab		Recruiting	NCT04523493		ECD	2024May01	No	No		4	NCT04523493			"OS, PFS"	519			Lenvatinib + Placebo																																							COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 3	Icaritin		Recruiting	NCT03236649		ECD	2022Dec01	Expression confirmed	No		4	NCT03236649	Untreated		Overall survival	200			Sorafenib																																							COSO29825606	2022Jun20	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 3	Atezolizumab + Bevacizumab		"Active, not recruiting"	NCT04102098		ECD	2023Sep28	No	No		4	NCT04102098			"Disease free survival, relapse free survival, regression free survival, recurrence free survival"	668			Observation																																							COSO29825606	2022Jul28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 3	Nivolumab		"Active, not recruiting"	NCT02576509	PD-L1 PFS < 1%	ECD	2019May30	No	Yes		4	NCT02576509			Overall survival	595	295	300	Sorafenib	12.2	6.7							3.61	3.75	0.98	0.81-1.17										16.72	15.24	0.84	0.69-1.02														COSO29825606	2022Aug12	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
CD274	CD274_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 3	Nivolumab		"Active, not recruiting"	NCT02576509	PD-L1 PFS >= 1%	ECD	2019May30	No	Yes		4	NCT02576509			Overall survival	135	71	64	Sorafenib	28.2	9.4							3.84	3.58	0.71	0.48-1.03										16.07	8.62	0.8	0.54-1.19														COSO29825606	2022Aug12	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
EGFR	EGFR_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Varlitinib		Unknown	NCT03499626		ECD	2019May05	Yes	No		4	NCT03499626			Maximum tolerated dose/toxicity	22	22																																									COSO29825606	2022May03	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
ERBB2	ERBB2_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Lapatinib		Completed	NCT00107536		PCD	2009May01	No	Yes		1	19737952			Overall Response Rate	26	26			0								1.9													12.6						0	0	10									COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
ERBB2	ERBB2_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Varlitinib		Unknown	NCT03499626		ECD	2019May05	No	No		4	NCT03499626			Maximum tolerated dose/toxicity	22	22																																									COSO29825606	2022May03	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
ERBB3	ERBB3_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Varlitinib		Unknown	NCT03499626		ECD	2019May05	No	No		4	NCT03499626			Maximum tolerated dose/toxicity	22	22																																									COSO29825606	2022May03	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
ERBB4	ERBB4_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Varlitinib		Unknown	NCT03499626		ECD	2019May05	No	No		4	NCT03499626			Maximum tolerated dose/toxicity	22	22																																									COSO29825606	2022May03	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
FGFR4	FGFR4_unspecified and KLB_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 1	FGF401 + Spartalizumab		Completed	NCT02325739		PCD	2019May30	Expression confirmed	Yes		2	10.1158/1538-7445.AM2017-CT106			Overall Response Rate	53	53			8																													28									COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
JAK2	JAK2_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 1	AZD1480		Terminated	NCT01219543		PCD	2012Dec01	No	Yes	"Serious adverse events, no benefit of treatment"	1	23847256			Unknown	47	47																																									COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
KIT	KIT_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Sunitinib		Completed	NCT00247676		PCD	2008Feb01	No	Yes	Serious adverse events - 4 deaths possibly due to treatment	1	19586800			Unknown	37																																1										COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	liver / carcinoma / hepatocellular carcinoma	4	Case study	Refametinib + Sorafenib		Completed	NCT01915602		PCD	2015Jul29	Yes	Yes		1	29950351			Overall Response Rate	1	1																															1										COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
KRAS	KRAS_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Refametinib + Sorafenib		Completed	NCT01915602		PCD	2015Jul29	Yes	Yes		1	29950351			Overall Response Rate	16	16			6.3		0.16-30.23																43.8									0	1	4									COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 1	Tepotinib		Completed	NCT01988493		PCD	2018Feb05	Expression confirmed	Yes		4	NCT01988493			Time to progression	75	38	37	Sorafenib									2.8	1.4	0.53	0.33-0.84	0.0229	2.9	1.4	0.42	0.26-0.74	0.0043				9.3	8.6	0.73	0.43-1.21	0.304													COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 1	c-Met/PD-L1 CAR-T cells		Unknown	NCT03672305		ECD	2019Oct30	Expression confirmed	No		4	NCT03672305			Clinical activity	50	50																																									COSO29825606	2022May03	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 2	Capmatinib		Withdrawn	NCT01964235		ECD	2019Jul01	Expression confirmed	No		4	NCT01964235			Time to progression	0	0	0	Placebo																																							COSO29825606	2021Jun14	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 2	RC108		Not yet recruiting	NCT05628857		ECD	2024Oct15	Expression confirmed	No		4	NCT05628857			Overall Response Rate	240	240																																									COSO29825606	2023Jan10	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 2	Cabozantinib + Nivolumab		Not yet recruiting	NCT05039736		ECD	2023Jun30	No	No		4	NCT05039736			Overall Response Rate	30	30																																									COSO29825606	2021Nov19	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 2	Tepotinib		Completed	NCT02115373		PCD	2018Feb14	Expression confirmed	Yes	"PFS 12w 63.3%, Primary outcome met"	4	NCT02115373	Previously-treated		Progression free survival	49	49				8.2																	57.1																				COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 2	Capmatinib		"Active, not recruiting"	NCT01737827		ECD	2023May31	Expression confirmed	Yes		2	10.1200/JCO.2016.34.15_suppl.4074	Untreated		Time to progression	8	8			38																		50										3	1									COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 3	Tivantinib		Completed	NCT01755767	METIV-HCC	PCD	2017Mar28	Expression confirmed	Yes	Primary outcome not met	1	29625879			Overall survival	340	226	114	Placebo																						8.4	9.1	0.97	0.75-1.25	0.81													COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
MET	MET_unspecified				liver / carcinoma / hepatocellular carcinoma	2	Phase 3	Tivantinib		Completed	NCT02029157		PCD	2017Aug01	Expression confirmed	Yes		1	32716114			Progression free survival	195	134	61		0.7	1.6							2.8	2.3	0.74	0.52?1.04	0.082						67.2	55.7																			COSO29825606	2022Nov28	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
NOTCH1	NOTCH1_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Unknown	Ginsenoside Rg3 capsule + Pirarubicin		Completed	NCT02724358		PCD	2013Dec01	Expression confirmed	No		4	NCT02724358			"TTP, OS"	320																																										COSO29825606	2022Nov23	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
TERT	TERT_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	RZ001		Recruiting	NCT05595473		ECD	2029Mar01	Yes	No		4	NCT05595473			"ORR, PFS, OS"	42	42																																									COSO29825606	2022Nov21	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
TP53	TP53_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 1	Ad5CMV-p53 gene		Terminated	NCT00003147		PCD	2003Jun01	No	No		4	NCT00003147			Unknown	30	30																																									COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
TP53	TP53_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	rAD-p53		Unknown	NCT02509169		ECD	2016Dec01	No	Yes		4	NCT02509169			Overall survival	60	60																														9	15										COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
TP53	TP53_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	rAD-p53		Unknown	NCT02418988		ECD	2017May01	No	No		4	NCT02418988			Overall survival	120	120																																									COSO29825606	2021May18	COSO29825606	liver	NS	NS	NS	carcinoma	hepatocellular_carcinoma	NS	NS	hepatocellular_carcinoma
